0001144204-15-063851.txt : 20151110 0001144204-15-063851.hdr.sgml : 20151110 20151109165425 ACCESSION NUMBER: 0001144204-15-063851 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151109 DATE AS OF CHANGE: 20151109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IsoRay, Inc. CENTRAL INDEX KEY: 0000728387 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411458152 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33407 FILM NUMBER: 151216407 BUSINESS ADDRESS: STREET 1: 350 HILLS STREET, STREET 2: SUITE 106 CITY: RICHLAND STATE: WA ZIP: 99354 BUSINESS PHONE: (509) 375-1202 MAIL ADDRESS: STREET 1: 350 HILLS STREET, STREET 2: SUITE 106 CITY: RICHLAND STATE: WA ZIP: 99354 FORMER COMPANY: FORMER CONFORMED NAME: CENTURY PARK PICTURES CORP DATE OF NAME CHANGE: 19920703 10-Q 1 v423416_10q.htm FORM 10-Q

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

  þ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2015

 

or

 

¨Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to ____________

 

Commission File No. 001-33407

 

ISORAY, INC.

(Exact name of registrant as specified in its charter)

 

Minnesota

(State or other jurisdiction of incorporation or

organization)

41-1458152

(I.R.S. Employer

Identification No.)

   

 350 Hills St., Suite 106, Richland, Washington

(Address of principal executive offices)

99354

(Zip Code)

 
Registrant's telephone number, including area code: (509) 375-1202

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨     Accelerated filer x     Non-accelerated filer ¨

Smaller reporting company ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ¨ No x

 

Number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date:

 

Class Outstanding as of November 6, 2015
Common stock, $0.001 par value 55,013,553

 

 

 

 

ISORAY, INC.

 

Table of Contents

 

PART I FINANCIAL INFORMATION  
     
Item 1 Consolidated Unaudited Financial Statements 1
     
  Consolidated Balance Sheets 1
     
  Consolidated Statements of Operations (Unaudited) 2
     
  Consolidated Statements of Cash Flows (Unaudited) 3
     
  Notes to the Consolidated Unaudited Financial Statements 4
     
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 11
     
Item 3 Quantitative and Qualitative Disclosures About Market Risk 20
     
Item 4 Controls and Procedures 20
     
PART II OTHER INFORMATION  
     
Item 1 Legal Proceedings 21
     
Item 1A Risk Factors 21
     
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 22
     
Item 3 Defaults Upon Senior Securities 22
     
Item 4 Mine Safety Disclosures 22
     
Item 5 Other Information 22
     
Item 6 Exhibits 22
     
Signatures 23

 

 

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1 – FINANCIAL STATEMENTS

 

IsoRay, Inc. and Subsidiaries

Consolidated Balance Sheets

 

   (Unaudited)     
   September 30, 2015   June 30, 2015 
         
ASSETS          
           
Current assets:          
Cash and cash equivalents  $1,587,009   $5,226,740 
Certificates of deposit (Note 3)   11,891,312    9,362,574 
Accounts receivable, net of allowance for doubtful accounts of $30,000 and 30,000, respectively   1,130,540    1,049,041 
Inventory   460,557    403,955 
Other receivables   10,406    19,615 
Prepaid expenses and other current assets   260,549    263,597 
           
Total current assets   15,340,373    16,325,522 
           
Fixed assets, net of accumulated depreciation   441,890    574,840 
Certificates of deposit, non-current (Note 3)   5,135,116    5,106,775 
Restricted cash   181,262    181,262 
Inventory, non-current   569,854    569,854 
Other assets, net of accumulated amortization   240,403    245,031 
           
Total assets  $21,908,898   $23,003,284 
           
LIABILITIES AND SHAREHOLDERS' EQUITY          
           
Current liabilities:          
Accounts payable and accrued expenses  $411,032   $498,253 
Accrued protocol expense   152,465    124,131 
Accrued radioactive waste disposal   141,500    129,500 
Accrued payroll and related taxes   129,540    212,795 
Accrued vacation   96,847    127,515 
           
Total current liabilities   931,384    1,092,194 
           
Long-term liabilities:          
Warrant derivative liability   166,000    181,000 
Asset retirement obligation   969,336    947,849 
           
Total liabilities   2,066,720    2,221,043 
           
Commitments and contingencies (Note 8)          
           
Shareholders' equity:          
Preferred stock, $.001 par value; 7,001,671 shares authorized:          
Series A: 1,000,000 shares allocated; no shares issued and outstanding   -    - 
Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding   59    59 
Series C: 1,000,000 shares allocated; no shares issued and outstanding   -    - 
Series D: 1,671 and 1,671 shares allocated; no shares issued and outstanding   -    - 
Common stock, $.001 par value; 192,998,329 shares authorized; 55,013,553 and 54,967,559 shares issued and outstanding   55,014    54,968 
Treasury stock, at cost, 13,200 shares   (8,390)   (8,390)
Additional paid-in capital   82,546,112    82,467,111 
Accumulated deficit   (62,750,617)   (61,731,507)
           
Total shareholders' equity   19,842,178    20,782,241 
           
Total liabilities and shareholders' equity  $21,908,898   $23,003,284 

 

The accompanying notes are an integral part of these financial statements.

 

1 

 

 

IsoRay, Inc. and Subsidiaries

Consolidated Statements of Operations

(Unaudited)

 

   Three months ended September 30, 
   2015   2014 
         
Product sales, net  $1,261,322   $1,042,101 
Cost of product sales   1,177,863    1,096,903 
           
Gross profit / (loss)   83,459    (54,802)
           
Operating expenses:          
Research and development   143,903    176,610 
Sales and marketing   278,421    353,743 
General and administrative   751,712    575,951 
           
Total operating expenses   1,174,036    1,106,304 
           
Operating loss   (1,090,577)   (1,161,106)
           
Non-operating income (expense):          
Interest income   57,417    72,695 
Change in fair value of warrant derivative liability   15,000    306,000 
Interest expense   (950)   (3,451)
           
Non-operating income (expense), net   71,467    375,244 
           
Net loss   (1,019,110)   (785,862)
Preferred stock dividends   (2,658)   (2,658)
           
Net loss applicable to common shareholders  $(1,021,768)  $(788,520)
           
Basic and diluted loss per share  $(0.02)  $(0.01)
           
Weighted average shares used in computing net loss per share:          
Basic and diluted   55,012,901    54,868,053 

 

The accompanying notes are an integral part of these financial statements.

 

2 

 

 

IsoRay, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(Unadudited)

 

   Three months ended September 30, 
   2015   2014 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(1,019,110)  $(785,862)
Adjustments to reconcile net loss to net cash used by operating activities:          
Allowance for doubtful accounts   -    (11,321)
Depreciation of fixed assets   136,668    169,970 
Amortization of other assets   20,725    7,734 
Change in fair value of derivative warrant liabilities   (15,000)   (306,000)
Accretion of asset retirement obligation   21,487    19,644 
Share-based compensation   32,312    21,453 
Changes in operating assets and liabilities:          
Accounts receivable, gross   (81,499)   (37,889)
Inventory   (56,602)   (47,742)
Other receivables   9,209    47,824 
Prepaid expenses and other current assets   3,048    (46,136)
Accounts payable and accrued expenses   (87,221)   (65,167)
Accrued protocol expense   28,334    14,029 
Accrued radioactive waste disposal   12,000    12,000 
Accrued payroll and related taxes   (83,255)   (130,779)
Accrued vacation   (30,668)   (4,944)
           
Net cash used by operating activities   (1,109,572)   (1,143,186)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of fixed assets   (3,718)   (7,453)
Additions to licenses and other assets   (16,097)   (2,296)
Proceeds from the maturity of certificates of deposit   3,526,999    - 
Purchases of certificates of deposit   (6,055,737)   (22,355)
Purchases of certificates of deposit - non-current   (28,341)   (4,645,139)
Change in restricted cash   -    (13)
           
Net cash used by investing activities   (2,576,894)   (4,677,256)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from sales of common stock, pursuant to exercise of warrants   -    70,411 
Proceeds from sales of common stock, pursuant to exercise of options   46,735    145,275 
           
Net cash provided by financing activities   46,735    215,686 
           
Net decrease in cash and cash equivalents   (3,639,731)   (5,604,756)
Cash and cash equivalents, beginning of period   5,226,740    7,680,073 
           
CASH AND CASH EQUIVALENTS, END OF PERIOD  $1,587,009   $2,075,317 
           
Non-cash investing and financing activities:          
Reclassification of derivative warrant liability to equity upon exercise  $-   $(17,000)

 

The accompanying notes are an integral part of these financial statements.

 

3 

 

 

IsoRay, Inc.

Notes to the Unaudited Consolidated Financial Statements

For the three months ended September 30, 2015 and 2014

 

1.Basis of Presentation

 

The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries (IsoRay or the Company). All significant intercompany accounts and transactions have been eliminated in consolidation. Certain amounts in the prior-period financial statements have been reclassified to conform to the current-period presentation.

 

In the opinion of management, the accompanying unaudited interim consolidated financial statements and notes to the interim consolidated financial statements contain all adjustments, consisting of normal recurring items, necessary to present fairly, in all material respects, the financial position of IsoRay, Inc. and its wholly-owned subsidiaries.  These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10-K for the year ended June 30, 2015.

 

The results of operations for the periods presented may not be indicative of those which may be expected for a full year.  The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading.

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, the reported amounts of revenues and expenses during the reporting period, and the disclosures of contingent liabilities.  Accordingly, ultimate results could differ materially from those estimates. The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2016 will be 0%.

 

2.New Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, "Revenue Recognition". The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

 

In July 2015, the FASB issued ASU No. 2015-11 – Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

 

4 

 

 

3.Certificates of deposit

 

The Company has maintained all excess cash in certificates of deposit at certain banks in certificates of deposit and through the Certificate of Deposit Account Registry Service (CDARS), which is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 limit to be fully insured by the Federal Deposit Insurance Corporation (FDIC). The Company ensures that principal amounts of certificates of deposit are fully insured. There may from time to time be short periods following maturity that amounts held in the money market account at the CDARS host bank will exceed FDIC coverage. In cases where the period that uninsured amounts will be held beyond ten banking days, the funds will be transferred to the primary operating account of the Company’s operating subsidiary, IsoRay Medical, Inc. (Medical), that incorporates a sweep function that keeps the funds FDIC insured during that time.

 

   As of September 30, 2015 
   Under 90   91 days to   Six months to   Greater 
   Days   six months   1 year   than 1 year 
CDARS  $6,528,858   $-   $5,362,454   $5,135,116 

 

   As of June 30, 2015 
   Under 90   91 days to   Six months to   Greater 
   Days   six months   1 year   than 1 year 
CDARS  $3,523,167   $500,064   $5,339,343   $5,106,775 

 

4.Loss per Share

 

Basic and diluted earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents. At September 30, 2015 and 2014, the calculation of diluted weighted average shares did not include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company’s net loss position.

 

Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of September 30, 2015 and 2014, were as follows:

 

   September 30, 
   2015   2014 
Series B preferred stock   59,065    59,065 
Common stock warrants   360,800    396,574 
Common stock options   2,364,346    2,180,858 
           
Total potential dilutive securities   2,784,211    2,636,497 

 

5.Inventory

 

Inventory consisted of the following at September 30, 2015 and June 30, 2015:

 

   September 30,   June 30, 
   2015   2015 
Raw materials  $264,900   $143,669 
Work in process   156,759    204,760 
Finished goods   38,898    55,526 
           
   $460,557   $403,955 

 

5 

 

 

   September 30,   June 30, 
   2015   2015 
         
Enriched barium, non-current  $469,758   $469,758 
Raw materials, non-current   100,096    100,096 
           
Total inventory, non-current  $569,854   $569,854 

 

Inventory, non-current is (i) raw materials that were ordered in quantities to obtain volume cost discounts for key components of our brachytherapy seed including titanium lids, titanium tubes, gold wires that are used for imaging markers, and our proprietary seed core, which were ordered based on current and anticipated sales volumes and will not be consumed within an operating cycle, and (ii) enriched barium, which is classified as non-current, and is only expected to be utilized if required to obtain volumes of isotope that is not able to be purchased from an existing source in either the short- or long-term. Management does not anticipate the need to utilize the enriched barium within the current operating cycle unless there is an unanticipated interruption to the isotope supply that requires its use. If such a need were to occur, then management would evaluate the need to reclassify some or all of the inventory as a current asset.

 

6.Fixed Assets

 

   September 30,   June 30, 
   2015   2015 
Production equipment  $3,180,933   $3,180,933 
Office equipment   226,995    224,576 
Furniture and fixtures   148,265    148,265 
Leasehold improvements   4,129,977    4,129,977 
Other   7,224    - 
           
    7,718,394    7,689,676 
Less accumulated depreciation   (7,251,504)   (7,114,836)
           
Fixed assets, net  $441,890   $574,840 

 

Depreciation expense related to property and equipment for the three months ended September 30, 2015 and 2014 was $136,668 and $169,970, respectively.

 

7.Share-Based Compensation

 

The following table presents the share-based compensation expense recognized during the three months ended September 30, 2015 and 2014:

 

   Three months 
   ended September 30, 
   2015   2014 
Cost of product sales  $17,558   $7,972 
Research and development expenses   3,565    3,117 
Sales and marketing expenses   3,492    2,158 
General and administrative expenses   7,697    8,206 
Total share-based compensation  $32,312   $21,453 

 

6 

 

 

As of September 30, 2015, total unrecognized compensation expense related to stock-based options was $381,596 and the related weighted-average period over which it is expected to be recognized is approximately 1.56 years.

 

A summary of stock options within the Company’s share-based compensation plans as of September 30, 2015 was as follows:

 

       Weighted   Weighted     
       Exercise   Average    
   Number of   Price   Contractual   Intrinsic 
   Options   (Years)   Term   Value 
                 
Outstanding at September 30, 2015   2,364,346   $1.93    4.52   $591,185 
Vested and expected to vest at
September 30, 2015
   2,267,045   $1.94    4.40   $570,238 
Vested and exercisable at
September 30, 2015
   1,967,880   $1.96    3.55   $583,083 

 

There were 45,994 options exercised during the three months ended September 30, 2015 and 133,564 options exercised during the three months ended September 30, 2014. The Company’s current policy is to issue new shares to satisfy option exercises. The intrinsic value of the employee options exercised in the three months ended September 30, 2015 and 2014 was $21,654 and $252,308, respectively.

 

There were no stock option awards granted during the three months ended September 30, 2015 and 2014, respectively.

 

8.Commitments and Contingencies

 

Patent and Know-How Royalty License Agreement

 

The Company is the holder of an exclusive license to use certain “know-how” developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor’s patent application was ultimately abandoned, only a 1% “know-how” royalty based on Net Factory Sales Price, as defined in the agreement, remains applicable. To date, management believes that there have been no product sales incorporating the “know-how” and therefore no royalty is due pursuant to the terms of the agreement. Management believes that ultimately no royalties should be paid under this agreement as there is no intent to use this “know-how” in the future.

 

The licensor of the “know-how” has disputed management’s contention that it is not using this “know-how”. On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time.

 

Class Action Lawsuit Related to Press Release

 

On May 22, 2015, a class action complaint for violation of the federal securities laws was filed in U.S. District Court against IsoRay, Inc., our CEO/Chairman and our CFO.  The complaint related to a press release issued by the Company on May 20, 2015 and is purportedly brought on behalf of all purchasers of IsoRay, Inc. common stock from May 20, 2015 through and including May 21, 2015. 

 

On October 16, 2015, an amended class action complaint for violation of the federal securities laws was filed in U.S District Court for Eastern District of Washington against IsoRay, Inc. and our CEO/Chairman. The class period remains unchanged at 27 hours and our CFO was dropped as a defendant. The Company has until December 15, 2015 to respond to the amended complaint.

 

7 

 

 

The complaint, as amended, asserts that the purchasers were misled by the press release, and seeks, among other things, damages and costs and expenses.  We cannot predict the outcome of such proceedings or an estimate of damages, if any. We believe that these claims are without merit and intend to defend them vigorously.

 

Property Transaction between Medical and The Port of Benton

 

Initial Property Transaction

 

On September 10, 2015, the Company’s operating subsidiary, Medical, entered into a Real Estate Purchase and Sale Agreement with The Port of Benton, a municipal corporation of the State of Washington. The Agreement is for the sale of undeveloped real property of approximately 4.2 acres located adjacent to the Company’s existing manufacturing facility and corporate offices. The purchase price for the property is One Hundred Sixty-Eight Thousand Dollars ($168,000) which is payable on October 30, 2015, the original expected date of closing prior to the First Addendum/Amendment.

 

In addition to the feasibility studies required on all aspects of the property required by Medical to close, Medical is also bound to comply with a Development Plan for a ten year period which requirements include but are not limited to the following:

 

(1)         Certain specified site configurations and design with a minimum of 12,000 square feet of warehouse and production space and 4,000 square feet of office space;

 

(2)         Completion of all construction in two years;

 

(3)         Use of facility as primary production facility for ten (10) years; and

 

(4)         Provision of jobs for not less than 25 full time employees.

  

Failure to comply with these covenants will result in a breach of the Agreement and if not cured, will obligate Medical to pay the Port the difference in the sales price and the appraised value of the property at the time of default.

 

First Addendum / Amendment to Property Transaction

 

On October 15, 2015, the Company’s operating subsidiary, Medical, entered into a First Addendum / Amendment to Real Estate Purchase & Sale Agreement to the Real Estate Purchase and Sale Agreement with The Port of Benton, a municipal corporation of the State of Washington, that was entered into on September 10, 2015.

 

This addendum modified the following:

 

(1) Extended the feasibility contingency from a period of sixty (60) days to one hundred and twenty (120) days to expire on or before January 8, 2016 with no further extensions.

 

(2) Extended the closing of sale to on or before February 5, 2016.

 

All other terms and conditions of said Real Estate Purchase & Sale Agreement dated September 10, 2015 remained the same and continue in full force and effect.

  

8 

 

 

9.Fair Value Measurements

 

The table below sets forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015 and June 30, 2015, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category.

 

Fair value at September 30, 2015
                 
   Total   Level 1   Level 2   Level 3 
Cash and cash equivalents  $1,587,009   $1,587,009   $-   $- 
Warrant derivative liability   166,000    -    166,000    - 

 

Fair value at June 30, 2015
                 
   Total   Level 1   Level 2   Level 3 
Cash and cash equivalents  $5,226,740   $5,226,740   $-   $- 
Warrant derivative liability   181,000    -    181,000    - 

 

10.Preferred Dividends

 

On December 17, 2014, the Board of Directors declared a dividend on the Series B Preferred Stock of all currently payable and accrued outstanding and cumulative dividends through December 31, 2014 in the amount of $10,632. The dividends outstanding and cumulative through December 31, 2014 of $10,632 and through December 31, 2013 of $10,632 were paid as of those dates.

 

As of September 30, 2015, there were accrued but undeclared dividends on Series B Preferred Stock outstanding in the amount of $7,974.

 

11.Shareholders’ Equity

 

Warrant derivative liability

 

Based on the guidance contained in ASC 815 “Derivatives and Hedging”, management has concluded that the warrants issued in the 2011 offering should be classified as a derivative liability and has recorded a liability at fair value.

 

Change in fair value of the warrant derivative liability is as follows.

 

   Three months ended   Three months ended 
   September 30, 2015   September 30, 2014 
Change in fair value of warrant derivative liability:  $(15,000)  $(323,000)

 

A summary of the change in fair value of derivative warrant liability is as follows for the fiscal years presented.

 

9 

 

 

   Quantity1   Amount 
Balance at June 30, 2014   238,696   $573,000 
Change in fair value        (374,605)
Warrants exercised   (13,209)   (17,395)
Balance at June 30, 2015   225,087   $181,000 
Change in fair value        (15,000)
Balance at September 30, 2015   225,087   $166,000 

 

1 Quantity of warrants either issued or outstanding as of the date of valuation.

 

Warrants

 

The following table summarizes all warrants outstanding as of the beginning of the fiscal year, all activity related to warrants issued, cancelled, exercised or expired during the period and weighted average prices for each category.

 

       Weighted average 
   Warrants   exercise price 
Outstanding as of June 30, 2015   385,800   $1.22 
Warrants expired   (25,000)   2.00 
Outstanding as of September 30, 2015   360,800   $1.17 

 

The following table summarizes additional information about the Company’s common warrants outstanding as of September 30, 2015:

 

Number of       Expiration
Warrants   Exercise Prices   Date
 130,713    1.56   May 2016
 199,437    0.94   October 2016
 25,650    0.94   December 2016
 5,000    0.98   June 2017
 360,800         

 

12.Related Party Transaction

 

During the three months ended September 30, 2015 and 2014, the Company continued to engage the services of APEX Data Systems, Inc., owned by Dwight Babcock, the Company’s Chairman and Chief Executive Officer, to modify and maintain the Company’s web interfaced data collection application to aggregate patient data in a controlled environment. The cost recorded during the three months ended September 30, 2015 and 2014 from APEX Data Systems, Inc. for the maintenance of the web interfaced data collection applications in combination with the updating of the Company website was $3,000 and $3,000 respectively. An additional $3,000 was spent on the implementation of Customer Relationship Management (CRM) software in the three months ended September 30, 2015 and 2014.

 

13.Concentrations of Credit and Other Risks

 

The Company’s cash, cash equivalents and investments are deposited with several financial institutions with FDIC coverage. At times, deposits for a limited period of time in these institutions may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances.

 

For the three months ended September 30, 2015 and 2014, there were two and one customers that each represented 10% or more of total net revenue, respectively.

 

10 

 

 

At September 30, 2015, two customers each accounted for 10% of the Company’s total accounts receivable with a single customer (a group of seven legal entities) that represents 30% of total accounts receivable. At June 30, 2014, one customer (a group of seven legal entities) accounted for 27% of total accounts receivable.

 

Accounts receivable are typically not collateralized. The Company maintains ongoing dialogue with its customers about invoice payments. Some of our customers are small outpatient surgery centers that pay invoices for our products at the time they receive a decision regarding payment by the insurer providing benefits which in the case of prostate cancer is predominately Medicare. A qualitative review of outstanding customer balances is performed at least quarterly and the allowance for doubtful accounts is adjusted based on historical performance of the customer and management knowledge regarding specific invoices. Accounts are charged against the allowance for doubtful accounts once collection efforts are deemed unsuccessful.

 

Single source suppliers presently provide the Company with several components. Management believes that it would be able to locate other sources for these components subject to any regulatory qualifications, if required.

 

ITEM 2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Caution Regarding Forward-Looking Information

 

In addition to historical information, this Form 10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA.

 

All statements contained in this Form 10-Q, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words "believe," "expect," "anticipate," "intends," "estimate," "forecast," "project," and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties described under “Risk Factors” under Part II, Item 1A below and in the “Risk Factors” section of our Form 10-K for the fiscal year ended June 30, 2015 that may cause actual results to differ materially.

 

Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company's views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

11 

 

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of the Company’s financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, management evaluates past judgments and estimates, including those related to bad debts, inventories, accrued liabilities, derivative liabilities and contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The accounting policies and related risks described in the Company’s annual report on Form 10-K as filed with the Securities and Exchange Commission on September 30, 2015 are those that depend most heavily on these judgments and estimates. As of September 30, 2015, there had been no material changes to any of the critical accounting policies contained therein.

 

Overview

 

Products and Market.

 

IsoRay, Inc. is a brachytherapy device manufacturer with FDA clearance and CE marking for two medical devices that can be delivered to the physician in multiple configurations as prescribed. The Company manufactures and sells these products as the Proxcelan® Cesium-131 brachytherapy seed and the GliaSite® Radiation Therapy System (GliaSite® RTS). Each brachytherapy seed order is manufactured to the physician’s specifications for a named patient on a specific treatment date. The GliaSite® RTS utilizes a balloon catheter system, which allows the physician to later place a specified dose of isotope in the treatment location.

 

These brachytherapy seeds utilize Cesium-131, with a 9.7 day half-life, as their radiation source. The Company believes that it is the unique combination of the short half-life and the energy of the isotope that are yielding the beneficial treatment results that have been published in peer reviewed journal articles and presented in various forms at conferences and tradeshows. In the case of the GliaSite® RTS, the Company believes that in the long-term, Cesitrex®, which is Cesium-131-based, is the best isotope solution for this treatment, but it continues to offer Iotrex®, an Iodine-125 based isotope solution, as it works to reestablish the market for this product. To date, Iotrex® is the primary isotope solution utilized in the GliaSite® RTS; Cesitrex® is available for sale and only utilized in U.S. treatment.

 

The Company continues to enter into distribution agreements outside of the United States through its subsidiary IsoRay International LLC. These distributors are responsible for obtaining regulatory clearance to sell the Company’s products in their territories, with the support of the Company. As of September 30, 2015, the Company had distributors in Australia and New Zealand, Germany which includes rights to Austria, Switzerland, and Luxembourg as well, Italy, and the Russian Federation.

 

Management is encouraged by the growth trend in our core business of treating prostate cancer, with four of the past five fiscal quarters experiencing increases over the same quarter in the prior fiscal year and with growth in total revenue during the past three fiscal quarters over the same quarters in the prior fiscal year. As the Company has a very small share of the overall prostate brachytherapy market, there is significant opportunity for expansion.

 

Management believes that the current growth is the result of additional peer-reviewed articles that share the treatment experience and these publications are building an awareness and communicating the treatment advantages of our products. Management also believes that as the impact of the Affordable Care Act’s cost containment measures is felt that the payors will have to react by modifying methods of reimbursement to encourage facilities to utilize other modalities that deliver comparable or better results with a lower total cost. Management expects cost containment to be favorable to seed brachytherapy as external beam radiation makes up the majority of the overall treatment market for prostate cancer and a significant portion of the market in other body sites in which the Company competes for business.

 

When brachytherapy seeds are implanted during a surgical procedure for brain cancer, lung cancer and certain other non-prostate cancers, under Medicare, the brachytherapy seeds are not separately reimbursed when surgery is performed and the patient is admitted to the hospital. External beam radiation treatments for these same cancers are reimbursed separately following surgery. While the cost of external beam radiation is significantly greater than the cost of brachytherapy at the time of surgery, this separate reimbursement for external beam radiation treatments results in the hospital receiving a payment in addition to payment for the surgical procedure itself. With brachytherapy performed concurrent with the surgery, the hospital receives the same reimbursement for the surgical procedure whether seeds are implanted or not, resulting in brachytherapy treatment being a “cost” and not a source of additional revenue for the hospital.

 

The Company believes that long-term success of the Proxcelan® Cesium-131 brachytherapy seed is dependent on a number of factors including the following:

·Increased awareness by physicians of the benefits of utilizing Proxcelan ® Cesium-131 brachytherapy seeds;
·The Affordable Care Act (ACA) implementing cost containment measures in the evaluation of treatment methodologies and reimbursement, particularly in prostate cancer where costly intensity-modulated radiation therapy (IMRT) treats an increasing percentage of the overall U.S. prostate cancer treatment market and growth in the market is expected with the increase in men younger than Medicare age obtaining health insurance;
·Increased patient awareness of the comparability and benefits of low dose rate (LDR) brachytherapy when compared to external beam radiation therapy, including comparable urinary symptoms, fewer bowel toxicities, and better sexual function, with respect to which management believes that the Company’s Cs-131 brachytherapy provides improved outcomes in these areas when compared to other types of LDR brachytherapy;
·Increased attention by payors and patients to the increased cost being paid for IMRT and the potential conflict of interest resulting from the in-office referral of prostate cancer patients for IMRT utilizing equipment in which the physician has an ownership interest, which can be allowed through an exception, for in-office ancillary services, to the federal laws prohibiting self-referrals;

·Changes in the reimbursement methodology regarding the utilization of brachytherapy seeds in the treatment of brain cancer, lung cancer and other cancers;
·Continued evolution in protocols demonstrating the safety, efficacy and other benefits of using Proxcelan® Cesium-131 brachytherapy seeds to treat tumors throughout the body;
·Continued publication of peer reviewed journal articles and presentations at society meetings about the treatment outcomes achieved utilizing Proxcelan® Cesium-131 brachytherapy seeds in the treatment of prostate cancer, brain cancer, lung cancer, gynecological cancer and other tumors throughout the body;
·Expanded sales through distributors into other countries particularly those in which external beam radiation has not established a significant presence; and
·Continued ability of the Company to deliver product that meets the standards of the Company and the expectations of its customers.

 

The Company believes that long-term success of the GliaSite® RTS is dependent on a number of factors including the following:

·Implementation of a protocol to support the publication of peer reviewed journal articles and presentations at society meetings about the treatment outcomes achieved utilizing GliaSite® RTS;
·Greater awareness among doctors of the historical use of GliaSite® RTS and the treatment outcomes achieved;
·Greater awareness of the availability of Cesitrex® as an alternative isotope to Iotrex®; and
·Recovery of foreign economies and currencies to increase the overall market.

 

12 

 

 

Results of Operations

 

Three months ended September 30, 2015 compared to three months ended September 30, 2014.

 

   Three months ended September 30, 
   2015   2014   2015-
2014
 
   Amount   %
(a)
   Amount   % (a)   %
Change
 
Product sales, net  $1,261,322    100   $1,042,101    100    21 
Cost of product sales   1,177,863    93    1,096,903    105    7 
Gross profit / (loss)   83,459    7    (54,802)   (5)   252 
                          
Research and development expenses   143,903    11    176,610    17    (19)
Sales and marketing expenses   278,421    22    353,743    34    (21)
General and administrative expenses   751,712    60    575,951    55    31 
Net loss attributable to shareholders  $(1,021,768)   (30)  $(788,520)   (76)   (30)

 

(a) Expressed as a percentage of product sales, net

 

Revenues. Total revenue from product sales increased approximately $219,000 or 21% in the three months ended September 30, 2015 when compared to the three months ended September 30, 2014. The 21% growth during the three months ended September 30, 2015 compared to the three months ended September 30, 2014 was the result of an increase of approximately $244,000 or 24% overall growth in seed brachytherapy treatments which more than offset the 100% decrease in GliaSite® revenues. During the three months ended September 30, 2015, 100% of product sales came from brachytherapy seed treatments compared with 98% during the three months ended September 30, 2014.

 

Prostate Brachytherapy.

 

During the three months ended September 30, 2015 and 2014, respectively, prostate brachytherapy was 88% of total revenues. The growth in revenue from prostate brachytherapy of 22% was the result of a 16% increase in the total number of seeds sold combined with the change in product mix ordered by physicians during the three months ended September 30, 2015 compared to the three months ended September 30, 2014. Physicians ordered 18% more seeds configured into strands and pre-loaded in needles and 20% more seeds configured in Mick® cartridges during the three months ended September 30, 2015 compared to the three months ended September 30, 2014. These configurations result in more revenue than alternative configurations.

 

Management believes that the growth in the Company’s prostate brachytherapy revenue is the result of physicians, payors and patients increasingly considering overall treatment cost in addition to quality of life in combination with treatment outcomes. Management also believes the recent publication of additional data in peer reviewed journal articles on treatment outcomes achieved with low-dose-rate (LDR) prostate brachytherapy with the Company’s Proxcelan® Cs-131 brachytherapy seeds, indicating it is more cost effective, has faster resolution of urinary side effects and a reduced impact on the healthy tissue surrounding the tumor, when compared to competing treatments such as high-dose-rate brachytherapy and intensity modulated radiation therapy, is a driver of the recent growth in the Company’s prostate brachytherapy revenue. There is no assurance this trend will continue.

 

13 

 

 

Other Brachytherapy.

 

The strategy implemented by management in diversifying the number of body sites being actively treated with the Proxcelan® Cs-131 brachytherapy seed has continued to provide an additional source of revenue. While individually these treatment sites do not represent a significant contribution to revenue, the sites as a group increased their revenue contribution by 44% during the three months ended September 30, 2015 when compared to the three months ended September 30, 2014. The largest revenue contributions in this classification came from brain cancer and lung cancer treatments. During the three months ended September 30, 2015 and 2014, respectively, other brachytherapy represented approximately $146,000 or 12% and approximately $101,000 or 10% of total revenue growth, or a 44% increase. These other brachytherapy treatments continue to be subject to the influence of a small pool of innovative physicians who are the early adopters of the technology who also tend to be faculty at teaching hospitals training the next generation of physicians. This causes the revenue created by these types of treatment applications to be more volatile and vary significantly from quarter to quarter.

 

GliaSite® Radiation Therapy System.

 

All product sales are generated by brachytherapy seeds and their related methods of application except for the revenue generated by sales of GliaSite® RTS, which come from sale of the liquid isotope, catheter trays and access trays. Product sales from GliaSite® RTS decreased 100%, with no revenue in the three months ended September 30, 2015 compared to revenue of $25,000 in the three months ended September 30, 2014. While the recovery of past sales levels will be dependent on economic recovery in Europe, the Company expects to see some mild recovery of prior sales levels based on discussions with its German distributor, however, these sales may not materialize. The lack of sales was partially impacted by the change in the exchange rate between the US dollar and the Euro as the dollar continued to be stronger during fiscal year 2016 compared with fiscal year 2015, which effectively increased the cost to European customers as all transactions are conducted in the US dollar.

 

The conversion of prospects to new GliaSite® RTS customers has been a longer process than originally anticipated by the Company. The Company has experienced lengthy timelines in the internal processes of medical facilities in reviewing and approving the use of the product at the request of their physician(s). These longer than anticipated internal processes are compounded by uncertain timelines and delays in receiving the approval for the requested modification of each facility's nuclear materials license, which is required to begin using GliaSite® RTS and is dependent on external government regulators.

 

Cost of product sales.

 

The cost of product sales for the production of brachytherapy seeds increased by approximately $81,000 or 7% during the three months ended September 30, 2015 when compared to the three months ended September 30, 2014. The increase in cost of products for the production of brachytherapy seeds was the result of increased material consumption of approximately $98,000 or 23%, partially offset by a reduction in depreciation and amortization expense of approximately $31,000 or 19%. The increased material costs are the result of the additional costs related to producing the 16% increase in the number of brachytherapy seeds produced and the related changes in configuration, with the ability to produce those seeds within the existing isotope that was purchased to ensure the ability of the Company to produce orders on a weekly basis that were previously expensed as the isotope decayed and was unable to generate future revenue. The decrease in depreciation and amortization is the result of reduced depreciation expense as equipment has continued to reach the end of its depreciable life without requiring replacement. Although not required by our contract with our Russian isotope supplier, we purchase isotope in 20 curie lots weekly and therefore incur this cost regardless of usage. The Company is a just in time manufacturer of brachytherapy seeds which is the result of the unique properties of Cesium-131, primarily the half-life or decay rate of 9.7 days. The Company requires isotope on-hand to meet known orders as well as anticipated orders which may or may not materialize. The Company does not manufacture to inventory as other brachytherapy seed manufacturers may. When the Company has isotope available for production in excess of the current demand, manufacturing of orders due to ship in the near future will be manufactured to allow future flexibility in the manufacturing cycle.

 

14 

 

 

During the three months ended September 30, 2015 compared to the three months ended September 30, 2014, the decrease in the cost of product sales for the GliaSite® RTS was primarily the result of decreased isotope consumption which was the result of there being no orders for this product in the three months ended September 30, 2015.

 

Gross profit / (loss).  Gross profit for the three months ended September 30, 2015 improved by approximately $138,000 or 252% compared to the gross loss for the three months ended September 30, 2014, primarily as a result of the increased product sales, with minimal incremental costs related to materials and labor to increase seed production outputs. This increase in gross profit was significantly impacted by the ability of the Company to utilize isotope that was already purchased to ensure an adequate supply of isotope on a weekly basis to produce orders and that would have otherwise been expensed as it decayed during the operating cycle.

 

Research and development. Research and development costs decreased by approximately $33,000 or 19% in the three months ended September 30, 2015 compared to the three months ended September 30, 2014, primarily as a result of the decrease in legal expense related to the protection of intellectual property.

 

Sales and marketing expenses. Sales and marketing expenses decreased by approximately $75,000 or 21% during the three months ended September 30, 2015 compared to the three months ended September 30, 2014, primarily as the result of decreased conventions and tradeshow expenses of approximately $41,000 or 84% as the American Society for Radiation Oncology (ASTRO) convention occurred in October 2015 versus September 2014. The Company also had an expected temporary reduction in travel expenses and payroll related expenses of approximately $17,000 or 29% and approximately $13,000 or 6% related to the open national sales director and territory sales manager positions that were unfilled during the three months ended September 30, 2015.

 

General and administrative expenses. General and administrative expenses increased by $176,000 or 31% in the three months ended September 30, 2015 compared to the three months ended September 30, 2014. The significant increases were in auditing, Sarbanes-Oxley and tax compliance of approximately $28,000 or 93%, legal expense of approximately $92,000 or 219%, and occupancy expense of approximately $16,000 or 160%. The auditing, Sarbanes-Oxley and tax compliance cost increased as the result of the Company’s change from a smaller reporting company to an accelerated filer June 30, 2015 and the related reporting and compliance obligations that came as the result of the filing status change. Legal expense increased from a combination of the expanded reporting obligations related to the Company filing status change from a smaller reporting company to an accelerated filer June 30, 2015 and the cost of legal counsel in defending the Company and its executive officers against a class action shareholder lawsuit. Occupancy expense increased as the allocation of cost changed in the three months ended September 30, 2015 compared to the three months ended September 30, 2014. The overall rent did not change, however, the amount of cost being allocated to general and administrative functions did change, resulting in reductions to other functions which offset this increase to general and administrative.

 

Operating loss. Operating loss for the three months ended September 30, 2015 decreased approximately $71,000 or 6% compared to the three months ended September 30, 2014, primarily as a result of an increase in product sales partially offset by an increase in cost of product sales and general and administrative expenses.

 

Interest income. Interest income decreased approximately $15,000 or 21% during the three months ended September 30, 2015 when compared to the three months ended September 30, 2014 due to a decrease in the available excess cash to invest in laddered CDs in the Certificate of Deposit Account Registry Service® (CDARS) and which are in amounts that are fully insured by the Federal Deposit Insurance Corporation (FDIC).

 

15 

 

 

Change in fair value of warrant derivative liability. The warrant derivative liability requires periodic evaluation for changes in fair value. As required at September 30, 2015 and September 30, 2014, the Company evaluated the fair value of the warrant derivative liability using the Black-Scholes option pricing model and applied updated inputs as of those dates. The resulting change in fair value was recorded as of September 30, 2015 and September 30, 2014.

 

Liquidity and capital resources. The Company has historically financed its operations through selling stock to investors. During the three months ended September 30, 2015 and September 30, 2014, the Company used existing cash reserves to fund its operations and capital expenditures.

 

Our cash flows for the three months ended September 30, 2015 and 2014, respectively, are summarized as follows:

 

   Three months ended September 30, 
   2015   2014 
Net cash used by operating activities  $(1,109,572)  $(1,143,186)
Net cash used by investing activities   (2,576,894)   (4,677,256)
Net cash provided by financing activities   46,735    215,686 
Net decrease in cash and cash equivalents  $(3,639,731)  $(5,604,756)

 

Cash flows from operating activities

 

Net cash used by operating activities in the three months ended September 30, 2015 was $1.11 million as compared to $1.14 million used in the three months ended September 30, 2014.

 

Net cash used by operating activities in the three months ended September 30, 2015:

 

·Net loss of $1.02 million;
·Net loss was increased by non-cash items of approximately $15,000 related to the change in fair value of derivative warrant liability;
·Net loss was decreased by non-cash items of approximately $211,000 related to depreciation of fixed assets; amortization of other assets; accretion of the asset retirement obligation and share-based compensation expense;
·Increase in accounts receivable of approximately $81,000, the result of the increase in product sales of approximately $219,000 when compared to the same quarter in the prior fiscal year;
·Increase in inventory of approximately $57,000, the result of purchases of inventory, consisting of titanium lids, titanium tubing and gold wire produced to the specifications of the Company, in quantities to obtain best pricing;
·Decrease in accounts payable and accrued expenses of approximately $87,000, the result of the timing of paying operating expenses; and
·Decrease in the accrued payroll and related taxes expense of approximately $83,000, the result of the number of days of unpaid payroll and related taxes in combination with the payment of commissions due that were accrued but unpaid at the end of the prior fiscal year.

 

16 

 

 

Net cash used by operating activities in the three months ended September 30, 2014:

 

·Net loss of approximately $786,000;
·Net loss was increased by non-cash items of approximately $306,000 related to change in fair value of derivative warrant liability and allowance for doubtful accounts;
·Net loss was decreased by non-cash items of approximately $207,000 related to depreciation of fixed assets; amortization of other assets; accretion of the asset retirement obligation and share-based compensation expense;
·Increase in accounts receivable of approximately $38,000, the result of delayed payments from customers;
·Increase in inventory of $48,000, the result of increased raw materials and work in process on-hand at period end;
·Decrease in other receivables of approximately $48,000, the result of receiving a refund of overpaid payroll taxes from the third party processor of the Company payroll related to the exercise of non-qualified employee stock options;
·Increase in prepaid expenses and other current assets of approximately $46,000 which was the result of prepayment of directors and officers insurance;
·Increase in accounts payable and accrued expenses of approximately $65,000, the result of the timing of paying operating expenses; and
·Increase in the accrued payroll and related taxes expense of $131,000, the result of the number of days of unpaid payroll and related taxes.

 

Cash flows from investing activities

 

Net cash used by investing activities in the three months ended September 30, 2015 was $2.58 million as compared to $4.68 million used in the three months ended September 30, 2014.

 

Net cash used by investing activities in the three months ended September 30, 2015:

 

·Increased by purchases of fixed assets of approximately $4,000;
·Increased by additions to licenses and other assets of approximately $16,000;
·Decreased by proceeds from certificates of deposit that matured of $3.53 million;
·Increased by purchases of certificates of deposit of $6.06 million;
oApproximately $3.53 million of the cash used for the certificates of deposit purchased came from certificates of deposit that reached maturity during the three months ended September 30, 2015;
o$2.5 million of the cash used for the purchase of certificates of deposit came certificates of deposit that matured during June 2015 and were in cash and cash equivalents at June 30, 2015;
oThe remaining cash used for the purchase of certificates of deposit was from interest earned during the period and added to the existing certificates of deposit; and
·Increased by purchases of certificates of deposit, non-current of approximately $28,000.

 

Net cash used by investing activities in the three months ended September 30, 2014:

 

·Increased by purchases of fixed assets of approximately $7,000;
·Increased by purchases of certificates of deposit of approximately $22,000; and
·Increased by purchases of certificates of deposit, non-current of $4.65 million.

 

Cash flows from financing activities

 

Net cash provided by financing activities in the three months ended September 30, 2015:

·Increase from the sale of common stock from the exercise of stock options of approximately $47,000.

 

17 

 

 

Net cash provided by financing activities in the three months ended September 30, 2014:

·Increase from the sale of common stock from the exercise of warrants of approximately $70,000; and
·Increase from the sale of common stock from the exercise of stock options of approximately $145,000.

 

Projected Fiscal Year 2016 Liquidity and Capital Resources

 

At September 30, 2015, the Company held cash and cash equivalents of $1.59 million, CDARS of $11.89 million that mature in the current operating cycle and CDARS of $5.14 million that mature within the next twenty-four months.

 

   Amount 
Cash and cash equivalents  $1,587,009 
Certificates of deposit maturing in less than 90 days   6,528,858 
Certificates of deposit maturing greater than six months and less than one year   5,362,454 
Certificates of deposit maturing greater than one year and less than two years   5,135,116 
Cash, cash equivalents and certificates of deposit total  $18,613,437 

 

The Company had approximately $1.72 million of cash and cash equivalents, $11.90 million of certificates of deposit and $5.14 million of certificates of deposit, non-current as of November 3, 2015. The short-term investments have maturities in December 2015, January 2016 and June 2016. At the time of maturity, Company management will assess the cash requirements of the Company and reinvest excess cash as it deems appropriate. The Company’s monthly required cash operating expenditures were approximately $361,000 and $381,000 during the three months ended September 30, 2015 and 2014, respectively, which represents a 5% improvement.

 

Management forecasts that fiscal year 2016 cash consumed in production operations will be similar to the prior fiscal year. Company management is early in the design process of the future facility and with the goal of constructing a facility that will have non-cash depreciation that is less than the current monthly rental cost of the current facility while providing long-term security for future of the Company. It is expected that the long-term production facility will be owned by the Company or a wholly-owned subsidiary of the Company.

 

Capital expenditures

 

·The Company has not required significant capital equipment investment despite many of the significant items of manufacturing equipment having reached or reaching their depreciable lives this fiscal year. Management believes less than $200,000 will be required to be invested in manufacturing or other capital equipment related to Company operations during fiscal year 2016, but there is no assurance that unanticipated needs for capital equipment or a yet to be determined capital project may not arise; and
·The Company has placed $25,000 in escrow on raw land as disclosed in financial statement footnote 8 Commitments and Contingencies under the section “Property Transaction between Medical and The Port of Benton”. An additional amount of less than $175,000 including closing costs and due diligence is expected to be spent in fiscal 2016 if the purchase of the real property closes. Future cash requirements related to construction of and moving into the new facility are difficult to project until designs, architectural drawings and contractor estimates of construction costs have been made, but management does not expect to spend more than $50,000 beyond the amounts needed to close the purchase prior to breaking ground on the new facility.

 

Management intends to continue its existing protocol studies and to begin new protocol studies on lung cancer treatment using Cesium-131. Management believes that approximately $150,000 in expense will be incurred during fiscal year 2016 in protocol expenses relating to lung cancer, inter-cranial cancer and both dual therapy and monotherapy prostate protocols, but there is no assurance that unanticipated needs for additional protocols in support of the development of new applications of our existing products may not arise.

 

Based on the foregoing assumptions, management believes that the cash and cash equivalents of approximately $1.72 million, short-term investments of $11.90 million and investments – other of $5.14 million at November 3, 2015 will be sufficient to meet our anticipated cash needs assuming both revenue and expenses remain at current levels for the next three years.

 

18 

 

 

Management plans to attempt to attain breakeven and generate additional cash flows by increasing revenues from both new and existing customers (through our direct sales channels and through our distributors), continuing to develop the sales of the GliaSite® RTS, and expanding into other market applications which include brain, head and neck, and lung implants, while maintaining the Company's focus on cost control. However, there can be no assurance that the Company will attain profitability or that the Company will be able to attain increases in its revenue. Total product sales have not shown the increases necessary to breakeven during the past seven fiscal years ended June 30, 2015 and for the quarter ended September 30, 2015.

 

For the three months ended September 30, 2015, revenue from other treatment modalities with both brachytherapy seeds and GliaSite® RTS has increased 44% when compared to the three months ended September 30, 2014. These newer brachytherapy product sales (including brain, lung and those reported as other) remain in the early stages of adoption and application in the clinical setting and their purchasing patterns are subject to the influence of a few key physicians who can significantly influence revenue from quarter to quarter. There were no sales of GliaSite® RTS in the three months ended September 30, 2015.

 

There was no material change in the use of proceeds from our public offering as described in our final prospectus supplement filed with the SEC pursuant to Rule 424(b) on March 24, 2014. Through September 30, 2015, the Company had used the net proceeds raised through the March 2014 offering as described in the table below and held the remaining net proceeds in cash and cash equivalents and certificates of deposit. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.

 

Offering description  Period  Net proceeds   Remaining net proceeds 
Registered direct offering  March 2014  $13,814,742   $13,814,742 

 

The Company expects to finance its future cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing shareholders Management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to shareholders.

 

Other Commitments and Contingencies

 

The Company presented its other commitments and contingencies in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015. There have been no material changes outside of the ordinary course of business in those obligations during the current quarter.

 

Off-Balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and on various other factors the Company believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results could therefore differ materially from those estimates if actual conditions differ from our assumptions.

 

19 

 

 

During the three months ended September 30, 2015, there have been no changes to the critical accounting policies and estimates, as discussed in Part II, Item 7 of our Form 10-K for the year ended June 30, 2015.

 

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

There have been no material changes to the disclosure in the “Quantitative and Qualitative Disclosures about Market Risk Factors” section of our Annual Report on Form 10-K for the year ended June 30, 2015.

 

ITEM 4 – CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-14(c) and 15d-14(c) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act), as of September 30, 2015. Based on that evaluation, our principal executive officer and our principal financial officer concluded that the design and operation of our disclosure controls and procedures were effective. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. However, management believes that our system of disclosure controls and procedures is designed to provide a reasonable level of assurance that the objectives of the system will be met.

 

Changes in Internal Control over Financial Reporting

 

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Inherent Limitations of Internal Control Over Financial Reporting

 

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

20 

 

 

PART II - OTHER INFORMATION

 

ITEM 1 – LEGAL PROCEEDINGS

 

On October 16, 2015, an amended class action complaint for violation of the federal securities laws was filed in U.S District Court for Eastern District of Washington against IsoRay, Inc. and our CEO/Chairman. This amends the complaint originally filed on May 22, 2015. The class includes purchasers of IsoRay, Inc. common stock from May 20, 2015 through and including May 21, 2015 and our CFO was dropped as a defendant. The complaint asserts that the purchasers were misled by a press release issued by the Company on May 20, 2015. The complaint seeks, among other things, damages and costs and expenses.  We cannot predict the outcome of such proceedings or an estimate of damages, if any. We believe that these claims are without merit and intend to defend them vigorously. The Company has until December 15, 2015 to respond to the complaint.

 

From time to time we are also involved in legal proceedings arising in the ordinary course of our business.

 

ITEM 1A – RISK FACTORS

 

A description of the risk factors associated with our business is included under “Risk Factors” contained in Part I, Item 1A of our Form 10-K for the year ended June 30, 2015, and is incorporated herein by reference. There have been no material changes in our risk factors since such filing.

 

21 

 

 

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM4 - MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5 – OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

Exhibits:

 

31.1*      Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
   
31.2* Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer
   
32** Section 1350 Certifications
   
101.INS* XBRL Instance Document
   
101.SCH*   XBRL Taxonomy Extension Schema Document
   
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

 

* Filed herewith.

** Furnished herewith.

 

22 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: November 9, 2015    
     
  ISORAY, INC., a Minnesota corporation
     
  By    /s/ Dwight Babcock
 

Dwight Babcock, Chief Executive Officer

(Principal Executive Officer)

 

  By   /s/ Brien Ragle
   

Brien Ragle, Chief Financial Officer

(Principal Financial and Accounting Officer)

 

23 

EX-31.1 2 v423416_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATION

 

I, Dwight Babcock certify that:

 

1.           I have reviewed this quarterly report on Form 10-Q of IsoRay, Inc.;

 

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.           The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.           The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 9, 2015

 

 

/s/ Dwight Babcock

  Dwight Babcock
  Chief Executive Officer
  (Principal Executive Officer)

 

 

EX-31.2 3 v423416_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

CERTIFICATION

 

I, Brien L. Ragle certify that:

 

1.            I have reviewed this quarterly report on Form 10-Q of IsoRay, Inc.;

 

2.            Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.            Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.            The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.           The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 9, 2015

 

  /s/ Brien L. Ragle
  Brien L. Ragle
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

EX-32 4 v423416_ex32.htm EXHIBIT 32

 

Exhibit 32

 

Section 1350 Certifications

 

Pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of IsoRay, Inc., a Minnesota corporation (the "Company"), hereby certify that:

 

To my knowledge, the Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2015 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: November 9, 2015

 

  /s/ Dwight Babcock
  DWIGHT BABCOCK
 

CHIEF EXECUTIVE OFFICER

(Principal Executive Officer)

 

Dated: November 9, 2015

 

  /s/ Brien Ragle
  BRIEN RAGLE
 

CHIEF FINANCIAL OFFICER

(Principal Financial and Accounting Officer)

 

 

EX-101.INS 5 isr-20150930.xml XBRL INSTANCE DOCUMENT 0000728387 2015-09-30 0000728387 us-gaap:SeriesAPreferredStockMember 2015-09-30 0000728387 us-gaap:SeriesBPreferredStockMember 2015-09-30 0000728387 us-gaap:SeriesCPreferredStockMember 2015-09-30 0000728387 us-gaap:SeriesDPreferredStockMember 2015-09-30 0000728387 2015-07-01 2015-09-30 0000728387 2014-07-01 2014-09-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2015-09-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0000728387 us-gaap:EquipmentMember 2015-09-30 0000728387 us-gaap:OfficeEquipmentMember 2015-09-30 0000728387 us-gaap:FurnitureAndFixturesMember 2015-09-30 0000728387 us-gaap:LeaseholdImprovementsMember 2015-09-30 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0000728387 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember 2015-07-01 2015-09-30 0000728387 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember 2014-07-01 2014-09-30 0000728387 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember 2015-07-01 2015-09-30 0000728387 us-gaap:SeriesBPreferredStockMember 2015-07-01 2015-09-30 0000728387 2014-09-30 0000728387 isr:DerivativeWarrantsMember 2015-09-30 0000728387 isr:RangeOfExercisePriceThreeMember 2015-09-30 0000728387 isr:RangeOfExercisePriceFourMember 2015-09-30 0000728387 isr:RangeOfExercisePriceFiveMember 2015-09-30 0000728387 isr:RangeOfExercisePriceSixMember 2015-09-30 0000728387 isr:RangeOfExercisePriceThreeMember 2015-07-01 2015-09-30 0000728387 isr:RangeOfExercisePriceFourMember 2015-07-01 2015-09-30 0000728387 isr:RangeOfExercisePriceFiveMember 2015-07-01 2015-09-30 0000728387 isr:RangeOfExercisePriceSixMember 2015-07-01 2015-09-30 0000728387 2015-06-30 0000728387 us-gaap:SeriesAPreferredStockMember 2015-06-30 0000728387 us-gaap:SeriesBPreferredStockMember 2015-06-30 0000728387 us-gaap:SeriesCPreferredStockMember 2015-06-30 0000728387 us-gaap:SeriesDPreferredStockMember 2015-06-30 0000728387 2014-06-30 0000728387 us-gaap:WarrantMember 2015-07-01 2015-09-30 0000728387 us-gaap:WarrantMember 2014-07-01 2014-09-30 0000728387 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0000728387 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0000728387 us-gaap:SeriesBPreferredStockMember 2015-07-01 2015-09-30 0000728387 us-gaap:SeriesBPreferredStockMember 2014-07-01 2014-09-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2015-06-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2015-06-30 0000728387 isr:MaturityLessThan90DaysMember 2015-09-30 0000728387 isr:Maturity90DaysTo6MonthsMember 2015-09-30 0000728387 isr:Maturity6MonthsTo1YearMember 2015-09-30 0000728387 isr:Maturity1YearTo3YearsMember 2015-09-30 0000728387 isr:DerivativeWarrantsMember 2015-06-30 0000728387 isr:DerivativeWarrantsMember 2014-06-30 0000728387 isr:DerivativeWarrantsMember 2015-07-01 2015-09-30 0000728387 us-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0000728387 us-gaap:CostOfSalesMember 2014-07-01 2014-09-30 0000728387 us-gaap:SellingAndMarketingExpenseMember 2015-07-01 2015-09-30 0000728387 us-gaap:SellingAndMarketingExpenseMember 2014-07-01 2014-09-30 0000728387 isr:MaturityLessThan90DaysMember 2015-06-30 0000728387 isr:Maturity90DaysTo6MonthsMember 2015-06-30 0000728387 isr:Maturity6MonthsTo1YearMember 2015-06-30 0000728387 isr:Maturity1YearTo3YearsMember 2015-06-30 0000728387 isr:EnrichedBariumInventoryMember 2015-09-30 0000728387 isr:EnrichedBariumInventoryMember 2015-06-30 0000728387 us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2015-09-30 0000728387 us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2015-06-30 0000728387 us-gaap:EquipmentMember 2015-06-30 0000728387 us-gaap:OfficeEquipmentMember 2015-06-30 0000728387 us-gaap:FurnitureAndFixturesMember 2015-06-30 0000728387 us-gaap:LeaseholdImprovementsMember 2015-06-30 0000728387 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2015-09-30 0000728387 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2015-06-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2015-06-30 0000728387 us-gaap:SeriesBPreferredStockMember 2014-07-01 2014-12-31 0000728387 us-gaap:SeriesBPreferredStockMember 2013-07-01 2013-12-31 0000728387 isr:DerivativeWarrantsMember 2014-07-01 2015-06-30 0000728387 2015-10-19 0000728387 us-gaap:ScenarioForecastMember 2015-07-01 2016-06-30 0000728387 isr:WarehouseSpaceMember us-gaap:CapitalAdditionsMember 2015-09-30 0000728387 isr:OfficeSpaceMember us-gaap:CapitalAdditionsMember 2015-09-30 0000728387 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember 2014-07-01 2015-06-30 0000728387 isr:PrimaryUseAgreementMember 2015-07-01 2015-09-30 0000728387 us-gaap:CapitalAdditionsMember 2015-07-01 2015-09-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure utr:acre utr:sqft isr:item 1587009 30000 30000 1130540 1049041 460557 403955 10406 263597 16325522 441890 574840 181262 181262 569854 569854 240403 245031 23003284 152465 124131 141500 129500 129540 96847 127515 931384 1092194 166000 947849 2221043 0.001 1000000 5000000 59065 59 1000000 0.001 55013553 54967559 55014 54968 13200 8390 8390 -61731507 20782241 21908898 23003284 59 1671 0 0 0 0 0 0 59 0 0 0 0.001 1000000 0.001 5000000 59065 0.001 59065 0.001 0.001 13200 0.001 0.001 54967559 0.001 143903 176610 278421 353743 751712 1174036 1106304 -1161106 57417 72695 15000 306000 3451 71467 -1019110 -785862 2658 -788520 -0.02 -0.01 55012901 54868053 1261322 1042101 1177863 1096903 83459 -54802 20725 7734 19644 32312 81499 37889 47742 -9209 -47824 -3048 46136 -87221 -65167 28334 14029 12000 12000 -30668 -4944 -1143186 3718 7453 16097 6055737 22355 28341 4645139 -2576894 46735 145275 215686 -3639731 -5604756 5226740 7680073 2075317 169970 3526999 1.94 P4Y4M24D 570238 1967880 1.96 P3Y6M18D 21654 17558 133564 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="width: 1724px;"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; width: 923px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0pt; margin-bottom: 0pt;"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font-style: normal;"><b>1.</b></font></td> <td><font style="font-style: normal;"><b>Basis of Presentation</b></font></td> </tr> </table> </div> <div style="width: 100%; margin: 0px;"> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries (IsoRay or the Company). All significant intercompany accounts and transactions have been eliminated in consolidation. Certain amounts in the prior-period financial statements have been reclassified to conform to the current-period presentation.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; background-color: white;"><font style="background-color: white;">In the opinion of management, the accompanying unaudited interim consolidated financial statements and notes to the interim consolidated financial statements contain all adjustments, consisting of normal recurring items, necessary to present fairly, in all material respects, the financial position of IsoRay, Inc. and its wholly-owned subsidiaries.&#160;&#160;These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company's annual report filed on Form 10-K for the year ended June 30, 2015.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; background-color: white;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; background-color: white;"><font style="background-color: white;">The results of operations for the periods presented may not be indicative of those which may be expected for a full year.&#160;&#160;The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission.&#160;&#160;Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; background-color: white;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; background-color: white;"><font style="background-color: white;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, the reported amounts of revenues and expenses during the reporting period, and the disclosures of contingent liabilities.&#160;&#160;Accordingly, ultimate results could differ materially from those estimates. The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2016 will be <font>0</font>%.</font></p> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; width: 923px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0pt; margin-bottom: 0pt;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0in;"></td> <td style="width: 0.5in; text-align: left;"><b>2.</b></td> <td style="text-align: justify;"><b>New Accounting Pronouncements</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif;">In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, "Revenue Recognition". The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; text-indent: 27.5pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">In July 2015, the FASB issued ASU No. 2015-11 &#150; Inventory. The guidance requires an entity's management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted.&#160; The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.</p> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; width: 923px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0pt; margin-bottom: 0pt;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0in;"></td> <td style="width: 0.5in; text-align: left;"><b>3.</b></td> <td style="text-align: justify;"><b>Certificates of deposit</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><font style="font-weight: normal;">&#160;</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">The Company has maintained all excess cash in certificates of deposit at certain banks in certificates of deposit and through the Certificate of Deposit Account Registry Service (CDARS), which is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 limit to be fully insured by the Federal Deposit Insurance Corporation (FDIC). The Company ensures that principal amounts of certificates of deposit are fully insured. There may from time to time be short periods following maturity that amounts held in the money market account at the CDARS host bank will exceed FDIC coverage. In cases where the period that uninsured amounts will be held beyond ten banking days, the funds will be transferred to the primary operating account of the Company's operating subsidiary, IsoRay Medical, Inc. (Medical), that incorporates a sweep function that keeps the funds FDIC insured during that time.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><font style="font-weight: normal;">&#160;</font></p> <div><br/></div> <div> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="14" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">As of September 30, 2015</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Under 90</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">91 days to</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Six months to</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Greater</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Days</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">six months</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">1 year</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">than 1 year</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 407px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">CDARS</font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 102px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>6,528,858</font></font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,362,454</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,135,116</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><font style="font-weight: normal;">&#160;</font></p> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="14" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">As of June 30, 2015</font></td> <td nowrap="nowrap" style="text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Under 90</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">91 days to</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Six months to</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Greater</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Days</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">six months</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">1 year</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">than 1 year</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 407px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">CDARS</font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 102px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>3,523,167</font></font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>500,064</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,339,343</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,106,775</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> </div> <div><br/></div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> </div> </div> 7972 3565 3117 2158 8206 21453 2364346 1.93 P4Y6M7D 591185 2267045 252308 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="display: block;"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; margin: 0pt; padding-right: 8px;">&#160;</td> <td colspan="6" nowrap="nowrap" style="text-align: center; border: none #000000; vertical-align: bottom; white-space: nowrap;">Three&#160;months<br/> ended September 30,</td> <td nowrap="nowrap" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; margin: 0pt; padding-right: 8px;">&#160;</td> <td colspan="2" nowrap="nowrap" style="border-bottom-width: 1pt !important; border-style: none none solid; font-family: 'times new roman'; border-color: #000000 !important; white-space: nowrap; margin: 0pt; vertical-align: bottom; text-align: center;">2015</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border: none #000000; display: none; vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border: none #000000; display: none; vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td> <td colspan="6" nowrap="nowrap" style="border-bottom-width: 1pt !important; border-style: none none solid; font-family: 'times new roman'; border-color: #000000 !important; white-space: nowrap; margin: 0pt; vertical-align: bottom; text-align: center;">2014</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border: none #000000; display: none; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td nowrap="nowrap" style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">Cost of product sales</td> <td align="left" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; padding-right: 8px; margin: 0px; vertical-align: bottom;">$</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">17,558</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="left" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; padding-right: 8px; margin: 0px; vertical-align: bottom;">$</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">7,972</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">Research and development expenses</td> <td style="text-align: right; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">3,565</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">3,117</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">Sales and marketing expenses</td> <td style="text-align: right; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">3,492</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">2,158</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">General and administrative expenses</td> <td style="border-bottom-width: 1pt !important; border-style: none none solid; text-align: right; font-family: 'times new roman'; border-color: #000000 !important; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="border-bottom-width: 1pt !important; border-style: none none solid; font-family: 'times new roman'; border-color: #000000 !important; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">7,697</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: bottom; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> <td style="font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="border-bottom-width: 1pt !important; border-style: none none solid; text-align: right; font-family: 'times new roman'; border-color: #000000 !important; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="border-bottom-width: 1pt !important; border-style: none none solid; font-family: 'times new roman'; border-color: #000000 !important; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">8,206</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: bottom; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">Total share-based compensation</td> <td align="left" style="border-top-style: none; border-right-style: none; border-left-style: none; font-family: 'times new roman'; white-space: nowrap; padding-right: 8px; margin: 0px; vertical-align: bottom; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: #000000 !important;">$</td> <td align="right" style="border-top-style: none; border-right-style: none; border-left-style: none; font-family: 'times new roman'; white-space: nowrap; margin: 0pt; vertical-align: bottom; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: #000000 !important;"><font><font style="margin: 0pt;">32,312</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: bottom; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> <td style="font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="left" style="border-top-style: none; border-right-style: none; border-left-style: none; font-family: 'times new roman'; white-space: nowrap; padding-right: 8px; margin: 0px; vertical-align: bottom; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: #000000 !important;">$</td> <td align="right" style="border-top-style: none; border-right-style: none; border-left-style: none; font-family: 'times new roman'; white-space: nowrap; margin: 0pt; vertical-align: bottom; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: #000000 !important;"><font><font style="margin: 0pt;">21,453</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: bottom; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> </table> </div> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;" width="100%"> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><br/></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><br/></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Weighted</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Weighted</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><br/></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Exercise</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Average</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;"><br/></font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Number of</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Price</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Contractual</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Intrinsic</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Options</font></td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">(Years)</font></td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Term</font></td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Value</font></td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Outstanding at September 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>2,364,346</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.93</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>4.52</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>591,185</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left-style: none; border-right-style: none; border-top-style: none; padding: 0px 5px; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Vested and expected to vest at September 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>2,267,045</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.94</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>4.40</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>570,238</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left-style: none; border-right-style: none; border-top-style: none; padding: 0px 5px; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Vested and exercisable at September 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1,967,880</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.96</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>3.55</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>583,083</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left-style: none; border-right-style: none; border-top-style: none; padding: 0px 5px; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> </table> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; width: 1887px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0pt; margin-bottom: 0pt;" width="100%"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in; text-align: left;"><b>10.</b></td> <td style="text-align: justify;"><b>Preferred Dividends</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">On December 17, 2014, the Board of Directors declared a dividend on the Series B Preferred Stock of all currently payable and accrued outstanding and cumulative dividends through December 31, 2014 in the amount of $<font>10,632</font>. The dividends outstanding and cumulative through December 31, 2014 of $<font>10,632</font> and through December 31, 2013 of $<font>10,632</font> were paid as of those dates.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">As of September 30, 2015, there were accrued but undeclared dividends on Series B Preferred Stock outstanding in the amount of $<font>7,974</font>.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> </div> </div> 385800 25000 2.00 360800 1.17 1.56 199437 0.94 25650 5000 0.98 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; width: 1887px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0pt; margin-bottom: 0pt;" width="100%"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0in;"></td> <td style="width: 0.5in; text-align: left;"><b>11.</b></td> <td style="text-align: justify;"><b>Shareholders' Equity</b></td> </tr> </table> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><i>Warrant derivative liability</i></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">Based on the guidance contained in ASC 815 &#147;Derivatives and Hedging&#148;, management has concluded that the warrants issued in the 2011 offering should be classified as a derivative liability and has recorded a liability at fair value.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">Change in fair value of the warrant derivative liability is as follows.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <div> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">Three months ended</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">Three months ended</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;">&#160;</td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;">September 30, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;">&#160;</td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;">September 30, 2014</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 1121px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">Change in fair value of warrant derivative liability:</td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">$</td> <td style="width: 238px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>(15,000</font></td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">)</td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">$</td> <td style="width: 238px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>(323,000</font></td> <td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">)</td> </tr> </table> </div> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">A summary of the change in fair value of derivative warrant liability is as follows for the fiscal years presented.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <div><br/></div> <div> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Quantity<sup>1</sup></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Amount</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 657px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">Balance at June 30, 2014</font></td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 204px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>238,696</font></font></td> <td style="width: 11px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 11px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 11px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 203px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>573,000</font></font></td> <td style="width: 11px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Change in fair value</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font> </font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;"><font style="font-size: 10pt;"><font>(374,605</font></font></font></td> <td style="text-align: left;"><font style="font-size: 10pt;">)</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt;"><font style="font-size: 10pt;">Warrants exercised</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>(13,209</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">)</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>(17,395</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">)</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">Balance at June 30, 2015</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>225,087</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>181,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt;"><font style="font-size: 10pt;">Change in fair value</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font> </font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>(15,000</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">)</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">Balance at September 30, 2015</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>225,087</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>166,000</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><sup>1</sup></p> <div>Quantity of warrants either issued or outstanding as of the date of valuation.</div> <p><br/></p> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><i>Warrants</i></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The following table summarizes all warrants outstanding as of the beginning of the fiscal year, all activity related to warrants issued, cancelled, exercised or expired during the period and weighted average prices for each category.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td nowrap="nowrap" style="display: none; font-family: 'Times New Roman';">&#160;</td> <td colspan="5" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Weighted average</td> <td nowrap="nowrap" style="display: none; font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">Warrants</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; display: none;">&#160;</td> <td colspan="5" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">exercise price</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; display: none;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td width="100%" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Outstanding as of June 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>385,800</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.22</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td width="100%" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Warrants expired</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 1pt solid !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 1pt solid !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(25,000</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid !important; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 1pt solid !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 1pt solid !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>2.00</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid !important; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td width="100%" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Outstanding as of September 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>360,800</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: #000000 2.80pt double !important; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.17</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: #000000 2.80pt double !important; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> </tr> </table> </div> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><em></em><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The following table summarizes additional information about the Company's common warrants outstanding as of September 30, 2015:</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-size: 10pt; widows: auto;">&#160;</font>&#160;</p> <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; border-collapse: collapse; width: 100%; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; text-align: center;"> <p style="margin: 0px;">Number of</p> <p style="margin: 0px;">Warrants</p> </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; text-align: center;">Exercise Prices</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"> <p style="margin: 0px; text-align: center;">Expiration</p> <p style="margin: 0px; text-align: center;">Date</p> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; padding-left: 5.4pt;"><font>130,713</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>1.56</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">May 2016</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; padding-left: 5.4pt;"><font>199,437</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>0.94</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">October 2016</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; padding-left: 5.4pt;"><font>25,650</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>0.94</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">December 2016</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-decoration: none; text-align: right; padding-left: 5.4pt; border-bottom-color: black !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important;"><font>5,000</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-decoration: none;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><br/></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>0.98</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">June 2017</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-decoration: none; text-align: right; padding-left: 5.4pt; border-bottom-color: black !important; border-bottom-width: 2.5pt !important; border-bottom-style: double !important;"><font>360,800</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-decoration: none;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><br/></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; padding: 0px;"><font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> </tr> </table> </div> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><i>&#160;</i></p> </div> 2016-05 2016-12 2017-06 Yes <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td nowrap="nowrap" style="display: none; font-family: 'Times New Roman';">&#160;</td> <td colspan="5" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Weighted average</td> <td nowrap="nowrap" style="display: none; font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">Warrants</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; display: none;">&#160;</td> <td colspan="5" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">exercise price</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; display: none;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td width="100%" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Outstanding as of June 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>385,800</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.22</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td width="100%" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Warrants expired</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 1pt solid !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 1pt solid !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(25,000</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid !important; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 1pt solid !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 1pt solid !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>2.00</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid !important; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td width="100%" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Outstanding as of September 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>360,800</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: #000000 2.80pt double !important; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.17</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: #000000 2.80pt double !important; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> </tr> </table> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; border-collapse: collapse; width: 100%; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; text-align: center;"> <p style="margin: 0px;">Number of</p> <p style="margin: 0px;">Warrants</p> </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; text-align: center;">Exercise Prices</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"> <p style="margin: 0px; text-align: center;">Expiration</p> <p style="margin: 0px; text-align: center;">Date</p> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; padding-left: 5.4pt;"><font>130,713</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>1.56</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">May 2016</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; padding-left: 5.4pt;"><font>199,437</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>0.94</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">October 2016</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; padding-left: 5.4pt;"><font>25,650</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>0.94</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">December 2016</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-decoration: none; text-align: right; padding-left: 5.4pt; border-bottom-color: black !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important;"><font>5,000</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-decoration: none;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><br/></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>0.98</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">June 2017</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-decoration: none; text-align: right; padding-left: 5.4pt; border-bottom-color: black !important; border-bottom-width: 2.5pt !important; border-bottom-style: double !important;"><font>360,800</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-decoration: none;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><br/></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; padding: 0px;"><font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">&#160;</td> </tr> </table> </div> 3000 3000 3000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font: 10pt times new roman, times, serif; margin-top: 0; margin-bottom: 0;"> <tr style="vertical-align: top; text-align: justify;"> <td width="24px" style="text-align: left; border: none; font-family: 'Times New Roman';"><strong>12.</strong></td> <td style="text-align: justify; padding-left: 0.25in; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none;"><strong>Related Party Transaction</strong></td> </tr> </table> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">During the three months ended September 30, 2015 and 2014, the Company continued to engage the services of APEX Data Systems, Inc., owned by Dwight Babcock, the Company's Chairman and Chief Executive Officer, to modify and maintain the Company's web interfaced data collection application to aggregate patient data in a controlled environment. The cost recorded during the three months ended September 30, 2015 and 2014 from APEX Data Systems, Inc. for the maintenance of the web interfaced data collection applications in combination with the updating of the Company website was&#160;$<font>3,000</font> and $<font>3,000</font>&#160;respectively. An additional&#160;$<font>3,000</font> was spent on the implementation of Customer Relationship Management (CRM) software in the three months ended September 30, 2015 and 2014.</p> </div> </div> 3000 0000728387 10-Q --06-30 Accelerated Filer 55013553 2016 Q1 false ISR 0.00 6528858 5135116 3523167 500064 5339343 5106775 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="14" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">As of September 30, 2015</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Under 90</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">91 days to</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Six months to</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Greater</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Days</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">six months</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">1 year</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">than 1 year</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 407px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">CDARS</font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 102px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>6,528,858</font></font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,362,454</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,135,116</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><font style="font-weight: normal;">&#160;</font></p> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="14" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">As of June 30, 2015</font></td> <td nowrap="nowrap" style="text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Under 90</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">91 days to</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Six months to</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">Greater</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Days</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">six months</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">1 year</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">than 1 year</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 407px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">CDARS</font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 102px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>3,523,167</font></font></td> <td style="width: 10px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>500,064</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,339,343</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,106,775</font></font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> </div> 59065 360800 396574 2364346 2180858 2784211 2636497 225087 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; width: 923px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0pt; margin-bottom: 0pt;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0in;"></td> <td style="width: 0.5in; text-align: left;"><b>4.</b></td> <td style="text-align: justify;"><b>Loss per Share</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">Basic and diluted earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents. At September 30, 2015 and 2014, the calculation of diluted weighted average shares did not include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company's net loss position.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of September 30, 2015 and 2014, were as follows:</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <div> <table cellpadding="0" cellspacing="0" align="center" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="6" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">September 30,</font></td> <td style="text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2014</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 548px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">Series B preferred stock</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>59,065</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>59,065</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Common stock warrants</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>360,800</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>396,574</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">Common stock options</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>2,364,346</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>2,180,858</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 2.5pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">Total potential dilutive securities</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>2,784,211</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>2,636,497</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <div style="display: none;"></div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" align="center" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="6" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">September 30,</font></td> <td style="text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2014</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 548px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">Series B preferred stock</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>59,065</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>59,065</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Common stock warrants</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>360,800</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>396,574</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">Common stock options</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>2,364,346</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>2,180,858</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 2.5pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">Total potential dilutive securities</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>2,784,211</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font>2,636,497</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> 264900 156759 38898 55526 469758 469758 100096 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" align="center" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">September 30,</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">June 30,</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 548px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Raw materials</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>264,900</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>143,669</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Work in process</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>156,759</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>204,760</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt;"><font style="font-size: 10pt;">Finished goods</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>38,898</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>55,526</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>460,557</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>403,955</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" align="center" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">September 30,</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">June 30,</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 548px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Enriched barium, non-current</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>469,758</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>469,758</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt;"><font style="font-size: 10pt;">Raw materials, non-current</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>100,096</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>100,096</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">Total inventory, non-current</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>569,854</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>569,854</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> 3180933 3180933 224576 148265 148265 4129977 7689676 7251504 7114836 136668 169970 166000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Quantity<sup>1</sup></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Amount</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 657px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">Balance at June 30, 2014</font></td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 204px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>238,696</font></font></td> <td style="width: 11px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 11px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 11px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 203px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>573,000</font></font></td> <td style="width: 11px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Change in fair value</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font> </font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;"><font style="font-size: 10pt;"><font>(374,605</font></font></font></td> <td style="text-align: left;"><font style="font-size: 10pt;">)</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt;"><font style="font-size: 10pt;">Warrants exercised</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>(13,209</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">)</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>(17,395</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">)</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">Balance at June 30, 2015</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>225,087</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>181,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt;"><font style="font-size: 10pt;">Change in fair value</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font> </font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>(15,000</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">)</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">Balance at September 30, 2015</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>225,087</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>166,000</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><sup>1</sup></p> <div>Quantity of warrants either issued or outstanding as of the date of valuation.</div> <p><br/></p> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">Three months ended</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">Three months ended</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;">&#160;</td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;">September 30, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;">&#160;</td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;">&#160;</td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;">September 30, 2014</td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 1121px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">Change in fair value of warrant derivative liability:</td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">$</td> <td style="width: 238px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>(15,000</font></td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">)</td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;">&#160;</td> <td style="width: 17px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">$</td> <td style="width: 238px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font>(323,000</font></td> <td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;">)</td> </tr> </table> </div> 59 1671 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; width: 100%; margin-left: 0.1px;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0in;"></td> <td style="width: 0.5in; text-align: left;"><b>6.</b></td> <td style="text-align: justify;"><b>Fixed Assets</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">September 30,</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">June 30,</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2015</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2015</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 1359px; font-size: 10pt; text-align: left;">Production equipment</td> <td style="width: 19px; font-size: 10pt;">&#160;</td> <td style="width: 19px; font-size: 10pt; text-align: left;">$</td> <td style="width: 208px; font-size: 10pt; text-align: right;"><font>3,180,933</font></td> <td style="width: 19px; font-size: 10pt; text-align: left;">&#160;</td> <td style="width: 19px; font-size: 10pt;">&#160;</td> <td style="width: 19px; font-size: 10pt; text-align: left;">$</td> <td style="width: 207px; font-size: 10pt; text-align: right;"><font>3,180,933</font></td> <td style="width: 18px; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left;">Office equipment</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>226,995</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>224,576</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left;">Furniture and fixtures</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>148,265</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>148,265</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left;">Leasehold improvements</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>4,129,977</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>4,129,977</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt;">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: right;"><font>7,224</font></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: right;"><font>-</font></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>7,718,394</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>7,689,676</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt;">Less accumulated depreciation</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: right;"><font>(7,251,504</font></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left;">)</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: right;"><font>(7,114,836</font></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt;">Fixed assets, net</td> <td style="font-size: 10pt; padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-size: 10pt; text-align: right;"><font>441,890</font></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-size: 10pt; text-align: right;"><font>574,840</font></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> </table> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">Depreciation expense related to property and equipment for the three months ended September 30, 2015 and 2014 was $<font>136,668</font> and $<font>169,970</font>, respectively.</p> <p><br/></p> </div> 0.01 1587009 166000 166000 5226740 181000 181000 192998329 82546112 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; width: 100%; margin-left: 0.1px;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in; text-align: left;"><b>9.</b></td> <td style="text-align: justify;"><b>Fair Value Measurements</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The table below sets forth the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015 and June 30, 2015, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category.&#160;&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: center;">&#160;&#160;<br/></p> <div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Fair value at September 30, 2015</b></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: center;"><b>&#160;</b></p> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Total</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 1</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 2</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 3</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 831px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Cash and cash equivalents</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>1,587,009</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>1,587,009</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 207px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Warrant derivative liability</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>166,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>166,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: center;"><b>&#160;</b></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Fair value at June 30, 2015</b></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: center;"><b>&#160;</b></p> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Total</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 1</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 2</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 3</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 831px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Cash and cash equivalents</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,226,740</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,226,740</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 207px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Warrant derivative liability</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>181,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>181,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Fair value at September 30, 2015</b></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: center;"><b>&#160;</b></p> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Total</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 1</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 2</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 3</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 831px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Cash and cash equivalents</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>1,587,009</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>1,587,009</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 207px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Warrant derivative liability</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>166,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>166,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: center;"><b>&#160;</b></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Fair value at June 30, 2015</b></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: center;"><b>&#160;</b></p> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Total</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 1</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 2</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">Level 3</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 831px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Cash and cash equivalents</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,226,740</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>5,226,740</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 208px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 19px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 207px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="width: 18px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Warrant derivative liability</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>181,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>181,000</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> 10632 10632 573000 13209 17395 225087 181000 15000 0.30 0.27 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; width: 100%; margin-left: 0.1px;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in; text-align: left;"><b>13.</b></td> <td style="text-align: justify;"><b>Concentrations of Credit and Other Risks</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-weight: normal;">&#160;</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-weight: normal;">The Company's cash, cash equivalents and investments are deposited with several financial institutions with FDIC coverage. At times, deposits for a limited period of time in these institutions may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-weight: normal;">&#160;</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-weight: normal;">For the three months ended September 30, 2015 and 2014, there were <font>two</font> and <font>one</font> customers that each represented 10% or more of total net revenue, respectively.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-weight: normal;">&#160;</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-weight: normal;">At September 30, 2015, two customers each accounted for 10% of the Company's total accounts receivable with <font>a</font> single customer (a group of seven legal entities) that represents <font>30</font>% of total accounts receivable. At June 30, 2014, <font>one</font> customer (a group of seven legal entities) accounted for <font>27</font>% of total accounts receivable.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; text-indent: 0.5in;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-weight: normal;">Accounts receivable are typically not collateralized. The Company maintains ongoing dialogue with its customers about invoice payments. Some of our customers are small outpatient surgery centers that pay invoices for our products at the time they receive a decision regarding payment by the insurer providing benefits which in the case of prostate cancer is predominately Medicare. A qualitative review of outstanding customer balances is performed at least quarterly and the allowance for doubtful accounts is adjusted based on historical performance of the customer and management knowledge regarding specific invoices. Accounts are charged against the allowance for doubtful accounts once collection efforts are deemed unsuccessful.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-weight: normal;">Single source suppliers presently provide the Company with several components. Management believes that it would be able to locate other sources for these components subject to any regulatory qualifications, if required.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-size: 10pt;">&#160;</font><br/></p> </div> 4.2 168000 P10Y 12000 P2Y 25 2 1 1 11891312 9362574 19615 260549 15340373 5135116 5106775 21908898 411032 498253 212795 181000 969336 2066720 7001671 82467111 -62750617 19842178 192998329 0 0 0 59065 0.001 55013553 1000000 7001671 0.001 575951 -1090577 950 375244 2658 -1021768 21487 21453 56602 -83255 -130779 -1109572 2296 13 -4677256 70411 46735 11321 17000 136668 100096 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; width: 923px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0pt; margin-bottom: 0pt;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0in;"></td> <td style="width: 0.5in; text-align: left;"><b>5.</b></td> <td style="text-align: justify;"><b>Inventory</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">Inventory consisted of the following at September 30, 2015 and June 30, 2015:</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <div> <div> <table cellpadding="0" cellspacing="0" align="center" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">September 30,</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">June 30,</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 548px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Raw materials</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>264,900</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>143,669</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Work in process</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>156,759</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>204,760</font></font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt;"><font style="font-size: 10pt;">Finished goods</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>38,898</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>55,526</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>460,557</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>403,955</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font>&#160;</font></p> <div> <div> <table cellpadding="0" cellspacing="0" align="center" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; border-collapse: collapse; margin-left: 0.1px;" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">September 30,</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">June 30,</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center;"><font style="font-size: 10pt;">2015</font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 548px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">Enriched barium, non-current</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 9px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>469,758</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="width: 116px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>469,758</font></font></td> <td style="width: 8px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 1pt;"><font style="font-size: 10pt;">Raw materials, non-current</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>100,096</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 1pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>100,096</font></font></td> <td style="padding-bottom: 1pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: right;"><font style="font-size: 10pt;">&#160;</font></td> <td style="text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">Total inventory, non-current</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>569,854</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; padding-bottom: 2.5pt;"><font style="font-size: 10pt;">&#160;</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">$</font></td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: right;"><font style="font-size: 10pt;"><font>569,854</font></font></td> <td style="padding-bottom: 2.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; text-align: left;"><font style="font-size: 10pt;">&#160;</font></td> </tr> </table> </div> </div> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">Inventory, non-current is (i) raw materials that were ordered in quantities to obtain volume cost discounts for key components of our brachytherapy seed including titanium lids, titanium tubes, gold wires that are used for imaging markers, and our proprietary seed core, which were ordered based on current and anticipated sales volumes and will not be consumed within an operating cycle, and (ii) enriched barium, which is classified as non-current, and is only expected to be utilized if required to obtain volumes of isotope that is not able to be purchased from an existing source in either the short- or long-term. Management does not anticipate the need to utilize the enriched barium within the current operating cycle unless there is an unanticipated interruption to the isotope supply that requires its use. If such a need were to occur, then management would evaluate the need to reclassify some or all of the inventory as a current asset.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: left;"><br/></p> </div> 3492 7697 32312 381596 P1Y6M22D 583083 45994 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font: 10pt times new roman, times, serif; margin-top: 0; margin-bottom: 0;"> <tr style="vertical-align: top; text-align: justify;"> <td width="24px" style="text-align: left; border: none; font-family: 'Times New Roman';"><strong>7.</strong></td> <td style="text-align: justify; padding-left: 0.25in; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none;"><strong>Share-Based Compensation</strong></td> </tr> </table> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The following table presents the share-based compensation expense recognized during the three months ended September 30, 2015 and 2014:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <div class="CursorPointer"> <div> <div style="display: block;"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; margin: 0pt; padding-right: 8px;">&#160;</td> <td colspan="6" nowrap="nowrap" style="text-align: center; border: none #000000; vertical-align: bottom; white-space: nowrap;">Three&#160;months<br/> ended September 30,</td> <td nowrap="nowrap" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; margin: 0pt; padding-right: 8px;">&#160;</td> <td colspan="2" nowrap="nowrap" style="border-bottom-width: 1pt !important; border-style: none none solid; font-family: 'times new roman'; border-color: #000000 !important; white-space: nowrap; margin: 0pt; vertical-align: bottom; text-align: center;">2015</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border: none #000000; display: none; vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border: none #000000; display: none; vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td> <td colspan="6" nowrap="nowrap" style="border-bottom-width: 1pt !important; border-style: none none solid; font-family: 'times new roman'; border-color: #000000 !important; white-space: nowrap; margin: 0pt; vertical-align: bottom; text-align: center;">2014</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border: none #000000; display: none; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td nowrap="nowrap" style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">Cost of product sales</td> <td align="left" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; padding-right: 8px; margin: 0px; vertical-align: bottom;">$</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">17,558</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="left" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; padding-right: 8px; margin: 0px; vertical-align: bottom;">$</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">7,972</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">Research and development expenses</td> <td style="text-align: right; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">3,565</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">3,117</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">Sales and marketing expenses</td> <td style="text-align: right; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">3,492</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="font-family: 'times new roman'; border: none #000000; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">2,158</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">General and administrative expenses</td> <td style="border-bottom-width: 1pt !important; border-style: none none solid; text-align: right; font-family: 'times new roman'; border-color: #000000 !important; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="border-bottom-width: 1pt !important; border-style: none none solid; font-family: 'times new roman'; border-color: #000000 !important; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">7,697</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: bottom; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> <td style="font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td style="border-bottom-width: 1pt !important; border-style: none none solid; text-align: right; font-family: 'times new roman'; border-color: #000000 !important; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="right" style="border-bottom-width: 1pt !important; border-style: none none solid; font-family: 'times new roman'; border-color: #000000 !important; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><font><font style="margin: 0pt;">8,206</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: bottom; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: justify; font-family: 'times new roman'; border: none #000000; vertical-align: bottom;">Total share-based compensation</td> <td align="left" style="border-top-style: none; border-right-style: none; border-left-style: none; font-family: 'times new roman'; white-space: nowrap; padding-right: 8px; margin: 0px; vertical-align: bottom; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: #000000 !important;">$</td> <td align="right" style="border-top-style: none; border-right-style: none; border-left-style: none; font-family: 'times new roman'; white-space: nowrap; margin: 0pt; vertical-align: bottom; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: #000000 !important;"><font><font style="margin: 0pt;">32,312</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: bottom; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> <td style="font-family: 'times new roman'; border: none #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td> <td align="left" style="border-top-style: none; border-right-style: none; border-left-style: none; font-family: 'times new roman'; white-space: nowrap; padding-right: 8px; margin: 0px; vertical-align: bottom; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: #000000 !important;">$</td> <td align="right" style="border-top-style: none; border-right-style: none; border-left-style: none; font-family: 'times new roman'; white-space: nowrap; margin: 0pt; vertical-align: bottom; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: #000000 !important;"><font><font style="margin: 0pt;">21,453</font></font></td> <td style="text-align: left; font-family: 'times new roman'; border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: bottom; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> </table> </div> </div> </div> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">As of September 30, 2015, total unrecognized compensation expense related to stock-based options was $<font>381,596</font>&#160;and the related weighted-average period over which it is expected to be recognized is approximately <font>1.56</font> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">A summary of stock options within the Company's share-based compensation plans as of September 30, 2015 was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <div class="CursorPointer"> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;" width="100%"> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><br/></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><br/></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Weighted</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Weighted</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><br/></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Exercise</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Average</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;"><br/></font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Number of</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Price</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Contractual</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Intrinsic</font></td> <td nowrap="nowrap" style="font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Options</font></td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">(Years)</font></td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Term</font></td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;"><font style="font-size: 10pt;">Value</font></td> <td nowrap="nowrap" style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> <td colspan="2" nowrap="nowrap" style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; vertical-align: top;">&#160;</td> <td nowrap="nowrap" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Outstanding at September 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>2,364,346</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.93</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>4.52</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>591,185</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left-style: none; border-right-style: none; border-top-style: none; padding: 0px 5px; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Vested and expected to vest at September 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>2,267,045</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.94</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>4.40</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>570,238</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left-style: none; border-right-style: none; border-top-style: none; padding: 0px 5px; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">Vested and exercisable at September 30, 2015</td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1,967,880</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>1.96</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>3.55</font></td> <td style="font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000 !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: left; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="border-bottom: #000000 2.80pt double !important; text-align: right; font-family: 'times new roman'; border-left: none; border-right: none; border-top: none; border-color: #000000 !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>583,083</font></td> <td style="text-align: left; font-family: 'times new roman'; border-left-style: none; border-right-style: none; border-top-style: none; padding: 0px 5px; white-space: nowrap; border-top-color: #000000 !important; border-right-color: #000000 !important; border-left-color: #000000 !important;">&#160;</td> </tr> </table> </div> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">There were <font>45,994</font>&#160;options exercised during the three months ended September 30, 2015 and <font>133,564</font>&#160;options exercised during the three months ended September 30, 2014. The Company's current policy is to issue new shares to satisfy option exercises. The intrinsic value of the employee options exercised in the three months ended September 30, 2015 and 2014 was&#160;$<font>21,654</font>&#160;and&#160;$<font>252,308</font>,&#160;respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">There were <font>no</font>&#160;stock option awards granted during the three&#160;months ended September 30, 2015 and 2014, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;<br/></p> </div> 4000 1 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; width: 1887px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0pt; margin-bottom: 0pt;" width="100%"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in; text-align: left;"><b>8.</b></td> <td style="text-align: justify;"><b>Commitments and Contingencies</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><u>Patent and Know-How Royalty License Agreement</u></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The Company is the holder of an exclusive license to use certain &#147;know-how&#148; developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor's patent application was ultimately abandoned, only a <font>1</font>% &#147;know-how&#148; royalty based on Net Factory Sales Price, as defined in the agreement, remains applicable. To date, management believes that there have been no product sales incorporating the &#147;know-how&#148; and therefore no royalty is due pursuant to the terms of the agreement. Management believes that ultimately no royalties should be paid under this agreement as there is no intent to use this &#147;know-how&#148; in the future.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The licensor of the &#147;know-how&#148; has disputed management's contention that it is not using this &#147;know-how&#148;. On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><u>Class Action Lawsuit Related to Press Release</u></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; text-indent: 0.5in;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">On May 22, 2015, a class action complaint for violation of the federal securities laws was filed in U.S. District Court against IsoRay, Inc., our CEO/Chairman and our CFO.&#160;&#160;The complaint related to a press release issued by the Company on May 20, 2015 and is purportedly brought on behalf of all purchasers of IsoRay, Inc. common stock from May 20, 2015 through and including May 21, 2015.&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; text-indent: 0.5in;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">On October 16, 2015, an amended class action complaint for violation of the federal securities laws was filed in U.S District Court for Eastern District of Washington against IsoRay, Inc. and our CEO/Chairman. The class period remains unchanged at 27 hours and our CFO was dropped as a defendant. The Company has until December 15, 2015 to respond to the amended complaint.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">The complaint, as amended, asserts that the purchasers were misled by the press release, and seeks, among other things, damages and costs and expenses.&#160;&#160;We cannot predict the outcome of such proceedings or an estimate of damages, if any. We believe that these claims are without merit and intend to defend them vigorously.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><u>Property Transaction between Medical and The Port of Benton</u></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><i>Initial Property Transaction</i></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-size: 10pt;">&#160;</font><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">On September 10, 2015, the Company's operating subsidiary, Medical, entered into a Real Estate Purchase and Sale Agreement with The Port of Benton, a municipal corporation of the State of Washington. The Agreement is for the sale of undeveloped real property of approximately <font>4.2</font> acres located adjacent to the Company's existing manufacturing facility and corporate offices. The purchase price for the property is One Hundred Sixty-Eight Thousand Dollars ($<font>168,000</font>) which is payable on October 30, 2015, the original expected date of closing prior to the First Addendum/Amendment.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">In addition to the feasibility studies required on all aspects of the property required by Medical to close, Medical is also bound to comply with a Development Plan for a <font>ten</font> year period which requirements include but are not limited to the following:</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">(1) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain specified site configurations and design with a minimum of <font>12,000</font> square feet of warehouse and production space and <font>4,000</font> square feet of office space;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">(2) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Completion of all construction in <font>two</font> years;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">(3) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Use of facility as primary production facility for ten (<font>10</font>) years; and</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">(4) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Provision of jobs for not less than <font>25</font> full time employees.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">Failure to comply with these covenants will result in a breach of the Agreement and if not cured, will obligate Medical to pay the Port the difference in the sales price and the appraised value of the property at the time of default.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><i>First Addendum / Amendment to Property Transaction</i></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">On October 15, 2015, the Company's operating subsidiary, Medical, entered into a First Addendum / Amendment to Real Estate Purchase &amp; Sale Agreement to the Real Estate Purchase and Sale Agreement with The Port of Benton, a municipal corporation of the State of Washington, that was entered into on September 10, 2015.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">This addendum modified the following:</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">(1) Extended the feasibility contingency from a period of sixty (60) days to one hundred and twenty (120) days to expire on or before January 8, 2016 with no further extensions.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">(2) Extended the closing of sale to on or before February 5, 2016.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">All other terms and conditions of said Real Estate Purchase &amp; Sale Agreement dated September 10, 2015 remained the same and continue in full force and effect.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><font style="font-size: 10pt;">&#160;</font><br/></p> </div> </div> 1.22 130713 0.94 2016-10 2015-09-30 IsoRay, Inc. 5362454 59065 143669 204760 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; width: 100%; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; border-collapse: collapse; margin-left: 0.1px;"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">September 30,</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">June 30,</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2015</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2015</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 1359px; font-size: 10pt; text-align: left;">Production equipment</td> <td style="width: 19px; font-size: 10pt;">&#160;</td> <td style="width: 19px; font-size: 10pt; text-align: left;">$</td> <td style="width: 208px; font-size: 10pt; text-align: right;"><font>3,180,933</font></td> <td style="width: 19px; font-size: 10pt; text-align: left;">&#160;</td> <td style="width: 19px; font-size: 10pt;">&#160;</td> <td style="width: 19px; font-size: 10pt; text-align: left;">$</td> <td style="width: 207px; font-size: 10pt; text-align: right;"><font>3,180,933</font></td> <td style="width: 18px; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left;">Office equipment</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>226,995</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>224,576</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left;">Furniture and fixtures</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>148,265</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>148,265</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left;">Leasehold improvements</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>4,129,977</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>4,129,977</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt;">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: right;"><font>7,224</font></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: right;"><font>-</font></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>7,718,394</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;"><font>7,689,676</font></td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt;">Less accumulated depreciation</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: right;"><font>(7,251,504</font></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left;">)</td> <td style="font-size: 10pt; padding-bottom: 1pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; font-size: 10pt; text-align: right;"><font>(7,114,836</font></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt;">Fixed assets, net</td> <td style="font-size: 10pt; padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-size: 10pt; text-align: right;"><font>441,890</font></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; font-size: 10pt; text-align: right;"><font>574,840</font></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> </table> </div> 226995 4129977 7224 7718394 1587009 5226740 7974 238696 374605 Quantity of warrants either issued or outstanding as of the date of valuation. EX-101.SCH 6 isr-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 004 - Statement - Consolidated Statement of Operations link:presentationLink link:calculationLink link:definitionLink 005 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 102 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 106 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 108 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 112 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 109 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 113 - Disclosure - Related Party Transaction link:presentationLink link:calculationLink link:definitionLink 306 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 308 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 312 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Share-Based Compensation (Schedule of Share-Based Compensation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Share-Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Shareholders' Equity (Schedule of Derivative Warrant Liability) (Details) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - Shareholders' Equity (Schedule of Warrant Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Commitments and Contingencies (Royalty Agreements) (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Commitments and Contingencies (Operating Lease Agreements) (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Related Party Transaction (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 104 - Disclosure - Loss per Share link:presentationLink link:calculationLink link:definitionLink 304 - Disclosure - Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 110 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 310 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 111 - Disclosure - Preferred Dividends link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Preferred Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Share-Based Compensation (Schedule of Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 103 - Disclosure - Certificates of deposit link:presentationLink link:calculationLink link:definitionLink 303 - Disclosure - Certificates of deposit (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Certificates of deposit (Details) link:presentationLink link:calculationLink link:definitionLink 41205 - Disclosure - Shareholders' Equity (Additional Information about Warrants) (Details) link:presentationLink link:calculationLink link:definitionLink 105 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 305 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 107 - Disclosure - Fixed Assets link:presentationLink link:calculationLink link:definitionLink 307 - Disclosure - Fixed Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Fixed Assets (Details) link:presentationLink link:calculationLink link:definitionLink 114 - Disclosure - Concentrations of Credit and Other Risks link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Concentrations of Credit and Other Risks (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 isr-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 isr-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 isr-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amended Supply Contract [Member] Amended Supply Contract [Member] Class C Warrants [Member] Class C Warrants [Member] Class Of Warrant Or Right, Corrected. Class Of Warrant Or Right Corrected Warrants corrected Correction to warrants Class Of Warrant Or Right, Corrected In Period, Exercise Price Of Warrants Or Rights. Class Of Warrant Or Right Corrected In Period Exercise Price Of Warrants Or Rights Correction to warrants Class of Warrant or Right, Expired in Period Class Of Warrant Or Right Expired In Period Warrants expired Warrants redeemed in cashless exercise Class of Warrant or Right Expired In Period, Weighted Average Exercise Price of Warrants or Rights Class Of Warrant Or Right Expired In Period Weighted Average Exercise Price Of Warrants Or Rights Warrants expired Class of Warrant or Right, Grants in Period Class Of Warrant Or Right Grants In Period Granted Class of Warrant or Right Grants In Period, Weighted Average Exercise Price of Warrants or Rights Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price Of Warrants Or Rights Granted Class of Warrant or Right Issued In Period, Weighted Average Exercise Price of Warrants or Rights Class Of Warrant Or Right Issued In Period Exercise Price Of Warrants Or Rights Warrants exercised Amendment Flag Class Of Warrant Or Right Outstanding [Abstract] Warrants Class Of Warrant Or Right Weighted Average Exercise Price [Abstract] Price CPI Commitment Cpi CPI on date of modification Common Stock Purchaser Warrants [Member] Common Stock Purchaser Warrants [Member] Common Unit Warrants [Member] Common Unit Warrants [Member] Derivative Warrants [Member] Derivative Warrants [Member] Director Plan [Member] Director Plan [Member] Document and Entity Information [Abstract]. Document and Entity Information [Abstract] 2014 Employee Plan [Member] Employee Plan 2014 [Member] 2014 Employee Plan [Member] Current Fiscal Year End Date Employee Plan [Member] Employee Plan [Member] 2005 Employee Plan [Member] GliaSite Radiation Therapy System (Iotrex) [Member] GliaSite Radiation Therapy System (Iotrex) [Member] GliaSite Radiation Therapy System [Member] GliaSite Radiation Therapy System [Member] Hologic, Inc. Intellectual Property [Member] Hologic, Inc. Intellectual Property [Member] Initial Supply Contract [Member] Initial Supply Contract [Member] Area of Land Area of land Area of Real Estate Property Area of property Issuance of Common Stock in Connection with Warrant Exercises, Net of Issuance Costs, Shares Issuance Of Common Stock In Connection With Warrant Exercises Net Of Issuance Costs Shares Warrants exercised Warrants exercised Document Period End Date Maturity 1 Year To 3 Years [Member] Maturity 1 Year To 3 Years [Member] Greater than 1 Year [Member] Maturity 6 Months To 1 Year [Member] Maturity 6 Months To 1 Year [Member] Six Months to 1 Year [Member] Maturity 90 Days To 6 Months [Member] Maturity 90 Days To 6 Months [Member] 91 Days to Six Months [Member] Maturity Less Than 90 Days [Member] Maturity Less Than 90 Days [Member] Under 90 Days [Member] Noncash Investing And Financing Item, Deemed Preferred Stock Dividend. Noncash Investing And Financing Item Deemed Preferred Stock Dividend Preferred stock deemed dividends (Note 11) Preferred stock deemed dividends (Note 10) Total non-cash investing and financing activities, has no balance type for calculation purposes. Noncash Investing And Financing Items Total non-cash investing and financing activities Total non-cash investing and financing activities Officers and Key Employees [Member] Officers and Key Employees [Member] Option Plan [Member] Option Plan [Member] Over Allotment Warrants [Member] Over Allotment Warrants [Member] Patent Rights, Knowhow and License Agreements. Patent Rights Knowhow And License Agreements [Member] Patent Rights Know-how and License Agreements [Member] Percentage of Royalty Rate Payable. Percentage Of Royalty Rate Payable Percentage of royalty payment Preferred Unit Warrants [Member] Preferred Unit Warrants [Member] Property, Plant And Equipment, Capitalization Threshold. Property Plant And Equipment Capitalization Threshold Capitalization threshold Provision for (Reduction of) Doubtful Accounts. Provision For Reduction Of Doubtful Accounts Allowance for doubtful accounts Qualified Therapeutic Discovery Project Grant [Member] Qualified Therapeutic Discovery Project Grant [Member] Qualified Therapeutic Discovery Project Grant [Member] Range of Exercise Price Five [Member] Range of Exercise Price Five [Member] Range of Exercise Price Four [Member] Range of Exercise Price Four [Member] Range of Exercise Price One [Member] Range of Exercise Price One [Member] Range of Exercise Price Seven [Member] Range of Exercise Price Seven [Member] Range of Exercise Price Six [Member] Range of Exercise Price Six [Member] Range of Exercise Price Three [Member] Range of Exercise Price Three [Member] Range of Exercise Price Two [Member] Range of Exercise Price Two [Member] Royalty Agreement for Invention and Patent Application Royalty Agreement for Invention and Patent Application [Member] Royalty Agreement for Invention and Patent Application, Sub-Assignments [Member] Royalty Agreement for Invention and Patent Application, Sub-Assignments [Member] Tabular disclosure of proceeds from stock offerings. Schedule Of Proceeds From Common Stock Offering [Table Text Block] Schedule of Proceeds from Stock Offering Schedule of Stockholders Equity Note, Warrants or Rights, by Exercise Price Range [Table Text Block] Schedule Of Stockholders Equity Note Warrants Or Rights By Exercise Price Range [Table Text Block] Schedule of Additional Information about Warrants Outstanding Share Based Compensation Arrangement By Share Based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract] Weighted Average Remaining Contractual Term Trading Symbol Share Based Compensation Arrangement By Share Based Payment Award Optons Outstanding Aggregate Intrinsic Value [Abstract] Average Intrinsic Value Supplemental Common Stock Warrant Liability. Supplemental Common Stock Warrant Liability Reclassification Reclassification of warrant derivative liability to equity upon exercise Reclassification of derivative warrant liability to equity upon exercise Warrants And Rights Cancelled. Warrants And Rights Cancelled Warrants redeemed in cashless exercise Warrants And Rights, Corrected. Warrants And Rights Corrected Warrants corrected Warrants And Rights, Exercised. Warrants And Rights Exercised Warrants exercised Warrants Expiration, Month And Year. Warrants Expiration Month And Year Expiration Date Warrants Issued in 2011 [Member] Warrants Issued in 2011 [Member] Warrants Issued in 2011, Two [Member] Warrants Issued in 2011, Two [Member] Warrants Issued in 2013 [Member] Warrants Issued in 2013 [Member] Warrants Issued in November 2010 [Member] Warrants Issued in November 2010 [Member] Entity Well-known Seasoned Issuer Entity Voluntary Filers Warrants Value [Abstract] Value of warrants issued: Entity Current Reporting Status Entity Filer Category Enriched Barium Inventory [Member] Enriched Barium Inventory [Member] Entity Public Float Customer A [Member] Customer A [Member] El Camino, Los Gatos, & Other Facilities [Member] Entity Registrant Name Customer B [Member] Customer B [Member] Bon Secours DePaul and Maryview Medical Center [Member] Entity Central Index Key Primary Use Agreement [Member] Primary Use Agreement [Member] Term of the unrecognized unconditional purchase obligation, in ''PnYnMnDTnHnMnS'' format, for example, ''P1Y5M13D'' represents the reported fact of one year, five months, and thirteen days. Unrecorded Unconditional Purchase Obligation, Term Term of agreement Warehouse Space [Member] Warehouse Space [Member] Office Space [Member] Office Space [Member] Entity Common Stock, Shares Outstanding Number Of Employees, Commitment. Number Of Employees, Commitment Number of full-time employees, commitment Number Of Customers. Number Of Customers Number of customers Document Fiscal Year Focus Document Fiscal Period Focus Document Type Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Accounts Receivable [Member] Accounts Receivable, Net, Current Accounts receivable, net of allowance for doubtful accounts of $30,000 and $30,000, respectively United States [Member] Accrued Vacation, Current Accrued vacation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Amortization Amortization of other assets Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used by operating activities: Affiliated Entity [Member] Allocated Share-based Compensation Expense Share-based compensation Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Income (Loss) Per Common Share Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential dilutive securities Asset Retirement Obligation, Accretion Expense Accretion of asset retirement obligation Accretion of discount Asset Retirement Obligations, Noncurrent Asset retirement obligation Assets [Abstract] ASSETS Assets Total assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Capital Addition Purchase Commitments [Member] Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, END OF PERIOD Cash and cash equivalents, beginning of period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Cash, Uninsured Amount Cash balances uninsured by the FDIC Certificates of Deposit [Member] Class of Warrant or Right, Exercise Price of Warrants or Rights Ending balance outstanding Beginning balance outstanding Range of Exercise Prices Warrants issued, exercise price Class of Stock [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Axis] Class of Warrant or Right [Line Items] Class of Stock [Domain] Class of Warrant or Right, Outstanding Balance, end of period Balance, beginning of period Number of Warrants Class of Warrant or Right [Table] Commitments and Contingencies Commitments and contingencies (Note 8) Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies [Abstract] Common Stock, Value, Issued Common stock, $.001 par value; 192,998,329 shares authorized; 55,013,553 and 54,967,559 shares issued and outstanding Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Par or Stated Value Per Share Common stock, par value per share Common Stock [Member] Common Stock, Shares, Outstanding Common stock, shares outstanding Concentration Risk Type [Domain] Concentration Risk Type [Axis] Concentration Risk [Line Items] Concentrations of credit risk Concentration Risk Benchmark [Domain] Concentration Risk [Table] Concentration Risk Disclosure [Text Block] Concentrations of Credit and Other Risks Concentration Risk, Percentage Concentration risk, percentage Concentration Risk Benchmark [Axis] Construction in Progress [Member] Conversion of Stock, Amount Converted Reclassification of convertible preferred stock to common stock upon conversion Cost of Property Repairs and Maintenance Maintenance costs Cost-method Investments, Description [Text Block] Certificates of deposit Cost of Goods Sold Cost of product sales Cost of Sales [Member] Cost of Product Sales [Member] Credit Concentration Risk [Member] Customer Concentration Risk [Member] Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued Fair value of stock options granted Depreciation, Depletion and Amortization, Nonproduction Depreciation of fixed assets Depreciation Depreciation and amortization expense Derivative Financial Instruments, Liabilities [Member] Derivative Liability Warrant derivative liability Derivative Liabilities, Noncurrent Warrant derivative liability Description of New Accounting Pronouncements Not yet Adopted [Text Block] New Accounting Pronouncements Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-Based Compensation Share-Based Compensation [Abstract] Dividends Payable [Table] Dividends Payable [Line Items] Due to Related Parties, Current Amount accrued for payment Earliest Tax Year [Member] Earnings Per Share, Basic and Diluted Basic and diluted loss per share Earnings Per Share [Text Block] Loss per Share Loss per Share [Abstract] Effective Income Tax Rate Reconciliation, Percent Anticipated effective income tax rate Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Common Stock Options [Member] Stock Options [Member] Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation expense related to stock-based options and awards, weighted-average recognition period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation expense related to stock-based options and awards Employee-related Liabilities, Current Accrued payroll and related taxes Production Equipment [Member] Liability Class [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Measurements, Recurring [Member] Fair Value Measurements [Abstract] Measurement Frequency [Axis] Fair Value, Hierarchy [Axis] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block] Schedule of Fair Value of Warrants Fair Value, Measurement Frequency [Domain] Level 3 [Member] Level 1 [Member] Level 2 [Member] Furniture and Fixtures [Member] General and Administrative Expense General and administrative General and Administrative Expense [Member] General and Administration Expenses [Member] General and Administrative Expenses [Member] Gross Profit Gross profit / (loss) Income Statement Location [Axis] Consolidated Statements of Operations [Abstract] Income Tax Authority, Name [Axis] Income Statement Location [Domain] Increase (Decrease) in Accounts Receivable Accounts receivable, gross Increase (Decrease) in Other Current Liabilities Accrued radioactive waste disposal Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Other Accrued Liabilities Accrued protocol expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Other Employee Related Liabilities Accrued vacation Increase (Decrease) in Inventories Inventory Increase (Decrease) in Other Receivables Other receivables Increase (Decrease) in Employee Related Liabilities Accrued payroll and related taxes Increase (Decrease) in Restricted Cash Change in restricted cash Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Interest Expense Interest expense Internal Revenue Service (IRS) [Member] Inventory [Line Items] Inventory, Finished Goods, Gross Finished goods Inventory Disclosure [Text Block] Inventory Inventory, Noncurrent Inventory, non-current Inventory, Net Inventory Total inventory Inventory, Current [Table] Inventory [Abstract] Inventory, Work in Process, Gross Work in process Inventory, Raw Materials, Gross Raw materials Investment Income, Interest Interest income Investment Type [Axis] Investment Secondary Categorization [Axis] Investment Owned, at Cost Certificates of Deposit Investments by Secondary Categorization [Domain] Certificates of deposit [Abstract] Latest Tax Year [Member] Operating Leases, Rent Expense Operating lease rent expense Leasehold Improvements [Member] Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Liabilities Total liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities: Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity Total liabilities and shareholders' equity Long-term Investments Certificates of deposit, non-current (Note 3) Long-term Purchase Commitment, Category of Item Purchased [Domain] Category of Item Purchased [Axis] Customer [Axis] Maximum [Member] Minimum [Member] Customer [Domain] Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Income (Loss) Available to Common Stockholders, Basic Net loss used in computing net loss per share Net loss applicable to common shareholders Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used by investing activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used by operating activities Net Income (Loss) Attributable to Parent Net loss Net loss Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities New Accounting Pronouncements [Abstract] Noncash Investing and Financing Items [Abstract] Non-cash investing and financing activities: Nonoperating Income (Expense) Non-operating income (expense), net Nonoperating Income (Expense) [Abstract] Non-operating income (expense): Number of Operating Segments Number of operating segments Office Equipment [Member] Operating Expenses [Abstract] Operating expenses: Operating Expenses Total operating expenses Operating Leases, Future Minimum Payments Due, Next Twelve Months 2015 Operating Leases, Future Minimum Payments, Due in Two Years 2016 Operating Income (Loss) Operating loss Operating Leases, Future Minimum Payments, Due Thereafter 2020 Operating Leases, Future Minimum Payments Due Total minimum future commitments Operating Leases, Future Minimum Payments, Due in Four Years 2018 Operating Leases, Future Minimum Payments, Due in Five Years 2019 Operating Leases, Future Minimum Payments, Due in Three Years 2017 Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Basis of Presentation Basis of Presentation [Abstract] Other Commitments [Axis] Other Assets, Noncurrent Other assets, net of accumulated amortization Other assets, net of accumulated amortization Other Receivables, Net, Current Other receivables Other Capitalized Property Plant and Equipment [Member] Other [Member] Other Liabilities, Current Accrued radioactive waste disposal Other Selling and Marketing Expense Website modifications and maintenance Other Accrued Liabilities, Current Accrued protocol expense Payments to Acquire Long-term Investments Purchases of certificates of deposit - non-current Payments of Ordinary Dividends, Preferred Stock and Preference Stock Preferred dividends paid Preferred dividends paid Preferred dividends paid Payments to Acquire Land Held-for-use Payments to acquire land Payments to Acquire Property, Plant, and Equipment Purchases of fixed assets Payments to Acquire Intangible Assets Additions to licenses and other assets Payments to Acquire Short-term Investments Purchases of certificates of deposit Plan Name [Axis] Plan Name [Domain] Preferred Stock, Par or Stated Value Per Share Preferred stock, par or stated value per share Preferred Stock, Value, Issued Preferred stock, $.001 par value; 7,001,671 shares authorized Preferred Stock [Text Block] Preferred Dividends Preferred Dividends [Abstract] Preferred Stock Redemption Premium Beneficial conversion feature Preferred stock deemed dividends (Note 10) Preferred Stock, Amount of Preferred Dividends in Arrears Accrued but undeclared dividends Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock Dividends, Income Statement Impact Preferred stock dividends Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock [Member] Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Proceeds from Warrant Exercises Gross proceeds Proceeds from sales of common stock, pursuant to exercise of warrants Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from the sale of preferred stock, pursuant to underwritten offering, net Proceeds from Issuance of Private Placement Proceeds from the sale of common stock, pursuant to underwritten offering, net Proceeds from Issuance of Common Stock Proceeds from the sale of common stock, pursuant to registered direct offering, net Proceeds from Sale of Short-term Investments Proceeds from the maturity of certificates of deposit Proceeds from Stock Options Exercised Proceeds from sales of common stock, pursuant to exercise of options Property, Plant and Equipment [Table Text Block] Schedule of Fixed Assets Property, Plant and Equipment, Type [Axis] Fixed Assets [Abstract] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Net Fixed assets, net of accumulated depreciation Fixed assets, net Property, Plant and Equipment, Gross Property and equipment, gross Property, Plant and Equipment [Line Items] Fixed Assets Property, Plant and Equipment Disclosure [Text Block] Fixed Assets Property, Plant and Equipment, Disposals Value of disposed assets Inventory [Domain] Inventory [Axis] Raw Materials [Member] Range [Axis] Name of Property [Domain] Name of Property [Axis] Related Party Transactions Disclosure [Text Block] Related Party Transaction Related Party Transaction [Line Items] Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Software implementation costs Related Party Transaction, Amounts of Transaction Costs related to development of a mono-therapy registry and a combo-therapy registry Related Party [Axis] Related Party [Domain] Related Party Transaction [Abstract] Research and Development Expense Research and development Research and Development Expense [Member] Research and Development Expenses [Member] Restricted Cash and Cash Equivalents Restricted cash Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents, Noncurrent Restricted cash Retained Earnings [Member] Accumulated Deficit [Member] Retained Earnings (Accumulated Deficit) Accumulated deficit Revenues from External Customers and Long-Lived Assets [Line Items] Concentrations of Credit and Other Risks [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding at September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and exercisable at September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested and expected to vest at September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Options granted, maximum expiration term Sales [Member] Sales Revenue, Goods, Net Product sales, net Scenario, Forecast [Member] Scenario, Unspecified [Domain] Schedule of Inventory, Noncurrent [Table Text Block] Schedule of Components of Non-current Inventory Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Value Measurements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Stock Option Activity Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Cost Method Investments [Table Text Block] Schedule of Certificates of Deposit Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Assumptions Used to Estimate Fair Value of Stock Options Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] Schedule of Stock Option Within Share-Based Compensation Plans Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Schedule of Revenue by Geographic Region Schedule of Inventory, Current [Table Text Block] Schedule of Components of Inventory Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-Based Compensation Expense Schedule of Property, Plant and Equipment [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Stock by Class [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Warrants Activity Segment Information [Abstract] Segment Reporting Disclosure [Text Block] Segment Information Geographical [Domain] Selling and Marketing Expense Sales and marketing Selling and Marketing Expense [Member] Sales and Marketing Expenses [Member] Series A Preferred Stock [Member] Series D Preferred Stock [Member] Series C Preferred Stock [Member] Series B Preferred Stock [Member] Share-based Compensation Share-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock options granted Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Stock options issued, exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and exercisable at September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Stock options expired Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Stock options forfeited Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Vested and exercisable at September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares authorized under plan Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Discount rate Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value Aggregate intrinsic value of option exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Vested and exercisable at September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Vested and expected to vest at September 30, 2015 Exercise Price Range [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Outstanding at September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest at September 30, 2015 Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest at September 30, 2015 Short-term Investments Short-term investments Certificates of deposit (Note 3) Statement [Line Items] Consolidated Statements of Cash Flows [Abstract] Statement, Equity Components [Axis] Statement [Table] Scenario [Axis] Consolidated Balance Sheets [Abstract] Class of Stock [Axis] Geographical [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options exercised Stockholders' Equity Note Disclosure [Text Block] Shareholders' Equity Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity: Shareholders' Equity [Abstract] Stockholders' Equity Attributable to Parent Balances Balances Total shareholders' equity Summary of Investment Holdings [Table] Summary of Investment Holdings [Line Items] Tax Period [Axis] Relationship to Entity [Domain] Title of Individual [Axis] Treasury Stock, Shares Treasury stock, shares Treasury Stock [Member] Treasury Stock, Value Treasury stock, at cost, 13,200 shares Unrealized Gain (Loss) on Derivatives Change in fair value of warrant derivative liability Change in fair value of derivative warrant liabilities Change in fair value Unrecorded Unconditional Purchase Obligation [Line Items] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Unrecorded Unconditional Purchase Obligation [Table] Warrant [Member] Common Stock Warrants [Member] Warrants and Rights Outstanding Balance, end of period Balance, beginning of period Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average shares used in computing net loss per share: Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted Weighted average shares used in computing basic and diluted net loss per share EX-101.PRE 10 isr-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT v3.3.0.814
Shareholders' Equity (Additional Information about Warrants) (Details) - $ / shares
3 Months Ended
Sep. 30, 2015
Jun. 30, 2015
Class of Warrant or Right [Line Items]    
Number of Warrants 360,800 385,800
Range of Exercise Prices $ 1.17 $ 1.22
Range of Exercise Price Three [Member]    
Class of Warrant or Right [Line Items]    
Number of Warrants 130,713  
Range of Exercise Prices $ 1.56  
Expiration Date 2016-05  
Range of Exercise Price Four [Member]    
Class of Warrant or Right [Line Items]    
Number of Warrants 199,437  
Range of Exercise Prices $ 0.94  
Expiration Date 2016-10  
Range of Exercise Price Five [Member]    
Class of Warrant or Right [Line Items]    
Number of Warrants 25,650  
Range of Exercise Prices $ 0.94  
Expiration Date 2016-12  
Range of Exercise Price Six [Member]    
Class of Warrant or Right [Line Items]    
Number of Warrants 5,000  
Range of Exercise Prices $ 0.98  
Expiration Date 2017-06  
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`!N/:4?SW$M9R0$``$H:```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9RT[#,!!%?Z7*%C6N[?(494/9`A+\@$FFC=4XMFRWE+_'3@%!51"O M2G>31^]X[DW&.9N>WS\Y"H.U:;LP*9H8W1ECH6K(J%!:1UU29M8;%=.MGS.G MJH6:$Q.CT1&K;!>IB\.8>Q07YS;"/7X4C?)4WT6?YKO[VWA? ML+\<>:[]]6=#[\7`^M,>(?&C'`(DAP3),0;)<0B2XP@DQS%(CA.0'*<@.?@( M)0@*43D*4CD*4SD*5#D*53D*5CD*5SD*6#D*604*604*604*604*604*604* M604*604*604*604*624*624*624*624*624*624*624*624*624*624*6<[%````*P(```L```!?.0Q(OW[CMB` MPD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^#*G*_=ITJK$"2+8CCVG!D4*>-BP> M-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26M#;3"&>6X9MY6&3I//B) M]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O]C^AY%.!)T:'B1?4C9@,2 M[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P"4$L#!!0````(`!N/:4<;CBH[JP$` M`(@9```:````>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V<>$5==>.V[0L$'8UH+F2FM+Y]4Q?%7N:C"^';)"0#9_X0^!&291/R MQ9,_E_'8-J$Z=F'T7I^;L!CNK[(JQF[A7-A6OB[#0]OY9EC=MWU=QN&R/[BN MW)[*@W>:YQ/7W\[)ULN?LT>;W2KK-SO)1B]E?_!QE;VU_2E4WL?@KB=YX MEB^=_\_V[7Y_W/K'=OM:^R;^4>&^-LA<.DC304H)LG2048**=%!!"1JG@\:4 MH$DZ:$()FJ:#II2@63IH1@F:IX/FE"#)@8PY)PEAS=%:`-?"\5H`V,(16P#9 MPC%;`-K"45L`V\)Q6P#RM%;@=Y*>M=&+]LBM'+T5Z*TBM'+T5Z*TAM'+T-Z&TAC"4=O`WH;1V\#>AM';P-Z&T=O`WH;1V\#>AM';P-Z&T?O`NA=#G[^Z=(^_739?T!4$L#!!0````(`!N/:4>[T-$DV0(``/,*```0````9&]C M4')O<',O87!P+GAM;+U6WV_:,!#^5ZR\C#UTH;2:)D0C4>BT2OV!!NN>7>=" MK!H[\QD&^^MW<8`E;9*1/8P7G/-W/M_WW9T\TM@?SJS)P#H)R+8KI7%(QJL@ M=2X;AB&*%%8]#)8LLECYH(K MF%"L*.$*H4#],7K,Q*PRKG=A\74G]0M^RQ9FRAV4O:H;Q>DIMQ!3T,KI1Z/' M?-E1GBKWG:1<+R$N8]]N'KAX`HMYIN>##WWZ'2DXV(NS@<=2+V=<6HQ&&S?< M@'#&[F7:N']5*38B%QV?%G0_#-@S1\B75\&&6\FU"QC*7_0Y"(JPA=6O58;. M1M^-?<$4P.$H/!K]LHPMK^5E='GN$;2J(L-C9M&>MDK>N64AG0)\3&;5#*_G`$XSIF-]I1.;);780B\R:*ZX%L/D; M"D_!L]Z,_]UG[NC/W](D[)'JL(L/YDX3CFFMSS5'Z1$S"TCHYJP?X"<;"V'6 M1))>$MYH6HLB1OU]\JF1Y(,`?(@8,H/2U6+O#"*CS)COR5K(K=Y0*&-WM;N? MY9:R'B,VJ>`//J-\"9;/$=#8)O%J)5U!7UX91&V>-6A!8[`^/E4X>^)J#>P> M.*YM"S'$=0*61@^;RHV,:=!=9-$#C_7Z-&C)>@O^K!HHJ6IZ@+YO%[<=5E:Y'=DD]]ZK M@X8GQ'FE4;M';"F'UB1O]!E!+`P04````"``;CVE'">&D[3X!``!I M`P``$0```&1O8U!R;W!S+V-O&ULS9--3\,P#(;_"NJ]2[-I0T1=#X`X M,0F)(1"WD'A;6/.AQ%/7?T^6=2T#+KMQJVN_CU_'22D<$];#D[<./"H(5WM= MF\"$FV<;1,<("6(#FH=1K#`QN;)>+?S=8))0:`#H2-*LNK%;(UM3$D&?55&QS4/N+!2 MK13(VW8H^YV*G1&\#DY#ZJO:IIFU$Q271R8DK?%XW,Z MFUR9@-P(B*J@&+8.YMFI\^OD[G[YD%7C@DYS2O/B9DFOV73&IO3],-F9O\&P M[H;XMXY/!M-V46$-%^XV:61:;OI,(`E!>.5067,1+F&^B1,L[#X^0>#EH$Z8 M+ML6VL9Z&:ITOX;H\'+BRM;6M\?4C^CL555?4$L#!!0````(`!N/:4>97)PC M$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V M;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[ MSD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\,`*I4Q>M5II M`,,X?+&A`T%11 M6F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_. M;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4(,@T[.IU8SG9\]L3M MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ- M4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ)QJO0=.MI)B?]KFND MZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;% M!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\IM5`:")K(@?5'@B'% MW*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+`GQ^R-; M88C'(CN]WV6'WV M3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0'`*D"3&6H8;XM,:L M$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6 MQKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+ MRO`JQ`GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q? MY[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.7 M0[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&P MH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L1K=@N-?Q+!3@9&`M MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG" M:9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3 MON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QY MQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC" M1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO3_DEG#NT>_&!()O\ MUMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA M9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9MC:CY$X*/-S^[PVP MPL2.X>V+OP%02P,$%`````@`&X]I1T%A_-)=`@``3@L```T```!X;"]S='EL M97,N>&ULS59;:]LP%/XK0AFCA1';V9JNJVT8A56ZP@Q5 M4U%BKG=R(1E2>BD+KRHE1EEEG!CU9KX_]Q@B',8AK]F"J0JDHN8J@I]Z"#C_ M.Y'A"#Y>O/]="W7[#KAQ\F$R\1\O;\?XA=VXA,!Q?,LB&,ROH/=\TJGO[R0]V::Z;.<^3XV3AZ;6;C,!=\2/`,.B`.JR>P1E3;!\8\ M%51(H/0-Z@@6X8AA9W&'*$DD,6".&*$;!\\,8"^]M6.$"VECNPCC.%-_B"2+ M)()^^WM^N&1@MX,Y'J%T]W@:B,,2*84E7^@%:.?+3:D/QP7'3J2U.V!=2+0) M9E=;#G;0<1,A,RS[R`'LH#BD.%?:09)B948E2B-=*"68GF0$%8(C:B@[CW:B M:5-,Z8/YQ'[E.]Q-#IR-N6,?`J.BF^I$M-.A#&Q2O6TVQ[U-.SN*%S1Y'T![ MH[*DFZ^4%)QA)]9!"]&N#M$'>^CC$'6L8"4D>=+VIA!2#6`)P1I+1=)MY(]$ MY1(WJJU@K\GW*3SVR*^IZ?19&]3H$GSK]!P=W$+W-4NP7-B_O9=+^GA]^,KL MUPE',M^V:HZ0<(+DF(YXMM+FYROM=6KJ%-5^\2K?: M`P``J@T```\```!X;"]W;W)K8F]O:RYX;6R5ETUSTS`00/^*QA?*`1+;22@9 MPDP_H3/0=FBGG%5;:7:0)2/);>'7LY(;6#>;TIYB.]YG:?=Y+7WP\SOK?EQ; M^T/<-]KXN5MDJQ#:^6CDJY5JI']K6V7POZ5UC0QXZFY&=KF$2AW:JFN4":-B M/)Z-G-(R@#5^!:W/'FC^.33?.B5KOU(J-+J'-1),]O&#GR]!JROE/(*%;-M3 MV:A%=J\SH:4/1S4$52^R"9[:.S6XX+IVOP,=3Z;C:3:*L/54SYVH;*UZV.4* M_/>'/S)1JZ7L=+C$P:Z?N\CR8E(4LYX1;[L"=>>^96]^VP=_+8F2'U1 M.:MUBHI_I"!\@O][!<<8H!K<&.3UMUB)138;(_`6/%R#AO!KD:5CK>),1H^F MDM+_[TB8E)QUB84TM3@R`2GBQ/3%P]3$,>#-)W5ZL)L#'KB3.N]314$'*(;5 M4&,N:K$OM325$FDZGD`*`BE>!!$[YY*`2@(J_P.Z"/B3)FF7XJQ5CH(F!#1Y M+LA'TH'T*P*:$M!T$[0O/:2P2\9E_QU+M.JT$ M15&?2\;G)U'E+D51K4M&:QZU5V.KQRH.ZD<5+QG%MWYW^GS111QU?<*X_N37 M9Y)3%'5]DC^LI/\MGG'_`$;5<6OATV-P;5[%_0;^]`N+R31^=N+Y5]R#++*X M4<`]0:?U`5X[,U^L3,OIGKS>87S\`U!+`P04````"``;CVE'B3K)@ET"``!9 M"```&````'AL+W=OVW`D&B3.+4-V;Y];8\)L/(FW)#8G#.?QXP]%`/C[Z*B M5'H?;=.)E5])V2^#0.PKVA+QPGK:J6^.C+=$JB$_!:+GE!R,J6T"'(9IT)*Z M\\O"S+WRLF!GV=0=?>6>.+*M/E523P1E$8R^0]W23M2L M\S@]KOPU6FY1HB5&\;NF@[A[]_3B=XR]Z\'/P\H/]1IH0_=2AR#J<:%;VC0Z MDB+_M4%O3&V\?[]&_V[25R;F1;VSX06T.9H5[ MU@CSZ>W/0K+V:O&]EGS`L^[,^):'R@VH$CG`8D3 MD!A[-@$`13X/2)V`U-@7$P!0H'">D#D)&?C1!,)*\#PB=R)R\$>/B,Y($D"` M),-YE&?SF(43LP!,/)&)E23S"!0Z&69:14@G>3&=II99C M-4\4%\)N"AQ/-%5?5H.?*#`4N2EPBC'Z>L^V5I,D(8J2Y(G[`KE//((#C9UW MTC4CJWF&XC[V"$XUGBJUJ^9SK05W-WE+^UP0``#(9```8````>&PO=V]R:W-H M965T&ULE9E=;^(X%(;_"N)^!A]_IZ)(0T:KW8N51G.Q>YV6 MM*`!PB1IF?WWZ\3';%M.#MZ;0M+'SAO'?FR'Y;EI?W3;NNYGOP[[8W<_W_;] MZ6ZQZ!ZW]:'J/C>G^AC^\]2TAZH/A^WSHCNU=;49"QWV"RF$71RJW7&^6H[G MOK6K9?/2[W?'^EL[ZUX.AZK]9UWOF_/]'.;IQ/?=\[8?3BQ6R\6EW&9WJ(_= MKCG.VOKI?OX%[DKM!F0D_MK5Y^[-]]D0_J%I?@P'?VSNYV+(4._KQWZHH@H? MKW59[_=#3>'*/['2_ZXY%'S[/=7^VWB[(?Y#U=5EL_][M^FW(:V8SS;U4_6R M[[\WY]]KO`N;0RHRGQVJ7_%S=QP_S_$_7F`QNH#$`O)2 M`#1;0&$!]:'`(B8;[^MKU5>K9=N<9]VI&IXVW`6\'2H)-<_"S72AG<8ZV[&E M5LO7E;3+Q>M0SSM$CL@:D6FB1,)=D$6X/AE"O@\13WZ1L;R_75Z]+Z]C>17+ M%^\C'D?$Q9N("!COA&"X,G)&2NNTN)U'DWGT6(D2U'5,S!,1`%^``CD-EA$L ME)7&Z=N!#!G(Q$#`!#(82`FCF>`EYK[7$=%6&..8.(@) M51AS.XTCT[B81C%I7+IK89DP2!46,K)X,HN/6323Q>.0#0^*[,D8)F'*%!D# MLR#3%#&-8=(4.+!4>`:.:<(20:ND"3" MP/(Y@QV`3A3UIYANND;&@#(`7!>Z@,(ZE]&+0-*9HE*5YS)%!CQ(RQF(YJ83 MT8Z&:%;%=-DU,L86WC`CH*2YZ42TI4&C.[A$D9$ZC'RNE`8G12Z1P>=>*&YM4"9..Y_51O0"5EK<)S!;#F2DL-9)LI%PSY%`*<," M,\-IDK:LC&8T'RS[EEDG1D\SY34SG<33?3`:,6=%+FD;R@)G>*Y]D>&V<]?, M]-:2MJ!*:T2F[R7&".!&>,)TD%-&'MJ!"A>(G'*0^>05N_PEL>D\M`*59)Y" MRA.9,&-K"^QN]T)JZP`R9E,U\48@6M!R#D/FDPUS@+#`S187%)P*"W!<2L\)*5P7LJ]-`[IR:&<^HU,YV$-J**)K,9-6A!MH86V:VA M:?=HN&WEQ'!6OF:FD]#6T=$3-N=>Z'625OFM,?&63]_N&XGA^L8U,YV$'K\: MQZ_-J('>XVF;WQKTZD.[C-;(6'U<,S')XLW;[5/U7/]9M<^[8S=[:/J^.8SO MLY^:IJ]#'>)S\..VKC:7@WW]U`]?W2#.^$H_'O3-*?U"&PO=V]R:W-H965T&ULE9A=;YLP%(;_"N('%-M\5P1I99JVBTE5+[9K-W$25,`9.$WW[V>PDZ;I M.>#E(GSD\?%C8UY!BI/L7X:]$,I[:YMN6/E[I0[W03"L]Z+EPYT\B$[_LI5] MRY4^['?!<.@%WTR-VB9@A"1!R^O.+XOIW&-?%O*HFKH3C[TW'-N6]W\?1"-/ M*Y_ZYQ-/]6ZOQA-!6027=INZ%=U0R\[KQ7;E?Z'W%(T7.U[H_RS ME"_CP8_-RB>C@VC$6HTEN-Z\BDHTS5A)]_S'%GWO?*&`Q^O-KW7>#\6T94] M/9A!S]-4LY]FJBQ>RR0M@M>QS@>$3%999N"A##?>`HI6PY M,RQ#"<'BU$XQ`N).<*12$X5I,N=DXW+.YA;!/>`XI38$TSF/:-GC%L$]X!BE M)OZ2R*$"''XT<5AUB=NJ@S#RQRN<[9\G6\1W`-..Y8O/PM;9M;C%C$>P=6K M[H'OQ$_>[^IN\)ZETF_-T\OM5DHE=`ERITOM!=]<#AJQ5>-N.O9AWN_-@9*' M\]\5E_],RG]02P,$%`````@`&X]I1S8:E--_`P``(@X``!@```!X;"]W;W)K MH/2@W1GZ9N^Z?X,`S' MQR3I-P?5E/V#/JK6_+/375,.YK';)_VQ4^76!C5U0@GA25-6;;Q:VK9OW6JI M3T-=M>I;%_6GIBF[_]>JUN>G&.)+P_=J?QC&AF2U3*:X;=6HMJ]T&W5J]Q0_ MPV-!TQ&QQ(]*G?NK^V@4_Z+UK_'AO^U33$8-JE:;84Q1FLNK*E1=CYE,S[]= MTK<^Q\#K^TOVS[9<(_^E[%6AZY_5=C@8M22.MFI7GNKANSY_4:X&-B;5R)?)ZYCG'4(MLD8$ M)B(QR;T]T-@73FTXO=U!@820]WM(W_>`C<^IC<_)_?CL?7R&\1G&PWN)K44$ M%H$(4`XII;>YPG$DHT!FC!CSZF&HQ]L/0SV(``B1\_0V5SB.2"Y)>E\/]^KA MJ"?0S_J"9$P&U""U8%E.Z'TQPONR!?:4W8_/O<7D&,\"Q2`"67H]9O]6XS#! M.M*K1J(:'E"#"!6YF5,!-8BE+!79C!<-Q"O'-AL](J#',8*!@,`4+1S' M!)-LQE(`\"M"]\GSD"*XK(:,I(&A+":0\)3,F$%`_9K0L/+`5%\[9F&6'F$B M,)[%1`(?A#7BBSD!QD M!&0\^+X02P6CV9R%X?=60$N4(7-UC%D8(`&"8^1(D;.@-]B`9U1ACS6 M,0O*6SOD]UB*OBB]K\-M-QQC!HF:[XM7DMMP7$B1YXS.F-G4;[,4 MG5%ZNY).%#(+\D"\*U(Z16_8G#WC!XMU9D;1%.6,/2%-_16E;NL3F&)K!S%& M@$H2^KQ>R"SG.6$?O[#)U=:[4=W>'DGZ:*-/[8#[XJEU.O8\V\/!A_:U.0[A MX>4MS6IY+/?J:]GMJ[:/7O1@#@9V_[[3>E!&''DP(@_FP#8]U&HWC+=B5(]' M&'P8]/%R(IN.A:N_4$L#!!0````(`!N/:4<&1<23O00``*(6```8````>&PO M=V]R:W-H965T&ULC9A-;^,V$(;_BN&[U^0,/Z3`,1"K*-I# M@<4>VK,2*[&QEN5*2K+]]Y7$H>/LCL>\Q+;R^\/^6'UM9]UK79?M?YOJT+S?S_4\7OBV?]GUXX7E>K4\ MC]ONZ^K8[9OCK*V>[^J@. MU5,_ABB'C[>JJ`Z',=)PYW\IZ,<]QX&7WV/TWZ=T!_N/95<5S>&?_;;?#6[5 M?+:MGLO70_^M>?^CHASL&/"I.733W]G3:]R+]>KMGF?=:=R?-KZ;I"W8Y`A\FQ( MIAOJ-,5LITJM5V]KK?1J^38&^J2!2;,AS5FQ'**SMX`Y-QRFX7#]!D50^/SV M'?#S'<+%!Z0DX'8`\SF`"0',%""WGST>)XD/603)8JA4KK6Z+BQ(Z#.;N01# MELW(4D9X.X!C,W(4P'!E#YI-T%C#)6-#,HZRU@@)S]^S5CQ9D:I+&G3.98(= MDKD\]^JVG8RUDY$==_T^FZ`!Y8$U36Z"RGLTM[WDK)>`H;$H$VF6"\B+%R9Q(*I#5O*`(JEPP%$0)JD`SI MZ-LFK"L-[,K4`5:7#+@>`OFA?$HQ4"#HVT[Y!FD2%8:>>).HW*I[1- MP,,5-*T,R9(^;RSBUAQU)D^A/0!O*,)5XA")AJ9$Y=9+)/I0&M19PF(#OK^$ M".R$;0-XP(*A$-+R(-'`PDH9XWZ@#R ME"KSB`7J6;6X0HBQ%H8F\"?J7T8KX)?N]KH?'K%`W:86ET=DI[+6HU@C'VN$ M%VO[NBF>LD!HY"<(==,D6@R<-1+XH\XX8S6F<(1'+1`?M?!`-B027S<@-KL) M\QIYS***K!8*1*(%6.^R7'(4E<;YX64@87*C9A&"U,>FO$8A#TY16JY1:9TR/FDN\J!%`BU(H"61!7#>2,T1 M"8>%I)1/6;<\;9%H"P)#-U%D,Z_$GI^$PQN\19W0TV+&KUJB+60)(7@V8NP= M)3:BQ$;:/S"RT?_:A2XOCO[JJGV9CD2[V5/S>NS#L=SYZOG8]0'&H\.?KF_T M71$.3S_"K%>G\J7ZJVQ?]L=N]MCT?5-/YX?/3=-7@S7U9:CZKBJWYQ^'ZKD? MO_KQ<80CU/"C;T[Q1/A\++W^'U!+`P04````"``;CVE'L\4D#Z(!``"Q`P`` M&````'AL+W=OV>]LX-.\9LW8/B]@8'T/Y/BT9QYU/3,3L8X$TD*[JA2^%9=+T+!5:5;.4U0H&V`C4QT.[I_69WV`9$ M!/P2,-FSF`3O1\27D/QH]C0+%D!"[8("]\L)'D#*(.0;_YDUWUH&XGF\J'^/ MTWKW1V[A`>5OT;C>F\TH::#EHW3/.#W"/,)M$*Q1VO@E]6@=JH5"B>*O:14Z MKE/Z4Q0S[3HAGPGY2OB:1>.I4;3YC3M>E08G8@<>SFZS\W`31+PR\=ZL'SMJ MFCAX59ZJ39&5[!2$+C")>)@Q*X)Y]:LMOY\UD="Z$'[QL4E7*B4.A^6!K*^T^@=02P,$ M%`````@`&X]I1QH16\>B`0``L0,``!@```!X;"]W;W)K!I"3+DN0+4UP,M"I#[4E7)4Y6B@&>-#&34ES_/8+$^4!3NA:>1==; M7V!5R39>(Q0,1N!`-+0'>I_NCX5'!,!O`;.YB(GW?D)\\NB^=[2$R_C5?TQ3.OE2/OX!?7G1@,.:%U)QL.H$6TX-HG=SM*>O=^MD1" M:WWXU<4Z7JF86!S7![*]TNH?4$L#!!0````(`!N/:4=U:F]BH@$``+$#```8 M````>&PO=V]R:W-H965T&ULA5/+;MLP$/P5@A\0RI+S@"$+ MB!,4[:%`D$-[IJ651(3D*B1EI7]?/B3%+HSF(NZN9F9G^2@G-&^V!W#D0TEM M][1W;M@Q9NL>%+#\BOH7D1[.G6;``$FH7%+A?3O`$4@8AW_A]UOQL&8CG\:+^+4[K MW1^YA2>4OT7C>F\VHZ2!EH_2O>+T'>81;H-@C=+&+ZE'ZU`M%$H4_TBKT'&= MTI]BH5TGY#,A7PD/632>&D6;S]SQJC0X$3OP<':;G8>;(.*5B?=F_=A1T\3! MJ_)4;8J[DIV"T`4F$0\S9D4PKWZU14ZOT?-(S[^F%Y?T(CDL9H?W7PML+P6V M26#[OQ$3YK!@'OYIPL[V5('IXM6QI,91N[2E:W6]G8]Y/)-/>%4.O(.?W'1" M6W)$YT\V'D"+Z,"WSVYN*>G]^UD3":T+X;V/3;I2*7$X+`]D?:757U!+`P04 M````"``;CVE'5@\*6*0!``"Q`P``&````'AL+W=OX+M-.S?KR]I M:%$%+_',Y)PS9WPI)S2OM@=PY%U);;>T=V[8,&;K'A2W5SB`]G]:-(H[GYJ. MV<$`;R))299GV0U37&A:E;'V;*H21R>%AF=#[*@4-_]V('':TA4]%EY$U[M0 M8%7)%EXC%&@K4!,#[9;>KC:[(B`BX(^`R9[$)'C?([Z&Y*G9TBQ8``FU"PK< M+P>X`RF#D&_\-FM^M`S$T_BH_A"G]>[WW,(=RK^B<;TWFU'20,M'Z5YP>H1Y MA.L@6*.T\4OJT3I41PHEBK^G5>BX3NE/?C/3+A/RF9`OA)]9-)X:19OWW/&J M-#@1._!P=JN-AYL@XI6)]V;]V%'3Q,&K\E"MUK]*=@A"9YA$W,V8!<&\^L46 M.;U$SR,]_YZ^/J>OD\-UZEYDWPL4YP)%$BB^&C%A=C.F^#PD.]E3!::+5\>2 M&D?MTI8NU>5VWN;Q3#[@53GP#GYSTPEMR1Z=/]EX`"VB`]\^N[JFI/?O9TDD MM"Z$/WQLTI5*B>Q3"Z4&!-S39>)Q1H*U`3`_V>/N2[0Q40 M$?!#P&(O8A*\'Q%?0O*MV],L6``)K0L*W"\G>`0I@Y!O_&O5?&L9B)?Q6?U+ MG-:[/W(+CRA_BLZ-WFQ&20<]GZ5[QN4KK"/A'IQ;_IY36]3`;+U+WZ#X'J M6J!*`M5?)DR00[7V*-_U8!<[JL`,\>)8TN*L7=K0K;K=S8P)%W);4]T-ZY8<^8K7M0W-[A`-K_:=$H M[GQJ.F8'`[R))"59GF7W3'&A:57&VK.I2AR=%!J>#;&C4MS\.8+$Z4`W="F\ MB*YWH<"JDJV\1BC05J`F!MH#?=CLCT5`1,`O`9.]B$GP?D)\#D[S"/L@F"-TL8OJ4?K4"T42A1_3ZO0<9W2G[R8:;<)^4S(5\+7+!I/C:+- M)^YX51J+@57FN-D51LG,0NL(DXG'&K`CF MU6^VR.DM>A[I^>?T[35]FQQN9X>[SP6*:X$B"13_&S%AC@OF_I\F[&)/%9@N M7AU+:ARU2UNZ5M?;^9#',_F`5^7`._C)32>T)2=T_F3C`;2(#GS[[&Y'2>_? MSYI(:%T(O_C8I"N5$H?#\D#65UK]!5!+`P04````"``;CVE'5,8\Y*0!``"Q M`P``&0```'AL+W=O[ M0Q$0$?!+P&3/8A*\'Q%?0_*CV=,L6``)M0L*W"\G>`(I@Y!O_&?6?&\9B.?Q MHOXM3NO='[F%)Y2_1>-Z;S:CI(&6C]*]X/0=YA%N@V"-TL8OJ4?K4"T42A1_ M2ZO0<9W2G^W=3+M.R&="OA(>LF@\-8HVOW+'J]+@1.S`P]EM=AYN@HA7)MZ; M]6-'31,'K\I3M2GN2W8*0A>81#S,F!7!O/K5%CF]1L\C/?^SP MX7.!XE*@2`+%_T9,F,."^?*A"3O;4P6FBU?'DAI'[=*6KM7U=C[F\4S>X54Y M\`Y^``MH@/?/KNYI:3W[V=-)+0NA/<^-NE*I<3AL#R0]956 M_P!02P,$%`````@`&X]I1ZH+82BB`0``L0,``!D```!X;"]W;W)K&ULC5/;;IPP$/T5RQ\0`\NVU8I%RJ:*FH=(41[:9R\,8,5F MB&V6]._K"Y#=:)7T!<\,YYPYXTLQH7XQ'8`E;TKV9D\[:X<=8Z;J0'%S@P/T M[D^#6G'K4MTR,VC@=2`IR;(D^<84%STMBU![TF6!HY6BAR=-S*@4UW\/('': MTY0NA6?1=M876%FPE5<+!;T1V!,-S9[>IKM#[A$!\%O`9,YBXKT?$5]\\E#O M:>(M@(3*>@7NEA/<@91>R#5^G37?6WKB>;RHWX=IG?LC-W"'\H^H;>?,)I34 MT/!1VF>XBCZL4_R3IS/M.B&;"=E*^)$$ MX[%1L/F36UX6&B=B!N[/+MTYN/8B3IDX;\:-'31U&+PL3F6Z30IV\D(7F$@\ MS)@5P9SZU189O4;/`CW[FKZYI&^BP\WL\#_ZYY<">13(/QLQ8@X+YJ-+=K:G M"G0;KHXA%8Z]C5NZ5M?;>9N%,WF'E\7`6WCDNA6](4>T[F3#`32(%ES[Y&9+ M2>?>SYI(:*P/O[M8QRL5$XO#\D#65UK^`U!+`P04````"``;CVE'K![*2*(! M``"Q`P``&0```'AL+W=O*FQL-#&C4ES_/8#$:4\W="F\BK:SOL#*@JV\6BCHC<">:&CV M]&ZS.^0>$0"_!4SF+";>^Q'QS2=/]9XFW@)(J*Q7X&XYP3U(Z85D1YA&V7K!":<*75*.QJ!8* M)8I_Q%7T89WBGVRA72>D,R%="3^38#PV"C9_<?D_/+NE9=)C- M#O/O!?)+@3P*Y/\;,6(."V;[I0D[VU,%N@U7QY`*Q][&+5VKZ^V\2\.9?,++ M8N`M/'/=BMZ0(UIWLN$`&D0+KGURLZ6D<^]G320TUH<_7*SCE8J)Q6%Y(.LK M+?\!4$L#!!0````(`!N/:4=/G."UHP$``+$#```9````>&PO=V]R:W-H965T M6CG-"\V1[`D7U#`R5[$)'@_(;Z%Y'MS MH%FP`!)J%Q2X7\[P#%(&(=_X]ZSYT3(0+^-%_6N;$9) M`RT?I7O%Z1O,(^R"8(W2QB^I1^M0+11*%']/J]!QG=*?33[3;A.*F5"LA,PTT0\[-^[*AIXN!5>:[RW7W)SD'H"I.( MQQFS(IA7O]FBH+?H1:07G],WU_1-W_1DR8XX)Y_*<) MN]A3!::+5\>2&D?MTI:NU?5V/A7Q3#[@53GP#GYPTPEMR0F=/]EX`"VB`]\^ MN]M1TOOWLR826A?"!Q^;=*52XG!8'LCZ2JN_4$L#!!0````(`!N/:4>^S(_+ MI`$``+$#```9````>&PO=V]R:W-H965TZ:EE42$Y"HD9:5_7SYDQ0Z,Y"+NKF9F9_DH M1C2OM@-PY%U);7>T"B^B[5PHL+)@,Z\6"K05J(F! M9D=O%]O]*B`BX(^`T9[%)'@_(+Z&Y*G>T2Q8``F5"PK<+T>X`RF#D&_\-FE^ MM`S$\_BD_A"G]>X/W,(=RK^B=ITWFU%20\,'Z5YP?(1IA'40K%#:^"758!VJ M$X42Q=_3*G18]=[PL#([$]CR&7BO5D_=M0T*C!MO#J65#AHE[9TKLZW\S8> M(ON`ET7/6_C-32NT)0=T_F3C`32(#GS[[&9-2>??SYQ(:%P(?_C8I"N5$H?] MZ8',K[3\#U!+`P04````"``;CVE'Z:]Z(:(!``"Q`P``&0```'AL+W=O&]%E@:.5HH<73B'7^'W6_&SIB:?QHOX8IG7N#]S`/81K+UBA-.%+JM%85`N%$L4_XBKZL$[Q3W8[TRX3TIF0 MKH1?23`>&P6;#]SRLM`X$3-P?W:;K8-K+^*4B?-FW-A!4X?!R^)8;F[2@AV] MT!DF$O!?+O1HR8_8+) MOS1A)WNJ0+?AZAA2X=C;N*5K=;V==VDXDT]X60R\A=]*5B8G%8'LCZ2LO_4$L#!!0````(`!N/:4=X MUWS[HP$``+$#```9````>&PO=V]R:W-H965TZ:EE42$Y"HD9:5_7SXDQ0Z,YB+NKF9F M9_DH1C2OM@-PY%U);0^TZ(K.A1?1=BX46%FPA5<+!=H* MU,1`O&#="\X_H!IA&T0K%#:^"75 M8!VJF4*)XN]I%3JN8_JSS2?:;4(^$?*%\"V+QE.C:/,[=[PL#([$]CR&7BO5D_=M0TKW;9@YR!TA4G$XX19$,RKWVR1TUOT/-+SK^GK M:_HZ.5Q/#G=?"VRN!39)8/._$1/F.&/N/S5A%WNJP+3QZEA2X:!=VM*ENMS. MAWB([`->%CUOX1"BGPJ`$``+$#```9````>&PO=V]R M:W-H965T&+"!.$;2'`D$. M[9F65A(1DJN0E)7^??F0%;LPD(NXNYJ9G>6CG-"\V1[`D0\EM=W3WKEAQYBM M>U#91NFN-"T*F/MQ50ECDX*#2^&V%$I M;OX>0.*TIRMZ+KR*KG>AP*J2+;Q&*-!6H"8&VCU]7.T.ZX"(@-\")GL1D^#] MB/@6DI_-GF;!`DBH75#@?CG!$T@9A'SC]UGSLV4@7L9G]>4/X1 MC>N]V8R2!EH^2O>*TP^81[@/@C5*&[^D'JU#=:90HOA'6H6.ZY3^%)N9=IN0 MSX1\(3QDT7AJ%&U^YXY7I<&)V(&'LUOM/-P$$:],O#?KQXZ:)@Y>E:=JM7DH MV2D(76$2\3!C%@3SZC=;Y/06/8_T_&MZ<4TODL,B=2^V7PNLKP7626`]C_CM MUH@)OY\ED="Z$&Y];-*52HG#X?Q`EE=:_0-02P,$%``` M``@`&X]I1\X#N]2D`0``L0,``!D```!X;"]W;W)K&ULA5/;;MLP#/T501]0V8Z[#H%CH.DP;`\#BCYLSXI-VT(ET9/DN/O[Z6*[ M21&@+Q))G7-(BE(UHWFU`X`C;TIJ>Z"#<^.>,=L,H+B]PQ&T/^G0*.Z\:WIF M1P.\C20E69%E7YCB0M.ZBK%G4UT;O#%9I2TT/%)NA>T"QWW.9U\S1;:;4*Q$(H/!)82Q3*_<D6W5[G8Q%G\@ZOJY'W\(N;7FA+3NC\9.,`.D0'/GUV=T_)X/_/YDCH M7#`?O&W2DTJ.PW'](-LOK?\#4$L#!!0````(`!N/:4?BZJ"4L0$``!8$```9 M````>&PO=V]R:W-H965TJ!^E.&J4%M6ZI6V)Z#;0.),%)FB3W1%`F<5F$O6==%FJP MG$EXUL@,0E#]YP1\P?/&"VL[ZS=(69"%5S,!TC`ED8;FB!\VAU/N$0'P MB\%HKN;(9S\K]>H7/^HC3GP$X%!9KT#=<(%'X-P+.>.W2?/#TA.OY[/ZMU"M M2W^F!AX5_\UJV[FP"48U-'3@]D6-WV$J(22L%#?ABZK!6"5F"D:"OL>1R3". M\23;3[1U0CH1TH6P3T+P:!1B/E%+RT*K$9F>^MYM#@ZNO8A31BZ;<64'31T* M+XM+N=EE!;EXH1M,))XFS((@3GW5(L5K]#30TZ_IVUOZ-B;<1O?L/P2R6X$L M"F13B?E:B1%SFC'W7YODJR;Y)+#[A\F,V7\R(5>-$Z#;<#\-JM0@;>S;LKL\ M@8$GU2V3!IV5==&ULA5/;;J,P$/T5RQ]0$T*VW8@@-5VMVH>5 MJCYTGQT8P*KM86T3NG]?7P)-JDA]P3/#.6?.^%).:-YL#^#(NY+:[FCOW+!E MS-8]*&YO<`#M_[1H%'<^-1VS@P'>1)*2+,^R'TQQH6E5QMJSJ4H#\@OH7DJ=G1+%@`";4+"MPO1W@`*8.0;_SOI/G9,A#/XUG]=YS6NS]P"P\H M_XK&]=YL1DD#+1^E>\'I$4XC;()@C=+&+ZE'ZU#-%$H4?T^KT'&=TI]\IETG MY"="OA#NLF@\-8HV?W''J]+@1.S`P]FMMAYN@HA7)MZ;]6-'31,'K\ICM;K] M6;)C$+K`).+^A%D0S*M?;9'3:_0\TO/OZ>M+^CHY7*?NQ>9[@>)2H$@"11*X MRZZ-F##[&?-U2':VIPI,%Z^.)36.VJ4M7:K+[;S/XYE\PJMRX!W\X:83VI(# M.G^R\0!:1`>^?7:SH:3W[V=))+0NA+<^-NE*I<3A,#^0Y956'U!+`P04```` M"``;CVE'!I>]#K$!```6!```&0```'AL+W=O;9@0M8M3&U3>C\_7@!FE2H M><';V:ZN33Y*]:Y;`(,^!>_T`;?&]'M"=-F"H/I.]M#9DUHJ08U=JH;H7@&M M/$EP$D?1E@C*.ESD?N]5%;D<#&<=O"JD!R&H^G<$+L<#WN!YXXTUK7$;I,C) MPJN8@$XSV2$%]0'?;_;'S"$\X`^#45_,DS^I.OUJ8_40T/DO]EE6EMV`BC"FHZ82O`) M2\FU_Z)RT$:*F8*1H)]A9)T?QW"R32;:.B&>"/%"V$4^>##R,1^IH46NY(AT M3UWO-GL+5T[$*B.;3=NRO:;RA1?YN=CLXIRG)-3T+")+BGN]L"Z;5`&@32J<1DK<2`.$ MG"D.IP$``+$#```9````>&PO=V]R:W-H965TUWC)FR!<7-#?;0N3\U:L6M2W7#3*^!5X&D)$N3 MY)8I+CI:Y*'VHHLZ/W,`#RK^BLJTSFU!209O;GF1:QR)Z;D_N]7. MP;47<3-N[*"IP^!%?BI6V[N0$H?.QBU= MJLOMO$_#F7S#B[SG#?SANA&=(4>T[F3#`=2(%ES[Y&9#2>O>SY)(J*T/[URL MXY6*B<5^?B#+*RV^`%!+`P04````"``;CVE'8QVZQ;X!``![!```&0```'AL M+W=OGC12"6KL4K5$#PIH[4F"DS1)(/GC1?6=L9MD+(@"Z]F`GK-9(\4-`?\L-D?1 MMDY((R%="%\2'SP8^9A/U-"R4')">J#NWVWV%JZ(R8!4&L^JI%BM?HJ:>GM^G;:_HV)-S&A/_AO[L6V`6!711( MUTH,F..,V=XVR59-LBBP^\1DQF2W3?)5DSP*Y)^8S)C[?TS(17<(4*V_!!I5 M\+`;:PD^J6M9K=)+&]JAOI49*`]8^N=#TS$[&.!--"G)BBR[8XH+3:LRKCV; MJL312:'AV1`[*L7-WQ-(G(XTI\O"B^AZ%Q985;+5UP@%V@K4Q$![I(_YX;0/ MBBCX)6"R5W,2:C\COH;@1W.D62@!)-0N$+@?+O`$4@:03_QG9KZG#,;K^4+_ M%KOUU9^YA2>4OT7C>E]L1DD#+1^E>\'I.\PMW`9@C=+&+ZE'ZU`M%DH4?TNC MT'&EP8G8@8>SRP]>;@+$DXFOS?JV M(]/$QJOR4N4/]R6[!-`'33*>%LW#JF&>OYFDH%N`(@+\I?@L'VQ\PP'N!S,3+^)FI*9?#>M;W8A+64PSJ*Q*&F'1%/;*"] MNE,QWA&IEOP4B8%3^%EPI)8@:KC0'6U;K:2>_-N)_GNF)M[.K^I?S7:5_3T1=,?: M7\U1ULIM'`9'6I%S*U_9^(VZ/6`M>&"M,-?@$Y`CH`^$R#HS^_I")"D+SL9`#$2_;;!6<*Y%E'*@-B-43D:3 MFZ3*XE+"."FBBQ:ZPT"#V3K,YXB=0V03)%(&O"[@O8O$NH#.!9X70/<"MOB, MG$`Z+Y!X'21.(+O?96\PF9?@FVL=N%9,/UG)H.R_(O4$L#!!0````(`!N/:4?(>C<900(``(@'```9 M````>&PO=V]R:W-H965T!\M MZ?C2KX7H%T'`=S5N$7^B/>[DFP-E+1+RRHX![QE&>YW4DB`$(`U:U'1^5>K8 M"ZM*>A*DZ?`+\_BI;1'[L\:$#DL?^F/@M3G60@6"J@RFO'W3XHXWM/,8/BS] M%5QL8*0@&O&KP0._>O:4^"VE;^KR8[_T@=*`"=X)18'D<<8;3(ABDI7?+>FE MIDJ\?A[9O^EVI?PMXGA#R>]F+VJI%OC>'A_0B8A7.GS'MH=$$>XHX?K7VYVX MH.V8XGLM^C!GT^ES,&]R8-/<":%-"*>$J8X[(;()T24AUIT:9;JO9R1053(Z M>+Q'ZM^&"PEGBD0R>[(9+GW2G$P[597G*H2P#,Z*Z`83:LS:8"Z(0+([2X2^ M*STT);XNL#&(K'A<(;JM8(*KR#81/B:(;PEB0Q!;@NA69*M M:]S&XM(HC8OLL:#$*2C1)&G\.#]U.I+.=R1S"LAF.&(P20'2Y(X?+M278G*G MF-R*F6%'X;2CF&\'!$X).OS($`N*4I`#<,>2$5>D23:C)PC=DL9O=X:O,'3Z M`L/_,"9RJXCF&&-!\IN(XO2>,R-;#O(D_R0JN!IP+69'/?BYMZ.G3ICA,T6G MY;(*U8#\%%^KI:,'YX6F*GMTQ#\1.S8=][94R/&KI^2!4H&E-O`D-=9R+4X7 M@@]"/69*O%D4YB)H/^Z]:?E6?P%02P,$%`````@`&X]I1]'A#`1.`@``'@@` M`!D```!X;"]W;W)K&ULE9;=CILP$(5?!?$`BPW8 M0$20=JFJ]J+2:B_::R=Q`EK`U';"]NWKOZ3)RH'T)L;FS/$W0QA33HR_BX92 M&7STW2#682/EN(HBL6UH3\03&^F@[NP9[XE44WZ(Q,@IV9F@OHMB`'#4DW8( MJ]*LO?*J9$?9M0-]Y8$X]CWA?UYHQZ9U",/SPEM[:*1>B*HRNL3MVIX.HF5# MP.E^'3[#50T3+3&*GRV=Q-5UH.$WC+WKR??=.@2:@79T*[4%4<.)UK3KM)/: M^;G#KR^/KM_->DJ_`T1M&;=KW8G&T4+PF!']^38R3WS9B63C^32^?!)4?P%02P,$%`````@` M&X]I1\85BE?H`@``Q@L``!D```!X;"]W;W)K&UL ME59=;YLP%/TKB/<5_`'&$4%J$DW;PZ2J#]NSFS@)*N`,.TWW[V=LAS:5H>Y+ MP,ZYYQX?<^U;7D3_+(^#9`.P"\(>`Q"[%&+%ABE5E+RZ1/+'A\P`+#>\'$LT< MZ=5+;:SA[(VU5?E209B5R:?$^!;`CMYCQT!N179&0RQ*[480D"!*)[&;1PN+VA. M`@1E7D&9$U3X$F56D,5\(S`#6>I59(&;*Q``7*``2;E74NXDT1E)%H,Q*&@Z M(\C",H(+G'XNAWCE$"L'S>1960Q`>9Y[C;0[MG:PG%(2(*?PRBF9OYC8HP%Z=,#YK/&>''3 MDOR%#:Z5C0,H"K\QQ1>,H7X5-,08"\(`ZJ-CYN[83`"G[UI_A4-7X2C`70B\ MUD`0;@V$?A5PSAIW6SH0T57BN_BQN_@M*ONXUH MF^IQT/"]&E[)L/&VS;0#)4[7KGELW:O_4$L#!!0````(`!N/:4<&Z#;@9P(` M`(\(```9````>&PO=V]R:W-H965T,?<@'0M]9 MA3%W/MJF8VNWXKQ?>1[;5[A%[(7TN!-OCH2VB(LA/7FLIQ@=5%#;>-#W8Z]% M=><6N9I[I45.SKRI._Q*'79N6T3_;7%#AK4+W''BK3Y57$YX1>Y-<8>ZQ1VK M2>=0?%R[&[`J02PA"O&[Q@.[>7:D^!TA[W+P\[!V?:D!-WC/)042MPLN<=-( M)I'YKR&]YI2!M\\C^W=5KI"_0PR7I/E3'W@EU/JN<\!'=&[X&QE^8%-#)`GW MI&'JZNS/C)-V#'&=%GWH>]VI^Z#?I+X)LP=`$P"G@"F//2`P`<$U(%25:F6J MKF^(HR*G9'!8C^1J@Y6`4TDBF!U1#!,^*4ZJG"KR2P&#./N+'B`)@B1Q@EV/V M;.@OH(!63P#\@BF!746PQ!0-"L+,NF=&4\S^!=&"3Q[8=S`P&R]<<$R!R&Y* M]`538KN*>,%!8D!)G"5/#A*#2J$??Y+CW9SS+:8GU?^8LR?GCNLS>)J=>NP& MRC[Q:7XK>Z_J'U>:(N_1"?]"]%1WS-D1+KJ0:A9'0C@6POP7L6J5^#N8!@T^ M"3.?4_XOQ7MV'49@W@TO+:'H]2&I*F3R6_7]G00+1LB M3O?+^!D\K:&!&,3OEE[%S7ND@]\P]J87/W?+.-4QT(YNI:8@ZG&A:]IUFDDI M_W6D'YK:\?9]9/]NTE7A;XB@:];]:7?RJ*)-XVA']^3B=QL\*3C7)(HY4LD(52?#R4VEFOK2P`S6R443W6&@P:PL!DR( M1+%[)6#L$V3W!)DER!Q!=A_D8##8IN$P M*,]0EC\6PEXA[(1P0,AA8%ZD-[@OA7*O4.Z$\H"0Q8`J+\HR?2Q4>&M?.*'B M,4'IC;0,U;ZRD5H,6%0S=KCRJE2APNNFUS+5*),]E@&I5\>8ORR\2\>!E-", M@P2`M^Y@[-QR!@7TQPK]I;\%K2;0C.X$R*^#_,6_UW$@/.,D`G\7@\Q?^WL= M!\(S[C.`_:5W'8KA#`I_>X(\=.H+%ZH%X0J`23?:4F/#N/?=`T]8D,4E56.E" M[&PO=V]R:W-H965TK#S+,#ET7U0FT3VK^O%Z!)A907O'"VR[7)!JG> M=0-@T"=G0A]P8TRW)T07#7"J[V0'PKZII.+4V*6JB>X4T-*3."-)%&T(IZW` M>>;W7E6>R=ZP5L"K0KKGG*JO(S`Y''",IXVWMFZ,VR!Y1F9>V7(0NI4"*:@. M^"'>'U.'\(!_+0SZ8HY<]I.4[V[QISS@R$4`!H5Q"M0.9W@$QIR0-?X8-7\L M'?%R/JD_^VIM^A/5\"C9_[8TC0T;851"17MFWN3P`F,)/F$AF?9/5/3:2#Y1 M,.+T,XRM\.,0WNRBD;9,2$9",A.2M0\>C'S,)VIHGBDY(-U1U[MX;^'*B5AE M9+-I6[;75+[P/#OG2;K)R-D)76$"\1@P\8P@5GW1(L%+]&2TV-X66%T+K$+& MU2BPNRVPOA98!X'U*'!_7:3PF&U(&3"K79S>;V[[I(L^:?#91$L?,V".$^;W MYR07W>.@:G](-2ID+TQHWKP[WX.'Q'?_!YYG':WA+U5U*S0Z26//D&]U):4! M:Q_=I1@U]J;."P:5<=.MG:MP>,/"R&ZZBO/_(/\&4$L#!!0````(`!N/:4>; M,3&PO=V]R:W-H965T)EZZ8ZO,1-;4 MV1RW[WHZR(X/B:"'=?H('S8(&(A%_.[H)*^^$V-^R_FK&?SB`GIE[X M](/Z'`I#N.-,VF>R.TG%^TM(FO3DS;V[P;XG]P?G/BP<@'P`F@-098T[(6OS M&U&DJ06?$CD2LWGP0<.%(=',B?8F==J64]C$F_K MH+Q/4`9=EIX`W[H<+`8[EPX#RQ4`X+X.#NI@K[,*Z4!W+C8.E"_0?9554&7E M5:J02N%$/"9BR:N@1N7B<<120!#<-#L=N6L0!DU`7T(8?G*Z9E#$>D(4UO%U MA"/J"(8+"2Z_D&VXE*"O$YQ_LJ\>!%'4*85%6,D7%(XX'K`,YUM^(=]PL4`< MDZ^OEKATP_4"?3'@&*]5.-TJ/ET$@BX0B#C,,PA_T,FN.E!/Q=$V6IGL^&E0 MK@'-LW,S?T2V@[W#FWHD1_J+B&,WR&3+E>Z#MET=.%=4ZX.%7O967S?F`:,' M93ZQV0_7@-U`\?%RGY@O-&PO=V]R:W-H965T?O\B2Q1!Z$[#Y_0_'/K%-UE/VSDM"A/?9 MU"U?^Z40W2H(^*XD#>9/M".M?'*@K,%"-MDQX!TC>*^+FCI``,1!@ZO6SS/= M]\KRC)Y$7;7DE7G\U#28_=F0FO9K'_I#QUMU+(7J"/(LN-3MJX:TO**MQ\AA M[3_#50%CA6CB5T5Z?G7O*?-;2M]5X\=^[0/E@=1D)Y0$EI8DX+6OZN]**5;X'M[6MQU8CB1F%06"4)@!,<(7A(H3B)`2/ M_81./Z$1`:[W1,:/06`<`S"!%19+X34VZB9RNHG,[*0S!&)G/O'\?!*G@^1Q M/LG,?)*OY9,Z_:3.?*Z1C47"<:2X0T9=+)TNEC87^%@``F-U,S"33NX8XR2X.L(Z?"0_,3M6+?>V5,C3 M4!]:!TH%D1K@26Z0I?Q*N31J+Y56ZP$``"4%```9````>&PO=V]R:W-H965TFZJ6 M.N!FJ3OSBH9"*QK6(@[EWCGXNW.L$0;PJX%!W,V1]GYA[$TO?A1[Q],6@$`N MM0)6PQ5.0(@64HG_C)JWE)IX/Y_4OYEJE?L+%G!BY'=3R%J9]1Q40(E[(E_9 M\!W&$HS#G!%AOBCOA61THCB(XG<[-JT9![N3;$;:,B$8"<%,F/,L$\*1$/XO M(1H)T8T0F=;84DPCSECB+.5L0*+#^G3X.P7G6D0I(U6]4(TUFMRT-DNO6;`- M4_>JA1XP@<$<+<9?1YPFE6C&N,K!HHW`64H16(%/4HR(;;R..4^8S=U&.`HD7PM$CP(V>(A&@>VCR]9@$EN)Q?C>)@S64>-%,/)IY7D]S MM)CD.?GXZ]R[TT2!5^9:"I2SOI7V+\[1^>8?`GT:/\1/ZD6P%_@FDZ4=KN`G MYE73"G1A4IUU&PO=V]R:W-H965TC`SC>U.N^A,IHMV36S99@+(17*< M_GWU`IOD@NF&ASCGWG,?TERR"VM?^9%2X;S75<.7[E&(T\+S^/9(ZX(_LA-M MY)<]:^M"R-?VX/%32XN=)M65YR,4>751-FZ>Z;7G-L_8651E0Y];AY_KNFC_ M/M&*798N=KN%G^7A*-2"EV=>S]N5-6UXR1JGI?NE^P4O-CY2$(WX5=(+OWEV ME/@7QE[5R_?=TD5*`ZWH5B@3A;R]T16M*F5)>OYCC5Y]*N+MY$T>I%KG.CNZ+O,K0M1 MY%G++@X_%:J?\$+"6V5$6G9DNKBLA+;9ZEKDV5ONIRCSWI2A`<;7F)7!X''$ MQB+2M,=X4@$HPWYB;1!Q.J'"&HGOBR!#$<3D@MA_!#-\1.!?B+K)YCP8S`D0K?Q M?()MHO\*.P;K$ULYX7T#"1A/8@U$D-#8Q&,P#WB0MT^PM841%,W*;PKJ2:V> M&1V+$9@2O3RS9S$&16`,=^TMZ*D')1.MT(%DSR7Q.&[=X4@2P:6P/0/CQN/S MX?CLL9""1T<7GW\_OHT%/6#BHQDG'2:P'@+OJJ$>,B??9%:^-S!N7'<`MUHP M?_MA^-S"(=QJ@PUH03C!TSO0XL*83.(V,&Y<.GP4XFCJ[.@*$MTY/+J"6!R) M@PC-26<,:XKASA[ZBJVFF,RJ''QRX@1NVF'E#`A'T9V*)%"%QR7UAV=CQ:B% MZ2$#@5'X"-Y5@ZUG0>23-.]FOJII>]"3+7>V[-P(,Q'TJ_WT_.2K^>S#^@HO MUAA8EX')#RGP18I:K,T@[EU=Y]FI.-`?17LH&^Z\,"$G1CW8[1D35,:"'F4Z MCO)?H7^IZ%ZHQUCER4S/YD6P4_B, M!`(``/H%```9````>&PO=V]R:W-H965T[6&*NJ!D[53'30FC<'(3G5YBB/6'42Z-XE<8830G+, M:=-&9>%B;[(L1*]9T\*;1*KGG,J_6V!BV$1Q=`Z\-\=:VP`N"SSF[1L.K6I$ MBR0<-M%+O-[&Q$(+T_LW]SY1K[.ZK@5;#?S5[7QBV)T!X.M&?Z70S?(=206<)*,.6> MJ.J5%OR<$B%./_W:M&X=_)L\"6G3"4E(2,:$U'4">R%G\RO5M"RD&)#JJ/UX M\=K`I24QS,AX4Z9LQRE=X65Q*E,2%_ADB6XP/G'K,1<$-NR3$DDTE9X$B>0Q M07I+D'J/:2!('Q/,;PGFGF`>".:W1;8.DWF7`;/,EH0\ULDF=;*@D]W1\9@O M24:>T$RPG#2Z#`3+*:,K;]1CXEGRQ/^Q MFE19!975G79XS!,2,9G4<&$C$I,[I010/(O_[QB^NIL%AT]PD\JCTVKT$YH,R'<13X(H<$8(#-3;6T&\7A@<-!VN[!M M\*/)'[3HSI-V'/?E/U!+`P04````"``;CVE'/IJ^GK8"``#2"P``&0```'AL M+W=OT4FF.G'Q*O>,J>B]:WNY MB/=*'1Z21*[WK*-RP@^LUT^V7'14Z:78)?(@&-W8H*Y-($VG24>;/JXKN_W$=&_(KS5[/XOEG$J='`6K96)@75ES>V9&UK,FGFWS[I MF=,$7MX/V;_:XVKY*RK9DK>_FHW::[5I'&W8EAY;]<)/WY@_@U6XYJVT_]'Z M*!7OAI`XZNB[NS:]O9[$#F`[)S0&Y/ZI39L3L/D-VS>`V'S,77P9(S*\3Y"Y![JOP061O,84[AL=,TWF: MWH8M/6Q>7,)NRBE0.867DV$\I9/C,&1"9K=!RP$$<%_*%)4R]5+R^PEF:&]F MX;V9HPKF`;UQ&)*ELXN:W>0I49XRH.BEKV`C-$[ATW@$)X M",XS.#O`5030UA$([QW)E`Z*;/RZA=`BWN5 M%"']'$#S`![A_V@FX M/2'$G@,(`HX'N#W!VQ-"/JNX/>$3]@3,`^N>SF%R,4!T3.SM:RFC-C[UR$]2X.XZOCV!'L#.\K@YTQWY0L6MZ M&:VXTH.VG"NF^=.)KNQ>#]CCHF5;96YGIN1NY'0+Q0_#!#V.\?5?4$L# M!!0````(`!N/:4=FQVFYV`$``,X$```9````>&PO=V]R:W-H965T(>59-I_47721O(+!2-./\+8"S^.82==3[1E0CP1XIDPYUDF)!,A MN1)27VEPYNOZ2@TM3G(HF3G)R= MT!TF]IA#P*QF!+'JBREBO$2//3U^G*`,B,V7SS,D]QE"<)],1:2?"Z3W`FD0 M2">![-ZD\)A-*&/"1%'T&%0N@!Y:R1:M9).5]3^L9/]C90$4K)";>\)!M;Y_ M-*KD29CP#^?HW*+[V-VSO^('V[JATZXR13[0%GY0U?9"HZ,T]A;[R]9(:<#Z MBIXRC#K[N,P+!HUQTXV=J]!O86'D<'D]YB>L^`-02P,$%`````@`&X]I1YPR MQ7P<`@``A@8``!D```!X;"]W;W)K&ULC579;J,P M%/T5BP^H"4L($4'*HJKS,%+5AYEGAS@!U<;4=D+G[\<;9)'3Y`7;EW..CR_< MZZ)G_%/4&$OP34DK%D$M93>'4%0UIDB\L`ZWZLV><8JD6O(#%!W':&=(E,`H M#*>0HJ8-RL+$WGE9L*,D38O?.1!'2A'_M\*$]8M@$@R!C^902QV`90%'WJZA MN!4-:P''^T6PG,PWN488P)\&]^)B#K3W+6.?>O%KMPA";0$37$FM@-1PPFM, MB!92&W\YS?.6FG@Y']1?S6F5^RT2>,W(WV8G:V4V#,`.[]&1R`_6OV%WA%0+ M5HP(\P3544A&!TH`*/JV8].:L;=OIE-'\Q,B1XA&PKB/GQ`[0GPF)#\2$D=( MS@1C"=JCF$1LD$1EP5D/1(?TWS&9*SC7(DH9J-,+E5BCR4UJR^)4QE%6P),6 MNL)$!K.RF,E]Q,8A\GS$0.7`:R,*?%M$1B"ZO\7:(K+\!Q=.)'ML(KXV88/+ MV.5B]E@@N1:(K4#B!)Y(0^IUD%J!.+P^96LPJ4U5ZDO5)6*=WGRONR:F7A-3 M9^()@EROXFO)O.U[9!GF;+HT`'_1OS0M`)L MF53-Q-3\GC&)E:GP19FKU:4P+@C>2SW-M&O;)^U"LF[H^N/54_X'4$L#!!0` M```(`!N/:4&PO6WXU39"C48S*B"&%?9+\8?MD!45N;+EV]?$E\E22H^;H,P^=.SNS3= MO7SQ(O'NY-9-NM%.AO!D'<5;-X4_X\V+9!=+=Y7<29EN@Q>#7F_R8NOZX3.1 MA?Y?,WD:96'ZIV?#X?C9UU\E_M=?I5^?15ZVE6$JW'`ESL/43_?B,N0Y_2@4 M)R*YREU7#'N.&/3ZX_+#*R_M MBOZ\_N%C\/RT6"9I['KI?S2^^6Z_D^6'_=[)]^7O%C!Z16]XY[M.2[@ MRPI-E$WGE!F[H28`46#R:.GA^77_HN"YL92T/O)@E, M\K+RV$WNB*T\_"#_FOGW;@#C*ULYE;#WM>\!9(F(UF(%V$C\5!R]C5(IAA6@ MX%!0L"0BEIZ$29>!=$0H4WS7#8+H@;8&/"Q64;9,UUD@7/T*#'D.^^GU>@2: M^NS`5,E.>JE_+X,*$5R&]P!V#75*+7;3J` M&PEBQ/=P#3S;1GP59JM'7@OX[A9YXI=:\!D_]7C19!GX[M(/_-275=HT)+1S M]WAR=#"P>)S)_+1J7J+GNS@"/H\"/;!I'')HY!)1B0"'Z^*B?+`UU&X.4EEO&U%UX]N3&IC!1+VWJ4- MZ>%5D8F'`M"G?BQ).D?+P-^T0-D"'8I5/\59F'4\L`%`Z,G0@\&*/&=E\D3S MY66R*]!L--`:L) M,#[,#09<@_FU6*U\/$$X+A1H)WX(G+_STUI2M@002!B_POE\[$D-_A\E$-K= M(6_>`J7"\(7(3Y"4L_CIC=PN95PQY]0+KY[ZPNE37S@[^(4VC7UT[2)KWP&; M@>ESW*S!:Y7E(UKR42Y`JH47@<92$D)`OV('TIQ.YM&WG\@HAD6:ERB^\,3Y M"^QST-`GL%<].S6AI!Z&IM$M8!1(!VU*)8K7XFJ'YBRP61[T31PE"0Y9@Z7X0AP%\&=E(PH@,).U M3J](>+!EP,'PV%)=2;#_HMVVQERY12!HT-:-/\BT!NG?R%"B=T2VQ&KKA^1M MH;:LEVM1!;IF^'%[Y:=OP;C*Y_!#+]I*<:3F.J[L]#($/0^6FQI9P?J="YH5 M'HJUZVN.@U-X>(+N-TLT6$;M$-<2PULP)NHV7V(*,*WN_14XV%4LJ0F$N]L% M("S1VDLC4'K,V)8N*;_YRDU\C^G"#S(D=YJG40K]*/W-'5FN][!%P*7BTRR! M[U!C1MM=1CL/-4QFKLII519_`A^2YW4!(KZ%QT\7M]^*B]=7/]Z*BYNK-^+J M^OQF\>[R[3=B?5SEBA[#'`(*B4"4PP0:C8$W^)G=D##=8Y$]326>6;X-;7EO.4#7PDCL2.#:R/(]#N<"B?LT0+78KFN=2 M+^<>;A"337JR=!%Q2"W`%O7>&T&9()@6I[%`B-.#FLE==_Q:H'$_*52+6<;05,!!D>)K% M&(&!];QZ5[@5QL_X#K!HBY>G@GZ=X#5ZX&%:*\9J![68COVNJ'VE\PY8&C7%=N>&>]QQ%KH92`K2NV"2 M^%L,'>3J4J$&O=!<<8+H!=D0,4G9P7"'T.G#D`>P%(+]2?00HMV1+1-_Y;OD MU1WQ"^@5H7PY95".NP+TFDC\34@8#E.&1T&:AR5Q`8S,)WA4*-[NP(8`FI&` MX<`'4])-M0VAMP'#N@+#>"Y\[6YY'OB(R^^`O.(3IK+ZS>;SQX8",-B$AA&E M/_`C3J7DDIYL9Z&]"]BA,=$.;%VFG:T;@N6#:SCTZ+>?"F`FC%!D*H`.?Q6C M180`/$`6R6[%"8@S\232>+&1/-JWV05!$`7:EK0 M(P`,O4WQXX1WG8-#(E[AQJ:IQTFJ*X"J@1@_!6G)790%(.ZDP/RR08W+P/OK''@@S>9MY^N//!V<-!,``]#X_W!-@08'`&!`VOG&/^<03E M_+3#F#_Z);:V0E#C3'N0L=Q@A(PV0H!)<8O4EX>XSC]ZK/@I`@K<:3.[;^4G M2="K`\'PL@=6>(9.!U-U@':`%V0KEAZUH!N`D::!7>,5F>%$)1MV:0,257)' MS@W++&04$#,PVRZ01O"\#WWCCH!0_&:QN#ZV<`-X7*')MD(Y&6W]-*W@"<^H M%E,8M8+'V>9./.!T@0_..KS@IK2RO7>4Y.X*U!1`82C%QAK2!ZP&%`#(#21E MTOC,&1F66U&#,&8GG`W5(.$)-PK`@F+$]7,AB*MLW0]`:2!NMH04B@XD2;;= M*4,6=^"NUT"(3";$+YS_T"FK>M,>^4^1#U*F_EP'L],X=0Q8##,%E\E3K3*2 MA/E+=-S$:ZP-RR@G6TT%YPNN$6A`HBEX@G(36)GP8-C:(TFU\@$!L1&G0&_* M5$=R,+CC(SK5RA.6`^HCI#(2$P4PSIQ#E)&<+T12U'9QM*V;*0E5&7CO^@%% M#0@D4JV`8\HXHZP`W*(VO@F)_`R(2XW],.A>&J*R7;C'ZZ,8@?E]% M\(\XNEC]W1*I'B]OWQS3]26_NB&`?FC2'[)(41Y"Q;VGD>".^CC MGG$/9`HB0W`4%(04X',3H:+#L+N,[\'U)8O(T\C1$IA9FZ>,Y3J0>DXR>E9* M@>*KC#U\I"!D;9@HR4A?!FP3^FCH*XW$\A3YD@&BC(R"J(0*3>0Y;Y">M>V" M7*XDEHODKD$.B#,PP#`Q(OIC,@BFCE)F'#QD8TB_C*1"**!]UXDL7^^,`H&8 MGY5I'.5I?X?)#5@4U1T'"XVV@(E8715E$,RI#&1X1V*TB&4'8C4$#DL481ES MSX?W0-!'96/I40N#C.WOLH"8U/`FI^4Z'B7+8%$S.J,2E3+ MZXJ"H--O(EADI>+PQQAATA7G%2KUDW\"(CVPS.30"J!:?XQ^RC5PWDXV/ M.Q?)W2?G$(VA`"LYT-<3*HK2&*K#9+DRPI=N^"%I'4L&1DP&*Z$Q'X?#SM0P MI85T<=X>/`&2I>+H]&QQC?)>9FT"O5S+B.$)O(%"8RS$A62]_)8*4ET#8*Y5YE`;4WI"4@G9FX M0_&'!,(:4&$1-PPLQ+DA$N<>A88?"-#65LU"C5<.@M2G!LI3["`E,,B4B MY"MWK\,/6;C*QVMC(F9=KN)#6Y2A=D"?]Z%\B)SG\R$F.($A#(YVO4'QBM*3 M0AI'ZL]CA[>`AC`?N"3B?9!RA[!Y.8%]@*\2"V;"D=ZX<4(0N7!LW<*.W_D<\*RP:AK^^`;4`LK1SAD^3_%&?C7)8 M)%2?.WR(S\7$&0]FSFP\@\\G\-_8&4X&SF@\HL_](?S7GRB8"H&+?PPX0P!G MZ/0G4UR^!\PX84"&P[DS'`T9J-[$F4['E6*GUSK9>%N7N"P^?:K4'75%:8)J MXA3V@?K,2GB25G(#3Y4*@>R@#*[.CNK<,*7U+1^L/G.K1<]#.0,;9D0G5B:A M4CK!VGD54$2#ADH/0@..$BG792BBB?OE/:%AH"=H+`#_N#VIC6$2FOE M7I5&@`Z\*VQ5MJ&@7OFK`HR@C^]1(")B=N4BD0)D.NWB4."E$'F`H[!W9L\) M*C(JSD,N-H71=(`1O7"#C54FM8C))4B>[%:QT*X=[<+]:-=$&AG[-,2`Q90I ME\?3QSHA>=DIC.[0:!S9,25C)=R+\1R8)-'!XRFS!&I M/$D&4`&N`DL%I-A!!'TD)8R"W4M.?$I&L4\QBBRTSXS\Z#C;Z3`6*6J%@B0# MAWBO@T`JRH$>+5`5B+(U#,!*/X:52`4QZ@$LI(]#.PK"&DZYR\4MFI0I$"!: M*1C4`K)1PC"/F;AH]A::."H.,C=Q+%H://A9BY">=(4]\G$IIBHP$7^((RIW M)/L258W%%&BNH545@Q?$P=B1TQ_,G?ETFG_J<&?(U($5Q$EGZDS[,VJ+3,@JD=]T`NH M5T`-.[-13Q1JRU1*)&_'B$@`@8FTYY2)08Q.-(&#+:6VYSFMV6)O8&<(ZC30 MTI/)3/0GB(-*5H`+PUX1&Y^V%(8UC7NJ33_MBL:IWA44/@?75/HU41*DOHK- MPJ4*A:_L1-/3\/:R\\X:;UEEM=7#B&%LED#=/`4$#SI-=;]Y#@S\+:!?X(3^ MM%-3_6L/',T':*&!PF^N`<['`QV#/09LT=-:OQ%CP(E@`_8':/_TP?4AS-@(+1.NN.)6(#)N"6OVA&@?O&L/$)G>449=J"L0%KFCG M2D%[A,VDX$^^PX:G'S#LW+&:-!N,U]P(!R+JSH=BU!WC@8SG?9"2X\X/DDQA MG3_5.ISB<$TS#B93IS<:\XPCF''$`JCG#(:SXHRT8>Y1JYVL3WU`LUF/)YN( M87>,$X]G0Z3;Z$'<1'LW`!']FFM$Q6(#PH+;M8N1 M<:18>ZWFR4.6PSNZ)/^]63:.P7C@C#_9CGR;@Z2!MXG,\@+UI'(WUC/V-.9\/8L^?J MBJO0XL$!I6-Z4Y;V&R0.F.H*,$4G3N%,=VYLV[+H#RQ]%C_@:BBC(Y8; M-UX9$&#W<*)?`IT^`+G%Z.]AX54:*$O5I:07&=J4PFPDFJY84$+)S=OYK'G0 MWZ5*E88:$WH MLL\EN)B2$WZ8[R$3[=Z/\L`2L:K*5UCQDP"6)+1RU1KL_WWWMBO.?"[!AL/, MXI1/'(1\L5847=33\ZL7IW>N'\-VC=]Z>G'%&,GAL50Q"0G*7O*F5%I7B0!- M/9&NR["L(4S\93%7]L!!+RF]0]F[I;QS@[5JBS>.(`NE0C%B(<9';F)A%9,R M"FWGGH;T=:G>54[X_8DY"*Q,91KZ1YQ(^4!PLG-LM([#_!',^:.;@)&R29', M:LXL/R'KV-11$=0J+Q-+S!J"0`JY%&*%1#N8`EMF<6(?,P&Z`B]AQSZ_BV(2 MT.!JGK`SD5B"$E12O&-FJ61'69Y(E78H5&KLE2I],Q16H#Y'577(#QAW`=+8J/X*-/8V\-W*W;H;J9NRD[18/M8%@TUX;DB% M$YR"Y]Q]EE)4/U*.^(Z+_BDQ0(4A)OM/05]>P\$("""+)BV7_25T1/Z6:_Y0 M^,$:($ACE8#%8`$CD$\`W]D"P6TBH.@D@$FOM3/W+B^_AF72!ZQ75`DMF@I1 M?8TY0P#M%3KX(1"/3R'8VCD*FJ*?6^D'9-=,6DU2/]V*`_$N"#Q8[)S2[4*W MEA!LJ)4M$X>40!5>%(S;+/0YJ^I9R5A=A)HJU.<,PR263^WGI;>HS'$P&CK: M",*JCMP_1L&S@[\^:OT]Z@Y`.LPHCWP9&C6D"7P-M.>K/H,D!2DCDSSV%:E" M;JZSUB";M\$/LEB6D:.8+;J7H6NRT:K4D@K9 MEFP`J'/)*8;8<,UY'DSK.ORJ:H*3]F'M7)9%1+9<88IEH63&Z-HCLC^I),B4 M<"*-N50B9]KU"J2AY!]E_JEF8.T"U!@UBT$3+%;8-@JG\T+D-S21C5'/U$;+ MC3\'2[?#4,OP_^9N=U^665YQT/^"A%#)?E1YA;U%=?(/Q0GRH-[OELHM58F) M"2J])&X[_YBROBN+AOP6$%7;X6H-C8K%_PA#CB:]8Y-Y1[?L#O@]5CXUR/80 MQ_0'UB#07>@1X59CD/_`&E)\YX89LM?,T46[@#6PO==@;*`VE`@AV:R%\]@2A4;W#E%)0E MHP!-P&2P;E?APE1JA0`X%9MQY5NW$A6XP"99"J0`A5/)8&V=TA::`E&D9>W#"VI+:TU MN5S(?Q8OG,I+ZJT5[!2X'X+W*NY\D"QPWGL0V/!:P3$@)U>DS MUM.<=-KN%0)#84):\L3Z5(2T6'3SZ4".'4QJ3#D&9WT^!,A97P-I/C5?57#6 M=$E!S9"G,D>_UQ5UTX#*RIV+J6-5GW#1/M8B@N3#\`Z2$)C3)"?-A0HZ"M1X M08XV6TR):=V=6I$=9L53X-0-%8T84+6?:>#E$$I_5"INQTO<4)A-AH/2/RW1 M\3RZJ6'"HA$T7M66?V-135CGDP#?96W*<_3 M2L.O[&"?J7=6W9,J_'-[*F8@R'[]VYF9@47GMW*%:?I?_^[8R5,41W@W!'>> M&1?45+^HZ(9"()Q0']`'>":SR30O%C/G;CWT",0=1<"PS8A(UWIH"^VN:+K= MP8*M?A'?3DQT"ZDG%2.K?M6I4025KT:=3[EWY250VA%0-IYQV6W\ST7DH`T!/,5>:&C;ZLJ">F1&`QGSF0^H60' M@5R__Z/A=.1,>F-QK,5O8EK-5[!UO*MLCME=D&C#.0YK6!'SU("G&9;Y*`G= ML*)&ISU37>XFGTYII;XP^[/V^RX+M/*I^O_ M@NP'4M#`+\F)]"%"NCN9#%598X MU=*4J_54)P>2$UDEN052OCJG>NK\UI?\C97-78-^GTYW-G-)R*'J8@M5M+3P!)DW&/'QAE M3$\8>_!@QHC'MJR.1E#U<@DFJ6NWY$PL[U45`K>OE*9ZD$NNCUJ#8;!"V>+"%@)L`B0: MM#)K&'W8;##1E&*.!EP?=AA=CN;@QO$J4JS=#N_].`KSC`[5!AIU^\D5'.R[ M-V#/Z!S:*<:(%&N;J`YPCPSY42R[J`X>Y*::GJB"(VJW_ MUUS"Y:7!7=T8":!YTI4J)6ZBS!C;`(Z M%+9C2J?;>*R9,:5HM2CE=KAO6H[,U3^8WL*<@UZOFHC!""5F,,#P#ST*%>UU M#[BO7B[:80"&\T>_]L=K\PR5%;O7&,!W9'O9HT<%4U%PKQC?J['<8 M^`SVJM(_0(D=NU3;6CP#+=/0_]I$U-$$M!1M,K4:$DF^!=:G0)D1AH)5$0.@ M\E8EF#`59XT&2)(M%6EFJ99V0",;B>7L%+?4;6?N7L_*-*E*CC&^GA1"R?!A MKW8KR3GQ.+J>)^]U:85*L7%?4ZQHDL)&,I1KO@6&BH5U\P-'^F$<1_G(_(HI MT0N<'/%U0('.<\3(3UC,#98[V_.QO/?E`V,AMR@T-@S=J991M%$XEXFYOQ1G MB@$?P3X/L#]RJ3I%=/%^';OF^LZ'Y6(*[:M%;!EN@&%M9AQ'K+4`I;.1%AI5 MNL4SY]+-J0T/%CR).(D`R.R\.B'7@1Z(J; M)57)-!4:^S)W@ZC9F$1-49W8\C$OGB\45%?D2-Y;HZJX@XB[1DEV,P3&*4ND M792?9,N?Z2(1ECWJ^A0LW"'ZT#<;<%)5I\RJ8=W&&_G?T37WU0MCL?8DXW1@ M^=VSVI;?>O7U>W_?9^GO.^B<%G;CEM60=?Y116W471QX9ZG)`;7V$=:?Z?_U M[JF#>*+0-M/T>Q('X.^?HU&J&M]LW.M;JS/I,^_[GZH9J[5WXQ`2:6D$^43\ M_-[FT=[F<7#OQ"''U_CR>>U-V/5'^O^SHZ$5K230N7Q?_,B]!HVHQHJ=PWCG M]\:"S]!8<%B2_S#A=U`90?U9_IZ\_HNW#'B\QJE?] M-93ZX[>BVN4W?L\R?ZFGR_E\@O=3JL^6YI]P^;?\S`A"8HX-/X&55X;<&F"^N);$.]4 MA-\FL`^+ZWP][S,$*B*B\-\(3SX$7NCSCWTV#58Q%1T\:1U;#HA8"&SXA;-/ M"8>-T6=JCKH=0_*9HS9O-OA5FCM57:--@*7CQ.6-8],2U; M*_C6E1_&*<8?JKZR'7XH/RVYXHW@.1AK:/@5#1,J>,7W4%A[:D`1[N>-":HT MC2IZ^8_C4M>4.^2KJ!\=-BYW*^G4WCG0\,,MK7YS_1XL9[GUIW;("[1_3Z?A MEYZLX(.UP08TJN##XP.+08@+'81H%`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`L`'_3*@,`:=W2:](BK=]8;0ATX4V%'J-U^D#WVN-] M'EN3G*@=?'")OKV?.KNV&*P!QM4_EE7L`J#96F+'96@\A@;+U9N9PE17UZAH M+K*]R4O!;1!Y\D\%D*!R4%0I1Z<2#ZA-K0RFQ6]?)$GZ]?\`4$L!`A0#%``` M``@`&X]I1_/<2UG)`0``2AH``!,``````````````(`!`````%M#;VYT96YT M7U1Y<&5S72YX;6Q02P$"%`,4````"``;CVE'2'4%[L4````K`@``"P`````` M````````@`'Z`0``7W)E;',O+G)E;'-02P$"%`,4````"``;CVE'&XXJ.ZL! M``"(&0``&@``````````````@`'H`@``>&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"%`,4````"``;CVE'N]#1)-D"``#S"@``$``````````````` M@`'+!```9&]C4')O<',O87!P+GAM;%!+`0(4`Q0````(`!N/:4<)X:3M/@$` M`&D#```1``````````````"``=('``!D;V-097)PC$`8``)PG```3``````````````"``3\)``!X;"]T M:&5M92]T:&5M93$N>&UL4$L!`A0#%`````@`&X]I1T%A_-)=`@``3@L```T` M`````````````(`!@`\``'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL M4$L!`A0#%`````@`&X]I1XDZR8)=`@``60@``!@``````````````(`!#Q8` M`'AL+W=O MUP0``#(9```8``````````````"``:(8``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`&X]I M1S8:E--_`P``(@X``!@``````````````(`!%"$``'AL+W=O&PO=V]R:W-H M965T&UL4$L!`A0#%`````@`&X]I1QH16\>B`0``L0,``!@` M`````````````(`!E"L``'AL+W=O&PO=V]R:W-H965T&UL M4$L!`A0#%`````@`&X]I1SG4?JZC`0``KP,``!D``````````````(`!'C$` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M&X]I1ZH+82BB`0``L0,``!D``````````````(`!K38``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`&X]I1[[,C\ND`0`` ML0,``!D``````````````(`!.3P``'AL+W=O&PO=V]R:W-H965TT_``!X;"]W;W)K&UL4$L!`A0#%`````@`&X]I1]X**?"H`0``L0,``!D````````` M`````(`!QT$``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`&X]I1UR2;!&E`0``L0,``!D``````````````(`!:4<``'AL M+W=O]#K$! M```6!```&0``````````````@`%%20``>&PO=V]R:W-H965T$G"D.IP$``+$#```9``````````````"` M`2U+``!X;"]W;W)K&UL4$L!`A0#%`````@`&X]I M1V,=NL6^`0``>P0``!D``````````````(`!"TT``'AL+W=O&PO=V]R:W-H965T&VP(W(P(``#@'```9``````````````"``=U0``!X;"]W;W)K M&UL4$L!`A0#%`````@`&X]I1\AZ-QE!`@``B`<` M`!D``````````````(`!-U,``'AL+W=O$,!$X"```>"```&0``````````````@`&O50`` M>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`&X]I1P;H-N!G`@``CP@``!D````````````` M`(`!4UL``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`&X]I1YLQ-SI@`@``X`@``!D``````````````(`!Z&(``'AL+W=O M^*C0%0"```7 M"0``&0``````````````@`%_90``>&PO=V]R:W-H965T+Y56ZP$``"4%```9``````````````"``0IH M``!X;"]W;W)K&UL4$L!`A0#%`````@`&X]I1VHF M`"<.`P``G0P``!D``````````````(`!+&H``'AL+W=O&PO=V]R:W-H965TM@(``-(+```9``````````````"``:QO``!X;"]W;W)K&UL4$L!`A0#%`````@`&X]I1V;':;G8`0``S@0``!D` M`````````````(`!F7(``'AL+W=O&PO M=V]R:W-H965T v3.3.0.814
Share-Based Compensation (Narrative) (Details)
3 Months Ended
Sep. 30, 2015
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation expense related to stock-based options and awards $ 381,596
Unrecognized compensation expense related to stock-based options and awards, weighted-average recognition period 1 year 6 months 22 days
XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
Shareholders' Equity (Tables)
3 Months Ended
Sep. 30, 2015
Class of Stock [Line Items]  
Schedule of Fair Value of Warrants
    Quantity1     Amount  
Balance at June 30, 2014     238,696     $ 573,000  
Change in fair value         (374,605 )
Warrants exercised     (13,209 )     (17,395 )
Balance at June 30, 2015     225,087     $ 181,000  
Change in fair value           (15,000 )
Balance at September 30, 2015     225,087     $ 166,000  

 

1

Quantity of warrants either issued or outstanding as of the date of valuation.


    Three months ended     Three months ended  
    September 30, 2015     September 30, 2014  
Change in fair value of warrant derivative liability:   $ (15,000 )   $ (323,000 )
Schedule of Warrants Activity
          Weighted average  
    Warrants     exercise price  
Outstanding as of June 30, 2015     385,800     $ 1.22  
Warrants expired     (25,000 )     2.00  
Outstanding as of September 30, 2015     360,800     $ 1.17  
Schedule of Additional Information about Warrants Outstanding

Number of

Warrants

  Exercise Prices  

Expiration

Date

130,713     1.56   May 2016
199,437     0.94   October 2016
25,650     0.94   December 2016
5,000  
0.98   June 2017
360,800  
   
XML 16 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814
Shareholders' Equity (Schedule of Derivative Warrant Liability) (Details) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Jun. 30, 2015
Class of Warrant or Right [Line Items]      
Balance, beginning of period 385,800    
Warrants redeemed in cashless exercise (25,000)    
Balance, end of period 360,800   385,800
Value of warrants issued:      
Change in fair value $ (15,000) $ (306,000)  
Derivative Warrants [Member]      
Class of Warrant or Right [Line Items]      
Balance, beginning of period [1] 225,087 238,696 238,696
Warrants exercised [1]     (13,209)
Balance, end of period [1] 225,087   225,087
Value of warrants issued:      
Balance, beginning of period $ 181,000 $ 573,000 $ 573,000
Change in fair value (15,000)   (374,605)
Warrants exercised     (17,395)
Balance, end of period $ 166,000   $ 181,000
[1] Quantity of warrants either issued or outstanding as of the date of valuation.
ZIP 17 0001144204-15-063851-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-063851-xbrl.zip M4$L#!!0````(`-2&:4=<&LU]0X0``$A1"0`0`!P`:7-R+3(P,34P.3,P+GAM M;%54"0`#'Q9!5A\6059U>`L``00E#@``!#D!``#L75MSVSB6?I^J^0]<3VWW M;E5D\T[1Z61*L>.L:Y/89;M[=IY2,`E)F%"$&B!M:W[]`B0E@A1OHBE;DCD/ MTXY(`M^YX)R#`^#@M[\_S3SI`1**L/_A2#F6CR3H.]A%_N3#44@'@#H('4DT M`+X+/.S##T<+2(_^_O&O?_GM/P:#,P)!`%WI?B'=3:'T!_(#,('2%X+#^3OI M&C]"$C^]O+F\E[#L:_46]`,4+)+? M5K\BE_\^1I!($1Z8H6#)HK/+_SWZ*+/_6>I0&UJ_G>0_7G9U4M!7TM,<$H3= MM?XC*04?4]BKQI,GV9:%5I8_)>0WX,B/6_8UI*-KQE5(V/"[#;#S\QNN`S&T]Q##@IBC)*+V'NQ/4K4\/0V8%:&?WWF`4JOQA%) MHR=$CSZN7BFG^K>3PHY2@"=%"/=#S)_>I)@+J3YD,9^]23$74GW(8CY_DV(N MI/IPQ'P>-VVQ..K''?ZQ9[$+XP$)SIDD/Z9DK'B_>I;["/JN\(G(U.63+IBJ M9YBJ[RM3]\ULJ)F'JP*%ADOIU6.G#9?2:VT!5[1>:W=::[5#UMK/?X9H MSO'NMQ)>$\SX$"RN/<:@D>^NR/JTN%O,85;(.9H/4[!7XS%RX%L4;R'EARGD MBY#X*&!VE/'D`CWQO^@;DG0Y^8FD,D/P&@)3YO0$L,8"]`O<*O-\6F$`7!67J.W(<',9Y?(@>P+VWYRZ] MF2Y7L>1U-+E,#KU=+E'K?@/N*VW9VU%-N=RS36A",E+??O;YG'W]$$U;_@$( M`7N?>DY&2$+,%;E!DVD0#Q5$R6D9N8>3:1:%>P/\";P:?WZ"Q$$47A/DP+LI M@7ONRF^G@,!/@$+W#,_X7#ORHM&O=!0&4TS0OZ'[N^]"$IG!JSE_SAD(LR&]BK27$56['H[*G*+GGH-::PA M*VX=CH)4K'KWD:^4,N!BEG?SVA% MWPY'RN<(R:KF?BO^B+7I(B_DR[2W_!@Q"IB6?WYRO-"%[@7!,SY7"(-HJL!" M?$!\Y$_H-9LB1+.)17$#V:&3X=0;GP^4;W+L]6E_]&D?]AQ^GLT]O(!0F,OW MNE6K6Z57_@.D`?^<^6'LNX`LSIB/FO`E?.'X/%^$3H'=;X?][>""^@_N#$ M;?9')U_YZ.26%YI[X;Z:<%]\S;P7=9]UK:R3@FEP-3Z`9X)S+'VU[]_>P3Q,3D?@($ MA3/.*3_`9+'?`K\.[]D;OP?(BW9@K:A*Y5Q)]F&N$?22WA5);WM,ES'E!CPR M^\::!MZ>6_1JL=>]MVK-KSX6:+#58'"HV9:KQX[?=1,.S2M+=IFHJ@#33G$(^3[4?7P^5M+ M(@%VO;6$:XJ6T12MUY0=TA1MG[#8W]6XI4WT+>P)#F?T^TF-44> M*/:^E6E,8&_#"V>W")O+:J4.]`%K[@(3Z`"ZYY/)E5E=DI4SJ87$OLIH:;$1 MV-SF:%D56813'%)X.P=.LN/U1S+?'KDNXKME]MRDWD#@?:9<3T:^.W*<]Y?>[ZW07;YJ;-K@A@7%[]3.)H0"/=_B:*UB>/&MY0;^Q)VOOPIYX/RWWON M'W=(>T(?Q:KS^^UY3AMF<8:?#3BLJXIURMY8-K1\)#;.6RIK>5G/,]>#BQZ8 M?N0)Y1]^#V>0N1&\YH<:PQ)94=RBT-TY]/$,^=4=)O*)[BYKTN-ZH\NG`MVU MW(OO2BL131VDVM;9\,@+)=OVG/W9JN614]IR&)!3X+1L]_;/D%%[@7%0T3K] MRQ[#TH=X*U0VD`4%.`-UBO_0=^TY.A,4FNE[3 MAXIJ"@)LWO.S$1?;ZWJEZPAQ:E;6H14;[5IF&J8]-/0BR]4"0[')KE>Z33$( M%J,`1;$-K^6$JC,+JN4L:+Z337`4&_)Z>ZD;LJ9LA"-^NNJXK:%FL8^F#O6\ M:2RBV7%("-VO"-PG1\/R,6.Q>6X0Y*JZ:>2)+^NM%;)B>UT_AE5=61?+!L@J M(+6,L!5=,<1@M:2;S;"TC)L5U=XVNHEJ&8FR&I$)&+>VNK2F::'3JA%*! MH*7%561;5>P-(*2;AX0WUSV`6FR(Z[76-#.3T)KN"GS!#0Q0O&OWZMY#DTB< M!0"UED&TK5M#W<[YB9H^2X6X`M/2,*NJRN8^6J'TUN8ZPG[`:T"N2+3KQ8TR M)*+HU$?>AZ.`V:TCZ:1Y M_^4ICFWU7RJ[\CQ'Y>[=6MD9W2TE#`76[NGXG;EL4(L!Q)9;]1 M_WS1$_N-/);>-*'2U&,UZ+L4;)'-T!N%\65VP9`5S3"T0GCE=J$.4J-D=QDD MW38M0S0%FT+*ZE/+E#?GC%Z(H<`6E7;>,O7->3!LVOD=B9;3%@*#5OTWRGN7 M63A-%>U;03<5.+)L:!FS#S6[#$`='S+]&RU#\LWZ9[$Z0#YTES=Q9C9'COF> MB!6>EE'YP%0L33%D2\QZUG6:!1F!Y_4,(*$\.1HL5J!:9K=5V1JJJKA$M=Y' MZ3QEY+L5B%KFLMF\4QX.[6'A[*6PQY;X6F:NUW."F^&K\)Y&VXQU]Y&749Y` M:>C(R^R2:95.`#,UK&V*MD`;S-J`_/G<[5(;S/*UTUW3!K,VUF^98GFV-F2,JMDR M??]LHYKC5KF[V=FQ4^Z.7L>2-L6]+=_5#>ZZ.:O9=-JQS2QKNK&8QS1G#`ZC M"OJ.D)TVFZ\M=)$5-,O7<'UG:CBR$5;NXT2#+]M)J5"2*VC6/W1=%[;))@X3KM@UYPV2IU731?&O)THID MF-7(*W:4#-M0!\KS=+NA`QN24^MH7]FZK,U?"DS+L%'2L'T2NR/S,7RV)]TR MKV\@A;SD&`L"SWE),1QM=4UV*J^HR+G4TM-X-7NW-%O<;5C9=1N4VCK*PCOK MJE%:IJG(K5"6WP:W@JAWP4C5&NJJF-$M[7=C?$87+-0,S1)WIS3%]P7ZD`"/ M5RYP9\A'-#IP_0#S(,TNF&@9BJ4(&Y1K.L_M*)SS(W+0AWU]3.,-.AH0BFYJL;PXGOD/Q*Z8I(+L+0`-%,3FH`D1IE^M[N.-KG>(W M+AD&9N;3DQYR%X(S+%W)'<0IZG1#:$H7/+-4TS8VA?:[SR*IJ';N%X!\SM4K M/]V:MY*JW8U_,#)3PYJ^VP'MQ$5HLMD>Z9+1.:-F%WB&%LAT0Q%EG.DJB^,[ M]G%VT.01%?B"%F96T4UA1)3VF@,'@W7;87=B]P>*K-B*Z.$SG37!46#C6]@P M:V@,Q1,R%3"R@=UY=,C:=VGNBMK+V1PXJ=7HQ/2KIC$L"S"K<50P/ MZ-UA(>Y.EE0_`8J<%1'=N`MK.#34,HG7H\GMX$_6\I?Q=/0*CPZ1%P9I#DV1 MVWF4HF!?932P6%]0EAH0+1&W>E*Z(X>F*V8P.\AGQ1=C:,/ MA9E9*2$M_-'Z5#'99J3:(AGMD'5+70LG5DR=/C2'LKB]K`OJ;H$'Z0V;*ODA M_(*Q2\4SFG(G$R!%-15-/-!:U.S#374,LG;@[1;;-S.R_$LL7P@SS-<%C)`BIP*%MSI,A"Y&$ MO(_040,$W7@C-NQ$4UX*8>3^*XQ#]`M,1C-,@N0&VO0<=B>3%E6V5/%(5%FW M&Z/K9MYB:?KFX,I.Y_#S7I#_D0MVE?SI\99:;IMZ_C!I$Q@Y6Y7X1^BR@(0_ MS_&UP/YO+G5-U<3T1W&?^:F+PQ/K\!S&_[WTU\M=I"@[L?1#1;=M<493C^`Y MF+M)?[%PLV/,R^/APNJ\DC]ZW@ZL;EFZ6@56Z+H.9;X`1PJUDZS8P%;E2K[F M^V^/MY.YTT"WAJK>)>"DCLAY,@LKK">2$E'@K5HP79/U814-33!U2E?^G'U+ MO6<1I+EMNI8#_1HLN'SCDKRYT_,I707NLH6\AI:J*DVL3Q6H;@GKQ+4.3$,Q MK6T35E+B(*6E$]^K#C6MWC!L`7TG249%E]5Z.]P2?7+XO!!])PE)9C_$W&UC M&,]&WXF[WBKZ\E(1*17=>')--LU*KU*#IS-R.G+TMEX_G)M2P\N6`3IE,T*> M7G4_\6+`+FMCF38?.0%ZB`LU1+LV0_9;\A#[`FE=K;3IFC(T,[G39\#+Y;7! M(MJ!>H='SI\AFR65UMY*"VAU,N75+$5,:S>&\7SXWV4S?YYK>1T*5-`W(F?CNHJ:E68BT`\"WH>6'JH`QT)XZ9!47B,<4F")Z#N9O9LZD;BF8_!_6ZM\B6RDL1 MMW6]U9OS2^QYC+>YN\D7G&@9&*B&90[%ND3/@[=61=*!T*47!,^B1;ZKZ!(4 M^OD)$@=188DE7Y>B'36Z:6F971T5I<\/YI2L3CSH0#,UVQ)+\FT"I@LR.MD_ M,S!,6;<,\SEDQ)=E,''R^Q,N,+F!;NC$5QKEBU:GZ-NFI&O*E6Q4";U9]8V" MK66J:EIB8;\6M=`W1%IP7$!O@)19<%FVM)=$6G!VH)&9D"U#$S?L;8"4*^!M M.)][T=(.\(2](\GUFLL9WN(&.OQF3C1&3G8E)U\`I".%%"_[XEFPHL6Y?-&/ MEC[#M&TK4[:OM.<*Y\:XS/<85(3%^1(A+6=]ALKPVB4NKA1%D\6Y$9?X!,87 MM:2O).'@Z!$0-W&??[!FH'>.%Y0;.`.)[D[CO)\`)0N!Q%5!29C?VWA^O]7_J MWU3]/,?;G:#GI15Y-)D0.`$!G]D3Y%/D9,UVVPHRAB6KVO`EM;>$DFX9FHR) MZ-*(:.-5RJCG%!%3;-,:#N7NV+6&$YE:8\^HFKQQ+`Y/7 M>`?:QVOMG^8W9;A]D]>"GJVH)J27?CPWN<,L\BNS;ITLE:B*:73HJ)M0D-M* MY7G8X0L6Q5WG]U'EJQU57-P7;0",]D@V*#ZJ6(:X$[T9JH+B:G&YE/.0T3N) M.1";S>H,2[XP4KLMM\E19 MY"LO55B(7[S@O8L>^*>_?G8G@-R.1HJJZ88UM'D]B%\E&BP\^.%HS-H;C,$, M>0OI5/KU#LT@E;[#1^D&SX#_Z_NC7R;!^[_^9=E>\M4CJ%/V;SH&S_/=ZWP5=OY.B7]Y)E(EG_%[R8!!`,DC:.95\ M3)B0WTN8S*?`IZ<2"`/\7N+<&2"?WQ5Y*LD,7?P+LU$^';-/^(<^?"\Q$O`C M^TIA?V+BINU&WPP>X?U/Q#[CW]*`X)]PD!`=/4_^ME6-_RLB)"(JA17]]@`( M`AQ(YM?'R)3F?F2=P,"9YG]%_V9M*O(\8`Q`/AQ,<]_.`)D@?Q#@.4<6K'ZX MQT&`9_%OB7P2"9$E^YDA#YCN>0/@,3T\E5@;&5&Z.6G+QP;RXS?X3;6/O7M.&9.E!&0N'H0NBH[D\!.6:,;]8.)XV8_CI9_EZI@X M6HG7A`BFF$5*S"I<4GP#%N^D2]\Y?B>Q*::$V"N/4^QYBP%^]%DC-+RGR$4@ MVO+[7_$'C*>L#2B=Q5#^^UAB89!$4[<=XTF01IBC_#?O(&(T<.+%EBEX@-(] MA+X$/13=Y!K1(I#!7CN6SIA)9F&U!&9)'MV/NI^S^(0,XEMXBXE-VR>KU"?K M(<"\!RYM_B=O*KDH8]G87+"6Q_V@V.5!T1NOG9>3=`^P4LX9@ M=4"(J1+_%$7;!#CDF'G<)#&K$Y428@VPMWSH0$H!6?">$Q,DC0$B'C/12;,S MP,%$7U.>DJ`QU2F<.:;1A>MY\UYOW8^%H;3ZB_DBYS/HRJ&!I MU?\5^I'I9\H83"4<$FG9<#/!D'C/(M-&',1"`JPGR-B$"6LP<0R)7_KU_]G[ MUN9&D271[QNQ_Z&N=S:F.T)V\Q!(ZIWN"+?=/>N]TVVO[=FYYU,'AI+%:00: M"NS6_OJ;58``"23T!I0G8D[+$E3EN[*R,K/X.VXHB#6!WV%8!]Z%V;]PTR]+ MY_^7OR=>F5+#)Q0TRR+_%;J4J%*'\)WCQ:*+C":F<28&UXB&,W"=-8*[R6`= M0R<0.U\OS>U)E#WR\EAB8T'GQ^#4@CWAU@I()X['7X2''+G*,+HY$@_!`S2. M!8OA##(,P2QS\U%F/S/6<[612SW6":_[\>&Y2>BSD#O5\7KDA[Q$++*&S_P. M!X&;@)62![ZH1+GE_(G//\T1C\@2T6:7,>'/%H"9>-BV\(JC$WK^?F)GB34+ MT+&8L>7#.39]X;LD(Q`S9W'GVR?#HG^'`,5,GK)4XU($LX&<`+T=6/D` M&UQ$VF"#POD2F7OBMW#+&D0\`PXA*(OBK3J:2 MR)@M`7QU23X7P=PI'=J/6H1$@].DA9\E3H,R+PG[+);0*&8T;R-A)-.+^[@' M62`+EYY+L2[`PWR7`XNV(,UL`3?%)L*R@2;^;/,#:\;0]\:Q29^1\X(\ILX_ M0!;8L(((.D=T93$.?.04R%#LRI*J(0)(L)@"_.EL4,N%?<;B@TG7I@@D$9," MLC/3B+P"(#??=5'!5.Y4V*+A$PF,G\1/%I',\WS7H8,@@5,!:T@BLUPDI=PJ M\N_+%Y5\<#[Y*].G\,"G=?.)@P*_`O/O_/$KAC/^UISWE<>;BP[!,P>`%^9F M<.@PF#NX4^9/!HO'+`^+)@-Q24K5B^3U:\D<*P[_T.>IB<^#OFF3^%1T?E^5 M"4D`_*LQY4Y"-_+C9LMS5LL?>+JHX5N,?/+@'_+FR^7#I[?$CBZ**GSPSXGP M&]]-BYR;)*F-18[N%:`&KHS/SL1KR5MO.W&\A(7@+,&. MG":.5S243TT/7`;A5L=N\LR7YG`6PW?E66G=`DQW]98\>A/;)+JD9>"\3P<_ MB_S!Y]".H@XSESSR!ET"DW*G/8;G?U,(>;2"O`*9Q9,6A6F""(=(R,`5!?=Q M`B01R5G/O'<<#SL`GUYL,SHY,!/B)/&+R,^.AO3IT*')F.)PP(J#5/S5B'K\ MIQC"*.+$XKB"^-*)CC%A;)J$>*)H!/>((X"X"YM`-$>*Q+U,O5(1R\H&RU,G MG\&3(-\\JQ'V)J"VY)J:(E&.R)J(DO^)X`T#CVP(A;N`<\V`1?\9,8RTP4!3LR7O_,&9\I@OOT!?# M"2.OG5/5!0UCL6#-CD7LJ&FM-W^"L#)D=YK!G9I;V_PBH?0NM,0!/+VELHDI M2;#,_5?HB'5.B]P"N>VA M%^1;P;?"\HW2"`:WU^*&"AY&,-/0MXB/\'-A6!?]*'/G*63`?P9BY\#_\Y&9 MY\+(4QZULF"]BG:@`%,HU9!@]P>A)(Z,GZJZB)_Q<--IV1'%MV`OP M_!J,F[3!R2C_!X`)4I M>8@VZ>3-U?7E_<,L?`*.BT'8E(%W$8.(']Y0M\C2-?'/* MPQ?.#,,;_K-P(*]`GKPXLO'FR_7-U=O\-IVZT9&AF#O.^8"!,F>2I<3VYX`1 M`\.7/$LG.AVT^3&;%_T+H#/>4F'FB@X]3DWN"(+GS5-FXFA/,O6(.E;B?X]! MG*=_GO9D_,5YF5_-&6 M34.N>.X)?H>90=@=8\*`R=TJ%SWRZHL=\AP/GSS'6ELU M-MR"K'\24EP+F#8Q/TX7J(`1&.JUOL93F&ZRM M:/8G>",^&4@H6:B!J(''H-E`%KMTV(:C;*$.H@X>@V8/]D\>P@M&J(:HAJB& MQZ+9[S[E]3LH6+C=;@"!6T"GXP6#6F;V:A8TO(8-Q4X#A(UA!&H^:OXI:SZ; M[610_U'_4?]/3?]ED2V/NH^ZC[I_:KH?C`R75#0`;5#X8\=,"IH)_9MI4CH< MSH53\@4*7:EWY&J./5%9)+I6E;Q9%EL[:;%^6EDC";*DS&8EB7Y9FS)*8TGC M\X'6$1\G[>JD=S2EW^EK_45ZH5CM4/,&3:(0TN.8ADAN+&FV,43GVQB@DY&F MT]`WI`?:GT/;'ZVCZDJGJW71#J'>H1U".W0T.R2K\)^LHQW:1^RMREV"6.7; M^BI?+-K=<=%N`^P,ENWNB098H;OO"MW'0ZH1IB'2YNMQM'8*3325JXFD4!MRFY;0S- M49_K12?4YQH7TC:&\JC5]:(3:G5-RV,;0W74Z'K1"36Z3D6O32'UL6,16-^* M]:U8WXKUK7M.IU8[FJ)V9+VW2"\4JQUJ7J,RSI$>6-=Q\+H.2>I(.E:7H=:A M%4(K=#0KU%'504?MJFB'4._0#J$=.IH=DB6]T^L5%+.@5!VFRK7P9E/^L?3V M4ZR+K5%=;%XD)JNX_-N[D)T_&\;D_97'@J\T&'G6C;BZ>PR(LFO*3-^>\'N2 M'P&X3XYG_OCXK_]"R&_):Y<.?&<$U'H8&3[]9#!J\3N;JR[USB7Y^Z/W/?IK<*Y*WSD\M\,'PZ'L MJ[B%\HQ?11V]]>?#]1FQJ&D#(1@OQOW8&_24%)=J0&V'2'<1$2V'B!8CKP)JJJ9KAT5-J\JCK5&3Y=YA4=.KHO9`'3`4SX#9 M5W'!.GRNCIE];8=FTP*S#B"ZV.7%^1],,BUZ^( MW`J>=#5U.[B+'[WT80EXIESR/TW31^Z,*?_J\M7PK5MA0=EM&,!BXO*.`M]" M<;'N#,5!'L6;U'YDD!*#LRQ>-]^^`&:JWE6[&9[L',Z]D>$OL0Q3Z_(%A/(9 MA)#ZILWHG6^;*?][4A7B`,?OJ"\FSE)(.?LH7PS4O1!G&?0%)'M:/>G3VI/> MT[$!:NP^7P&%?,,,0L-YI/Y82=?^A?^U=SQ'KL'#O3=9N8![; M9;;Y/X839J1+J2A=<_9$&\AR7]N+7.4AW2U!_@=<.V"":W$+9\+'1X]_56Z: M>NHVIDG1>U)WAU2J"OYNB99H-KMQP<;8'LP:&$Z90!5XAALL5YJB2OW=$:X* M"KLEVN_P8#";[G??8RRE48&+66R3%D7L)[/?N[;SX2SP0S#U[^:@-D?4"AUZ M._P\GCC>E-('ZK^`02Y!)W(#X-/M\)Z:WK,+&U`K`IGO0-ALVY/"7N!#EMC3 M>`?-7_WUL_5L^`^7E[*B=K5>?\"WR+\6-!$B!5OE_SC+[9(.^AVE(T8_#-D@3V(W)PM'-%8UU(ZF;Y8N4D?5*#/O^]W-HFSN2S9E>;,*DSK*YGX+^0YD MN$5"B;#:X^1<'VWVX?6B.VB/.X,VNTVRJ73D`V\7SP-ODHT[S;X7E"O\A0]? M^`,?:DD,*C?PZN?$-$L>J]7J]W%&FS>]Q0][?1_59L8$7> M%F$\F^E*'>Z MVF9],]!D[\2;7[^J?;'Z>6]E`V75"?LOA'GD]"@H7R@H%3U@^0*6'63*#J*_ M/ISQOW9<@["6/8EN?EXT)8N'"W/?1-#,?;E$\V.>OR]M6+#1N=INTM:+"A\: M0#]GMPUZ-JNM.%8#Z^;R+-M-!5F`+#A-%M3%XV,DY%VHX^U%(IZ&/"6B]&;?U##9V]1C%",MB$@[Q^/ M,H0RM`T!12/T%@L1>K?E%%K(B8?QMW!YBT9;O.YMQ2UI>_!-D1/(">0$<@(Y M<4J<.%SS@P9P,`I>I+52Q`CRUTZ0LF;_;?#T2OK.I",K%WU^JVA!'>7A^5PS MI-?KK+-WK#3[R(XM5-5F5+AF:.9 M7$K=\G)WU+4Y7>.W4**:G:2:U9]@K=*T[H56T$('->T$-`T7M,.IF3:0.W*_ MX.J%'3<[*>UU7-[M9*$_2A;M2&.:U^9DTWU[Q;[(3=FU1XU/1(]E&K<^(8$' MHLP"W,4WWH*CO[/)+E[1>QVI6]D4UUKLT>E!IZ>^N@:[^"ZJV4FJ6?T)UBI- MZUYT)=2TD]0T7-`.N(OO21U%+;CP"'?QM=K%M^[T/;>/%_7THC,H;N&;;K[1 MV=E@6]$9P!:^WT>/YR15!CV>PV[A,=_E--6L_@1KE::I%QK&I$]3TW!!.^`6 MOJ]VI'[EY#+]3ZR&`WPIN!.D?]480/I[I M&(Q].+L*?>;Y=YXMKOW("&^E2T,J-?GHD,?/QD9 M+GM/C##P8N-ANQ;E5XD(E17?!,!!-H17$OE^M2WO%=Z2X2-(73JN>.?\E3[] ML.$U_BX+?.\'3:XVB@QA?#E(O]_C?T8%JHGZ'/12D^B:H\BDB:?B+Q)S*^IE M-[B^9*&V);DILS"NE=#F0K/=@N4N[10G_'KI0NCATQKV+S?[;*29PI!K^\4& MGEMLR<@K[,(DF3=O>5;5\\S+Z0+;MA2.,KDOE(9-E2%OVJ.QMM.08IG.7,J5 M@:>0QWG[/D$^U9-/MRZYIF84!99[(@K<[9!@1,DG#]9%X@U!-WU8"SV?$8O" M^L'5U2!6K+#$<\73#\`5X-<7W:[?#OPR^A0UN_7M.QVP]]6QO.U7$NG;YF'W M_#8'-Z?-V)PBGVK%)^"(S3_$ZR0LM[[]$L6?'=MXLIU$1>V9BB(SZ\I,5+I& M\$GD@"3'5\^A;1FN2853:0#B%@_47CY=I"[ M/N(H(86U&%0]`;U%&%5H.MX4;'.&(+Z%);KNAI^?D#&,-6*$@F99191H*_8; MM5IO.=8H]2?,_SW?D,O'3BW84QR@D>B5L'Y9"7F,IZ+V&XMH5,B^4!+^ M1M8ZDE2YFU";&/ZV;7BBWIZ0WJJ*NHGBZHTEQ#+%72O%"Q.^2`-/K-K*IR8> M'E\2%H[AEVER8FR6N,T9=SGQH$M.DN%?7PPUM!EL2LB4&CXC$Y\ROJ>S\*"Y M!KS?XJ!9Y.[Z[V:+5/GY,QY&SQU&G]KY<^SDY(%/YRF2MPK^3U-H4!@XW`MA MLF'%IA'I<&'$2E3_[Q"($V'$2NKQ[43S((82N-2J@59W*GPQ')/<;`?FOT*7Y(ZTUHC]*.\FS_N+1 M2((LJ;#<'XD4J=M8&A7$3I<3*1-@5=1^1R_J_[Z&=+7A1'3/"M@H$B%!=B@S MOZQMB-3&DF8;0Z3U2@YZ4*B.Z(XNN2O[%.A.5E_HW:ZW9TJ>`:G'47_2UH]/:809SF*L*6AS9) M<['D>LNX4*E-MN-@IUKQ,+L/'3>&U`5;$`#;^OQUO3M+6T61$PGN8,AK MY^>JBM:1^KV-C'DCB84BA,;EL`>FC23&-C9%[LL;'Y$VDEAU/17%^&X1^4_A ML!3C%ZVR!$CG'2Y/!4?!%0A_LI&+%GM_:"3;*8!(YQT$>4L:T:"IQ"#O+FVN MC6;CI+!R$!TIO)/(O*[OS*M'6UGNX./5INUIF85\JA6?G"4]?18;G26M M@#)-HQFA=C""36-\6Z+G$R]SC[O!DBYZEA&(KGG\@,@(;,^]*%#B9.YL-[4) MJGPC1.GD5+Z)S2TY/[)W&3/!++RWN"8\0O5J.I\>>9=7T?65+W]1B\^HGRR0 MEA'#<=*5LWBA?*(PE_ZTO&9)?PX]"P9V++9Q#&F"4([Y)O6,K[]-6=:CT;D?=V0N'\[4$>V[L4* MS4&70"+#0BE2*'(P[9M&ZTEY=E]Q&CQN(EHD;U+V9Y>;*\F)UQRYP"?*^#TE MS6>OH&\$V03XMPO[M<5ZR26'O;7&;;GR%RAX5#O00L2B$\%Z8T;*%'`N(L+M MTN*YI=K7.OWJMVLUC.N%-)AE,<0`:/S!Y+L(3FTMB4$2-$XNRG1FCBYR*04S M.19H1H+_D"\4!6W(V@JTE[SE(H>J832?[Q8GPM1-M<#5K>A:&Z3#L[1&"!_( MHA[&>+Y1UKJ:^'BZO)P_QUF#EUUN7&NS;$:I4Y4BY.SQ;5V<=K M=]BLI-2L@09]:SNC7/1Y^D.40]\0PWP@I%ME8%5=:D;,;36/:F1G&V(ECNK) M--'"'"!6AZ8IC>/)!?6>:)=VX?]5*5TJJ6HX9!XEYA`7YQ!'0QVI,(>.9\J8 M?BRIC$$&-BD)',P)KX`R'&*['!51#T6,)R\,1$+VE3>>&.[T5T9,;SR&GY:D MC"_NI=ZC<#1`NY>5R>8A7%HT>YS4^/4$IXS1F_)T%?L.E(F?^AL+]0'9M/M8 M+F+O0;K@UU6>Y4(Y6^3E-ZV91,ZIRS4>*'+E%MJ*+7DHVV&LU&^/LQ+/"FQC MJKVQ>_$MD;V+[PCVM9`5+Q[DV`KK4*F)W[I+6 M-//1AXMN82L:JP9_VT`1F6-%'B>C%>W%L<2J2Q>#;MND]>1XF^)X M:P8>CX'LQ[*?ML>N:!U=JYP/TA1RG(QJM!='-.WMY6V*XS4UHU-#]-J7$LZB MIA<%P)+CIXH&_P@1Y`6=7:O$I.%\.1G-G<\":1&2Y4M/OYU2?))+CVB:`?HE*7C%BW4YY/A>S\V3`F[Q\"S_PQ\AQ8!-GGOT,[F'[S`GIM,]/Q M6.C31YCWDP//?/S7?R'D-YOY[Y,TL#1YXBO@,+ITK7]0PR>V]>'LT7B6!_(9 M,>$'&.">#C^<7?/DW7.I=R[)WQ^][]%?@W-5^G[/K]B^'2:)0"(/Z''D4_I5 M[.'//O)-_+FD_?9N]?3K@ZEL`^87^R4/I:SL!TIU&R@?[)\9(.$EO3J0%K7? M?Q;78ER%O@\ZO0F>&`B+6_J2[VYL9>0-B;>P_]?D[+C&!O;NS-O?,@"?;F7K9!JF\W-6R& MNY[QQ-[W/7P\XV MQ$I@;^[ZQ>K0-*5Q/.S-O2__;WEN=R8#>-/,RC2)==TA/DUSZ:DB9?61PUF0 MM:DW)VMSO11X;!N+;6/KUXT3V\9BV]A&""JVC6T3FCL5F4(IQ;:QS;6TV#86 MNU"U"T=L&]M>WF+;6&P;BU;]%#4?>PNVE[?8-O80MAW;QC8#HY-3?S3M[>4M MMHUM1O<^;!N+C?M.MG$?MHUMMP!CV]CZ+CS8-A97G]->?;!M[,F(\@Y2"_>3 M$YAO"'GEL>!V>.=[$U@'I_=T8M@^NW2MKP:_!]XU7).F282]JDF$)'3MZ)D_ M'Z[/"%@T&RC+>);?1Q6V#6G:9(7YMP"XOPAP-P=P=_\`WU/'"*AU9\#CCSS= MT#"Y;7^@#@C?\^_4I;[AP`"7UMAV;1!9,/TO]///"74995]\;YQYB_UE!Z/L MB"FN@]TS9[^@5R(3*^BAF^"L2-)1LUIS'9WYX*9C,*#C5>@SS[_SN$#XVV3! M1E:*S*5DSW<(C5-`1>*U-/LSR5^2$HA7.;[P_I+^R/,5;$IW\G-)GX+(L4N< MR^4&-5T'>5]G]UD<3BH7PA:FWRQ9*HJ`GO->I0M%L]UY2/9<9%*`5RSE)-+= MC)ROPG:M7N.3`B&:H_IL%7O("E'<*7M9G^S\NE:4L[7[2:]#GY<>!B,*__F4 MDC%,,6*$NA;0O3" MDQ]Y8>/EW>?_1ZZ-P"`/4P;#`K`WKGG1(=ZK"R\^3D$N`%ZP.!\YPJL\(X!$8!ECF13(`.U^'`)65Z`. MWA@(+PP()\;(GI"OA@LRS!\D;Z[NO[XES!L&KX9/22Q,Z_'P8B&)LO`&@Y7^ M0=&:?0R?"'#:O?]W")\HT],=>`OCW0#K?OY?FL&L:KO]LX_V;?_91EL[_.YHH.U(Z?MRE_@N(B.'P_OB?78LG M\*9S56^`?WXNZ?`AFJYLX'F2?K$=ZE_!#\^>GR%H];;VER:X;,!EOHZ+P;)T MS8V^P$UO#+HH-G(/(U!3EBVLGT$R5ZIU(^8&LLJ#C)A&[V;;E[./FB;) MJJ:I.58OF761[RG]OL`W+`6K\N9/W."0%X&Y0J=7W M!Q.6:B#>%P_\`X,%\>47J1#>@87/BJ`"UN8B:RRK@Y='Z\9]H2S@-+WE;M=E MP'?=*09*D89$]W9\-0)P88+I'Y2QQY'A#J1K8\H6(%^T\KJF]/M:/X6]$(:U MP%17@QF!]^CIXL:0$CA_,ON]:SNPT?%#H/>[M8#HK@9"YHKYZ*G\GRJDTL#$ MR%S%=TZVEK09F&6/EO7VDP\JST-59<4:W(U=>*O<>> MFE=>+1?65ND\ M1:&:-ITKE=<,[Y@PLRICOHXNNRV@"50K/[LOSQ1;EAY67I%9B0V7RSJ)+6-* M"1\**W>W@K"JH.SK/IXF"-5!"(QT6M]BE=]7=!HT^Q.\$9\,5B<)G3254`-1 M`_=%LX%,+-@+D\!#V4(=1!T\!LT>[)_)^1^J(:HAJN%Q:/:[3PUX`P4+M]L- M('`+Z'2\8%#+S%[-@H;\<&VG`<+&,`(U'S7_E#6?S78RJ/^H_ZC_IZ;_,IE2 M8^,=%.H^ZC[J?E-U/Q@9+JEH`-J@\,>.F:S;_2(6@J[4FUV1T2HJ7UU?WC]4 ME;Q9%EL[:;%^6EDC";*D1<5*$OVR-F64QI*FH*W2)VNW$$1CJ= MI(6K611PFY+;QM`<];E>=$)]KG$A;6,HCUI=+SJA5M>T/+8Q5$>-KA>=4*/K M5/3:%%(?.Q:!]:U8WXKUK5C?NN=T:K6C*6I'UGN+]$*QVJ'F-2KC'.F!=1T' MK^N0I(ZD8W49:AU:(;1"1[-"'54==-2NBG8(]0[M$-JAH]DA6=([O5Y!,0M* MU6&J7)._THM:U[J%-7^!ZZ4;V);MA/RBZ0=J\HMC;U\YMJ!Y*>N:=V)SCLE2PKKPU/R/*7X?L@^PNW]1:20=6E?O;& M\/K305FD0S='A^Y&=!CH6J_;)#JH5>7A\WCB>%-*A7K<3OCHU6BBJ'I7[>I- M(DJWJG!L3A2Y+^7NJ:\_4;2J-V6O0KW7[RJRW"34]8KRL!)U'71AT-LKZE>. MP=CM,#9;M_X]=SANPX`%ALO[$Z18%=\O+^3Z&M;$%X-#%8^S>&O[(H(WW[X` MBHHF]3,8K@(G#_P\@HL7MBO]HU[8WI9V#ZO::R3NL:(>V4&.^TT$WD1T]9A] MD32$GCFXJQM0P!AY%_J?(0OLX33'W_D-@F2[J9>]?"\A76CP\!(G_8E_Z%Z( MD9Y6C%D*YVR@/SS&R(3Z1&C*DD%7N/38JJ9&K6KRN[1)^[E49Y:4&XM/!K-- M`BL8$:LWM0B-5RZAD8QK)+$9`>MCAH[!'WB:PK,OMEB"70K.A6MZ8TK>.*#& M;XGQ8MB.6%L"#]:W\=ASHU%&GF-1G_'7@Q$E$?UA.`.LF_%,B1OR=9DW^,B^ MQ8B7+K&="%`/OG4],3'W+L1P]AC(%O"W#7=*)EX`O+`-QYF2Q"N9#F0IS"(;(*9*/=,L>,1AV$0@KTP1,NDI=;ME4;/#3W' MX31"4:JS*)6K_`;=_,0$P%B1"MR$W=XVS?VBES^<\9>QT]].3C1/F@:S4@.] M>:4%V_4.R:XF546E]AT`3HJ%[57U^MRYUS3"U:S$FG=?K/SR-8@045?E^=4 MD4_S0=M69^?MF(:GFBE;&SK*LMY82D:)M3LG93;]=M"1]*UR;]%F[D9.FT5' MI%J[I`^M)%K)&LKIJ<8TURP+N2K*H6A;2`3#0H>N86PD5;;J$:)+G;Y4<#M* M6XF%(H3&!27C0,9EH'>TWF9]/QI)K'W7MNX[+-Q?'NW8A\\YG7&N;NOD M^1"$7-]V[OZ,JS$,JJ-/5^LH]XVA'1KQFC&D MAL*,W#B8$9?[4J>O]=&(8UR]H9&=/=JA@\9@M@IMU!.UIL/?6M9@V&;]L(UR MH>W!57WT`L-)BZG3ZDDVJ]1L_19@/Y0]@-N9`%[D>%I>^.10](>0(4W9"O3Z MW8XBRSO9"L2,:"2M:R+\C:$=FO,ZPFI292#[V.ZB+G#:+CDBU=DD?6DFTDC64TU.-:6)7&#S+P<8- MV!4&10B-"TI&?:B"76&.+T)87H1=80Y&6FPH4#.&U&9KBMS`KC"G+?>-H1T: M\9HQI(;"C-S`KC"G(_0(=@5!H4?S3E:CY9)-#+DD.8^9U*6@43>#!)9TWO:H`"2W#0EH'RQ79L!_7_W/"L# MBK(9*&J_/^@70)*;93U(U$)(]%60:)JFZ!M"\LUS0?9\^",%HUM*D.^?7=_F M(OP)+$(XGHWR5;1I6`ID5Q_TM")ZI1"L`:)62JG:@*B7@W@':YMM_AG8CE#Z M0G6J`*\L2=*@B/%E\*;69_;H5?3<(S=W0HVB!UJA_5LAN:MV='V`5JA.;JBXAJ?8"3T%.O-L$&*[9!+E@^!) M8/M.0[&#SGZMNJ9W>MIF5KV1Q$(10N."DG&@C:O4[?1T[/UW=#=Q:;2RN90N M/-FH3OXD;Y8\\\39U@GF=L3!=A_UL@%(YUWVC>QW^@/LEH+^#EK*-@L@TGEK M2ZEI'4W!YH#U=.M;$/W%?D75)FM%OR)D36U1PQ##DB88Z"0?A338:&)#I:^< MTH`4WH6/W-6ECJ9ABPX,**"M;)P4HJT\K*V4U,Y`V^S>1[25^VQ4M+Q5R,H& M(VDODK(>(WWL,8(]1FJ@A^BA8(\1[#%2$U*=4!DN5MP>F&;88^1X$6+L,7** M)@X[#9QPIP'L,8*:CYI_BIK?!DT_ML/4UB-US"(YH2P29$UM4=MGLN'I]3M* MFL\#G7CW^0Z/U9_'YQ]5F=[$=C_[5((FT@,;CQPBO6;0Z6UXMS$V'FDCA9`> M:(70"M57IG"'O!VEMRQ(S#7CW,@U;0SIL'*S3?8`Z;S+SDZ2U)$&6+J).>EH M*MLL@$AG-)5UEE2L.-%9WHJU$6XFVLLX41EM96UNYBTKXLIKV?#'\ MG>]-8`,QO7.`Q)>N]?GOT)Z,X:7??8^QM/Y]D*]_OTDKWK_/7ODJRD;/2.C: MT5-_/ER?$8N:-E"9\1+UCZK=8-^.)[[U0_G85L+NR,ACT>ON%6ULBU,&(^E?&Q(8M-QA'JW3(8EQ^ M,ON]:SL?S@(_I&?DW6;PZ:7P+:5=3^\/]$WUZ](TPW'H&`&UKNG$AW&-P/9< M^.Q0_@%>OQQ[?F#_K_B^=.@4BUZI="S'0M%D3>JF6.P*LGWCV]^0:S*HJJKO M&]_L4"G,@ZIM8Y::&E77]7Z*0':J"D!HTB(0W1P0W2I`Z&`WI"I`_&7X/I"* M`:WNN9_%;L.`!8;+G;X4J.*%3]BV:_"S7F#@%YH,5<4>Z[HD9>!;!D4>WB^& M[?^/X83TDC'*YS(8K`'6K0L>%*`(/A2\\LE@-N-/"80?J3ER[;]#RA9;!6G* M45L%Q:[A.GV#%B=I4Z.@K".-O8%.+F:SMTR1;-UNTXA4LSK=_PZ!.'8PY0^S M<"*R&@3)XS].+YUAGP7G31/6VE3G-XUP-=-R<*K#Z@>JC=;EIAW^Q_S7M5Z3 MJCRJ4_F3`9LWDQ(C($E?+<+W/56%,=$/I9WDV;C0K%D$.4IMHB)U&TNCK:Y/ M5?L=?<.TU%FU7F,I=RCI:A:)D"!'K'U5)+6QI-GJJ+JG=B1ILWN<3TZH,"_^ M,'2^&AGN,R6V2X:&[9,7'GYNV\8=@Q>86+>9;>>?2:N1SHL"5F"4KN"5E_DW M:J_;T:55E[/LET9OCQG$::XB;'EHDQSU$OJ3^J;-J-4ZVX'USS4PTTCG.N[O MWLAJ1Y$&&YGZ1A\R;".I*Q8JM)"HN6@AZT3G[2QDKZ,.=G-M(5I(#(#M[/RU M26"A":%P.>V#:2&)LU4*L+V]\1-I( M8M7U5!3CNT7D/X7#4HQ?M,H2()UWN#P5'`57(/S)1BY:[/VAD6RG`"*==Q#D MU3;VX4_65&*0=_]-T#*QWP\>=@EN/ M1K.V4HA]-@\;F=?UG7GU:"O+'?SE?3:COR;)E$FP7A+_6Q>M!5)MR9"R1DR% M'-BT.Q/?QX@I,C`N;]D$<#[]L&$L/B#(B_>#)IHN9:KIYN0H:N#$'PDR\,1" M\,^0!?9P6LCB"?*IIGQREO3TR7`M5K6D%1#QAN1UEM=O\ZZ1Q&8LI!;0AGB9 MCG(&X\_"`\0R`LH_OR1MVBX*E#B9^\E_-P\&]DQ+>J9%+W\XXR^?Y8AS`@W4 M\H:EV:YU!8RR'8Y<[]4W)A_.HG^;U_&HK#_1X\BGE(QAK!%8$]`LJX@2;<5^ M.?]/$VN4^A/F_WIQ_;-3)U<+L%ZOA^#)6([#=0@L.?JI)F;M.9]$C4.-.Y;& M==N:`;#;Y7[#WIFRK+2A2U11KFTF%D.L66]^@,%XLAT[F+Y?(E@)=1K86+1* M'*"1Z)6P_I?5>"IJO[&(EO09*LV;:C_#W[8-3]3;$]);52GIZ[B^,'`WE][,7[]%A]2'41X"^$V,GMZ*4WP#F[COYP%PI>Q3_O4*5_YH@^Q5 M7`MS+P/N863XE%V&P2.]:7=O,=#S.MX);B+2CWD+4ED.T(QJ*W/G=YA<;!=YDR>ELB964;#>UN,L- MJG2AP<-+DC6>^`<].HI]6C'FTE-D\?(7^R=H:V2TE@RYPAZV-44@)AT+##]H M0-;`BD2.]E]E=D3S:MT<&'XZ;9:=/ZW`2:;A_&AXF;J]J M@]1C*:%EZM'"9LP*37&_+DWV816B#H53K!^N6@?2*F$AJ;]RP)+PB]J1^U)G MH*KKQE_606%[VM2`Q+V#DW@U4RN1>/_5KRNANQT.;9-6TK0=&N@MA'$3/BN* MWAD4M><\/+A-(EJWH_4*KA?;%[B'Z.VT$KXOH>_:0>A38K@6&=H_^6?62@;+ MW7Y'T5$KZDVT&JP1?U"#T1%LI8@]GOC>"^4+13MUHMN1E4%GT"NHG4:MJ!79 MCKU:E&\R;WDIU0&VJ_%P^^KLLQMI.C!T)?+9ZX`W4U4VJ\69=JEA*`#[%H#S M(S/_D*MX:Q><8P-6#RB.3)[#KKNM959N<>K)_8XZJ+Q`G;",Y\BF]P<=O5$1 MBJWV8N5NPA^4,6*89C@.'2.@%K'HQ*>F+9+*T!&IDR/R!EQ13>YHTD'O,+IC0GQ/J,DI\&FV1`X],XK(?<=0_RX"!&7S1["Y8:.Y3T%Y= MO,M+_\FKP<@O62LCJWI'U_LY*R,>SS^E\X.SO"WJ`)1L0DU>!.Y,+Q9D++%7 M!1WVLG8C6PQ5O<`I*HVRF?_^COH\Q=%XIK?#>V]J.,'T'FAW9TQ%I<"L$$HO M+>C*%&W=P1S9DBWE[*-T(#$B^OSQ-'V?5*>5Z%$3M;Z/4G*U,E5AF]KM/K;H94^=.-.PH#]04': ME&*4?S+[O6L['\X"/P0VOLO#?CUK6?!'W+'`!NLV@W.P3_+K.IC7E/J%H*P# MK2[M@:KR[JFJRX?C_K847U^V=:40.WTG,J,IBM[K2D=06;VX1K,2?%2NATFZB;RL:S27%^RGE:KX*X`P)4W!M=K>2FY M7KX"5B@7'RB#05]5LDMW^9QYX"YA0\B]2L.Y,VSKQKTR)G9@."E@Y4O>4H'J M*UI7EV4E!:EDICPX!28G[2`P`ZHG8<$Z%JQO7+!>J0I]L+,J=-X;*S([67NW M9/03+4BO\RX<[Q9H.I\>>1Q$&.XGZGBOA)]I\`!),!(A$E@P)X8[_16^LUW# M-6U8`Z.##Q'H<#(N3C`R`O)*>6&%:7JARV,P/-("WV;[X+G$(+/N..2)M\>) M[Q\HB;TDAX'!F9@`[:/(L"1X3LKF31$8V]0W?'$V!R?!:%C$R M@KDM"IP?`Y\M8DPFCD#&(]0P1Q&N.52G,$%`GSU_>I&1<93VNDI[28_4',-* MPFPG$9VO'R//P7T1S)Q]D9S+E!5H%W@6D2THOS#SJ8CAR.,Z*6O"SSGC6LBY MMNP]MKEQIMK>H`V7S"R5&3[2.HDUE1-+&T"7]3J&[YA8I=TU&D"XP_44KT3U M1R\PG!VD$#:`\JC*J,IM5F41H2WOL_O+KWVF:FX['0I^P10/CD>.:/C__Z+X3\ECSZ M8(ZH%3KT=CA[Z5)<'W_I6G^DE\=_I08?Q;IU[Y.KX3_QF^$?N?C,AB:V]>'L MT7A6>O(9,0$W^.&>#C^<7?/*XG.I=R[)WQ^][]%?@W-5.OO(,0`$^*N_?K:> M#?_A\E)6U*[6ZP^XL/U:4)=*"H0N&W1MJ]S63TCQ*O#V\QBKT;$:O>ZY]0VD M"Q;*;$BXFA7*8#4ZJC*JH[N6(V.=5=8=X7W[]9/K$Y$\Y`@:(K0%-5;K$Y$\Y`@:(H:DAMW,W8B\776'Q=]U3R!M(% MZT(V)%S-ZD*P^!I5&56Y%:J,Q=>HS*C,K5)F++Y&949E;HDR8_%UC3([L?@Z M1W<<%"IM,3'J0!2@;Z M+"A":%Q0,IIH7-!GV7/Q]>*UTCN]*SI_#?6=,1WS?*W;X;7]8EO4M=B=3X?4 MAW$>`G@\/0%O*/N5'_BIN'#XC MH6M'[__Y<'U&+&K:P#;&RR$_RI*N*BD=-@!VA]BJB]BJ.6S5FF$;1P*YE-QS ME6"W8<`"P^5)HBE:W3Q:-Q$3]7-5^GX]"R$F0U7`0NNIX'ND:"R#(H+79O[[ M&\9"`]"X'5YYX['G"G1NW"O/=:D9V)[[EQV,XJ$^_Z2^:3/*OM'@=IB\>>6Q M@#V,#!_4>X:JH1F-GL;WY]@6XIBK2X+=W.T( M%DAF3QUH$8[EP.2%[\HQ&(AN_/BM+QXN%,#>H@!NSQ5%T:1^+Y7"5>!LHCG] MK0`OH')?7E-SDB?_='T*:];_4NMWPW;_\`!5-P4AHP^#13'1YL5DL#D"6@[^ M%5#-R8OG\JQOW^!ZFZ86` M$ZR3%,"!Y7$!NSM82;/H*6GM!+5KFYF.Q]V0 MF<.1HEC@+Q1R[^PC]X/`#>*O_OK9>C;\A\M+65&[6J\_X`TO?BWHE$`*O+O< M,6!+.C`-"L]UE_KEHNR&K%\*' M?EJQ'RF=?3923K09\88D4CQ1[G`;C*A/N,"S)=-AEZ5Z-W-98/S"%F^.-BNW M>=BJI^GV"8V_#)]L%>((P,B?BF2_7-U>P(O('G^D%N0Q($/$^'HL!VCXQ M@#=C,?`$1,*SN"GBS\&`!,P0H_F1Q\:4T)\FA>?A5V*,N3O`WX&G0I]O,LC$ M]_B&$D9R"0O-T6R^"Y)!GXP,!J0)8#0^,=]D6H1_#^L[XTYE_+(1>QR"*D_4 ML2EW.8.1$1"PEO9L#(]O6`)/#,&`0_80U@0`S0EL,W>_@+'B)B<8^922,3PV8H2ZW-`\T$D@MB&S'G?"6O`]3H>_`_;SE?]? M-M`""0*3Y8:T`Q_8A(=J7J@S10O40AE%"]1F[H('M6AIP,"\>AG;(,Q" M[+2`4>`NEC`,0V&\4M\O,@\S[\:?!50BYRUKB8R\'6)`&AYJB*1O9J9JI8;G`U?Y#_[ZGI*H!->)'99J)@7RO9S`I` MYFF6'57IK0/B26I>S?5LSCR(6$N1P3P!3K7=1A88-+Y_#:83'J-SIF*_)AJY M!GP'R^/W^7WAV+#=`/YCL&M[]OB1B`7[6^\YC"TCW[BFYM9X\L*`[Y8]FV\] MXT/-"_(`/W,[X85^]FF`A`&L#GP?3`PP/!RET'^F_C1N"Q-[=S!2,FJT3^8# MP<[6"DV^%PTB5Y3OD^'#-,864!6!;P9;9?CJV?#%D4X,%7F:BK?$3IGZ\3Z9 M/_!$73KD>`'G8?6(=MX\+B!0@.=8`-2"+V#KZO,]+UARRQO#WC\`3Y)\I1;0 MUN?6F?P=`DV#J#`#_$X;%$-0(3U@FIGD9"\L!J0^ET"^!0]`Q@T6\)%\H`>, MSSUCL=EW'.]5;/$Y02PO?`J&8<8(PSB&Q<4&AGDR6!0!&-DPG<]YGTPB1HC7 MPQDP?`[XQ7BF@E0_7._5H=8SS9"1^\Y\5S_C"^`["PX`8\T1B#/'X)E+3U`) M9!Z%%=(8G:`2.H3G9B$7R@D2`KM,F(W!BZ>YN#349.'2T@P^55U:'B*_EX$E M!J5EX63BV-Q>QVXM&*HX\ICUM//A4A.^!#J(%>)K:FT6PHJO7NCP:",1ZU?@ M$< MPJ]_AS;8S,NK'OT+DTAR?R1_Z2.]<7S_^1'!PD4W:IG M\TL30/1^+@-DQ>QIBA-/%3%Y&T7K3Q?`L&Q.4<.Y`S4>@9]R^P1L%E1^I/XX M!;H@O:LX'>3.!R#]*Q385/BM(B/=[+TCRBU:2T@BOAZ3PWGL_`$[WP/ M?*E@FH*JEW+Y^U_@RXR\D-$'KD5Q'L>5,0$OT;FT(C`*$I^X^T>_>%XPSP0E MQX,RT+8F?J]R+DXQ*A_OE,T)SU_[%O)Q;H>?QQ/'FU+*>-:=+8[D4BB+D[3F M)!E,V'@QA2S.>%LRS2(L5[.=S`R"RCE7R;MEJ3T/AD,7Y:`8]CSH,ZBJ`#PH M2+*:3^O=.<#R-@`?+G5J`]AG2=PCV+=P`;[)'!S/4%"JB&F!P97[`UF5,PM! MT33K`%*\&NFK`!FHNJ+UNNO`(7)H4EKS1-BKT/>SVCLH2$ZN`HT\T&4MA:5\ MIKG%TJ<3P[8^_YQ0%U8*UQ(O1JGV"Z!IFW%,T26M.\@LD:OGG%MJBL$I7U]6 MI&RJ74GMJ9GUHGSJ/SSWN51PBM-X5P*@R:HFRWHZ?\$D:T!1GI.[`@I)[_6T M-:"(R)1./-A0'.2!U.\/^O/TGYLLMDS@3W$!!BF!;_R09JL_YB1"E:3-(.K* MLI0M0UAC[AT`+6_&O^Z@KVCJ#H!.%OE[RL.?2T$M-MDK055DI3?(2-K*&?,` MI@G4F2>_P8HV#]Z&AGP^"7W%?`5*<4\#\/2YRJ2.6R&$Q<9]I8`.](&JZG,* MLV+2.0N28I)"LZD]EW2]IV0(EAE\877)%.]$=0N780#K)`^QIX!4LN0E90\] M29+UGIQ;7I9,.L<]:^9YPXITX\9^>PI9>:7&4A+UE2[`)&>@*IDI#PZPU+!= M:GTV?-=VGQEH<#@.A9)N M[7PX"\#G.B/O5EBK0BFMM)\HXZHFP;8BZQ`NFW.C95I>4OT7L?1J,XF4H[.# MS9;PJL`7KTS5UH*M?(PU%4?6_$-AC6V79N)L-(+C??S*2(K M8U3=*IOEGC;0,A"OF'TNWC*A_%?W^<8UO3'E]9@I>)5+\Y:Z4[(TD+1>QILJ MF#,/U`W/Z(`=]@*]"JKMUP=HH&7T:&ZJ/!RP5?#RL"Y`5'!"LCX'U9ZF=#-A MLM)YEZG-K!]`](804FZ[;\83PTR]8J7J\!G+''NXO&F%F6)14-J^D6B"2ZUG,%D3GHH;71YFH/S#@OA4/2Y9$3SH M9JO:*X,Q'P$&._:)Y__P,WCX7;R3@MK?A:0#J-D%N'C.>6,`4,,CUS3Z]\;E MX3>79R=E_!"EZH'*.UH]8/E3^LI.1.S!7@K#O)A.3/<9YM'-W.A:%4M6#HW4%]ED(FQK9Q] ME73=P\+KVR8P4UP9-X-U)XNJK"X3IOS4E00HBOJO(4`K^\Q44HRNWNLIFKY2 M@"J"-^]">+PHE'WQO?%\#YH4D4T7V^4[OFIS%ZR0ZQ.Q)W7EG$]?/G,E4?@2 MU>]6%X6"Q7-]6P*2H&HKY:`B;.D9NAB`YSY_\?Q[RC.EX?/M\#K.NITEZ\Z0 M*5AJ-U!/&;8_T1EY10!2B!]X$J%P;@PGXYG%K$P6AND]-7F#GUGRW@R#;M5D MAA7]C\2.?`N`Y@]Q)CZ,'[EJL'D;>WY@_^\)3.7JRS/ MX[@=+LL;4+L5>L%M8#@2)VQ:<'[4+4^<^WX7@BML_AG$7L-LF'OC]2LO:["! M/I4ZLDE2=ADL`*<$WB5]<-1NY5P[[(.S11II_'F@J$?NFA,WR@F\BG7V1 MW-,\RTG=5^><62U7>3^A0L@Y_A>D9$O@$35SL6L^"0/(D0+NW"2%C3SZB8W('\)-CF#_F?TLV M`'SB_"\QGLQS;&M++O`=\:;"6R@3C6$$:CYJ/FI^MR3@YYZPJD\EY69.(M,\`51/IL8W0_+(F M8619;RQIMKD`4=&[G<&&MZO&I#L90[2QUC6*0D@/M$('O^.YJW9T?8!6J$YN MJ#CK+79"3X'.?WG^#]X;=\)S!UEEQ[,II,'34+Q<>]]67=,[/6TSJ]Y(8J$( MH7%!R3C0QE7J=GKZ9AO71A*KKF[BTFAE+)1G?Q?>`.#$;7(L^=9K7,> MMR3.^N9M]ZF#3E_K[L21QLI6M)5H*]%6UIG":"MK:RNQ"T!;N@#D&3YI/Y]B*K#`\(,& ML$YPZ:9PZT=L1M[8;XF?/9$FP<@(R"OU*1$+`K7X]45_AT!9.["!58%'O*?` M@"]?/"<<4V)Z+""6S4S8B@<,P/+)#SJ%K\<30)U_Y0V)%_KDR3?,T3084=^8 M3(&_8FC3";FQ)#"ZX=KA&!AA`?=G?P;A$Y>&9\^Q@%X^C0$T`+Z0P0A\.GML M//,Q`/G#=<2,TY\;^+;%%@5SV=Z/NUP9IBC/(Y/!A_,$2;P)X!APL$4-0&6#A_'!6&;X?GJA2"= M],5PPGD4?1KS%`30&W-Y(P:(#?!"`)/H)6>WD8S2X*#6H7/$C:TCFK.?, M>#Y$QC-G#*+_OU`TVYVS6^>Y;PM7_B?_W?]G[\F:V\:1?M^J_0_\7+N5I(I6 M1-W*)JE2?.QZ-XE=MF=2\Y2"2$CFAB(U`&E;WZ_?;H"G1,JT+,FDC8?)R#S` M1E_H;J"[XX5\OKHT?WP?\,,I(?,/L:HY!HW@>#Q@]!I&_>)XYJ_/?_V+IGV, MGAPY<`WI='4#TOP%^>X(=`9U.4&"G=SC3\"1]>G@FDS;G>X!BAF">$DGGPZ. M,?GIL-D_;!H_K[V?\J_A8;OY\XHZH,VG(]?ZA@H!.28<[)NH^W``;&++07Z[ M.C[0+&J"!G$XUICYW.X,6\ELRL'XM'GURL[KG]0%`7!@7B-KAIU!?!2'6UI^ ML+_?R?5+3FX]35IMXXE$.9G-'6]!*0C&K6W2_#>_>\"\'`8>W1%F<1$V M3=\_@I7NN^?_00%0TYNZ4NE&4QUDIWI6=G(#HSOL);/;&:1[0L@%J![/.O58 M>`F?,Q(L#MU;K>`^HR84YBZ_\CXT8&'IR%?BR2!ZY(`N\)"`X M%\L/_UW"Y%HGX>)][>&EDWO*3)OC(CR:3AF=`E^?N3ZS76Z;O\."DLA2M[D9 M@W4'[>:@G6#QV6:RA%`?5H0SS@-J'0?PU%0207R:BYOA]\*!4Z+6-1ZO5>2X M:=2=%&X>#51V4LFB=SY)8_>2.JBPD/?X"G)YO$`F,VR5%A-< MAF$5QE??G%A3PJY&(Z,%RV5_,$2'ZTU.G30MQ_%*[YKA>,)N^71P%##NL0M/ MV%+IC;52%=M6+19??-:%SS)IL?@9=R^LA`8F&E@M\9]1)*49`?G0'B&\O\9I MC0,V88FU5F=^?U"XT1E&QB)/;KW[FEA,Z+&Y4_RK+TVYY$+);=8(YCA,&]6' MD\9:%I`EO+Z)`WKR)0E[>(E%7F[JFL!XYDJ$='$Q9UJ"CP\%(VMI7G]HLH^* M_3S5Z"T=I=AT_&(NNP8#?^*!K7(G_%LA+W-0(\(EENX3(E!ZGF8*@<*_0RN* M)5:&);21>,V_891J,X#WAH/;9,'=3$DS#;6#\!?A1^?#'F?\+&@N_F@)+;9< MD3("T[+YW"$+#)R#6MZ):LPO9KFF2&1EXL?+JF99AZ>K7I;4U^LJ5^:JQ'+* M3RJO)/18=)0DQ6N)M@VUY"`*HBTQ6E&5DUYAE9.<4A^/A',IBHBC1[H&=$(" MH%0.*;\]3T_DS6)=?9;B->_Q\*[!Y0XJF=6,@XKKY!2=&-;^SY[-/>:#%HB7 M[UA3`/CBG_3YX8?-AFS4/O.!/*IF$5"$I:)B-W$=FTW8L2SI8ITNK9S'\&QQ ME9ZU%*TY^"54V@MFR$Z5*;I=)5KZ*.6SZ511*32M MT/-Y(HER.2M'O:>X[7[])/ZV!F`QX"X@+B,+*T<@EC?\TX.(AXV^WMTPYWK5 MR=[N_)-YLZ<:>W47>QF M::F][%='O\<%1EIZV]AO9$0M#14T"Y7*KK/(*Y5=;_H]+EYHZ)UN6ZGLY[/F M'U^=HU3ECA>2>3`2.?6KN1>ZY@M/(G!3"1P%"1XB+0P3Q3DFEX5NAR=SS+0[ MPK6_I46F/3#T[G(IW'CJ&!S%!)%H5)D!0*U#`AQ)IE2;BV0VS8,_HYH#H@S` M4CV!%-2853^?,^_>Q@(1SD)+0V,TNEE0M`4EC&\](04<(RA->)@NQ*N1L_/8]!F5]I)*>XE2"_&O M+>?`/&H]VT[V7XD@7TCS#TG1F6WLZVXG;2(O\:8&^'.V6X%OL]R>G8#RHFF6 M+I6B2*!(\#I)4!7-]6R)AB]CF=X-ZA7SJV6[=C3[$;K3BF**8HIB5;++U!JO MUOCJ:1^UQM>/9E%9-T6QNE!L)/#W<_ST0&W_>1"FL MNI#L@MFF6E]J0ZXCN,B(Z0?$442K"]'B0M'*)*BY25"_:6TH>4O019!@=I7( MG,K`M&L<;5\BPSKGVY''2C)%-13X"V>CMW_@D4S10/*1YZ M"@)%#Y(7S$3*NBW&T$I.!C8(V=SD?;#=2!Y*]A`L4Y10E%"44)10E'A-E-A? M\8T:4%`&+P*?PSW16)CX.0E7>31\"99>0=VC9.168X`983EYO/NG<\4F_;C* M3CN?]0:%#YPD-[.EMWL=O=W)*8940[8O53:ABP]F6^5U7ZO(%#+/$LZ,0NP6 MEUM0LK8D:T9CF%.E0(G9*Q"SZB/L14E:I]'-*>&D).T52)I:T/8G9MVAH1N# MG-8?6RZV4UAKN[C:SDI]GO2TI<34K\S.IGY[R;K<=?':96-Y4>,[79'F%BXK M+[[V&ES9.YMX\:U>7V]V2JOB2K.],GJ4T5-=60,OOJ/$[%6*6?41]J(DK=/H M-)6DO4I)4PO:'KWX?E-OM7,:;BDOOE)>_(O;?<_X\2*?7E0&52Y\W=6W,G8V M<"OT(;CP@X&R>%ZER"B+9[\NO#KO\CK%K/H(>U&2UFYT54SZ=4J:6M#VZ,(/ MVGIS4/IPF7+A]][O9C^=.9ZC]K>WLP]V&MIUIH.+&3!& M75^;>XYM+K`!CN_!OSR@0G!$@Q=Q#1N[\,DB[`<30\#E@'94T$2[Q;13;/N" M(-'9W/$6`-4JX&$OF?)80NBQ<4R"C4ROH):A][I%>(/WBU[KMO1V,QLUU)-G M8?)X,L.^II9DB7LC_5D<=]?H7R]`7[)5V0 MQ0P$CU\#%%\<0.3GO_Y%TSY&@XT8)>>32TJ<$^[#ZQ?,F\/2"A)J?3JX)M-V MMWV@F3!U>/V23CX=G"'R#IO#PW;SY_ED8IOT"E>B;P*[/X_(W/:),X(U2PBB MO'R@!:XM7[_Z,P#(3CW//]`L:MHSXG!L8/2Y`XM+,L1:7H!8.Z2 MFM2^Q;5K93:P$,_2\SC[?GKPV?CX/A?`+.*!^%`F>#W*/`"FM1 M7`$*NWP"KT2FU9UM85+QIU=90V>-B7 M:C#HXY^R-D)DN>VUGY;4-]*:%D^%%R)+7Y1JV*!SUDI:949[+5O)$6X:7=O- M\;22(J7X8R#U[/@1EG=6=48#I<1(:/2,(*WYQ@.V::SUL];O0SFERPR[0K\G M4VRV\;/CSQG,L41P91!(\8],)./@Z@`@IBN!T!QPM-N83\)9#0G?Z__B% MPGOCW457!O\`4Q><)##%+6T,+KH;.^`3/'F!1CA^1)N#70U&,P?[$$=/]7(5 M2B'\L+5\#X;$/[^2.P;K-]5.I4EZS6!^.@P;/2>"!7)2,BH`=)YQ"0I,.9H7 MB50,.'A_!C:C8O2Y](VRA71$'F%:4*M:QDZQ% M)\`^<50A_H2.X\7SFC//"DQ?X_AV0_M"38(8QC?D,QY[PP$2J2;G<[@HV]EB MO]K`\:.NP&0,Z`(L6S"\BW]G0S@9=_GOZPFW,M/-9LGH#'B$1T"#S004\#0+ MX-6!25TRE1@?4\<&5D'^(SX.`MB_(!\[S`L;"9 M\YS8EB9X7C)=PFR$A_.%J_`RND<2$LD"<'7MW$*<3P(?_+_B:(32M170M6I- MK`>=KE.*-U(#:X7P!I6@S>W<384C6UT,1S;[0J>1*2[`,/0YZ&41K#3D73VS3LX)^NGV7'2CMU&=NF-; M5N694'K>R#M>@6MX`B)+U(8(%7`T/83BD`<"K"@0 M$-D[7CC[],XMF#3@Y>%)%&J!:3)F7@"TQT?'](8X$^'?.PX^9((U%X8FTO-` MB&;PO-Q=GC!OEOV*?R/&E%]S32<0]H9XQ)"/-%Z?^%1<6)2BJ[^BBWP?HQ.ML:HC+"G?*5*BX127?6@4\;($6'T4-+P-Z#: M3X+A::M$'(.;V=Q)[)Z,3:0+E<`I_044(V"P3#4/X\L8UG&G<,TB,S*E4G.8 M>/8KKO3DXK')/'OL!T!*7`Q:X4X-JC?\K!?X`+_8TN&!>8,A>I-2M'K`=F)B M[XC+L#@^$GY6UVS<5EHTM!\T"J+'\^1"]=DS``D/_-D^Z#A?FP';^:%9Y5.I MF*1FPW=FH,BG'IA>?-UA/,7Q%>!XI9EJ0J?X8$9TN/,:H0ZMJ#'U[W!3[AMJ M`C"74#!1EUV`;X6"_@5F[+FO+Z934UHKF:P'G8`B-OXX<\$U`;'+DTU!0EL) M71V(B6-LVFBNX.B_(G*5B)S9MC6:47`B%:A\`W8RR+`\Q,*#,;=SMSXO$HD<1-* MN#V6&H;[@87AX?"Q&X3#(N236-MCVJ".-S3 MQG@V5MS'Z-!":G.B'4LE*[3PA4-M#IK?%.RPNQ/N7747@2 M'[6//;%!>#G,&X\>3NQI($T\&>6U*`>0(HTRLUU[%LQ0765,F=:*):-QD88+ M2I`*>_).'*@/0NLS/)N-RE+@>J5X0.?!`:65)E]7'%QI#E::IAYT>MO:@:9! MBX1&+B.:/*!D`,90^C$;*&V.W'FKY@A7;%-IME'B70\ZO6UO7[Q_XR+BD$12 M.$8=`*9%>HV/;XOP"76UMQGK83D&(H4>;0+%4%5F*"7X]:#3V\[V!?^">;05X0`\6N(#ZC(K>RM;=5*;!&`*8!Y-7%F+JTADI;E(27L]Z'1* M;"=@=#D<&!Z6\FZI2S"2=V>#`#+*`\='*YQH8YD;%T8BD_T;<8QJ(D3;A'$M M7;[JC>';N.&0"D_.B3Q>)C:1\(=E3R949OB%6<IF2 M>W$P-#S2)K0%G@NC$P)0*W51:394ZJ(F=(J.B60W"+7W6KQ%*-/OU.&1VI)8 MB6(MZ)1.3>ENX_3'>I'./1LB>`7_6SXA$N[N/<.!$EV>]L9*8>9;<)53[^_4AH1*U>M`)]_=/[GV9,KE\;@B+`8[S2(+4=L>"^;=A&<1A7M]!QB!9XQ6ZB%Z/\=: M=;CH,FTL2YS]F[@!1NT'8AGMR?7;];1)P$0N&$4(1=4=M<)6FIV4V->#3KC9 MGA'[Z-0N"C;:TM+"323TE(Z9$%'I&O24'%::ODH.ZT&G$<:R9;JSJ.$IJ2S;(F$A%7O-"S-$$H\)S,:?0]6^4`$R<7&&.`LC(_3R82:*M9= M;1[:4796?ONJI(7)XQI\+#4'P8(AYY,?A&&;FW-VB;0Y"7L:B3J]\4T>WN5& MTB.DE]NRI8==09+>);]='5]0)AK%I%N8M`X^&XU6*S6/36`I,9WSP`>!E54< M8\C[QQ4_MV M=5[%%&LVAIVM4`P;UT2W3M`1$>&_;P#Y#3#Q'YA^$$]I6+;-3NX$O8"%$_R, M]M*AT91M<]9_74)I4?O#L6<&*%P7PN$Z<:UC5/X1<+UFZ38YR>^/[PL'3KY[ M`G+L+R[I%"L#`:#?<9F(/VN4_FRZ=)#\<-[(61X\*>>P;P:PZ?]$3R.37GH'8S..PI;9,71BVTTTQ5RX,2SVE8"*6[0384>LJ M+KYT^PLIN);0#3G/8['53[:>V,8-5VKE8;?V2W`$U`%3X=C+)3DF5 MO02WT6GW>L,L=5:^4@#(#X_].G,OL,H+3T'2W0R25K/3[S5S(,E\)@M*M&V) MZ4\^2/C)GX$M$J+B93$!J_>L?:]>2E.KJ&E5L_GW)YN3^7;9BM&::UTF[5X= M,N?P;/0K;EXE6\@V&\;\/B+$0_VJPAZPN=VIRAA]:_HLKUCA$3+&GF,E37JC MCEM&N2_`I($\+B[AC_E:VM(UQ:;;4M/FJ&?KV"'FK^5[$0O,_>4[(2MPS[$M M"7ZF;>(:'.7-O\!]R4Q%4:$,%?X=N/29"!"W2:N$Y.V0P/NC)BY53Z6DPN'N M1+131;<*.2&$(@^ MDON)\CRT=I@"2-C<:O7TX;!;ELJ[!+=. M2.OHW7YO?TC;[6)4$K[3@('_C]D+N/_Q-W^1!#8Z`[W54U)1;:158(WX MBC6:L1>E9L_FS+N5E7A>)'D[NM$:ZL-^7TE%Q='VW*M%L9-YCGOY>W!7P^&V M[GUNU7?8,W0%_-G7P9HIRYOEXDS;E##%`+MF@,-G)OX^5_$7N^`\-V#5@.*9 MT;/?=??%$BNS./6-@=X>EEZ@7C&/9]#6&PSU7JTB%$_RQ8K-A*]4-`PS@UD@ MVPY:=,ZH*;LD*T.D2H;(6S!%NX;>;>[%''VGB%\QXAM&1Q^T2^NL[1)?K=TU M,K04>NJT%K<:W8@RI_:]:&;)J<]US:6/V5-;-^YN%)W\0+ZJL[Q@[-"M;-;N M'ZZB4&7'T`?#;,''1RC@$*R]AH,4#VR9![I]6(0[S\\#L0Z+_L03N*G;*_DV M#Q\F+GGX^)_,2Y^'7I.2(@\(Q"^6.$[?:O6&PVX)H`40FP&L#ZQJ`]W!"V(\(Q1P;_AX_=$@=)>TIL]CM6[4LRSA(PC6)\Q^]]`X8)PO8B MEY@(@:V9))*3A\[<>>#SK]C/Q"A!`*,[Z#>;J:2%TK`_>U_ MK5U1:X,P$/XKXIYKQ!9=I1OLJ2^%,49_0%K<*G5)22.Z?[^[:V)-%9H57P13 M\WE?+G>)E"_7<]#ZE#/6-$W4[E052?7- MDCB>,_R9X8,A@5MXV%,ZJ%3J4"H+6O%=`0%`I^:2P._2?%!(\PD&+DDR&QF3 M06(NFAIR,5 M;O\`4$L#!!0````(`-2&:4=6E=>$;P\``"CE```4`!P`:7-R+3(P,34P.3,P M7V-A;"YX;6Q55`D``Q\6058?%D%6=7@+``$$)0X```0Y`0``[5U9<]LX$G[? MJOT/6L_K*K*3S>XF-=DIC1VG5.7$+MES[-,43$(R-A2A`4@[FE^_($5*/'`T MH(.0-"\^I.Y&=^,#T&@V@>]_^#:+>L^8<4+C#V<7K\[/>C@.:$CBZ8>SE/<1 M#P@YZ_$$Q2&*:(P_G"TP/_OA/W_]R_=_Z_TB'G^[X>SIR29 MOQ\,7EY>7GU[9-$KRJ:#U^?G;P8E]5E!GGT;)BN&*O';P?++*BG1B"9Q9F&P M%AUIB'^]$8JL*9M*O[S)22_>O7LWR+]=D?)01BAD7@Q^_7QS'SSA&5H3$S-Q MOZ(W)^]Y_N$-#5"2=Z?1DSTE1?9?OR3K9Q_U+U[WWUR\$D: M?#C+*%^?7[P]?_?F/&OQNS7KP+'Q^T0`=8;CI'])8TXC$F;`77U*)[=SS'*_ M<0?]K*2[FI`[@=-@XNK`):]K\U>$!Q'E*S@H(AJYN,6%!* M%G^V(%!?=0J*`4]GLUQ:GX@)M.2?,#I3=@>U,^]RK7'O?:\NLY?0GD$692%F M(EXZZ[U@,GU*\C\[Z_O53&+L>0UEH]^EE#[WNMDT:)]+)14]_L:/'A]CGC`2 MB!CC$O&G89S_^OA[2IY1E*UZ1B#8"VC@PT:`S[!Q=@04338-%"#[AQ\@NV-4 M!%7)XBY"<2(4SY2>9T'5%ZR"%82E`20]B\_0L3`6"A:]R`(>;_V`QU+[2^TT M(Z61ADZ7AS!9Z,R!=G%#1M&G__2C3V]H/'W`;)8M@7RYT5+TK(:RT;]22I][ MV6P:M*^EDHH>?^U'C]\Q/$[#IR!``P6-399]7I?D5T0X#`*:BDELC`,L MXM?'"`LE#1$`@*49$&A9#@`,%C9;@D,OV:_X4+[=&2:7B+$%B:<_HRC%"M18 M\3;@`^0]`!RY>,$24,`F_(I2[Y\H2V!AJHZT@1LYZ0'`!&"C)2KD$OU*@>6A MT'H>Y,:5R,P@2WTK&`X`%F![+<&AD^O7WN:&H$<2D81@PU9&3=C;\Q#M,0MR,P*7'WJ-?T%+4T5@[[=@.-^$LJV*\]V,?9/*(+C,`"X#O4)!CZP(7$`':\&L>S6=\,(H,U+)%]I`1`S/7!2=*R7X% M8N6>]`XMLGA`[":*61*,&`<)BI0!2,*A(,O=+8Y+&[PUO])2RZRH)>A@3-)J MF,.'EI7QSG.7&4">I*HJ&@K)3H>XY:F&P<)]*F:GD721-^;2TJ%;C#1@6N*I5KYF@F<'438]5'2HC=P<#379GFT$Y:7ZMX\1F2[? MD3"6+]JPRLJ-C*Q>`4E9BF3G`2.86F5*1OE^+4Y7F)%GH>0SKAAEQ!*0JP$C M(Y?W"+*SVPH\1M&`9&AP,%H MI`L29$+;ZTZ_ZRP#C8T84)%)\@EULD/I?X.!+KW?%NE7+O].R,(B&@J-O:^A M;->;MRD/!0-F,UU@()6J2*G)K*7VI M/+]"\DO*D]M)KMV]F#"4JZV4JK78-JB\[W&]75:=W1+5#JX[C:L$]D:QF&7Q MC5!?TJ"5+5`1 M'_^(.`D@\R%)J_L!H>Y"ZFJ]?&"T M&JH."&,#?BV\]S@2,J="W<^(?<45JU2/E8P,S8=+&H8#`0W89@>\Z&3[M9Z. M,K2#PLVM>QD48-7\VDXHK+DF,8J#+0\*2Z&P00$6>K2#PLVM>QD48-7* M?*4GQYOLI>ROHX>PVP@V-JU8V4"'/12PR.X"_"U7-[OT\YJR,0[3(-/F=G)% MT\=DDD;E85`-L#AP%KZSXCPF8+F[;%=PL]+(LQJ`*SQG."!+,,3A<$990O[( M_U7,:P".UIO]&HYC@J:]BW8]`VHU\>O=^&'XOW19!"&&$`"'1OK6J\Q*^F/$ M(-0]NT:@1@^_WI/\L[AEQXC<2@7,UG`)+9-YZ\E"K3P^*#L3$F=_Z)_Q6?-# M3WEJ\Q\C>%W=M_/I%:Z7;U>.((9_1,+N2SK+--2M]7KBUK4C:&=^I!/$(\1J36>TX"HVDW[QV9-EP*4[[P%9?,2(S`R58Q&>+893P.C!H?M M'ZAMAR'!*>E+HH%K8-!H&!'Q;AG"[48>[K M*-[1`=J3)VH*S8NSL9T!K>:'`5K&?T*`-KJO(T#+]"H![1@H M]@GY]5JWD]493O7#=,0.8OD!C@.!TFRZU&@!` M36L'+[EHV*X&[O@T,!I@'/)KT9LCSE/A`WP[<1T%&PEKG1WF)NPHQ\(V'+OS MX>"HI%]O'LFMJ!S#9H5]"1\(YC6^TT&TVEW=@+>FCU]URU6%?T&,H>R`!\P" MHC[&",*B06>;Y=B!:7#2/C'95L6OF[>KNN;CY38_@Y*7"JLN(P#S:8"IX#MV M=$+$H:%'<*^9"%4CA,18&=O2,]U*+86H$A10`1XBV;;,QLDF0EK!UHA M&JB@+"$!47&YG MO4'6\IDE5SGN,D'5QV]XG5[E.GKUQVM+ZAL;3Q`V[&E83=*6L)X%520LP*^[12K*4<4X=N)371CQ:S+.6N8CW*5<'')-M>8=3AO.U@U_A M!)&(=W;@>ETO?ITFPI#/)":S=%;&C5>IZD@%2V[5_3XF[NYO--)K6!3=;^:D MAA`W7ZV$=+]HVF)#=O."B\<,US+H14JO:@!JX==[.#-T2Y`SGM:`3@;/" M:V)7U6-0`L>GC##:))@MAF:VW+# M6MH[U-),^?"LBJZ7"\E%^I5N66GY"V5?L]/$:("5EPKIB55@:!`?$!AT9CJ" MH2'2KY<>5UJ.TR MKLE&%8*V*>FZ[TOUP3`(TEF:G]12O;1)_!WEUS@T;F^R?==HV^*;MX-L3?SA M(7Q'KMUL+&Q/*?EK'W;E$\47V8]'L1T6G_P?4$L#!!0````(`-2&:4=-\0?4 M72D``#"P`@`4`!P`:7-R+3(P,34P.3,P7V1E9BYX;6Q55`D``Q\6058?%D%6 M=7@+``$$)0X```0Y`0``[5W=<]PVDG^_JOL?=+[7DV79R6:=VMS62+*SJI,] M*DE.=I]2%(F1>.80$Y"4/??7'\#Y(@F@T2!!$I3]DLA2?P(_`-T-$/C;W[\N MDZ,GPK*8IK^\.'WYZL4124,:Q>G#+R^*[#C(PCA^<93E01H%"4W)+R_6)'OQ M]__^]W_[VW\<'Y\S$N0D.KI?']T]DJ/?XC0/'LC1KXP6J_\ZNJ9?"-O\]?+F M\O;H/&#W-#T^%LQ)G'[^6?SG/LC($;77>Y:\ MI.SAY/6K5V].=M0OMN3BKU&^9Z@2_WBR^6.5-`9$QZGP,#R(3@#B?UYQ0PZ4 M3:._O"E)3]^^?7M2_G5/FD4J0B[S].2?'ZYNPT>R#`[$L9GXN&)W%O^\_XZ.-CT8L)#1A-R0Q='V MQT\WEW*7<%R<1/'R9$MS$M%E$*?'2[*\)XP;7\K*URL.KRQ>KA*R^]TC(PNM M([M>%O;]*"S[SX;+07J5T!U8'2>+0RE*:`ZOV M/AY'9!$42>ZRYV79;BTND=6/P5O157MWQC8M%7+CC+)@_3*DRY/2R#ACQ^%] MMCHU6R=(7[\Z_?'5VS>O2BLJO&W57\19F-"L8.3X?1"SWX*D(!](('[!/%OFVO]U,CYT4.W#\G+`\7L0\\"09741D1;,X M=^(9++F7/KL+[A/BO$-V4AV8?,W5$\8SJXOX*8Y(&KD!$2#6@=&7Z1-?LRES M,Z?*TER$+_%7$LVRC+@*6A3R>E[*MH-[QN?@IR'6+YV^CK%LAU#6323+@Q+^ MUP4?$AG'6>!LM83DNH`&>1"1<67*=X,`O5@7BP=-0RZ=E8)YXYSS*2@6!:=Y M_DC839Q]=C,<;?0X<6NYC/,R4>$ZN/(\3A](&L8DNZ'K(.%K]`,C#G.D5@JK MCO+,.4[+J$%4N&JVD*\Y7Q!(M+-&.(M,2DL%.Q4)#6MR$U&LHJSN9#4K7P39 M?9E$%]GQ0Q"L3H3W)R3)L]UORO8X?G6ZK4[]Y_;7?YPG09;-%[-!#F<2[@2U4FTC8L7>WN/?C[2*SG*Z9&-\++7N5LOCBCCZ^4O+\1* M5E9^?A;#E$2_O%@$B:AACPR<,VO@@!Q*X&@X_`4.QL76P(&%2\!Y[2EPSJV! M`W(H@:/A\!8B>SUE!#K_DJ31/@-\EI2R>F&_*(2,"8Y8D](LX^/&>L@M:W.>+ M(IF%(2UX:G]#0A(_"8?/"S[WI[D&,ZUD-.!D*6/8=1B'N2[-T`*2[=1-(#NH MQQK7`9NSLB6BKO;IL&B'7,#A%AF']'7RO$6L+/4,X&DHNY1:7XV*_)' MRN+_.]0I09SIF$!\R4S^X\K@:&<\:>5/(,=0>7*99845ANH,"/SL&*:"':6# MCG#3D"UAYL=)8&9>Y.4IZ3A]L`".@@N!GAK75""D=]41CE0*)##]Q3LPB6T[ MFK:)FBPXFSM9&$X?@67O<@MPV2B1`/:3SP!#ADD(#CV@IA$@X5WL!B!\:/17 M_X$#QD4&:A-@?(Z(<*ZY`(HI%GKK/TC,@1"&Q007[T,@"R==``<5_)R^\@X^ M=ZS\H&-=<46#&H"R`18EI8\8,;O4`AJ04!D1R$V/;NVE^^Y+TV;:+9OJ\#(= MVH);KJFB-K;THB>P9]3AV-L?I[K9UWCPS14^:@8[A8?DW#``,13J_W;2:#X^ MI#_W="03^SG=6,C=&W6VKICUGI$_"Y*&:V"3W(*S@6P4YVAC6=5->]O`P6W! MJ6L1B'/PP6_3P[1+,RAG!83VZOQ@HW4"*TJO*-2N.2/B$`I2^@,B;H$:$HK^ M;3)7O-__^(^8,&[UX_J*/)$$MTH@F/4+!<@\?M-4EW395.OQ:I2!&+>`C#%7 M$@P*#&,8VSJFL0R88AK.9A,FNL;TBEZK=6=P_")7H#X!;+T<#0MAC]>FS1>_ MLS3:W>40DVSK;#1/;TA8,!:G#YS@(TW9[I_EEZ'0.6?G\G7`[RY_C)/&[IM' M-7+0"28\6KK:J!Q0"-O:K@3/JPOQT=\HO8@Q;TKS876BWS<*^/F/#2MF^998 MA]T,L$G"3,LUW`HP7O7JC0NT3NV40LL.PU7:Q>EA;99WBMROSU?#?O713[.H MAHCCF*BW>5^Y8^?>"WE8R@>X/?_$Y3S('KFCXG_BTIFG(*DE"H?-#-WVEBU_ M<\\+SS_2:M+7H&K;\?;DV]$YW=WEC#[8TUW-X\([BIO>\?;DV]$_C4 M\(9D.8O#G$3JX%6#.2Q;`WAFMF<6_EFVT["1(-JX`XZ+C/]$5YM;G*N+]JA' M!QU=4C_6&'RW7"5T3<@M84]Q2$IC)5O%)0V;1U3F"][5]"$5G^Y<\V">]+2&.'.M8QWTK3\[BY2%SF'ZG;8[M*:(:N';/BKB(,\[!1T0##K%6K#3UN+(V<0"WC M,N7A$SE\J[5M%."`*H*C@6F0PS?/P<-[*!Z<]Z,=+<7T'VWGLG(X`OJJ0PNG M9P*[(\YQI3T$.@JRH$.?+J&%.]G9+[C\FZ[%TC1?W/)L/`,K@%HZZ8MUB6[8 MR`+7,Q3OF0U,Y!J>7OH$9IX;DA%1FYRET84H/M*5<'8;E(!PL>"4ZW=F3L\A M9>]]-Y#9Z)O`G'1+DF139/P0L,]$O.>"P1R63;I"W<3F.=HL_>X&-;2R">R# M_4I2PH*$^S*+EKQ-LGSS`"<&;%:\#<0A>3V'79L6Z(8].XUM=\8&NB&^UX*9 M.29&7S7?AYV(2+K3]QM^[1%)#_N.=G]G$G!CE@3,'-5$S=LY&T0MIG#50X9_ MS,MM/R%=.?E")%L+U23#3J6:)J0H!Y2CL"Y1#!]04J^IA;+C=I,#V'5ZHDKG MJ8A\ZCZC$Q8=",CJ-4Q7=N%%S$C(2<$NU!-5NE!%Y%,7&IVPZ$)`5J\1L'$4 M\C_^@!J),J%F-%8)?>I.E#,M1Z5"W@1.7.W\`C9=5"2:1=[Y,TJX;06EA109 MJ(#=W2SF:B1-H$#7(J+3%O_AF&Z(:K]=C^/J^5W[W,/JV#XCTZ1@XFGRA\TI MT[/U@>8Z6(O?S;X$+,(=%'(D7WLXJ+/\<1-W5\VC0+A]=M[1&-70F-JS<7>B MH>:+RS2*G^*H"*!+L4#:YKVZ:MIG!SY,FPR'0M@:&8XO_7LOQ=@:NL:X,KU[ MZ$QP^B2/F1YO\B^:%\J>F%WO6U M.??<3M_`MX2[@R\=OCO44V!GEZIS7_^N3&`Y[ZT1-KL1[RG;_DK0G0X]QD$C MAAKX&B.^SP8=.V[*4P3LWQ3RX[;M_+$0(-T&L>;7HGK3XRHFT^MY#@.\[^8? M8`SWY\($#M^4MM^;G;]O.O_NZRIF)?%FJH*&ITOYJF'I1OZS&8X]-/=0P]"I MZ:,)'FG`3,W%A3KX^W#5SN%_Q=W&V6+R(N;FM9SWV$>/M&X%; ML^;L)GYXS(%]6".]^DE&%?W83T_6;<*\00EQ8/P>+?PQ]YK\)B7"6>5)H2U#&!\,8IDDS/F@Z))2A$<04F7$C2'YQZ#T$JCU]?%RQ\Y"DIVYJHCT/P M3)5@!,,T;$2"Z1':TF,\3NKAAH6BX3_(F#\1)C[&RD5=P8@2!'4U5H6HO<4% MWL>V@,!H&.&[CF:PJ(>!B;3ZC8>6U%L`(+UKV_M&\1/8E%&Z*96!,3&(7#M& M!"%7'IPB4QH&G9UF>,NY[;58!*)^=%GN5!&L7I M@PW,%&P8L-78/)BO[<&G=[P/"*JT#?]UWVY9V5S4?"]N/PASQ2H.TE66<`V= MKWC`NM82`&;Q4H^_[;O'+[.L"-*0S!>57.,R/:=I2D+AH:B+;HU^]Y6P,,Y( M]I'D\\6.L[QS87-,1(&47N17$.98OL_([+,I.R"Z'[-Z_OI"7?U0^7M.F?C\ M6CJCAV>H5CT,##[#S\K9#GA"ZE$`I/?E46E:>42'1)?JLV*V;":P2&R3@PSL MN&O@Z+0IX./5Y4V(/,44P&*_K=.K,D:M4_M^"@A$\`.Y]21H)$G('^E3?Z%>6C(3T4Y'25*R17`T%& M+@]!9.>I/8ZP\HP0!*[_P/8\4V^MM.;@.W^4UJ`Z7 MB*$.KQ#[WN$ZOSIVN"Q6ZO#>,T,9A2)O31+D"&\2@R/\0.Q[A^O\ZCK");'R M"#<5`T8Z45<>(!2G^%F^ON->94%9`1G[R)S&+"EODVY8Q[%)UZN;V$:\;5YI MVFQ)"X[`^:+R.[LV@23@FDB*<.]N MR"J(R\/U'_A4Q9=A$0GH-JOQG,KW8PR<_D^\]@W0&:TV*B=PA^D\?R1,_]J$ M!GA(K@;HC%S^`\[.\+_6/(O]O\9HM%G,3"@RC'C)B17]0SR&T[QPQ]&7J;\IPYBC,OYH;;T"W, M0H1ID#D3N=-"G`OAG5N>)AY[V^W033,._2A."A'LWI*P8+'(/-]]#9."^RG" M7G$Y6)%OGS5\%["4A\O9]=817(7?I1)MZ=^-DO'F^F[FGZW5`H`P?@"-S56G M3XWCSL).(4['Z"3#?.["P=KJ.X!CAY6AR/A/M'PR,DBJ"X5GX]WXGA66#37R M^G_Q"DA$AP"`<2#9O:'6H\GFH0$^V#45?*/;2JH\NEV\Y,*FTY7JRH,311U= MV)Q5Z:?UZ[+=-OU.]K"9K',XN@L!E(W=Q_2F++N[-=[G">^6,.[9V34721@C M4?FU*5BQ07`TLQV(PP?$JQ^JM7?8`I_U-VQM5)G0]'IT-%U8HPGD4*))PS$5 M-&$<=H0F6)4)36^&.7#8YTK4:T5GL"6I)R^,:]/D+NO9?O\`SCI*&O57I].9 M62"G.L\E:N%&]$C3QQBOT8EI;UZ:!H+"2*][XTVF]Q\L6&<[`\>LR!C0C`FB MG@I>VLWRL4I>T-:Y9S4OW,[[Y*I>IR/O],FWU\^B*-Y8>9DN*%N6317*:Q>+*Q)VWV[]F MND?".\G"3%EF6;Z"TV43]3&YH4V0O^9U>N5EGT]?-U\)_L2#>E;)H*^30!PN MK#7%C7@`$S@XU:,FU//7'37Y?VE@_PWCVNC5]U'=[ZC6EH`G-*ZAJO%T!S:NP/R< MAG;O5WJ65LP7]=@])=IGK5#TE4J`@7[87*O/KJ/V[>,:O3H;=Q4'G&W#UZ-4 M=MU]H588E.@-&*S0?Q,8U+6/#QB4;?-C'KSC]'8SH8+#A,,JQ[>!1&T;>8%% MA77#/T^ELNP]+9@5&&4&`Q:K#-\$%+4MY`,2%<8-?P&XTK#XR6Y6E!E,0*PP M?!M`U+60%T"4C;._I[H?*-[&7ZV0*-$;@%BA_R9PJ&L?'V`HVR8?X1@)A>2) MJ$^P6G"8D%CE^#:PJ&TC+]"HL$Z^K,W3V_O/""T(DJU9RS6RC58\/UAT2T*:1MS,<]Y3 M#P+!):B!O60KWD:3('E'N1@#V\FT6U.H9Q:#\FIQV$ZI\>CQ*R]@F)VM-=Z` M6S/V`K2`-`L8?'O4KJ>5N+1L%B4X46:H$8I6WQ-,E?'5AR`71_775R3+[AZ# M].VKBV"=:8,K#'DELH+)APVK6G0$M7;:@!F3YET$A-(X!DPVAMS1OY1G)\TX M`>D50-'03PTI&+<=0P56:?RTK`>L;"VYHZ?B@*T1*A"Y`BEJ\JD!!>&T8YR` M&HT?P?<`D]*.._I&_,\\H0#4"I`HJ:>&$;/+CB$"*30AY(VS&F$`I:;;90HQVX5F;3;H$N`.1?I0 M)S@$]=Y\25^.T-$_DR\W),"!HB=4?_-6(_Q^Z]B@G_*I.LG=/6.R$M9#]W?BKK4P<0 M7S,:$A)EV[N2=J;-%WS.YVE'B>L[CL4S+ORSHG;545*EKM5:TGC`44Y$[EK% M;H)RH5?^7F/4DE?.,P0Q\55]ACY^-]$W%S4]_?!?R!IMEV]MT$?PZF*$3H7B M-@:5:*]/&+P/8O9;D!1DEF4DSSZ00&1IT3S]2%,FKFP3J#\+LC@35&7&>4?" MQS3^LR"9;H+K1W@#A:Z$>S8-]MIV[4(WQZ;('Q:-.EG6X]):9>(CS4GS"A43 MYCO+@S,(&WF>(MM5"SG)0UIHES]%ZFMIB^#3M1)E7.I.B6>('J0M MNT2SSDVRW^H=^M4V?76!VD>\A@?4)%VUB<:HP]B8/WA2!;0LBVOWBTQH=)#7:J96D85=V<]=3ERVCG"&T-E1G MB"ZZ59>(C`;4IK?0-@M(:QB4`VZM6($(XU-[F,#2$3=Y>+Z-\CPJFNAH%NY. M5W&L4DO;"-:'6N88)SF^E[B]6VJ^L5<;;4Z\M'ZG$7/B!?LRHP=/,7Y/;CU) M;J7W?<;(H>H!=?D\K=@(;N:WE[S;F/C\09=!M973S)_LY?BNP:R]X04W%%3Z@X.]XD'/4P?6G,3?#E`Y_C6!PD1@]5 MM#HGZ[3#?W6FZ1)JYY;V='M=?/,HNU[L!*[3WCOP.V6?+]/RG%!FQ(:26`>. M!K'7Z(`[R)UC(_WW/?LD42_4AH9\:$DUN&C0>PU/B#'NN!#+;?7 MVT$=X^,C@;ZT;)+HL%"2>(T`V8DN_5Z5-H'GN`YVTU0&I5EJ`%G&V/J`^Y6V\A:&5U51K7R`43"!Q$7G MQQU7#-8^\8Q(5%49!]]%074G`E]:[Y4H@[1BP*;0-OS;(.]2%HLS;VW>M0')0N3O9B5,UX4FI6AT"M^SL!2`G*94` MGQ'8N4$Z0+*#[@E4='I<.+6;B.,MG="FHONU$[?/.,3J:<#=2!L^[^.O)-I\ M;C7VEL\UHSQVS]?BFO9\ED;B.X*5R(ZDM$_:#\4R2AN@9L81=XLUQOW*J'8_ M`,>$;88MT\"K$KXW:4O'U7.`46]]SQ>ESZOS2K,P+)9%PA?*Z(*L&`GCS<5. M9)60LC_3:+:D+-]>^*1U48,]U^(;*'4G?@IX[JDQ'2#?N65>'=C2FJO?3<&P M8&?<$79;',^WR-T81[,MN%OS9D0<58>&!C`"<,H!#I325;MT M_LT?/.9>T4Q_R@?/B)U+*HQ30(YU`_0YK\@Z55M_KNJ>6C/.@U6U5@T;MHK.3C.;'@&W<3W*(+,:"SW`PW:T?A#;DI/AK>]H:" M.Y@:J@:.)"I/@CMX,Q+VS0X5ZP+Z(W[C50;`,WZ]E0:09_T&+`[L@WUOWD#;U>/H8GLY M[XQ/^$_\#V.?_MO>XK*U:GMCL%175]^:8V!2WY^C97*UJZ?4,R_R+`]2\6+D M[)ZOMT'8/%;2AK6RBX=G'>7V*%-7T4X-`%TII=&\VZVSUNBH`(2'SCEEC(0Y M46W_XAA,,*DP#`..5@T/043G<@T8-EI!>,C:9%"\='A.0&G$NZ^KF)&(A^R$ MQ10-#@V;"2(2VT2!`KO?#UQT.AW5")60N*G MS%_+5REL9TPUEVG";'+YCT![Y_N9+C4J_2IF&ARUR5L4;)C,I<;F-[I:NM\) M7M8Z56>@>IV-?B?BOR2:/1$6/)#:$SFV.:*-+-/,A9,UN2RR11.Y3BNM3/!_ MOJO9O__C_M6G4YM)$"L+,S.:98T\75KAP#1_6K8<;E+%6&B<9=&6C9`][U/X M79QA,-:Z]F(I%UVB0'=OI0+[/PU<.H*<;S\2G"BQ+$O9*GDN M8\1E6P\T8-R8W&<)36FVJ&=XZ(/C4A#?L]HUZ5$63^?K>H-!?S7!G$@8',:-\GFCO( M!!C\UXA:74;$^/SMH5/,F-ZZ&Q(UT-E55[#!G53M#SBCG$L5&4=XGYV.=L1T M_YJ@%(CH7O65(Q;-<[Y7'EP8N3<&O(]#2:1S:\"($6ASU3O$Z,A0EJM\>=@0 M``7YC#UEK^M'5"]9U\5V?KAY_U9[DR]4]OD9KA0%G;]%.$P<>O$O< MWQOF(SU+/.:E`)LWM6?6KYB#',I7S#4<_KYBCG&Q]2OFL'"O9HOO#]UK(?+] MH?NJP>?6$`$YE!#1R2LN?KHN5>UXGT*HX\#[+'61J)_XG;")Z"1%Q6-,O/`\;6 MTX/;=D)!P`-\GY"/)S\&' MT3$L\EM$`(NG^+#PLQU.4`J\BD8.;[UK7_=1D>B>1A_A]1YT[P-^M.MMI4"O M$L[R[K`#&#/C3&!F4-WZIF'P%`=H']NA`B'>JXR3Y\:K(([>?5V1-!/WL)8. MU-S4@,6"4[J8#<'I*7SLO6Z'(QL]7EU*B8$.!B33@(/[CD=VL9?7.3[;-P+- MA8VN[P'JZQOMWOX;,ZJ\HND#+A4%*)O78JLH?0.!V1W+OH<$RET^:N)YPPUD ML?CR5UU%^4C3$%P4[`4T(&(CP#?DM';>$E`M]'B5TAR2+A.<`$IM^NHQ0,SN M6"(!$NA5AE()?(V=#M*J9UK>.Q[ADV?6P2`^S"3"-`/,'__I3:72K+2\_ MDX.K.+B/$^X+R?CR4NZXUR[@-NQYVK(WPT0TNX\;XBV=;[%5;JW)JRB@8CUN M)]W,H,?1R'OJUCVEQE.++7>L9@VN)K$CO]NRN0[6HES+_>2_806)9$<,NV<6 M$C2;:2@)HX'/8H/-OBE,^$-LNMDH]0J"FVC,$G4X)F7$.TUL63G<`4Y(/9[M M^I=6VX''#C63A$OO.+$!R)@%V7?+54+7A-R0A`>%^%D&S==\2]?,YS-X;-WN M`".\*J\"\.T$^5O`-7"WC1$20"P'0TIBG_&"APHC/T?4\>FRH>":9J1N=[R-9!Y1Z%FU"E:RS"B6L+J\R[[*,?D/RF)6%TOE]$C^4*ZP9 M43:LJHT)(ZOGV&KA?S>`62GT:LJJN&A>^`8[IP`7ON#/X8%1ZM;UJO:%JO87JSZ9I%RQUVSQM M`Z4VFZCMGM9R=O*_\E4\].DI0"F?[)K.(\2#10,%`W$UX=M<^@P+G8`1DF!5Y5]7GBS9N7 M1.\"EO(`.9N%8;$LRBTKT01AK#_4CV64#O.;&7W&C[7C':!DH"6=_'>/>_8LX M$Y>6%XP M<.LVA;:"+U;S%6&;.K[N#)*U@.9A)`L!/GX4T+H!6GP6T$*75X6,[T]`]/<$ MQ.L74WT"XC8D:\I(V&0Y?!]S""Q!AM- MXH%C#&-W*)`!^J>&A4Z-"AH:\5[BHO/,H7TN9/"Y`_5^3.O)P_+E$(?3Q^N1 MD\K;3:1SF2XH6WJ14]Z0)Y(6)'O/^_@=]XRE07)>9#D/Z9E(V<6U,E<\RH\V M'Y*;,L^NXJ32;EMQ(\X&CR0J$C)?6!H/YB%.A$JS2C>A0^0YG?%$>VI$Y935 MUMKZK.;$RF>4D_U*Z`,+5H]Q&"28O$Q'K\O-9/I1\C,W_:[*YPP-HHG2NIBC MS`&U9O@5S6V`7S46CN9,]-*S*UKZ\?)`;==0>T?A8*ZIJ?X&BTE##TC)2/CR M@3Z=E%<#L+4`RIO=/P1&WE0PLOWU'Y]N&V"0_[!MC.H?!L[FC(U)`;O5G:@3 M*3I1(>IYCFM]EC;TR$9E:9V&MF6FYGAPCYVMG=.4IYCY=AN#+LX9B>(\V%ZP M?!-GG[.QT[>:B<(B4X)F9I".:.H91CR%VC#JF@=98IOV@9QB'5>PF%ROL0S\ M1)JYWV@K9]5OI6FUU4^M(K1XM0A(%D-)-TQLPLJ`27)';*#3VY:H>&Z)J>3@ MV?J,I.'C,F#0L_%8-A.P)+8QLE5#)T-P@]W&`4]*,M%:_)Z.]C;##XTCV8Q( M:K(-GH"BNPT$%.@]#E`-O3"T-/J\@M9MD)`,WJ&4*9H)395BY'!'U^@4XQ`2 M`W45M>1%(=JK[I;?$P/[WD1N?,-M.JA`NMH9(D8]7GW*U=/*HZV-C+7V0"62 M/A8?7,%DF.7'+WRM[[A.N_"XR6&.C`\U$2H:#\0^2JXD?$]?(T9"BKVA; MGY'SSEYC#41(37X!J2SN6\((P],$$Y[M^XL[/!7;]^\*KN;_V(? M'\V4P05`L75823%LX&!N0(KQ1-EU6MFB!R&90_39F;'/SHQ]=C:1/E-[TJW/ MFC*]6H>=S<':`&[P61@*WSI.P[B8S?E$W`X@RD']L1!8G"_VYBF&M9:F,K`5 M-#Z>#L*XT^+@!RQ6'V2-=JIO?X]KT+C']8:N@R1?SQX8*4^;C'Z\[U/*2"C: M+?J4AC3=7P-6L/`QR,CA:FNIOQLS57M!C0FLC:#Q[BT-UF4WWM%9^&<1,W+% M>_P?)(G>4_8IT]YABN-JWF=JXAIV1NC0X;1M4RCG#GM#:O>B(@WPJI0X8R28 M+X2ENNUWB:"YX5XAF")NM`[V`!&%+J^"RHU]-R1(WF7BH/PUHRO"M)>5F^OF@GI&VV,N#7 M&FY6RD[-T\/ZV=(>U?6RT_H:1'S^+B;KG:>'P7FV/N>!Q`-EZ_E"M->.(@(V M^#I*:]Y@VU;:&%N%+1%$73=>M\$A[3]V-41H:[`9I@V]_ M=H4$"O(V3:B^[KF=E3CLXZSS"OO;5Q=VCS'`']?`Q,U3/1KB@:\7[]A9U-)[ M2]"!1M1._\#*^]PDOF;Q,F#K3QG9;R%HMXN-M)4\"J"='$9L?'<-$9QNKZJ' M7JRXVNULS]9<:+-[_$47MU_NX[([Y@`XE&1G:51[KF;%0_)X>XEF%K)X)7Z< M+W:56R#+:1%1FY70:C^>-U$5@F8U63#QLJ= MFYNB76Z-&Y7^7:`,ZNT3"O/%(@X-.-#25$"@H)DF`DS.]M+]>J7?UT19G#9# M\FU5A%(D;Y9%7*;D\<)HO+ER^WOQGWL>Q_+?_#]02P,$%`````@`U(9I1\2@ MT[4ZE@``I$8*`!0`'`!I`L``00E#@``!#D!``#MO?MSXSB2+OK[C;C_`VZ?$W>Z(U337?;,[O;L M69WPHZK'L>ZRUW9WWXF*$Q.T!-OD6>:I&$<_<$1HMX&4:/__'--GT7I(LP M_(:D61`M@U4BRCE?_[' M-T]9MOG+]]]_^?+ECU_OD]4?X^3Q^Z,??CC^OFK]3=F<70T5[<.(=7NQ:]_S M_^68MW[_XX\_?L^OUDW34-0P=_O^^__OY\O;Q1-=!^\:`=+P+RG_\#)>!!G_ M,;7?@TA;L+_>5L8_>O3]Z=_S^CU_3Y3?YKT=(\?LE\8K>T`?"_OO+S84T MYH_?LQ;?1_21C=9E<$]7>9^YB^QEDX]I&JXW*UI]]I30![&O59*T7+&^_I#T:T:C M)5U6X5D`!49Y?,X([KGV'2]:7E<,[7'2_DYAFN1=?O_G'WX\_H%W./_@[R=K M'OYVN]FL7L[B*$N"1?8S7=_3VIIWG)M#6F=AQKZ!MO7W[2_`8K2^0D+3>)LL M:*<7_#]_!_8%\F,NX\4V]Y1Q=>A\"6BP]2KO'E-F&KW[Y?8;$BZAMO/R(BFN MDNHR^5PT^#__Z_O=M^__8B=)>]R#9%%]A?R?FJ]?MOA^$>=:NK9K4>$CB M-7S,8\.!*7]?SA+R%Z*Q(EE,@.Y=HNKO[XU(VA(:`SSQ,-:(RJU?&:9VP^(( M52S`]TAR>[8*TO3LMR!)@BA+I3JK:M806'&SP1Q01<>35$D4-?*%1G/^*3DC MU><>(5TYDC'T5Q<@6]2\#>D1T8$IC5+_YLA@8GBPV%#JGATZT)7NZJ$,<)7< MA(]/V5F<)'21[,OZ*T*&H#L:"KJC;^9UDE\<-,:.QL'8D7N,'9M@[)DF]_%`E!T/ M1=EQ+FW%'WDJ9S_GEQ)S!XFTXW&0=CQ6W7D17=,DC)LF3';=@5;^$C-= M8=\SNDS-+Q+DO'=5%=MB5AE:0]%0$96/0<5\-,2^". M.8"?TP#4>1DJBC<=[.#9/XYI>LBDR^"]&E% M4X;3HC(\>*`:+[(/!ZKK!?=.O-\H^Y`N3_(9:?!(D5;?48(85NRF04:1`[MO M/NYLP+B/PR7&,*1\IM$OY6:DC>V*!C.\+2JL$]W#?9"%0;/.?W2A='FLX;=&F4OV/`NCBX/ M>SNO]I3-0^?LGK'9]/'D@[&]QZU M?AICI7=01,5";S<)'M8Z+PJ%3-7.[2KOD%C&.KK_@C!RW3K."N_`F`8U\4&M M[^Z!&@RMTKW2@[%F`#XN[0[NX=BRL&=S$3_9.W">XQ=[7<^A+M)TB_Z`JI53 MW2S)T*D;S;/Z9H[G0:9]LA`ULQ"*F4[AZ%!G.G:XU\OA$#YIU<_(.4#N]H^G MSJ;WC!2?,9Q:2L=#=G,.O&*),$\RXY)V=[?T?1UM<9 M@1_\,J[YI^67755?CA\?NY0N_O@8/W^_I&$^AN__Q/[!2OX_O?OA?7DV_/_( M/RI.F&6%Y<=5\-CAJO1Z^2,*K@]2!6F\86E7Y%9.T7[K>?TG87]/RS/YF,3: MG[&#_5Z['8SU(XL[R[S:9ORE$6'T>'*?\E..H7-)A:ENQB@T=9/7%+UT5%.* M(UJD)I$C16W8:$X^5P:^'&MK`AY]"M)#3YMF!"X`R61:X)I-AVS++EE@'`2S M^4V5=5\+-LTG&6CH='Z$LVK5U#2CF/C2I1B8+S?4-?D>CI(0L`L6G`9Y5J0I MW;*B]ZG+"*5ZO;``O58^(#X!>N([A\;)A^">."(3RYC\@S<^V"?4$1F!FG+C M]3K,V%SP;!.*TJCH>C,UMJ\/IZHH'N)=M(Y[#:-:K>=GUQ<>,$0X(+'V-Q3A MN-FN@TV7PXIZTZ7GV&!(^:V0^@.2?[)_XZM6*N`(XZSZMSRB+^#WO)L,]!%G M+XDCL@PR?F=Y'2_#A[!X1^<>CKIRU1LZZI@[3'+'<72;Q8O?KW.4/`4I3:I9 MN/RM8V"C3L;1&:%@&=8SW-RDC:D'O<;%O&A#>"-2M_+R=55P>/288@2K+GG4 MQGU&>0!'[)P*B#84BE7V?>U@U&9P7#ABSQ[BZ);"2!#B"`PKLK!+_C)$,<("7FCQT.="WT3$@%'1@R^^DAAVR&D([6%C!Z"D MMNC!5,USFH3/N7H\4ZUJZIHV5%/>=##N=;W`4TU%)#7VI8;SW14?@:\=X-AD M(`2PEYFT83\!>#!%4QG##CA,-%\#=)2:.0P\J)H9LK?4981_Z!&?YX,6PGUH$X%[C#G3'`0.JUHF]FP*! MZ]O!04&M9L9@0%6PDN0GT?)#E/?NY2)ZB),UY[QB'XN)65/E0&;#H6[0.T0E MA$754`+B9%ZU(D&T)$4[TFC8V$SBP7L3C;`2VXZCB%D`\P[7_,$GJCA#XPW' M)A=P,#H/'9QJX7<"3\SD\&&]6<4OE++4PQ[ED):XZH:-!"!K.)A2ZA[@B;PT MCIHZ$K,Y^S>I+OI6\&A&-8;__@+TBPW:>!\9+9B2JXA@@Q0FJVV8<.0<$E:4 M6FF/%I1-)!+7V+M)%&&L0'-T\`*CW'$R`#3C/0]YMDT2]LQ;F"Z"U=]HD'R( MEN=!UL4BI&GC*4EYT\$/3.IZ,?S9244$]6.44L-Y>844EPB[EE>F2\*N3O]\ MI79@8Y,!$#QU*3-I/X`)!@U*00DJ)D&%I).R8(P"TJ)XK`K'?9!TJ)P;U8HZ M$7<(!E?UH55M**L+#P$*X%(0!@;T$G"$\L^J]&N6?3_\>2_*/D-@0,L](#`0 MMQK_M`J#-,SH3;`,>0:X>Z))L'FY?4DSNKZ(LX1^E:8\<^-&*C0Q'DP#\Y[B MI4ZCV&K6&+B:L[:W>5M2-R9E:U(T)]\6!M]YQ#$+1,7#QEG`2+B3-E,]131F M_C>,BH5F5B^\X1DXRI,@&G/]7AW5,AM9YJ&1^#I-[D').O!\LR^TM"?DP-1B M3L%1X3E>(D%*(2;)X[6`L(4G9F[X:[R*'\/%193_+Z.K%5UDVV!UG<0; MFF0OTMQ@8M;(#3"SP>0SZ1U>;@!&51,0Y&1>MIJ1O-T?2;,EJ9IZ1$`CL,2V M`RF@'\2\33^/`(J9'<#QAH.398(J&<32`8N:'BRC,PF!UN]UL5B]G<<0W M%TG3`J!U(QLH6P_F&*`O>-JO#J9FE3/W]-5 MEE:?<&5N[!DI/_[[24*#JX?+(.J^[US>H/P91`T&T4,><1@?A'[E!!`TG[-_ MLW-UV%_3HELQ++'^A^P@N-]P!]H1AA?U`$*)>Y-Q9MI6C?1J3T=:JE9F8^V! M)MW08/4AS>LF6E6G2H62-Q?JE:@Y(KSEO<'4,F$4*.(%QC7ZV3527*QG7#ZQ M03'8$FYHX2'F2=],QIK1`>50/27![)'55-;-@>()J+Q#$(4Z,4_3;1"QM[@T M3E6ZB/+2-*(+-E?]+RD?>JX-:TT\TNWJH+,_B-$MOGX(YH))&JT>?4ADX_6H6IA1'8^R9?<:7UB>NUV1G+'S++V MPGW/2.'=@\FJ$Z;$SL$IF@YCQNE,H`^9[ZA+/^@=&Y'K?'FIXNE5A^T7+;;_ M)F0[)_M5E^QO7!\,S#UF.\K&;=P>8>_YQN_=F*3W]+V0>T=6U;;VO2%K?S/] MU&0]!I'UQX*L$7W,9VS+,>EZ/#)=C]_HBHNK?:;K\6B/.%?'EI2OHI4^WZQL MUWBX6=)N\)/-ROC#'VN6N5<_TRRVVIVQ4[T0W9N'F=6C&(-_<,%CS,+V[6>8 M8=BP7GS[./1]_%Q^P_\G-R`:T;"V/*UH,S*Z`O>(M6ZF#JE*>R MG5<7R?OB&?Z[F!SS?_ET!"IDV&/#L1%D&H55.V],!BS,U1%=&&M0L96+5PWSED^2?$IJGH?S7>PJB"F,'"BS55!8%6(C/;%=A M_N7G.,J>TKN8Q].F]W\,B"9/B!R$+,[Y_RWR9(GRZB9YIF8?1X$BT_AE$0+?)_7V1T?4[IFBZO MB2;YXY#Y_#)>T]0HWEKE$?#',WF'T8WP:OOAC8&S5Y!SF?E]:D-B>Y M/:D=$.9A1@H?I'92[G.OW'CPTC44^,;8$!((R1"W;:'98XIAEEB#^^&.7JQ$ M@Q!,QZ\W>LG@XRW!4&K(01V`U9@FF\$'=\>E+-G69!J639)R;>? MXHR2]^^_>^.3#"O^\@GC:8M!';!YN.)./W4;W">'I#J&D^J'-U))`>,OJ>R> MB;":CHJ.7@#;&$PL,1Z9!O=KO"FB_B@#O8?Y79P%*Q+%T3M>DH9U24`R4)V),%3D.8&Y#Y8\8>4V0]('N*$+(+58KLJ#L3>;)--G-)T#Z:! MDL>E3(%H0N74C*^CX'?,^1?DT7R(#]!,RH,GYUU!<-"DQQ2$HTQ?3)\N9^HU MK)B"/#$.\6&NI`>,RR&3!V-O[4\QL\!6,Y!CP1"^JK MAX=PD<\?\R#_25^JE_G)-W"`VC<*:4W[P2P#]0>O@-:%4[-*;3VO+G/^Y`WJ M5TWZ=#<4!H#8>(P$O%':M3DS*8J_Y.7G95Z'1BD]>4S8G3>5`%O9-R39 MT'XPG:SZBR?;IN'5M#/S-B^:DZ+]C)06?*I6VI"=D0;@%MC?RT MB>PUPC%3B'E@1'2S--/"=PWO$R&\//=S$+\$J>[EA;ZX)7H+[59;SW77^1J^B!;GAK_0JVOA03\%0$)N/DXA7 M2L,.D:9%&VH1I(\T!&F\S-EA[4J,M4.$FKIJ00,;3EVB#H%>B.C##<+<45?? MDA)SF^"%*>]!PDU9,^#!#;,JJ/9'_Q*%^I5S0.MF/:!J/9PO^KX@5@+*8!JB M*&P;CQFPJSZNZU\5IM0Y'@%5J"OG MY7M"V6W0+)_W??C'-MPP^3D+-F$6K,)_C#+-`6=#$&"(3$-G/59;OW M!,#--A:Q<<%?Y*7R=JYJ1J[T>E9@2?+GDM ML-=A+,1#CZA^`1>Y^`*'1`%M66J5L,W;DAUJKQ[ZH'T=F-754\Y0BU4]@6+A MGWUD$AD'OGF1Q/8P?N'G+C#575:(#5X78C65D3O$(M9!_[7-ZZR'D"[OGF@2 M;.@V"Q?G8;J(GVGRDO?GO^DB^XDMMDGO.5AZ:-1%QAX&T]6RSWAUDGD'U-PU M]3>O#4C#@M0FI+0AW,BCE6E;M,4(PR^@N:&G-MV]QSUFF643&A7SK.QZ0[W- MX$^,>Y0"S30F]NJ637Q<^!^]P=\.`5/#'[':N\GA1*\>/GRER2),Z742+NC' M\)E*BSN80:.6TQD,)C*L1WB5FC:>FJ4:\SF_SK9?52T(;T)8&X\8",1!;#Y2 M`G:I#=MDFAAOF!42(-(0K+'ZY]6B35G,X.$-/@[T[)%A1\N=VA#`G?'PYERKVY&&8$VIU8>. M-G.MML*;:ZV^BLS*ZEY[C5(WVCLA3J\_;G6Z&4X@$1JT%))#2$>AAJ6>1*/BSK5@=T,-PIQ*M%\# MZHREVQ9WSN4[_&HFWMWV.NG>M7=#H&Y_',MV(YP%@6IK.7G"K[Y3IX<`/7$D MH-&2IK(#4&8LG#F7Z5:@`1A32O1!H\QNO1L"=?OC6+8;X2P(5%O+R?,E]ITZ/03HB2,! MC98TE1V`,F/AS+E,MP(-P)A2H@\:9>;B;($S5&$N#I.JSYG\&"?LI5X1DZ>3 M:%D<3GFRV:S"!9^"")#S?6='$IU0X.5_4 MR7,RQDR9;F^W]R=I&CY&ZO=G8+H=D(K%;D?7&]6WFRY-2WJ%JT?"();:-".Y MMW<-=WLL5DK`#Y(N`)6&R)C(_3!1\YBD4Y8(TOZX)ZA]^?!&T>%0VQN28M8A MMXLGNMRNZ-7#=1(O*%VF'_.!.XO7ZSQV%B]^OWIXH$D8/=ZQ\Z7OZ-?L-'?^ MNZ#T&.BI46U8>QJL70._`UY-8=\1M4K9^IWG?V]704*68;I8Q>DVX4MZF]() M86PG*7.0?UQX\.'(JZ&8C!'!(9`72X]M1=D[MF`F]R%=<,(4EL(K4W:F5F5, MF#4IS`FW)Y4#\IF[(,P'X4X\2-H^,$>9FJ?D#LJY$+:QL<^'&-(/-Q0Z:E`H M;E"()YDV=]Z(TL:$;T1!/$%BUP4>D!W+FH.;G=R:O7R*,UH=S7^5%*]0.WUI MW33C-](,BECL(,+Z%B\(HAQA?W,753%B'Z$:AA:R)6Y-KZ1P2YC?V>[E'.R8 MSO(=N_N6N_D-:A='UX?.K.ADN0Q9L12LR$7T M$"?K8AM!PH2>AJD=)G/!C/-,D>*0W=!V$40[7 MLSC*DF"1;8/5'4W6)_Z!W7"/W(_9ES M;X2[(\V0I!&3%83-=F5\%L\_^OM=$K"9WNW+^CY> M=?1/>KT<'L'U04HKC3>L!A2YE8M3O_6\_),4?T^K#?(QB;4_8X=5O78[S.M' M=I+)7\ZDQNK$R>-CPE\Z=9&3*(S2*QF9IU>2L(SYOBC,^E%^AYJ`^)['=;%:\=\&JL>VMO/=R&0;W MX2K,7F[H8A6D:?A0/KXAJEN'>6I6H;:>ADOQL.^`N"/,NB,:E;3T.V\:MK=[ ME[:D-O;A^8B!6(P102$2*#N/';G9-Y:@;HX:T`4G#.';G.`<(5W[-\ZT(>(9 M:W`V%5G&QG_%^9">N*'/T3?SWL#%#^1+29PE3<+G_--G2E8UA_*!I<4&PNTF M;T[+W2%O5&JCQCE8PLJW0$FP@.ZXX9/QV(^-7A44>N-3X;0\8U/ MQWBSP6K+W4FT+/;G8,`J:W&;M5A1;)$FS=M7@D)!DF+5-L>0H:]?N\1?C-,&L0=7,VXN# M1))9CC9&DLL<73W*!LK1O<:J'-UHC,^#7D\0@1W_XN@F3XGC\.,J>\J!_HX'H4'J8@2!7RPS0.*'N$7[. MEL:#$4-BOJ/&KL&,\"9<@5DCCQ*X!@9"PH"@(Z*,V%!,FXG@YB*I*R(-@5HK MN>^:=+!VB%`#9?KA8$/-^)(0KM;3%>$&82[/_0VHG>=%R$$"#%(`(`#,02%P MD:9;NKR(\@;OI6^FT3<6%`"BQFCTD/<$/_$+8\%8(3#=:7!QD=UE8I<]>ND# M8+B%Y-#"0T2+OI&8$B/#R45BET2QA5(KH;\",('2N#V<,)\X$451O2D9U%ZC ML9AOL`7UQZW2PM^4K+:6463FV4ML81#04@7RJF2EG9XNHP'-M0:;O"I99_]: M868LRC9`X='0IWY)H0[$HD?/7 MAT8CG1^.QQ$/-_P0Y=_HY3>Z6OUG%'^);FF0QE'>*]:W;D8`MV\JHD3].2DN M^$($V2`*"*`>[S[P.^U%@-=!8_`<07=(J+*=8":`?6:=,CY>=65VJ*78:E<_ M^7=`I'H8A242].!%87MQ&30*.-`/'Y1'L4`)J[,+>.P.'4GSWY'5AW_9?YR` MJF=3I(Q>(Y]MDX1&V0W=Q$G&3GW.@FPKS_/JYKUT+VN.E/75O<%*_M(HD!I` M8ER5`N5E4E\G10-?2@+->`LJ`Q!"^@6"V$Q4)P`QY98VO$8Y"S+Z&"#'<:).%V?1$]Y_S)`T@7R$'M&Q6QIOW@X@?4'[P5<5TX=2VDMIY7 METEQG=0-/%IRA(U_;#Q$@D)):=8ZMS[0`(2QJOLU8DQ9CF.A;/3R M_'I[OPH7'U=QT%VQ4+;IU1BM-D@5AB`N5GW1=@VI+IH656U1?$;XA[Y4%J+! M$M05\C'M5Q6-MJ*:0C7TUA7%V3;-XC5-3J0UA*1%HVKHM1BLX)*8>)5!/X!: MJ;OMY]4'Y,0C*98-50SX;05BVVG9EE?G@XZ9J$6NC0:<)>.#&7)EAC49=)0' MU[H^L9]4$_DW&WOV+-HJG]JNPRB>DJ MMWK>(257QZBJNG8?$_:Y+X679/@$M9=RH/OE5[NYJ`+30&)P$7:J+<).M478 M*7H^/G5=A)T:%F&GO2+LU$/-[0Z54'/%XRE2W%.5XCH;=!=%V*EQ$78J*,+V M?Q1!"K#U\+AI3EXU`483[8]TN4 MY"5;LJ3+7Z+\MUF&3%>"U76.P:<@I5?WJ_"1:\T=3=8"<;6R;PBNH?U@^ECU M%T^83<.KJ6;F;<[^G^T1S9XHV7+3QRC\)UWF?S2LR:8T)W%M/V,/;OWA#]?1 MWZ*?H_.[Z*_Y?V[_\`?R$"?K()NQ_Q+Z-5AO5G3&VKW_VY]_?G]\GK=(Z"8? M$\IVI+*P"=]-EH=\8/LT\[[$$24O-$AR'^S%7FMV+%8ZXQ.'["G,F]*(+(.7 MU(.S$NV@'@]>!!C/RT5<5KPF'F,//`B&1CN6YG0%H6I#(A5PV",:O7AW%E MGAP+Y2A+-&81L1=PS*-C@OUHEUN"JE1YA5A6+0F-AF7TF6%#5 M,0_29NW'N03-,![8D49'/;Q!%$7[M$[?:%Y_2OC''DU^E`/9?5!'-^1-\(N: M]Q[2&0L$@H:%[A,L"')ASX*N'AW"A$3EIFX;""=H,1K`T M+IZVB4*H\=NWF!8=;^;#%H%]9@-=>VS981P$!IH:)G1L"@*G7@4%`*5JF M(!C_>=/=2[AOGW+]3*^V69H%>?48/K.(72E,6-LQ8CA74#(#6C>I!V7IP"@'T!:^B4`=3IQ:5[;RX2*X>2'UY M1G8-/%@DAHQY;#@P@ORCL&IGHLE0A5FBZ,)8(XJ5+1I,'1:DE$4-!JA0UE)5 M_K%73G6Q[+%U5&,K?B`/V]7J71:N*:$[E"T.%66JE5`4E"&N9 MM>W<'\!`,J24`B@9L2=5U=YL!W!%`FMG+-M]3XO MM?]CF"Z"%7O)W,?\$]%Y8YJ6C>4>:L'ZC,2BO2@#Q#)FHD1*1Q14Q`^!.D]_Y+;]-UC M$&P8$O_\/5UE:?4)GWLW(%E^_/>3Q2+>1EEZ';P$]RMZ$BWS3Y(M75Z&P7UY M:D-Y&F4'30,\E#^4E8=!V!_0YV'TL`LL9Y"-OWG5F)2M^4[OLCUI&,RJ(UNG M)>(0@,4((]ZALX6G'>/W`NJH1VW;QD?%/%L=J5&_::`^*%%/OVYHE-*):Z6I MD"Y=:QD;ZPA;-(:GP!NZH.$SZZIP)QJTN22Y]9NCTEO6&]RT)8@"YVO/>$?- MW25/-B^!!UM*/PT\9$SKFLEII074E`SZ1#-8U:@RT3*I:>*(3?U>N6)4*Y(- MJQH.1,R:D;R!IZ6=$@4`BDFQHZ?9SA1"M5$1Y[0>DP8V&$UE4G>Y'\>_S#[X8)U6_GN6NTHW=)&%SW0U M\?D>[K`++L>&HQ=Q3RP/DKRP;'%<_<$2Q7$C490?_YWAJ46&_H7RJS.J?)"%L@5263)P*#V7EPX)09"T/@!#4Z^=;-?;59[8EN?LM)%% MR+N6_WM%V3_8HL^:OT"1[N^+.I)[ M+!JC?ENTQ('5*Y!"X`2;-SR1IJL9J9T5]S\:[F:D]\3C.ZH9+FJ9L\:"F^K+A M\8VNMO#:6\).6PPMZ_-A@G!Y$9T%FS`+5K+:1MVZ6ZK(6N,(E+HO2(6$-`A` M,R2V\]T%PJZPL_+*:YZP7S/*?3*#8-%CIMA*0+0I<.1F)JJ(90TH/A?=06J3 M7WN70VIQB)#2R_U`4/DHQNI;^Q`;F##CWN2'],NI2)O<[E=ZZ`KVNYU@>[(R M;@8&*-E@FP!4MF#:3;\=8/G?VY0_*_HQ3IIEFY1VFO8]RDG;(]%-TQ\LJLG# M0&@FLYXW__*%2[H1%O`(!HH^AR1V(OY,A"-']9`JV@!`\9JH^4.RHZ/YB_V" M-*69+WLG$2$&J(R&@VSBZJCJ57H7WU#V^X9\?\!%M(C7]#).\\_/@O0IGVD_ MATNZ/&5GX>V@B/(B!YPVOC)2U7[8+CA2>R;?,]W?L,G-/*O_D_H5\RT*0,/J.U%'( M+@SY7`7RIEAU2#*%<#JCM%QQ\4*JQ/I5"(CC.@2YH],H2;$BU-*2I-82MJEQ ME7MEG[)_+YB,;--"0N):.(+:ZU_>Y`(;N@ME MRL;=XDS2&$<=E3U!*I!D,0#")#:=[SXGQ07?UL#4`]QG.@00/:8*C01<@P%H M1*ZLN'.ZY*>>G@8YL<_B-7N@D$_P/A3/%LJX8V3]:2-)N2LJTGW#0#4)^K-@#L<1?D1,!E_P#LIAB&A\9",BM8 MFPA>-)J\)N3J*T2GV)VVBJN>LOH8)^?E,U;]QX$TCT?8^!#D*0,?:&PW[C=> MUC()#:,\W./\I/5T765`A$^#^O6LAA78A,I@BUF1/(!]B57":^@[RW=F/4#F M@/3Y4\V#IZ^7!J`\.181ILV:^;1R&:ZV["GC6[K8)GQ9YL/7Q6J[I,N/^4BQ M/+\M#G6^>O@0)%$8/:;7-.&5P&48T8N,KKOG'+IRW\VU:.YQM`CYVR)E:+Q> M`80+*]B\Z8GL7)'*%V$R0AK>V#WZRA\[%+*8TY+/S"?A3GU98<(F15\,W="N MIY)(800">IC$=E-_8'9N/(:SJJ5]3YIQMGI)%6OZQE9;=.TM7SVLA3X%:WH> MKX-0NI43:`:J79IF#J6KWSN7M48KFJW"-)S(:H,988W(YZ*9U]E>``^@+DB! M!6/[SAS*8@4DI^8F6&!.7\0.3KZ&CJ8ND(BXLQEU1!_J(,AOXL6<1]-1YT62 M,KYT9O297?9:]7#9@UU(&5`6N;)2148OMHQT8F\4_F3-5M?<:'G;-ZYJ5[Y] MT.?V]_1"B>LN.=?<,A+6NM.,%`X/0HX[!,`67B&_D"6VB($NIO[1U\^NE^%C[RW M[%0["M@O:6K?+4W@]CCZ9=I?I!+#("Q`?L#>YKPIV;4EN\8S4C?W;`NE,:;Z MJF()RYYN0/T(M,%79+O)OD;1$2%>'5-*JSJ7/_U,DAWBX]KV]<%;GQA'`/C@ MU_V:1S1Z%?`S3>YC7)"K7Q1LXZ\-\F68+CR:NHV):-GKAT=%]/#7%CLHV=)/ M^5"I-P\;F$(+M9:I6YH+>NFX/&M'',#HIB-54<9N$-8M/6>W"#1P8LLA!V9T MPX4!F:\^W44(&@T@X*CL=(8>H9(3.?5 M&RVJ"^0Z_Z9/04KY,YUA>92H7V?]:0:]1R`02+K\$1OU"00$U9C\29].HB7[ M#WO9V'.P8D/X,0B37X/5EIZ'Z6(5I]M$MGW-V+[',K`]$O$,^XO%17A8"#VA MWN;\`'#VLD_^CT;K&6'M"3<@.PM?.&N**@&-[8#99S;0CXCLGF+;245F%AT1 MY+QRJV#.3ZJFN_:O#\_:6F\,1$]<$XIZ>9*=!4GR$D:/O*]&^4QB"\IE/5N' M7)?TTV4.ZX>TI7;7DRIW!1FI&A>R]`#Y+@:?#!V=WQ`F3TA=LURU(8F M8;S\$`'>"@V/C@1DGI].;O]*3CZ=$_Z/#__UR\6O)YU4TCW=U2[A/3Q:#,(460L,!_OZ>T^*_1A$'M`C1OD+EP2')UKUW.(J21;9DN<:B:4Q0FI+(AWU96 MW_DL!1JD`14!A%>8+(A=0=7!&]0[V>IAW`%<^+.9"'M-Y+(:E#`JTMZ^Y3^7 MH+>2K:+_DI3Q;SELJ3UY2M!1DNEY+-&I+^H"7M_H!8/SLVO$L-"/U MQUX=(Z0:32&QU$,O8D_'0DR2T7#B[&Z(*(X58.H['/?!BKUQ("7;&CKW+R1[ MHN3C^<798>`'I+\V")I636F2A0\A>[]2>O5P3C=Q&F;JS2IZBZZZJBQPV*/O M$Y+:*@,!2*2PGSG=^" M)`FB["JY"1^?L@]?:;((4WJ=A`M:7TS+J^E[&?N&^.KRTLX7#F.'?`\D+EMV M`9FD6\,_>B-)'A(=4P;L9:A7=XI(2INF6+F>$5H39,*LWOO1!X2-? M_C3]XLEM%B]^O]2\\5795KSXT6V+J0OB?J`N7O1"@,G7U2^-A!@`5DK1'U9(*!/#M?]#%X1J+*7K^%Y]F9` M"`)@J0WT/D"%)3!)3?X60&&O%._PT[:',`SQ_7G:_CAD%_C==7)K%;,\>O>< M?M1AK`*\]TUJ!V34Q.]<$_8)6.%IC"#,[FQ\FJ4A@!DE&+3-WZ4C0.X<)J1W-,B4UG:@V2%SMQT(W\'!\LDT'I\6]TQFAT=*[1TV=(=)N&\$@ M3+K='-`,-/(^@&YH!%P>-7#I[X/0[M!I=K>^/#\#CIP\RBSMT%]ROIH\M:`TA-71JXHV&K1P[K MZ"J.)=\*<]6"#F_AU]14-?8PPHGP`B(:-P123(RQ$:FU.]V4/;L91UE.=AHM M0BI=0-5;=,FELL!AE[Y/2/12!@+P2V$_;YXTRQ_D;U[VA%R`P>^S"XR8'KWD ME@)^30DS-X]::N(-PAM_]+*#N$7K%_[V4YQ1\F^^'!*!##W]E!,)?-,^G2GO MU^Y,RSOZ-3O-._&[N>0KG,"S@-"):\8J>NX\5XAC#Z*SR*4ZHS3.1LXKN-R( M<"M?RC@[S)DH@!Z[!I(@<&:D$KYP8.Q$)NL"-AE$Z6Z_"BR'L!^2"QT`W_^, MJ7G?D94/FWR)_)8;JWZ/F"V-WJ=DYE&3*WU[ZY(=PNQD`OB6)B-?EA(AQ?NX M^A!'?..!\KAU23,!R]O-T(@LBH['U8YW&!U;1O/BDV)_RZPX['Q&+OAS/OZ0 M3#B&0AXI1EM$E69S,1M&P(6S:J\7Q!P@5<660R0M(/(___C##^_))DC(,VOP M[^3]CT>S'W_\M]GQT8\D?0KRGX`$V^PI3L)_TN6_DS__>?;#^^/9G_]\S!7] MSW^:_?@O_YK_63$HKP?#KJ27%C)9<.TL`P<8$VCCRW8DW"'%2&0\.''/FDFZ).E^D_3I(KI+; M+,CHDD\!KFG"NZJ7>)VE7.KEEMA,U/417?H5`8T(*?73205Y.[9!JVA9O@PU M;UND".\HJH6,BJI`O"D(*_.@).[T8'6=/I1Q45#;3R?UZ@[;6UXDE]>!5I,$ M@XI77Q*.^LQP63MY,L$]'UP6'SU1F)P%WK-J)0'?COV6#J&*+K`COKOME428 M_CCO;O4'>%848**;0CMX(`_0*T>3:.-G0U4.),N=_CT2"D&!?E9C\"BHPA0P MJQD7<>/,IBT>^U2[$,^G?;X?A80]\RFU-?HFKG'R'S?*DB`+X^@F3'^_RR.J M#\K06_3$7F&!Q#QMG["D7A4(0C>Y_;QUD;"KA%WV[7@-P/@+J`8%39]G4DL1 MS>!(FY!CIR^L7ZK3U?06.HXU+=QPK-\G1QQK!;+@6,->SC&?3ED#C+Z>85+( M:!FVLP0P3(&S"1EVJ3MI36N@X]EV2T<!(Q#_/GT@W@(V> MG39/G^M=`)@[+63'F0<->:H/%;N&KOF4R*32-W`#3'1YIV7BAKR"7CG*,^U(%AQM.A#DE1G9-?"4CR(( MZ'DH!XZ6?0U3`.O&A=LX.:(;CF!+Y+-V"[&`T>>N?);8\\OI3]]J9<. MS.XS"LWT-QL[9J[N.`I[Y^RV8S>:U;W'MA/-PIG?=R'%V(#96$$:FN>[_?.5G'VR@K/L[H M4C'M@=GUB:>SPV(?K']H%-2&`_%0XV6^:U*_36I&BF:D;N<-(8$0$;'2"%T" M:JKMA?ST`YC`^=*/!30C^LB>`0+-F`!Q$3#*YDXW=,'.1P\?PD51MK'=!D6+ MD-V1V.0*1I.$+HM]TFPT%HU]TV2[R?^YJ",=/IXATRYT1$\\`4NSJX<\#^9S MZNSEAFZ",&%GQ?T-%P%Q3L/69J_4@XJY'2'6T@@>+BP)9EI.:O_D[311)N6$&BWU5@:"_(-$![-!8; M]1DT=S+70>FL!)2W@:9(MJ#_(C)[R6XG24J M>'1$E/.;4&S&Q&=1E&]+6-)-G(;9ZT,S*(VYQO/D*>WJX:N/"/"/O,'R:)1DU2\,F&5US:U:UE99QC M'#B*![MVQ8-'V$ MVM=JAXAZ07Q,_6N[AP*^:54#GG_HW3T\V1A*,"\?;C'F&^UEJ!\!&0X5L1O% M`B)-5;PN5?'0P`*42#.X3"N3?,-R;V.'6C(A-EWY5-O@$`;2+R19U80"\$?I M85YN)!<]G^07FT!8Z#/+`$(]CJEL!7PS0MZ(S-NF6;RFB2'W8%9=]NFL%]76`C8:(G$\/IZ7>PO.XO6&1BGO MV`E[3?LC92L[OX79TT6T#)_#Y398?0S"A!^@FF=R_>MH,%UWF(WC&H7^F-\2 M1R.0>J07$I1`\\H+:;HA#3_D2^Z([#S-"/-5'NS-YF;%L8$^O:$'%?H]\7)` MK*["883HR^"!T=;)S!2M8^/PE\U_.1V?*SH6F]+B3?%TZ&/NSIM-EO[34CO5 M]I>8DT[HS^DFH8NPZ'BT/%G'21;^D_\IK4ZT%KVB0V&!)$K:/F&5"*I`$.60 MV\^;%]D>@\V*\I3.]KLU6\[(IS@J[R1XLV\5`@L!\Z%8ZM-9:BEBZ80`=)3L MU/$&(9&EIN9EEIP>PJ_LK:=I2GW9TH8-.$`&P8&<-WH/$'B`HCM@D#O--J9& MFPG^(1\&=0-DJZ'L8+"=ZZ.%(/84D*7@H$EX^I75>Y[L/3<'A)'8J2$QL9PE MX7/>C6?Z,63[@<-@=<&?@.2[JR[#X#YD*ADU7J75"4%; MJ1JTVB)S7M`/;&:W0YCPMVG99&GU^8MO'!2-JH)IY@M#H\&`'*,GL@>5*H-7KT*?]5MTF2IP03P>U;0:2W M:>6.4/V^.93C5C!+;C5\B"0Z9.^TV[7QF&D"5,`X)X43B'L[:R`+Q\;A>!+? MB3D8D'LL^PA@M$L%`^`X<7JHGX.Z>OA$OYPL%NP4B3!ZO$[B*/_G@M]/R[N; M_8UF)\MXDRFVSPSPU4LE5KZ0B#W@>V"E';LN0+AOXWG>?/`V?B"Y(=E9DK9I MGK=.V)XX8Q7*LDD1O/.D# MPD.F3)N\Z_/5KQZ:&V%NZ(J=&L:>8$GYAI?3(*7+Z^"%]U]W.`:2UVY"'^H5 M1Y%POAM2DA_<&8`X#8PQ;[SF@[TWH;GCM?1!N)/R3>SO[ID?4CGR,?4CP;LO M;JB\Z8G<,.\"N3L$0KHI%A#ZY)R9K(`H&,>OMYCY1C089O:$:OM18]PW^WYR MGV9)L)`N+Z,XM:TP)$['U3/E-QNYOI#U!5'$Q"&D"D8^5VWVK6I0(]9>RR!, ML!8RH?,!.@9CV)@B]APN:;1,\SZQ=R&JWM6I;-N3'&%;)"51]`-+(,0A(+P7 M6<[KCTGYN5]OZ50/K8";>B3T*2>P$3$)`ISI"'+9?3.WAB2]]AJB7"*_RUW; M'S>$:88Q)\W.6D0<=I7PRYZRIS_F6@;)8*)CT:7\S>UP9(W(IBV]B\ND>!TD M[';?F7J[A=:@RR>%`0ZAM#U"8I0J#H!2V1QH(%+IL$=KTB0)#SJ@,B<+H,;VF2;5Z&2Y.HN5YN-K*=PD! MK?JL45MA\0?2-S0F:8*!.*7T,:\:L+X MX]VM;^U(:UD$O%TM,],SR(-;S!\>'NB"/>-S$2WB-MR5%8[YHQ9J3&\JH%*ZJ M4^1R:"Z\6?VUP%:?U+;X[-$<[$A`?'\Q[J9F,PN/"79^5R/_>!%N^/TS6D,_ M+*"?Y=#/V_I2[(T*<7TY.`K(IRT8UYM5_$+I+4V>PP7=;6!MG+AMQQ6!^NKIE*D]@<6-)E!AQY(P@5"S<\ZO M^`..ZKO9NO8R\>RWQY5!67^0!4T0QD":>M;S'##K7#7X%7)5'C/OV4UN[9#+ MZ:Y!B92X73L%!<<&EIM:7AEM`,+XHV"O!%SZPAL!7OZ7U9]B_BIKNCSY$B3+ M]"[.@E7S.LL]Q7/JW:ST,4[*CUB[]T.J;O1.V!3EB)T8KV9'_^5&+.DQ^XY4 M\>-UR61"4$"/2[[[684KE3( M:L*!UAG+^/2FA>7/<7C3@;$K M_[&+?-\SV)Z4[M.FHX$%.:04/_!$,T%.F2IYC)@G?!>7_:J$IRYZD>O;-T5Q M!^<#UA0ORLSR.=S&0>7JDPO`=I*R3V&'JK#:_N&68:IP<*&3>ZG+HG>5*K5> M'.'5$0=PB$@%!8HNF2Q([>7TGAR83E.X.BH"0OGNP?(PA$WPDO=QQ3-DG42# MK]2S1.D"G^#$A8G0:1/)/[;AAIU[H=YB(F[531+=5CC,$\=&2@`]YP`R=6SF MU_4KQDE]S;=[^I(![%-$.=(].K1;"\"O@<1X0/\8A,FOP6I+3U_J]^J=K8(T M/?D:RC:S@FPZ)-#8H%`"U"\<@NA"Z>FB]C"O/R/\0_*9?>P):V#CW^.0"6RZ MC%+:]OEEAK8)V':2IC1+3Z)FWON9!NQ0TN55E,^F\AP81H]Y@WP.EE1_L@?B M4]6IG^C^92P>[A^7\5C?%UD=$+IEH"2#H\V9*\)]D=*P?`5R;C MXA-`+F/(')-*WM`X"GE$I_%^2>FEYJD=)S$<2.HE\A,[3KZW/])Z:?2T#F[$ MAL3.2.&12VKS?;R54\+?3B,57N[9PT=UW+#&B0[+R.E"BR_E#^FXU8`)-+E9 M/-2]5BZEF)C*%%1IBBN,@%XBZYTZHH&,J1RUU$E6`?JUA&,$'+F(P&$GU0:% M"P7E34`[`9-W+\O0O0T'8B)CKM`$E[&*7B$S51S)@*$B![*IF7?G[(!@(.>A M'CQ2_@E,%;R#0&Z29=C&Z'Y,Z#^V-%J\P!9C=9;R)5FY)?;"K*Z/Z,NSBH!& MB[12/_/&%5)?\G7!5HL1U;(M$&"*Q5N9!^42+AB=D_"U_N=?0YKD@_+TMTAB;N(">HG-7'=.(OBI7K:JWONXK@R&049$8#CD%CQ5.E%0V M@>RTU:[N@%^0#:#>Q3Z-%=0O=Q6OV8&_:@_-FK?1P,.#?V%@`%6]T`.`E;:P MNG=4Z#G9"*:/.!"#;`.89.9UN,C3;O?"Q-ZDV[R$JS#]''4>KX,P,EFYU/F` M+&'*?;A;R]3UV^&BIB*TY>JFU*-BF;-!]D8E6-CYEFR,``=;^@3B%K0&*O,% M7`P%PW^R>\Z[.S.]NS&L%7]$XHXNGJ(PG[/""TH4Y^J[S-;.7=Q>'OA-G=Q7 MMN^3\0UEVU"F=Y+[]XYGI`Y`=A'*#3W$WR(;AR"Z&\HX!-3<2;8,HKV%?`@$ M=SMC&-ZUL9C.#\9;/-'E-F=E_-`L4?*_?@N2)/!O.N(U1^$3'"]9ZMV4J5Z5 M-YXH22P!TZ.>I;-)D:2/[J9"_8!V$Z"N']FTIWG7RON9C@PQH/F-&FZ064W' M`VPNH\/J!.R]B#;;+.6+[\>PC5ER"QE;11:X+)7W"9F=PD`&K!38S_E?Y-C7 M_52*\99S30L2*&W/JO3&GWCOGU/NQ./5^(*?>MSGU?@\X MU1UO$*?$((%PZKT)IV3(FI931\:<.C+FU)%S3AV-Q:FC@9PZ:G/J:`\XU1UO M$*?$((%PZLB$4S)DC3F\_H:7ZRMKOI&+OW(][D%14N/6E)#`;/@"!N/6#_1B";!*N_2R7(= M1B';3?/:A.')-PBZ@58=B6BL4G@'[AD,V?3`]XW0^YF4#3KIV$U*V\8-Y M4%3TZ&<&IRX'-=9](GJ!0R=W""`Q!P.2K>DW(1FT&ATV%+6K[]A@G'2]7-,W M90%F9&N6*%#+,J-^CI(T#(HUF"=``O&LAC,#CRF)094=R('[A1YQNBE M:E!?4A2S,]J*MKY-1<:`\=",-`C(@NSD$LI')E!^ILE]C`?F(T0P'T$D^56" M^6A*,!]-66HE<9I>)_%#*'M&7="B6S8U6^#0LA\3J01J.0;PJM%^SO\@Q5^> M<$,P-GT&2`>PA_)=2P&678ZR8;7`#E4'"&S'O]%P\\S/!WQ3_"#?DV]7^9_? M[>?(Z],U<.PGG1A>1(MX36^S(.-[1"[+-W`KGAL&6'343&F!@GM`GW#43AU( M3P>5_;RX2.JKI+KLU4/`D/'O\08.FBZ+%)9]5ID@;3*.:4ZPT;16^.5MN#R%N@JWD-U*3^>$8>V1K5:\&K M=CG/'6*G7@#L=/`J>Z))^?JSQF/\X`2DL==F(:F](UYK^NLJ'\G#VM!:YDV6 MF7C[ZMV6S=,:?.6[#E4`TL.`J>>]Q`^$_)Y@V\E6$K/HB"!OOA\S"99A'"SX M[?6>MD^@@(Y-IG.Q!EX\J5V MYKBVA7P3UQ,T31^&%+U*U]I)7&E=[/0I]68/,J<12@UJ9P/4PVMIE5.3ZMI; M%HV4>L%=<46GUJQRTV!.4#*'EIOCWF@S*&./21S/U!/5/4JW.E1!ZWF$I"KQ`Z[FI\?VF!-5Q`0I]U=/5#=)G,6+ M>%7EP=<'9]OI*2J@?4MIQ=ZDZ/$LV(19L-+O%3-TH$]J4@>NF*_IL;.T)H]K M17F9.VEBJPQ(:>'C;C13=$'4`(90@!A('('4P!>4CY7@5.$QX/ST&Q=_$-_K;32*<$\"RW7D3/-,JCF>11@8TV9[9L'$F` MH%^N:/M_.S&'`A"ED*J M/U\.%VT6.<$>;YYI/<],N\VEAA,G@2%LIM0R=%G]"7KH="[4CF==UC7=J&<[ MC9:^,E0*%6@Y)X<9L'IK.`"7:U-`=+1$(0R,@5:6,@I@)J\+F+83BX'0]"R= M(*S((2S&3;#4,-T2'/KJF\7"VSXNN>$L-R`NM`U;8O`*\R.MK#E85(.MIVV" ME[SGQ2E^20GY+/CZ>L%ND?U]<9;A>-!MB=YS(,MFN&6'M?.6S!!X`#BN!I6=MVQS"U$D@.=I$2A!V.#IW MVR(8)),=)!>O`)(6J60H*#U+&=<)W03A\IP^T"2AR_*PVI-H6>Q*Y%MCP(G$ MQ)DVO<"<.6*XR3=QE8J`?;"1`)!K6=HJC>MC_5EA6NZ%YX:^BH81.@%28H%V MO;Q`G$)$QWOVC)8UP9UQ122682O.5(^6<=+$G#2+\J2#X(T\4HAX29^),WE& M6;&F?H>:I%4O]W9:(R,1.02C6X?:ZT6HM( M,`(*K%3_#KIFUP]EC(IB&T*)"\\>@++#!4!%S9`QO>Y%P>J&/M-H2V]I\APN MZ,7-K?)%84`KD2ZJK/`8HN\;HFXJ@P$9H_`QKQJ0L@4IFY!O\T;?>?;*&2@T MQ#0#8TI(.KFUA(0&8!R3DN6NK\3K-T3BFJP'6/02^(

VVPM'/K-/"?_8&\Y(!U)`$\V@]YG1-1"100N0"?#_D;WUZ8DN?XKCI98# MPL8R'G0:XW)!V!-D/G1C&'"B;;KCQ8Q45PB_-",_^70JJ'*8Y2Q1P4+*E):1 M@BWCPA8E,@84FN`12]`I9C<61##@D$$0RFG"?2D9>28V>AX,08,'$KM)TX5GAI MR>J,1''T[J`@`U=40]!XHI]4+YQ4KY@4GP/4F4924W&D'56DWF&;@D#=&T@Y MEJD2Q$Z&V['647.1HYG/12-XT`TD3#?L`M%"&/@CHX&'O>J[%\!PX(^^F=^Q M2"3<^^$_PAO^(Q]R5OF2ACOE:^44;659K-T6%^:B?B#GM4X(`[RW+)N9KGJ_ MSF=^R;>E&>'8RJF@@(*4$4T;!364R)ETM5-[`*O60K_6B7[XI+9/SE8Z#0]1 ME=LW[\QZ=RRJ?LPABT[@@T^EEJ`%)R]>VEWVZKNQ4VEK&I MTQB72,*>('.H&\.`/FW39OYA5XJ'"?@U/V_>BL=9SB`5+J3D:1DI>#,>CMQ. MU_JA;`'%IG`5CC;%1X<$(/CDS@I"?JQ2W01??@YR"(7!2BN[HK8RU6VWQ26+ MJ!_(FML)8<"0EF53I%1IVBB8,A9\W$IM+Y(ECIC0 M,OBLJP\.!S=PD;5`SN02FV;KO%<7T2)>TVH7OT)E50.`!TB\HC,Q/R9`$_.]%<:S!Y8K4>30G[I MT.`$4N-A@/)$D^_R4"=?0U7-*VXHU>%=0V3&='N`K;T-_R;DJ,V:>LL^))_9 MQQXMR4D&4L$*R:#+V5`9J'@@!<@4^+^E^8^W#)*7L[Q8>HR3\)_\I0$@2@!L MI2Q1VB(3!]!/;"ZI0YK02^6IR;BZ'6DW])2%$.PHB`F'GIRK"A\J^IH@=PI& M7WV)Z/(D.XL!4PQ!6REC6VV1&2KH!S8CVR%,&-BT;#*.?SXC04;8)=\()AI: M!:'D2)`3J&&C(LQ(P'$\A>A&LD00/^:-)EGX$.9:0%,2/Y!SNHG3\(`09#!] M,,>0)Q.']/1%D@G.XW401EKMA3J0"K+>`3+9H#W&EFY`7!,V:MTU1#XE]R^* MTJHP\*ZX`D-+06=#>,H9KG.DHKTQQ"=1@I/5BA]'U?Q(ORD(;BQ7`*4Q-OL! M/45GOCJF$>M5KGHI>5FD9"]W%AD`1\5O./`4W%8X4?+:!+CCGS[_`#`H<<0D8V`(V.CQ\FJ@CR2)8SX&[AJ(*WX8='\ ML0*O3D[$@)%V:6$(D"9=6N`]>HI7RXOU)HF?*2^*U$6(WD(DOC(+/!*I^X0H MQ-)`0!Y)[.?U1=*\ZEO-`AA^,:E`F!$22VPIH1<0:"-2;/?&H#/ED1;RAEU" M"1KB\$C:`R3ZB/P#6-,WFS<^JY]G\X0A\F'L$T,WY#T^]`P$-!@/'H:%"NP1 M7TD8&YRP$J5XW+JT7:'R^.)-@4R*T1-8[N(/P#8>S$K_X@^RZ,C67O5TMZG,-"AIU M$QE3CKLO0K4[O@U>:LIMY&(FLL%&OKQ?Z((G#&5$"H&'=N79.'W/X^)3@045 MC[004O"J;ZMDVC3(GR7=VCM=TV*!CP321\,/5]D_R1: MWF;QXG>V9IQC[\,_MF'V`L\`('-Y,M"88[,3U%OT%*&+:D15M;-FXN"OV"RN M^YPW8`A2,=D$@PI**]THV>T3BEVG&WUP/#CS)'1Q7%W\>&6G'PZ)[=_ M/;GY\->KR_,/-[=_(!_^ZY>+N[^]-DR;)"I'J/8Z?5FF+RTYR5(T'0]8*2/.AP+`J7GC@FTZ<@H67;/Q#Z*A`Z.(.88W3: MC)%/9>_RF6QCV[LL2>$$@QF'W. M:$>^1Y*^A8`78\+$3?4OB6.%%]%SN.5#/ZU7K)!O/\49)+T.>;_*AP9?KA[8VVFKZTOE([H#O4GDV=@;*C2# M.IV^2/JL.'YIH#>P.FF\.58GT'=QK4ZZ3@Q1)[7ON4I^/#K/:2@8#<3'!-UP M\5%Z-1$?,[J,)SX_!_\=)V?;-(O7>96MT!5YPXYDB!JBJ(&\!SA$%_K7TCNM%6!&;5N(^(XS#2XUC4IHOC=AL<'(OB M(N&XXQJ`XY;%O/S3-QP+1ZJ/8\6`]G#<;"O`L7+`W+K1LGBU?*%?IA[Y(`BHTL4J5V?-'`PC4@@FIT% MZ=-U$C^'2[H\??DEGUU<1!_#*(@68?1XLLC"Y^*^EWK;G+VC+N4L'.%PT?H; M()'4)CZ`O>9NY^R%LLR(5%;LP,)OF2$)H^](;4MVQM[MPAL`R+XX#`5W3S6, M'0KD9'^(XN3.G64W7#"&W_<[N?TK^7AY]=LM^7AS]3/Y>/'IY-/9Q:>?R,G9 MW<6O?).?)_O+IZ6&]F[A-.28]%YCWMWB12:7<9J>/`?ABKV2^"YF2X%QU-QO M@VV\]!.PF1MHO@LCO(/MOEGY0&@<22[Q8OC%+8( M!';JP9F%0&[_1#0*>O2#&3F'E!=BI2U4S_&9.RPMX7ZS%#!I"5U[L#JK?[_+"%-A0O;,C#%#M M@,[!:K=/1!RSO##IDFM&"LN+N&;AGI07$]/-MKR8B'!3EQ>[E1;('3#(_2T7 MBY,.[TV9KR<*[RME61+>;[-JV?`Z\.=T??$(JMSS\1NO[NN'?C[5YNXV8`$?6:_#C M["\#?(.QU]HQ-F*JW-JLJ>_+1DP((`V,.H"^`;C+TFC9&& M56YMUI[W)0U#`#E@T6M8&E8X'+*T-3E1QDS#NFZX8(PH#5]=?[@YV:LT/!(U M$->`,"O9%-@# MGNW"NY4,=#[DB2]OB3CFK623+KEF9.M6\J;!R8>:B7MR.WEBRB$^6CD&Z28N M,;Z<+!;QEG7K,?\"4?[/1?%*^9-H>?:4`YZF%U&S39A_I\T*,/5'\]PK-A`\ M(PD=VG?$*CLP.@11NN%Q'@6"!XV6?J:-SB"2/CPF3BB M]N6#GLOV;A$V6M:2SL+=YV;1Q?Y"] M"V0WK^'-_=,98U3UU<02F#W-@/H1*(.OV':SZ&@4'1'D?,[`WJC`N&1FF74.#V_30F:X]%;75_T-*4 M-`R(L1+K>?-2O06UO.K)JT_T0RXB(`@E`KJ)[83TF@98;E:@E-$&(*S*`3N0 MA27(:`FR&3L@Y/"0!I'VP5CS4[KU,Q.8'53*\:LU6/\<2[OIS$/C12WU/LXT M@"B!88@,]I,\F6G5%^]5!O M=;BECZIW9&K;=S.'O#T.*W7]0)]G M0)#TV"6S$[!J*ERY47EEM`$`XZI>0VRG[>G!0DPOX0@@FU2RKQX>P@5E;U;> ML,XHWU*B;-N1:DE;%#HI^X$CT;(0>O:(+>?%QZ3^W+/7FJB'MD<8"!*Z5!': M]&D"`\Z(!*GH6A9:NOMUVO9=HLC;XY!%UQ\DPBC"`$@CM9[O*IGJFG=37/V0 M]PD$1$F/1#([`9&F`I:3HD8=;0#"6%&SPU@Y/?7E'A8FLK2U#`:VIJUENKV" M2C14FETQQ[$4VQ%$)+V>LL*`#:8<`&#?%2JZ4?"]#TGR(KK[$O^- M!HEVAF'JQRY5-OV,J0[]_H^:,%OAT:2AX16>-F6VA!OOE:0(@&BK M*E),6\K*SI^ULDQ/CRGS9Z<7#GA29M%_>8,\5BY%!;T?&55[GK"BI2PKHI\E MJ^@#2@4?W82XFD.G)T5*"X7:XS/H!8;-G`C#^G MT0Z%"EQU#<'BAW*J=?[NB28T>,CDNS9L_=C-19I^QBRV^OT?=2[2"H]68S6\ MFLY%=J:>D=P8AK9EF131ED79SI]U438].::;3/?BP@8V4R:RCO0]:ZB#[F9$*Y)=5S9'M/JN%HW%7WWC<8 M^:Y4,S[BF^G"T7Z:70=MZE;YV.&"9?GJ:3'MWJMT-%WPI M[T_]VQOR,>]0H6)_3W)L^$QQ.[<%Q@-)(H&VO,Y7#(3HS.4TFSK&M;KC@2YEC?WQ#/FJ.Q<3^?N38NSPJ M3I+M>[+>7=GP-/(&LMYW&'N'9;,#F'O'=GYM=EDRZ[U,M0)0#MAV)D.XM>#L M/`[9>.8!72;><=GNAQ/>E!GW7]\(@+SS$I<"TV;=Y#&(PG\&[!4@9W&4QJMP MR?\XB9;7.?7R_O(_KQ[*(X6#U6W^27&X_GF8+E9QFG_#O/5M^!B%#^$BB++& M0?NYOT5(TSOZ-3O-O\;OLI0]43>Z^7[T;N"HWT2_'E*E,7[O`7([=J?FS8C\ M!6>[F/P@]694=KI6'9?L`I-=9&[3B-UZQ4D9G7QF\0GO@"\GI4PE!/T4,ZTD M];+3R-T1I+8W<81TVTU=.<67\$\E645[&J1AR@2P&>!-O"8?F#?YZO\D^UG6 MZ\ZOP_2-68!C'U^&^3T]*)7-SMM#B206:_^.YT-%-*X80X_]PXB!+)H>O%OO M*GNBR=EN8^3)UU!ZUT#1M*M2PJ8XHJ/H!9*&B",`)$%D..>?DL;'.;OS"[XP M6S6H?:+J(=#CGD(RLFAP8(0G9T;23T&!,W;N;HTDB6`.)/8W,(!26$ M(IJQ8BI8++;K[2K/LTL2K.,D*S/TX>!*/Y\<@"S!S`P36TX28ZV5Q@)P2FY>T M:EQDIV5F,W+F7?)7C[R831"T"`DE-)2P:AJ$N:L*Y.&&0&U7'R2[RX<(+U@U M,!A@TZ[8\BEBL`GS>B#\)UU>)_&&)MG+]8HM,T=+X`MX[+P(US<,O"`N?1CW M'7-5Q"0X=,$$[K-:2]E9D,J$`'[ZK'D9!O?A*LQ"F@*F._+6HBPH:HU'<'E?$+.: M,`B0IP+;DHV-*SY.;12C+&:@%A9"GO6M)'P:&T?N$H(DEC6@F,"?+!;)-B]W MDF`9QL$B8X])?@G2C))EF&[B-%@=%K1@(CX`7-.+\BU=Y8X?\WSQY>41Y0"P$%,/ MC"76$B).#41WJJ^).1B1+`O\1N_3,-?\=;SDV^O8;8>48W,=A%%&V0:3 M`T9>!44LZ'U!J8MJ]T)9FGE> M[^L!(;DY"`22^!ZAS%AVLW!2`#K<]*`,.12)S0G")HFS>!&OJA=)'C("@7L@ ML#`X:2:H'HV]BT\6_]B&";V,H\<<@NN+Z)FFQ:8Y23XP,>UD!9@I"C5->HF3 M(8`1]>P$.9K7Y^CFL"O;$=;P'6M)&DW]H*P1:GK$MX988$KY ML_QQ)[89WN@%C3)BAE(\?>2;N)\9D+>D2B. MWGFUB=,]CK5IR!V2O4A)5P_GX7.XI-$RO<[=TWSPE[=Y$?)[\0A$_@'-1XE_ MHLE0%IXD"UGI/9`N$'U M_'[II/C0+_VPP:943NR!+M,6`X]RJ=D+UCB9I=GVPPE]>+JM";*LS,@F")=O MI&ACP#-:H.VJ`%%@6_4Z&_\'X\:QQ;4N'.7.HZ= M\>/XC1]0*/C&CV,/YG*[R69>D?^5KI8?X^07Z8X$H)5V4;%CY6AU1M@W5TN) MW6`V"S%M'^(%1#9Q8HW>/<3)NZTOZ_U08`#66U2(TB^TM*PA:RP30-'IA$85 M7GNY0@&IY+W4$D`!_0#[6?2QU M!S#QWKNG]1!^94_T\\?57R.PS5.:$VC[E>@NHBP'7'B_HL4Y!M#\)K/3I;6^ MG1NBR_KG*(D)PEEPN>=%F+)VK@YKT*4E;M<>P->I@#E6XA'& M1<`HWYNW7(;%5FWV.X<+MB^OV+8=-PZ8.7R8FF<8!*#ZE4]NG^(DN[/;MJ>R MU>45L:T;"JOZZ2B_2$):\%?H29AG>,M]V;RGQ(Z>R0#H:;DL\@'@\]3('2L! M26,C@1BZA^_U`-@\'2%">-JTE`/J4["FBL-^14VZ2:;5!(>1@JA(*:/M&4"J MIL&<_478GUX=WBLT;CN/2I(GDXB//L-P9,"F:A0,KPW/16(YH"0!&Q'1K<\!UD%PE_)CX MY:_!:DNO:7+[%"32V_!&QET.`(UQN&'44R3.0&,"N`1SU=B!PQO.2-Z4Q$GQ M'K(EX:W)-3M>@+7WA']F(.KST@:$/;Z"G`AX[!^(W=S5AX?&0G-[,W):X'E3 MX#DM\/S,\;S)\9R^-CSKYQ!.$3WM+*+51=XO4()JM51FH[*E`]:V^N`BSU0! M3&E8V/4S"/]\1B[2=$M]V5NC&%4-G4004#.GR)D:FCC&RPB2OHMC!1RA6/_/ M/_[PPWLNV5RH_YW\ZRS_8/8O__J^T.N4!-OL*4[848:'@2Q#589CRR.]U;TP M6M-:J;O8;QC5],6%_IJ]S%AFV]5A#]\'K!MG#5^@;]>56.E8,Q*21E!FTS>_ MRJT;H*H?#C@L+!GJKSF:/-+A>@A/HF5Q?LSRO[?E(K_F/:'VCI3J#7/D@(XF MW\"%Y@/CFW(7Y%9$:N]>XSD`O_MLU(64;'YDM1X6&QCHXJ3G; ML]81="(\=0^,##;*MGVNO>&@TK"N' MXQ'O.`=-'$='-P"B#L?D46_-B2PI7;>>/__V4YQ1\OZ'[PXHC7 M_DV+PHIM+A3-CL*(E*8^BH()##4R88YHM6P`_.F$Q&-RC%"=07OA@"7-LYKO MMQG91DNZ6`5),UN^T<&PT!N'$!XM.O*;_VEQ,QB45$4&RNS9-G"@!*(>N=\(H.=-(V>4Z_?,G:ZW8MDQKN%"JN\G7F^0D0(" MQ#TID"#LVQG#&#@R`$?3_4[(H4A4Z;_?F[6PL&B5"^S1Z%%.:$P\%O&:\EV_ M[);EQ7ICO)5`Z0*VB4#BPN7V`66OG6XZOJ<)*#>T MFRH30M74`?G:O7`A_74$4W:5AOT'7XH+7FYD[@RJACI""*C94ICH*"(!S*BL M8._Y*%]<7F]ZYL?@J5\9;F#9YXS>$HM"T#ZB,0H0$$0PK9]YV8A4KZEGIT.6 M[Q?G#3U[I;@)8$1\-$2;@)XZ#T*V^@-55^46*"X*9LNRBZ.V?-EX\U#3\B6P M?AUNZABUD"+,"6XQ]REK8\'V*E?(C;-@A8-<\&YE@*?Y'>L7V;SA5SRT8^-W MVFW,\8+29?HQ_ZU_"Y(DB+(/7VFR"'-`2.LEO4FO4%*9()%7WRNLTD@9"<)2 MA8-Y=94P^)/R.JD;^$)&``8$+`0CIT\^N:F(=9/BS5%]HPDX#'BLHODIB=,T MSPM%JT-%&J!0P<(:8FFB"&)4DSS3Y#X>C#=H.:)TT9&Z-%B5AS/'ZW4M M;9-T&Q2YE9;6K-67PN'APE1?CZ#!U)<*A.U1#/+?NK$5O=B@+GTMJJ(V,7>F MJ%I,G*$SWOR;X%>.\81@]SDA$O5FB]8%B1I7F^"2;^"ZFN,OA M%"FK:.;_C%&$$2!QY?"",;9A#R7K!,@<,2EUHR)`U#85)?0Q3/,OPT_52.@B MVY]\A(-HRRPT#-/>Y)[;'"!7#R;O6C4R5F0AE3$ZX?4]Q<]'RIAFC%>XZI#^ MMB2\UZ]<-8.0DM)@"*I8+7>BIK8G$':>N#2AL;`L3F%K=EIGF+WX_R+646!M ME*[P@>U/XF)I](H?\)A6MR;EAX(`[53I2FR'3W-5_QPD*4DX0TX+O713$Z^5 MRE;U%B5OCF:`0D3-6P"ZE(05V6NX.B4PW:<>:50$A/83CN&NDKAP>/@0-LLZ M2"">.M=L\FKCA;WW-CN)EA_^L0TW+`7JWR8%->QG&ZTA%JN!/43+-_IX(#KK MW,RK-C/"6_%M'74[\ODNN,^G1QZ^F`H,&1%US>`F8*[&@9"ZOD#550:"A,7` M+,M!MXLGNMP6$_>/X==<+$^\>I3")3HAF<4!/OW,+:,K6L'1<"/?ZZ'K2U@PXI`+>^8$EU:*Q[[P58,:@ M*I8!#EX4UQY,JF(Y6CW@[R=JG%$;)E#&W&@=RX"R15P&'88XLB1=D6E$?Z1)2_'"M8++;K[8J= MWLIN_B9T$09LT?A0@6B_.F(,1+.``SQ%C`6[B MYXC%'>.G&IC6&RTC:,51&KGE7*MGCJN.*M8`NA4N=)4';^4Y`]N0@'-0!"4P M!XLC.>`L'`^"XU8ANY!#L5AN$>`M.`SI#H:/APY#^^K#"HA^WI.Y#"-ZD=&U M<5+H&4(30\/0+3-[/72<()KQ!A!SYT9WOY^U)+RI[\M&?;#`N2H#&IBMM0,# MQHX/TG%32#LL!EIWD]J]N+N/@DC[##((DWYFDO,P7:SB=)M0ZSUD"A?0[")T MX9;"BEX[SCCBR`/8+'*HR4([$_)Y?[:>J9`&%P(]7L&"('!E(`U^H'[<%";K M`"[\]RRM.<.U?:I#1[:WZ6\3I\'*>"+5,S1(=96A^@^K=7QAK&Y=*-; M<:M;^L_N#E2,."V$F0F/"P=F[!T9HJ/GH$98#*RR?/-KL-KRW=)+_FE]:^8U MH'-0GK''Y[0Y97N_"A>_9.$JS$*:LN=1HSS4BWYK%]BPFU,`ACB$!?<0*:=` MX@%XJG\6'!1]?IH"JL=.K0,!.\W!.#TW54\Q`$R`?,1\;@'0*[<< MA#^IH'+0Y)U/#R)`!AW,-\BC!PI3.,>F?MA`TJV;X,O/05ZX&D.8#`+-:"$,KIOB,XPP%`'H_O M-SFH5`\`]JYWV-JXCD+&7CP[';BGC57Q/"P4CL,QX'VSV!L'0KT!,LMO@E/^XTG2:JNX.B2/()`G'RJ+E``:J5/4-S;B)34 MMYU2P>DTIESQ;EX'>5?NDB!*@P4_W@J^"\C"0T^*##P@"8]QG[%DQB0P1%3@ M_N9E8\);DV9SOW?_V"!,H"6V,.TK!]B32"<\QKJ3FZZF\5%!SV[#2F'_.M&M MO3,[%KXGO5>EYC$*J!DLPUTB[TZ']LYI+KLT>GQ"ZT1.7P\?G`##`TI@ M&;"`G+V4;T\WAN3DW+REJSS4XT\THDFP8F7VO&QJEE!_4 MVE2>W\+LJ>G1C-G(06&Z@!;4I:H@_S).-0FOK]:*AM4%N1[.2!EC1LHH?']D M.PZI`A4G2;6I/X MX<#Q0_8E2"@)UYL5?W$A7_(BBSCU91EEZ]=#X MS*S*5'F`E8QB#RY%5]5GI\6<)+"U"@K]JQW-??_BZR2&;5Y&IX:/&3,]?6E>46Y],'4`O+DHB-E;XC^'T5`(RG8;MF4Z6LH8*] MR!LA93W`9Z/1YL6>69==GNU)E`ZDDD?`?81=`S4O/-C[)R:IYI4;4#-@9D-^ MX0:T=VZSF-'K-K1.5#<5/7OU!A@HSQX[<8-36G^HS^=1,OS MW8RF7'22TA)@T^.DT@:)D(!^8;%1'0I"196'>7693R`;#:K;5+YP$(($`0'A M`.JS3V$KHM[$N'.T'**+.!"`Q?:P!@0;RQV'"SW`T@0>^"9>?E#T3/E`LH&E M20I`?039H(\CI`.#AXXA?K2IP;,'D$T`8T97T"/'``^&Q!T;JN-GD$9<%,SV MLHD`M;X]-^\:ML-RS0#@3IUWLB1KO*/RQ6Z863_C M:,RP.`SJ'5JNT44#D5;M9+YK0=@U3EO^CT8K;Y@*`X>(IB:P$C!4:2ZDIP^` M=)51]$&'([/,)14V%_G50X`\K&O90E;HS$755/ ML%*1)`:$BD+3>?4YJ2YXMQ"J'&`!UP"`Z+-*9"1BT.@`))H!*#\&35^K;.C.+#RE0B>6&&E46&3HAF+R';M1:&,^<;P(W M`A7_5D#&[_PDH0(I6D)J4::C9M^!GJ83(G24="`)BP'5;II8%A^_!F`:9PT< M:$Z<39YIM"T>'_[P-8=C%*S.MFD6KW-DYC.0RSAZO`R?Z;)X^]^E]IBG8>YZ MF6Q7DHE2VIC?E:&#-_Q^W+UT=Z>?;40,P* MI`:%!7WYL7,K$B4D7HTH5&'Z.^O:+_EX)DQ2V4L>=,^'0&RZDJ.VP=$52+^0 MQ$,3"J`02@_S,T:PB!]&P8Y"BA_(64*78?&*R2OV2#/A'OQ[/@0$CCZW#3#5 M([#*5L!2(RB.1\7;IR"A]T%*EV?QFNT-[19/U>PF/W`3LBX#(@BH*X_T5PY,=I M/_7:Y3#\G!N^XY:DZ9TTW)/[%])L5X8@/,:,L"BD>-EI(\Z,5)$("^6'6HY` MP9[4CD;[KDZ["]P7^53XMX67R-EBQ[WN$75D. M[PE6R3FD)],FB.&_X<1%ZJ`OX#"3#.@71EE[5=6QC0[,2-4%4O:!U)T@C5X< M0LF+H`UX"0]-J-#RH'V/$!/D:U1-O^KM@=_#2_ED%7K#C`09N3EG0OYZ^R3^;(;5D&RZ\W#(DZW7I<3. MIV:O0XL/<2)G/I\=>2(WH(/C3.2L.NAS4A_PBWL]D;/[7I/E1>]UW MHAQHU5CEPW`]':EXL.CH:,7#F^;OUT3.]NOMD_CW)G([R7[./WZ%L[D#E>.I M9G,')LC[.9O+OW98/!IT39,P7F)/QF3^L>92??_3ID79]YUX)B/HEL->W7U6KL'C9B`ONX*M1$)/&V9%*RH^C0\08MNJ=)L@2-&_9A( MY4++,4`'&NWG_`_/#A\3C4Z?;](A[/%EUU*`>,4XCXS8\C2(G^)XF7ZBLL,4 M5$U%&.XUQ0.SI!>(J.Y'`,*[:UCBO/QX1OB%&01YV:B*L:_&@)`$'1,) M&\9#C)NR2A;(#CJLV+E.XN5VD9&479^1Z'!0HR\VK'$S;0FPH%&0%R(?XX0N M@C135P/*QEU1E33&(8FR)TC"*HL!X(?8=%Y]/B/5%=\J"O4(]ZD"042/*D(C M`5E@"!J?++]$Z88NPH>0+MOO-Y?P1=I>0AE!>U362/N#2QQ1&#AW^M8-^C0N MDL_%9<\8)!]S*8ET,)'QJ&66.RZ8DNMRMZ]7`1Y0DQC_*R.S#^CNT< MNZ-?L].\![]+^67LH<`KW-Z\:L_/6ZN;-%XV0S]R$ M,!O"C;SALSG&!`RW!6J?\V!/(A7P&.UNYCB&\5%ASV9$3>"SI<(XHNP]7?E? MN=6["ORUJ]>)>?WD:B343SP5J_K9/`V'9OR`TS"X#U!FF8&F9,Q!C2G(H2`UF'$+\W=E[&Z9J)A&%$;$G<[H3`676`,C]6 M>>>55&Y)')':,>&>]Z`(P*2-0C+QV2F75(18*M$]4!%P7*Y@]7!D->B6/(T3 M0TL'[$ZH)R_:WD=6&Y1*_O/:DW+K),K"9;C:9N$SO67=Y5_AP]?%:KND2W;F M/*O='"ML2W MZ97LW)+*;_$FC(9G9E2_[REW7NP_W(.J#)U8"A%W1&*YCF,%5(GYP0N&XW(- MM9M3*$>W<+/2CLLX3,++Q#OR&VV`[HCXG`6H=IB:KLV;P9X9YV M!WA4SO9@?CP8\@KU1**37#%M`ZA4WZW60O'#2-JA9 M$_.-A28XVBL>>C*!-'PO+6S".,2IM#:QWG?&X0L!7:AT`8N>K9.%$[PI!,8G MZ'<\'8'V`)D&O0W<-,G"AS`76\JW<)_339R&OCSC.@'J#68/[G'OR9Q@-Z5I MGOO1G-*P75/%>2&[EYU:KV$.#P)8SQP2Q-F"R?!O[FZ=[WUBO]7JK+_\]ZY"4Q_>UONVX$-R4>Y( MN^^0X9ULEQT:Y;::^U]TG#OG3K_'\+MW#KL'NE/O\FT<>U7>CJPFQK`M(*]#+3V9O'0W[++':A?YMSAG>W[S+V$V\[#R)ITV&'I#SCY6WP6[ M8#?MA(G4G>ZD MO!*>EI+DGS[FDYXWU7")UX/6#4^FO_41GF?#SHE6FNL/B9:8NSHS5]E;9\=# MRZ):'9(K=B8[&/IL_TZ%5B,*S#>K.*7RB]IT5[TO(CFNXH8OX,0K_29?% MZP/9MFC@8X4.8LD7@C%C82\3X_\.Z(O(J%TT6F)&C-Q>@"X=D]*SXIB%G?MB M.E,%*-]SS!]'\O891Q M=/-[>*K]MK<8D:./D0-\GAVZ(J'[E&!^SQ,W[@BI85^DQO&4V$5O)]26JVL[XWMFL>#BA:N_K!!B(*(4:&6%2 M+BUJ-RJE,$3U-+NL5D'&MK7FW;Q+@ER]%GQ3Z^E+ZPI(`RQ\*?9&&?A"WXA@ M_#WP=S29=,%LUP#<N"G9R]X'B=G M-6_@*YOE"%`]%*.!C9R9/4OE0R5:K'GYP'HJ>]8%R$D<__:/D^O\C_V<(NS[ MCOZPM[9;J`\/:J(9/XJ=*I_%]E:MD+@QY($_(_HIE'!8G$$/XQDR?+):YBE> M+6F2LBE?]O(ISNAO`?L267J5W(2/3R8WX"S]J>L@$W\NJB3S[^.DAC+JAG&% M9>"]7W^5QG\@A3EA]C-2>2!Q0@H?>W#WRA;!NCK.FA2:*@_N5UL#[@_/7!^" M8-$;AX3KWMVI>>7M2Q\FYY#)\_V3L6C:VRGTD=4C-W03)UD8/9[?JC"` M]'@H,1/0#`JIZ3AT'J:+5`J^MF.&6&F8)+9V03-%'-WP3!S2GGLA/S<*Z M%=DUR\M4[PI4`\!HN:E'FXZF`@]ZQDX*537IQ,1.TQ>2GO#VKB$(8!4T]@/6\=2_&Y^-2OA*`8 M:AG-M.B04*MO)R44`%!CDFBU8O5BM/PY2'ZGC.?E-D@IBW0&/1K)#9!XI.L1 M%I$4<2!,DIK/RVM\0U=]U;/]J/IQ%W`*B)4^J62&(E9-AB]'99,RW!"@\2(I M6-'BL*%U=?40`08HB3`@-G$!).O6SW1]3Q-C!6^;@76\,G/,MG;O7&MZ'6T( MX4HG:GTGGXMFWM1.0'@8L%$(+#@C"W,37HX*R9'30"/H<&RV4T(/F^FK`>>` MA&$+SXF31Q+2].0Z=TF3A!8O;M'D#:U%+V4H+)"HJ>T35J)0!8+P4&X_+RZ2 M$U)?+G=N^D8^/0`$O(.BID\XJ:6(:W"HC4VRT$R-0`D)(.@1DPRH:6,9#"HC4VR4V.2*2V$))-8()),V2=, MDLD"04DFMJ](=KH7)%,#0$(R"&K$)!-:RD@&@]J()!-NFI?Q2]FX2RU)8QQ6 M*7N"1"A9#`"7Q*9SV2,JGK!'/;Q]XD#@T..,T$A`E_'AXV9131[*%D=\`:V! MI,6!(DF_/C8(2].NA0U\A.O M5@]QP@R--'V,CH#RA=N..!23,7Y!EWG.9MOHWX,U+U@)1= M(%4?".\$^EQV"IK4WQ11T?,32SOG7\%$Z M64FJT;@W4?-BF-YD3?RS[-],X&,0)K\&JRT]2=/MNOCNK6^(7?&#`V)5]H"` MT^8C\"\R<:4.Z:?#M*(/CU%YLRB$AR&-.+/#2D-P#N*E&U/>HR45;6#$Y+'_ M6N-7C0OK[I2BPVK66ALV;]K@&I4'K0[[64*6%?-/_#R,BZ@X8_RG)$Y31ZO% MBDC(R\'"2%ZL7BA^`S\6=,4==+_L((J+NB1;!"!A5+["A7V2!]ESV0=0"WWI M0<]C[)4%043\I8.]$@V_ZCU-/R=1#WZCG&]3BHLVY)$UHLLWQN,"\,`XOY_% MW&48T8N,KM%KMYYCK%*MX7A:D>U]PXD+L69_'"KG+LSP,HM\9MX(=[?O-[#[ M@,>34QF9T+2S#H`HE7*B>J2+TN.=A4*ONC5D*Z#X/3!56LP>C"/)^+_92-J- MVG$$D4?L#R@;J(_25\ZZ#V.G@`.VFZ<99Y)CG(_P>F*1N%ZS[DVS#H#I:E[> M9#/INS?RQHKJ7VG*5(B=^T9W5B3(R&TN#L6#\\<_S`BK.=Y$:1JA,FW*:>.#@KG*61T(MD021/4H?T-_"E^!5U<(Q,T(^+7-36`7;KR8>2*.3$ M1!=2OT>2X6EE*>[G)-K17X:EK-&A;-^:FO$CE'S3<%Y0ROG# M^B,0ZW\L6!_1QR"O5Z?A_=%DO#]B#^:\,=T!Z`Z-Z4=[/&G[&"28:7DS99/R?1COZD[:%H="C%W-2<=SYMFXKUWDS;1'WS<]HFZ^DTS,^G M;1_?N.X&=H?&]7V>N#7N*'[:JEY'X"J.N^UH51PO=%CZ_?V8L(FZ-^INBS*J MNVUC18##D'(YF5QNN1#RUN'6BB*>TTT4?DN$EQ,T<2\GT(I7OP=K=.J/N:]J M-/+OYUXI\1E>&[K(Z?!KO,K=K,+LY2:?N6'7<^:1W9Z@*H[LX_&&JM_(RS-5 M)1T>_9Q#83_^#\L,7]%BV_ZE+# M?GNA7KQVK3]YDY5Q4?O*A&4_*]RB.K]ZX%?3DVWV%"?A/RGZMA)='*SJ51YG M6MG7??^)*U-%]QPJN30J1M593FWCAZ)12G;^]SP3:+F$I_M`VJ)IO"P>HJ+O MFT+X508J>SF!5+`2;\?TM&!ZL,/--EKFES9YM]Y(CX?$`Z+]?I9MHK+T)DQ_ M_YA0>A'E(D#3;*QE255Y5OX^'"Y*2[HX\H1?VPN5B)`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`)3PV(6^-"Y^(;^W M&N/E$H6ZMQ.*#5MB:%P\Y"4%GW3"^9*`#TKAX93>ZELY/35=&L==S>C5DG]J.YJPD,Z-5U.)I?2/LJIZ;UX3H7<;XGPO<0;]=1T4=Q76-*- MSOBGFD2/-+6"J?[0@X2W5UYIX[NFZ)#?BOO2D%- MIT<5?65?W)6-55A2QB7M^TP'EU]`G':9=0Q$Q6$F4O7":7XZ'%7SO7K5]MT; M>7N=E:[72C1F5>RE%NUU!:W?O>5T+=0T_.@/4'BU+&+Z:_E111OTVH>=N2Z6 M7^$//QS2VJPQN2?8P#O*2BZT&U-LSMU+@?.RH#;JO#]*]_;(P1X(E`TCZ.NI;>#.WJSB#Y MS**0,HS76H]&-I>+[7)R.UQ9;P1UNI"^+V+BY0J#HJM3J4K[C7AETS<)<`'$ M@Q0!#V?UF$L7$^Q*P^G4Z#?:]F"W!\XOZT=Y.OB[^+"`/=Y&./@-O%>Q2PY) M8R983I]P3]VPSDVQ\'[PFNQEE8_PE7P7Y[=[C@S,$45.D'"'O!58U+8P`D5&!X9Q_^BY/%VO2^-P7_5(, MJ4!5M`#H,[UO(N+?J'!QE.@E@>QPPY)B`SGAX2$'D"5LL2-05$3T')F@)]?[ M^]@:/T?V^#GZ9GY&DRQ\"//<05.V(+NDFS@-,_+MISBCY/B[@T'2D3LD'4V9 MF[-\Y%@W+L.(7N3_E&9F:<-N7A8TQ"&*M`=(.5GD'\",OMF\_HQ\9I\2_K$O M-RKE`]EG@F[0>RSH&0@XH`?(!/B_>C@+TJ>/J_A+>G*?9DFPR'1,4)C(."$T MP66'HE?(/!%',F",R,'\+)_LQ*MP&;#Y>=V4)Q?6FO#FY'-EX!NK5*"0\TL/ M)2G3!*8*SD$`.`'[/OQC&V8O;&8<1VRT5<=;0VQD_!/;X!)0U2]D!DI"&5!0 MZ&&7OV:D:$!V+?PZV!D$!CGO`!B2$D]DJV`>"'H34.^.OK($VO'OBC+I#T)FLO8VN_ M/2Y%9?U!YJ4@C`$9>]9S_@E;@BB>1/,R\4F'6LXR#3JDU.K:*?BD!=0$)/J) MQH])L'D*%\$*0B)9>QF)^NUQ223K#S*)!&$,2-2SGC<_\9-"TH&64TB##2F% MNG8*"FGA-":%K M.-TF](Y^S4[S^+^K4K&)O2@#P^SQY,*DOXCY%A@6J`D@;_-FTS]4]^/X]JI= M<_*9&1!NX4U1;0HKL3Y8(%,H"A`_$BWP$=SN4B`X.B+*BZVHN;YVUOC>-H466%_>0NQT#DPY, M-&?D'E^> MNQR$$(M:!H(1O./0D"A4>? M=6;`ZC%08R[@HRDDO>#FI>YY>0-3.$FCUW#W&DY>RE=X_G MF^#&A+PRU!D0^%+Q4+\-9L_UENPO-JPZYXJ'IL4(UH%_:MMGU\JP=^1""SWC.6+<.ABUW\>8TAM;CJ MV;N/;"'6)_$@K/9H;N9-(`0#03^A5*ARGZJMCO:8N5#5#T<4AN=&H>6>$K0L7V7AD_Y"V[[!"UQ.&&O`]( MS!`&`/!"8#>O/BR>F*Q>[><)(Q2CV>>#=NA[;.A;"+@P)DZ<;/Z1Q;$"#+L+ M5D,F+2"3'A!DM'?%;$$SZ9Z>5G]^ILU7%ZL$M-U2):!52WQBM/O@0$#K`(9\ M*.TZ`DH^%Y_[4E,HAE--!^'8*\E06&C((`'*1%3X-5AM93=NY`U51"@;XO.@ MU0,'-*C\&[*@,.M5$?QC#RG0'D@%%)_-#2,S!F&2Z?_;$#IE@YT4\!&%" MGKGH.!YU MFTS1\3CE]E/6MT6<+.GRERC_T9?\Q,M@=9V#_RE(Z=7]*GSD]S8O-1O>[!T) MBG-31VATMOL&>"6\<7P8R0W=SG;["/-.5RU4N_9PG=M*D<;YN/($^J8C2Y:N3X@RI@YE M)FWW+Z1RQG=XY.[J=GYMB43F@;T,FO#,6AJ500;(I1F//910U2-#=DYL)1'S M<2*[GH\L_6!/*)DYFR`FDS]^-)OQ5*2UGI!MBWGYIV=[+L0CU:.*:D"[3&BU[0/=^;@[N>_0CV`( M`'Y/(5ZOH0JC+!*8)F('\YHF^0>DN$X:#;PBC1H#,@Y!D",AE-!4 MRJ^I\.;LP!QMT&'@:QRB,R,TAU\^6=]X]/(`?-1!A1P!=V@W=Y5!W!W"HPT[ M$'M'#>S=T\CB3ZRFYTFDP[T5=TMM'7TR`- M%WGQ4*JN11;6.S/(Q2IGSC5'_TW:%$G=WT? M.R0*<*G'UKE!U7O?I92@#GYCF0A'?K*L7IYJ#MIE_J_\P^JC_/_8FV_S3_Y_ M4$L#!!0````(`-2&:4?J2HC#>T,``(C-!``4`!P`:7-R+3(P,34P.3,P7W!R M92YX;6Q55`D``Q\6058?%D%6=7@+``$$)0X```0Y`0``[7W;<^.XT>_[J3K_ MPYSY7L_<=K.;3"I[OI)O&U<\ELOV['YY2M$4)#-#$5J2\ECYZP]`B1(O:*`! M@@)!^R69E='H"W[=Q*71^-M_/R_C-T\DS2*:_/+VT_N/;]^0)*2S*%G\\G:= MO0NR,(K>OLGR()D%,4W(+V\W)'O[W__O?_^OO_V?=^].4Q+D9/;F8?/F_I&\ M^2U*\F!!WOR:TO7J_[ZYH=])NOWKY>WEW9O3('V@R;MWG#B.DF]_Y?_S$&3D M#9,BR8K__.7M8YZO_OKAP_?OW]\_/Z3Q>YHN/OSP\>./'\K6;W?-^5]G^9Z@ MVOBG#]L_5IM&DJZCA&L8'KJ.)8W_YXH)E M\9_>??KAW8^?WC,EWK+Q>_-F.X(ICAW3Y@?_Y MPUF4A3'-UBEY=_<8I.21QC.&O/,_UE&^X0K-UC&A\]^#-`V2?!+FT1/[PQG) M@RC.F(8%PWRS8AC,HN4J)N5OCRF9__(VRE(FZ*>?/G[^\2,7\[\Z\OM@J":7 M8Q:0R$#B`ZDI\Z;.[T[8^,U.Z7)%DJR`Q4'QNYR&WZ8K_J-]8YLRMJ4X,-AG M)(V>F#A/9#?L5U'P$,7'P!F"=1?(A1D-YX:8V]%:L/T5S;(520L[6+&HL,-. M=GK(/IF:J2#M!:'WP4-,K(.O[+47D2>S6<1=.(@ODSE-EX63!P]TG>_PG?7D M4AJ,.P)EU0$I*SM0N6%,2,IF46$?:!F"Q20HIV5K3JPK=?M6_I)H@9=(^F+\RP7T5[ M4\B2X&RRG.1I$3(R.F?K%Q9+&*MI_DC2VRC[9FM@\'SZF^KU,HWK4V!K7T&X MZZ-,K,4-SI_Y/^U,BVS)T)\YKOFWF,]V^]2WS<3R'-;>Y-6Z:#:<1=2?!3$O M@BC]+8C7Y`O[V+(?['WQY#WW)7H/,O7G1K;6S1VY@S1,YE- MLHS8FI$)^K,KII493;L[NT):$\^*8+-Y3L+.;)@G]Q*AOK=I;O<+>]"&UE(PGLM1>1;0O;TZF/[<,'3SX7L=0[=1;UGBI/^Y:VR MJ0J]JLQ]KM@/-1G(<\YF&6162L'Y])C048A5"A;3L"9+S)-8:*H^:OO7:1QD MV;1D,F6Q>IY1- M$,/\,&8J[5H$*ITJ!'5-JE":I'6M@C0L^V?_;.&HGFJT:_%AQ1"4Y._"QRC> M2S=/Z=)PK*B!%:I+@S=_?:/#]TU.X?85?C1E+O++VQ_>OEF5\_NK[9B!!BJL M\T32!]KPZ9Y`=?Z\BIA8E\D-22.*AA9`I@)8BVP\,)-;I"^PM;CN(/TGW0"7MZ8LW;%VF65KGAX[ MG?/$`IH4B8>7"5M,):18_/T>Y8\[=L6HTB;'1NDG,Y3>Y4&:'V/6^SOA_TMF$[:X"Q:D_#S.CMC[UZ71_&/YK3=9-9>^?XV#[']U"LSQ&-.E5YE6:G(W:C+N8]FM]H"NEH MT[O'+1&%RI\:SF2E+\S6B;HO_UW'IC%M>TQ'V<:Y?WA,9]';:7QU%UUS#M-A MW&QE]N@RD^>H.2%#M\<`?]M^6#J?T640)3I:URDP>I<4SMP:/XHJUQ4JWW!/ M)3>E"Y9<3!TM'J)W744)NTK6& MD*)!3/EUVK+Q.JWRD]K0Q\K^R:O<#(]_G,]1RB2TFJW,ZYI#J48Z!$UG%Q% MY!QZ2*U4\!,%.@!Z[Z:(T'5>LGV++!L."N)^C:;9#'XN%TG7(3 M7T19&,3_)$%ZGLS.@KPY6\,TK:`$;NH=8)!:=\0.S,7T[/2X,"IUO2GWUP$, M2=M5``2T\PX]&'T[0@=@89KG/+9$:>_T'@[Q#0KCVG:;;S%#5R?>W,8IHL3//!G>#F M4+=B6X4"O@VO1]1&E)3(5WCA+6$':U)^Y4?NX["15ZI]V#>_8+^(EF.*EH*M MYU9+[X"%T]G2]G.+B6F*ODL$;??0<1@2M`515&OK.8Y@O:TBJ<9FAZ6_^(&E M>]:M!#[5/PL0L_VSMR`1:&<)%]N>O4Q@L?2JK:7TET*$E@03GBVT*!Z*.-D< MFMP$FV*@O@?I;"M5UDACO24\\YU-&_@[>WS@UD%\3]*E))/&D025I)RC2^`N M:8^K\:#6]`'0M#(O1"K]`Y0)Z$Z29GJA"TF'-/R"#]&1[5)-TW1B M#_OW03P*9;^1C!N)S3F>5T7!IGO*?]K=P^`)LDA#0C=QAR>@Y#B< ML1AQF+1I)D?%HP8=/?4_0T>.GAT$/$[T-!+P-7H.9RQ>7O0T,I/IC8@^RH!U M&9+ZW'NR6*1%U?1+IF^49%%8/'G-S@AI?G.,$- M(\]K<',-@I$'-XP]'$VRAQ'<*@8Z2O!2\K,,KL'VP_OHU7W.C)%]1H[G3;"0-=.G5>_L605.H1L$*#<3C<5RS)P M1U?-_MKF1<.KRW;;8(&EJ937]0C/=A(#5N*O:EXR,SQ%,^9*%T&4%LI/Y]N< M^&WY?NC38+'KY@?"2M;=Z;F]J5V;B\PB#H'%G#E[ES+(["%1O9CBEHAK9B!X+A:XPP'Y_AQ@*$ M)L95`?UV^EV4K+]J^6M*,^BADQXY69XB"#F]^K?!B`S7L64J&%=N\,.C,RV; MR.8^IIYN7P+="&!3@I<8&7H;0?<1PZ9JQK43_8@D"DL5S\P7-'MS]30WD'"R M/#<0O5H@Q$9 MO$<+53"NG>VW1\N.3GZC;&2BF%?A;+]!XH!SO]MX8LZO$<#"B`TW(NBH5.[J MO[`C1)&);J/LVT5*>*(386.;'RL^R/CV&1W$?%]C0^?1\BLRB!4J$T5?6%R8 MUH]!]E.I>YKSPLM'N#.BP]KZ^A_#^C5`V!BSX<8(+9U,7\08192H9%'P3(F+ M8R49"9CUETA48_;J^V;C,GAOA[3P^L9742IWFR!]MF9A:[$-9(4ALDH=W7VL M`WW7N*.F7QIT-$:?ZVK/_OW)0$+3*N3#\!4[TP5!O;Q>L^7,N/NVMUPAWA`AG%1NC#'Q=+?0RKUJUI[37Z^4#2?M?,];Y M]+L)1ZG_^%%1L*>56ZG8ZQIM:_%>W1[DT]^ZZ]7MK8^2 MMVXO4.QU]2.=*O4:#739'WU%\QH[CC6FWH84O+[VUA6N7TA]I#%3)3O_8QWE MF\/CJ&\#MEU]%P4.1[6KYC=1=]YGJ+0]IN\J[&T`[6\^9E-TS MD-SRA6=V&B0AB>/6B3>NL4!P46.G-8?EEJ>:J@J*^PH9E/4791V7!1/?'[NJ M`A(:E,G#PP@*&LW&4F@<&OL(#4#5[M`X=*Q=2_/S%AA)4:%SUCVQ9K=WF0YJ[1=AH' M+%[/=WI.TT++,\I?``#`AJ!H($U*86N:>4J72YH42;4WZS1\##*2EJ/WA0@V M__2(*M-.#)'SC3;,*%%#(P![7!*6Y=04P^K@5+:@T=K/@0&A:EJ!`=S4I\%' M*FP^Y#"#PT&EK8&>/I%T$L7A]F8S;O?6?P6_EOOW#.A]6K>31U@6 M;.\Z5H]9!C^\F"R%3L,$,-B9^\]>9KX)-5?O^&+),-/+8>S[ZF/.T!;&$,3S MV^=F_.#O,41/P`2/(UXD-%5G%#V"TF!+7\F6O:0[EK.H1B:H;28B< MHPBIE0I)HO`#98]+.2J1M./4=,1C9U_S%7V8T7!ND#YM!\23V;_767$FD=W3 M6Q+2)(QBPA9REPF3DO#4I7MZ&F2/-RE]BIAN)YNO&=\4F;*/'[-"LIBPY>!3 ME$>D59FJ`?T^634!*&=,TD M%VS&:%)6MEG0E,YC2:\PH5WL"(2B/@0NU_=H07>1[./[GWQ-9#V8D>DZ6=(T MC_Y3F%H93H#V8$QHM1\]YG5M=F2D(\0KYWM'O]MA"=Q91O);DD=I#$^@+>;(]1+!?3Z@C\S4$J"C)R1[?]73'(:K*(\B!7K M*?T.&BZ@T\&+\0ACJSIR$!UY1UA(&=IFDS9&%9MX09A'6W7T1YV3]&'M]+0_6>4^%K,G89K"IY8ZI,K9CHC4N3,8 MS#^DLQ>E?0"*0` M+Y=HYQE^OGH)1(`.KJ"@QP7\%P%XG*6.$?!EL!Y-P"\T/5^N8KHA9/>\ES'` MU?W@@"[K9YR`1UON&,"7"5.^4SH:![A,GI@]::H#=@&-$M@UFM&!&+9(SX"M M,=:N^^[%.O.PDM8,QP)"7/RM$8X.JPK;'"/"UKCO-_C&L[]G84)A82[QHJ81 M0YE!("8/?QG-Y('9`8/'O$ZG2FQC^ML=%Y@8,.> M_0$GD;-ZQ78\XYKDHB.PBR@)DE#GSH!Y1PV/,.G(`_.=TH0A<,U^VZ&1)E"` ML=.IL5G%G3H/.!T`1GNR+1"`]"6M!J*N$I;YU_H;N)2%1M?QJ'R1?CH_B[C^ MR2R[*;4H;I*Q^+O]@20A*7X!O*A#3PW7,>II)/[2W8J].(F16!T/LP=1RIO9 M*R1DEEVPL6X6=8$<`4'21+R49"S0QMNE'PQ+^9=@U5YP/9'T@0X+J(<21::Q MO%-G$G#K=#9"V!O;LG>'T)',Z[>"(:5Y&B&YB8.PN$.DZ1=B8J0?-(E'CGNI MK8Z*\Z8D7C^&*U:R4J)."](".A2::W2C!C)LH2-BN":$]G--0X5OH4_]S>I6 MF6%M.@E\`;H1PA=CH=[A"PA13L#]3(0#S,,/W3.M6C#F'>$V(*4=#>C`Z)9) MF4:\BC77`GTT)"93'@(UR8;J^Q@82(]]I/;13\(]UE)(KFBS81WZY5;_X MF^(,`D,*'#K(24?B`09VZ@7G.#D\?X>VI20S%O/5?',3!TD^26:\2N-*MNND MW8$*VY(.QHIPK,V.@W.)-)Y?`6VI>LF,F2PB?@%*EN6%IE-ANTTW5D@K+'0< M)+>%Z/B"\^``?/=(T_S>;/XAHU4!64P[5C`C+'4<0(L%\3SML+;_%L1D.M=! MM1:Q;*-50CP67)O8JA]@(R7Q^M0+,)%^"6[SCG![+!KELX>#?>,:NKV5,=?S M%.WBNC;E]CI+`F_0[GN:FIT:^YM?>YJ:OF?5MKUX65<)C\+BU6&7E?+O6:?*V:)PZPPF>T/Y8LG@50S'UWZ)B3Q]+:> M"5&Q/"-D26;U1,8R;[UA!5O=51X4Z=:=>Y?6Q@.U;D;(Z;&BE8^$=!.I/'?X MJ!L78KL/&2O5-L"TZ"4E@TCT)1M6D+/56`:=R3OW"U8SQ;(#:6IEP$XZ$]P#M@ M;#WRQ.0HWI?:7HI8\KI^VY^9D)^`F16:KOF>J)K.3V";&L8&C#5XESNBIJ!U MC=<[9JGM2SASOD:ZB.EWU2(`0])Z>E-&XLY9F2P,"/S_^*'Z4Q#S?;T)6RVF MZ88!HW@/'G)8'=JFT^)HG3LN:J1I-YL`_BIC77-1'$O3)+?AO)K>-U3A]]-? M,EBQ[ZCW`U?MZPU#>DI=J.E-(6`SS5L+M_(N4."%NA@)AE$6Z@7($&?CZV;@ MHM6#P>E<=:GC$)GPMW_`[^]`X:]1]3-04O[V3XS]':C.*0$=!PISM&_QO,B' M@3(\)^HZ/GBVY;#H7WMICYPYR:-9%*_Y`UMW)%RG MA2.8,62H9RJ2N;,$&4MZTIMAR]D^4!2P`+*]@W5)>T'&B,$HTGU]=?RYP/+ MJI]*6)4+#NVEH7F"@Z43#L*?L3BK)VY(`8>@:)YOR"B\!!W>!A9@)V5FNB4Q M#-R=:.-.2B'$'4#A,>XP-K"&.X"9Z0Z+:]SM$BVD2!.V:6"KT<9+-,GTM("? M1O?E]-3/ZU$=Y^@G&W$'D^>HIR4]AJ/=I::MQ;+\NP=5?/F8@IL[FYB%3Z2V9I?4NV(G?OJ.^[-N5@O3)K3 M-\M,G$<@);CHD2P,!!M(OMJDT+)<5MYN;T-8^=)AD51^+NYP5 M/:RN/5XQTVGNZ!N,Y*I9F>4<^\237SX)'[)/[LXVBW)%BIF5N%%S!=)HY&ZY M)RNP):VB-9A268#!J4(/:"%2ZZWFD/5B57X^WK55XG2=`$:MH39@A%V62P9/7X&NO-NKC#+2M@W8`&T]``Y&2VWH M`)WZ_AR,N#[N-9&\S:4D:=_;Z^IF]0E-%*OX,& M\G0Z\`"'QO;01J4.)Z\K6T["D"=(9K%KG2GG3VH"T48$ M0.`/BM!JFV)*QL#K/5%FD%40S;UIIO&DA\8#'@-]K@.-,//W-Y20DCZH\4E_U_Z)I`_4/8Y.>1''774\ MZ3U&N&%S'B]HZ/@2ST3[$H^40GB)!Z!P[CN2<6M=V\%H#?A/FTW[H@[0O:^) MVZ\7$W6PU>$J(@9;\LN'VE/.86#K5!M;4@HAM@`*K["%T;H#MH#N7R^V^GJQ M50=;':ZR8K`ULLNK97EP[C6H5$4U03./2$+@_`#O)MCP70^VX&2_I&LV:"UI M%>=Y&CT`QWNH'IR[(&+F]]I]=OP;:8OQ*KDL9M M6`H;^X=`MIH$_G"(:M_F1MR2/TFW%ZH*ZY"*LBF5I$/R2%1R\WKCJ*+3)-GN83_2F"F4\3S4?(/_ZJN/3G'3\<]PR3:$A;1 M*.-I^CCR(*+E_FVX*\4#8G!#Z+'R*^A1+Q<5-6'I6W>3#1_7NQ*^W-3H<5S/ M&4J-:;BW8&1F/"^OIS9[(TA+;PL;04XZE-+7@-14(P"ID-.J%"OJT=?,S[TN MU:Q7R>,1RO808-KM?<*.0EMS"+4[]O9>3;Y_+7;W^FL0W]`L*@94-4?%DT+X MDI(.!VH8#44`U*BVC^$EQ&*]BTU9UJU?U(E9&;3&H[TH+.?77O MR6Q6((AA*8AFE\EIL(K8>A@Z4Y>W;AZC0ZT'@"6=%29.:Q!1F`4ER,+K?&-^ M=$.3P@+2.D5`,\&Y6KV99SA2Z-D)0.V^O5[:U.]AR<`C:=FNW]%NZ1F$U-IV M0I&P>Z^/]&Y)SK[/9%:^ZS$)P_5R7>33GY%Y%$9PH5$L8:O`J)K0,]1IVZ(3 M"#'<_*X6@SV$0A\[#?*@J>LVODU,20Z,_*P+>9^2(%NG&^7W$6[8P)"HH6<8 M4NK:"4.BWK7O7WW>8B@AB^)*5Q5%QWX'ZBS*PI@RCM+4B7,YH?YX MY-F+`K+M*'A-<[)[E3N;IK?1XC'/3C;GSR0-HXS!+,=4@LVER39.4OSK)`\E)D$49;U4,Q#T)'Y/HCS7)(-?KI_/&)]56Y\-W MM5[-J>MBMH4IMPO]=!_=8*/RF,[]@6^3:_?GCU_8,IJI*W3@7Z[C_$3_R,O& M5J;4TL)X8#OX(,FS(G@J#8U*WPDZ1,_&UUNN0:[TB(/1I.!.&DTVA MJC214DTA_^C7*9Q#"*,/D%$#[;)!VZLP)RBMIL(!`:2?_C2$!+F7F&JIAZ&N M>9Q$D^ M<^C#M"I+R7JMSDIG"CJHD[-#*M]E,J?ILN`9/-!U7JX_SWB"0^S\<&TGSFXU MW/JFBY>."B+Q,A(DLG6(45KV_'D5I87!O]`DYV_P_9,$S34!GJ!RN*`B<.[I MR/&A!OK+%P<`Q_(80,7)[P17D0EJQQC[/^YWG3[I.!BV+XS?J?OR",0VK6:, M[XY"E)N.GM8F%&H]7>=9'B2S*%GHX%Q`AH%TC6PLZ(5MT0]0:_Q,DWV']8!: M74'9KHZ:`(/#H>SI(+11H4]S;P?FJ,3=E>B:K<,G')EU3X*,S$[IDC]466A: M_)I-UODC6WW\A\R^LG5"NDWN*98F-W&0"#,79!M`_7%J/2#9`R?/0-Z_M3MY M1B_B#6%_W5ROME;2,\T>.=ES)YB381.P3]A-$[UPUVJO`%VE_4O%'&2R84"N M(MUQOK!WY(DD6I@34"A05Z-XJ;B#S38,Y-7D*R^>]OV9O8N>];#7;*]"WJ'] MB\4=8+*!H.X@79DIU3?F[EE[O:^L@$*!NQK%2T4>;+9A8*\FW^&:=*_8^T[U MD-=LK\+=H?V+11U@LH%@[B#=$$X47M/0S-/0T.=RG;/09)R:JX1C)YKQT!<^ M9*M/KG/%QGJU:'N%8:)]DT1*(;Q)`E`X=TV=FR08K3O<)`&Z?[V,]'H9"0LA MH/LRCCN])U((>*J-$RF%$"<`A53,*3K),]N24BB)SY! MES_$;M1'LX2U7A_.?0?YL$T'RZ@NDUV)\DXU&7I=<;9RG7Z[T7&99>O#F@^N M62!J#5Z(?392Y35UW.:$4^/6/KZA/=QS\@61FC$R>(=8.:0(H_+U4R`D>$P)B'BPDMW:UA3;"DP#\K M,'2\J2=S2"H$XGR-ZBL-N(^03]6#)/T;OV+DVH%>\OH$ M#:R.RQ0EL!"K%>^`Q73E&C%M#NK7/CV39+;]@20A*7Z!=FC->VKNVIKT-#B8 MRC=T.QL+"6+Q7J\)=Z^S+AOJ+7EJ*7^8M;G&N&1H24F00G'5N!_IP02J'\\` MWM%0G>"MSWM$V0%[]9@33_-'DDYF_UYG>>'PBETK\XZD\,9UY!S?';27S&XU MMKGT!9!->QM[7W9F)J\[9N".60?K.MQFX\E\T19403([I4D>)0OVU8](-ET1 M_B)#LK@B048FBY04%G*_#W<0>=(0^:"8(M(9]2%(%M7HPU9IDP/;TU744`_\ M>Z5T2>/OSOW;;"BH6EEH^TV'7UE.I,''[R/MK3\GLUMNG?C\F5=>@7;CI&T; M#@&T]1=A.D:PA38%3Z_3J^M?E.QBG3/EOT1)M%PORS7IV5IQ;].LDP94=3OQ M'\.=S&8;W+K">+WW@%3V,KG_3O\IV7LP[L<,^]5^7@S\0>,Y\H"J/%[O42#U MO6?K7!+,<_#,V;@?,R>H]O-BG``TGB,GJ,KC]25&I+[=H-\-\"\(YL,`=X<* M!)0M##R!]&7"Z_E;F=VT.C*=WE0Z>C&8A\WG;()3$W1XA:,G8L<3FAT9 M>\*AHY?D"8#YW'G"02"O+UOAUS:\"+B=)6^K)^-%;Z6G%^0,H`'=+7PK$MF[ M\#K,H[9;N@GB?/-ZQC:0,[8;DH8<`[R$_&YL;H.<[$[6!8=N.(+**9R*P-_0 MHVT.F^=T*L9>;R1_35(2<@UF7Y.0)K-H6_/Z9IV&CRR63A_B:%%8499>;]9) MPRUU._$7S5;,9OL;JBN,K]=&KFBRN"?ILE2L<@K/G'I!T\UTSK/_RK_/I->R M.O;6/.PV[>@D#-?+ M=\*-@*VO$W&,*UK(5S=/RY"DF7@OF[$7UE;J])[SDNNUK,*E`-A'&4K2A$[O6:KUNF M\_/E*J8;0K+#GI4`IXC6%51*6X\`@WAK6$>R, MQ;*Z>O=R1&WN@ED?UX["6=WM]')T.V_.6!]2$XE,UU(>%"-ZS83N/1/ZB/:Z M9R@YB>%:HF:=F%BLTHGS,-8Y2;63V6PGJ>H*8V_FZ#2")3S_/"UZSNC\E&D1 M\2>TB@I^MU'V;0!7.RHBP9JBI;K22C4T M`X@SZO&D9B8`@PC(L18RY)Q\/90_76H4_+#!WQI^+E MZR%V2Z&3#;>`).D#0:&*^56*X:%.H`\U^>1A$7?@5Y\D2?B,!FVM1;,*;-`J M&T-@^TBE#`I-X:5M!,/;6I$E@F`=+8"FUOEH)L&RH@SRQLK-M<$469!J(?OR@ZM+](*^>7XF9>'[ M@6<'2T-+*WN&OFH=2/I9T$^`H'W0TMLY$9*IMT\:9#ZC3FX#FT[>X./KY^-+ M\&^:[M?&$KC!#1L`$S7T"%)*/8U!).K92B;%D.P*.:#4::6+0OS&9XVSW'V; M''UUW^T=N!JRI`MR9?N&,TO:.\>>Q%.IOL8`S-I,JL"2=#Z0Z^"E6!/P,CC0 MHOJ25[.%\Z%7#RK%*`>,.=C[_I6N9J^.]O:D(WZB'/$3Y8B?^#OB8N6ZCOA) MUVVE0:PXBOR@2<(S/DF:,S7SB*C>;$71-&_?RVD5;(_,!%+B\X*:*N MG4X;H:IKI\[B-EKPDZK@JB1P2[V:&AGJU7DXLX0]VI>E@<#83>SZ2^<=Q1U% MJCD09XNOB+OL\M=HV_\)=/A(9NN8B7T`>56!XGWZ:7'1+YN$>?04Y9L"%:J` M:Z_CYGFWA8Y'&':MV[OWR&M#8J_/!$4&V!EL\CU(9U4#_!;$ZRU`LVR]W/YF M[(?=F2!\L@N3%^*?UL;!B:]VD=Y1H:;C?#,G:1HD"[*MA""V5VDJDK%Q8`O\ M\^<5"=D_[RG_:;K.,W[/+TH65KZU_0ND^8WN4Z`7$CN]\JK[P_"0/+>/?@8 MX,\O!_PAZ/:$I^N40#M&N%)Z)2\.3K7-Q=V]P*R29B778?70!8^L1-^\4 M(HF=A[>^($4[&A((8);%K=UF1(KI]97BRX3-6LD=+R;)0_O5SDZ2*P@(B@;V MI11#TUR:N(VBP6D_F`1NS'A2,Q,`/BOA6/4_!2=?9P8\X$SGZHO%8+O65;)6 MNZ%B2E+W2:&L'I($M9[:_7L=MG\E"4F#F-?_G2VC),J*S,(GLOLH28&E1=L` M&Y+6/P":&*4K*)$\38_0GTCZ0-U#]989B0W<(U/SC#R1F*ZX53!`U:!L/3B' MH/0/I/H&Z0I1%$>_SV5(S/I<,`6_!.DWPLO68K"))6MNBBG)_$.EIBFZ0E+- MSG[N@H-AZ'=3D!YK#PD8[5ZTJZ+$NE:^%Q$Y&I[P^P.NL"&5T,JR!.$2WU;YZ=AUFFNF9?TAI8ZI!#\$:7=/ MWL5!\?:U9*=WF-OCK! M5%A6XBQ*2AS22[U5&5%#CQIV#X?<[G`[WGD4#O4V MK5TZT%"3RC"WFPQ\D!4Z:0UQNR_H"^IT`\76O%LP"S'9)>DHCF@"T]P*<;>4 M-;UDTMJ/;*YAK77<7+Q:Z'C<6+=N^F-ZB`WA#U\M9WYUSRTWG5\FL^@IFJV# M6+*,E;9MH!]H.VY`8PQT3(P"\I3A_/U/0\^+OJ;)T_9V(-= MKFG^3Y(W-_PO:+K[B;>#GN)Q(X1)5K5%(=S[H+VXKWM\V==80E[=65/MHTR+ M&GJ=SM&;L8X=2HX=-5X#1,<1\CL6>)X/>SB!DEOYH6GE\^=5M"W*N8V&LN6B MS?Y%JT8[_8_4C?L:@:.XK47A_2ZH96K5\OW0XJ_99)T_TE3R5>Z-CZW-'IC/ MF-VWQQ$YGAO;5<+K.ENMC8;?H_RQ2`QA9LD>H]4]/4_8`&VD>06&O:AVGE2] M6#OWF<_93"SE5<#_03;E!$U\MPO=OGHB)&_O/%Z8#A_5-P?@Y)H2[$^;Y)P' M=/0DWV"4[41JN1+6O,VT%VVN3=,Z3)>]HEFV(FD1F)WEQ)X':1(EB^QF)X@B MVU75O+EE`#9WMTO3$$E5S$S97J'RD(J)*4>/ZNL-%4<`6-5V%&`6ZXQU38LS M^2#F$Y2(S5KRS2]O/QY<^*/7U;FJWN^XE/J+BP&'HZ\)^SC,HGC-KR?J$F6D9PO2Z^BX"&*B_"T$W0V36YYR$JW-Z"O:9*6_\F' M3%K\T7K_#:>UV+^SH&A#A]8^:`_CT-YKM3\65P-*2+2/77J<`0&BLS5]JN'< MLAY67T5WX<,GFTIXOTC)'VN2A!M)IJ,&)>1O,LH7XD5HXSGQ#9ETOI:4JRBW M_^??(Y+RRCV;*UZW!P=Z!#&,>RGQBX$^WH2.T"\5T&J1DV/65`PR7J**_]_Y M'^OH*8CYA'ZOZF'F#_B`-KW@V6DD_2@\H3W;H=V-V:-#7(E.\S7D]/J4_HRD M3#F^VU4Q'.`(TK;-^BCBMN,'.,9(QP8S(%,YH_$S7>R69'D:\;>AQ+X*@!A+ MUBX:J2`;/[0U37=LE*O%\SH]4O#M456^PI!`(:[R0B;&!K M=U#,:OPW;T3APO$-G!<=,PZIX+H;UX>=:OP=`8L\P)L#5GAX%\/ZM'''F&=9 M-(_CX/[IH7>G-,EH',V*9Z;+7^E\NB+;JB_NHF'CD21%(%2TEC^)/(#PMWT? M]E=*9]D=C:&R,D`KX8.\E5;.@XAJ=%H/\4(JXM[N$SE_J]]]-=(__^3E6;WB MQA2`("25XO9NB\HGA.F9P!QQ2CXE`C^_]Q.!OZ8TRVY2.H^@J"QHT7S/N=K" M)Q3!JIDCIM:G<MG4JVJ!2B)/IGZ=8"& M\,F\*44N9HVW9$:6VV?84K*,UDL`3TBJYNNP*BJ?<*9G`G/,*?GLIVSO?_X! M'\<^;S&8D`7??!X6"L]X(5&2S+*&>2Z7*_C[:=*%%)^J+OP%JY9Q;"%7Q?2P M1/46Q7=!3+);\D22-2GVNMGB"CH,E31MGFD*F_J$/H2RYB@3=UY][2GZSS+@V3&KXW)UQ2FW300J-^-3^CL:"1SY.HS/IQ9 M>'IL=IDP,4B6[Y9BX'&RL%7K&+G1RCGH\/LG%*LL@"XEIRK.6AS*3/WW/^// M-^I?VOMA@(F_'E]FOLU24D0\_>"?@VBA.\Y39-#O1=HQP])U0"@DLI/&.H9 MPP88E1SWWV"-U>Z00N&O)&&VB"?);#);1DG$3RAFF_84BG:!4V"OKW^L-XR4_!K MI3PKD-\;I2L^994',!1-N[*8C,8O@.D8H`O8%'S\?GN#Q/&VYM.7(/U&*J:` M=HN5!,T]8PF!7WA#J]X%;#(F^T^DIUMNLEW&RB8C+H&]6V<:V\JRSIP#V'C' M&+GKC+8D@'E=^;";TC*Y[+T?[_!:*M^X2I@?;EP_!K,7Y$KQF@C<4+"=V6SH M=.>V$.:"+TH>V2*9']RI5!0VAM1L-'8>,R0#135U!4^[*BGD67R_TL M=+W7\)HF_.8H^P\5HMHM(3A56_J&)5#+;D"J=BM"D?9TR779G8-F8-J&J`D( MF8&D:>AA!9^9@0,)`="A7Z)Y"%L&>[U^I^FWR^0FI2$!DV[EC2'8-!K[!B"9 MKMV@U.A9!"H_MP/V&MX&W[\$3*0HB)68$K6%(%5OZQNB))IV`U2]8V&5';_Q M=+K]/,M>A92VA?!4;SL&N2FA@CBA+"QT_?O[Q M8Z$A^^%?YTD:\<);)T$:K9=[5L(:LNCV.WT0[9V[DL8@47T+`%ZE9LJ="\%L MU`Y6G7Y+:QKK=X!T.%$'GB&VLXTZ0=B$>W_SX@$-%O3VB?8W0W-XFL^<8/C9 M#S)#.,%S?W0WC.FK6\U5-6$Q)&K=AU2QU73NKC:`I2F\D-&X3N\=5Y)^N1'@ M4.-7<$JH620:W0-8`AK1@V_APMP\W:*'%M_QG,P(U#[M!F8IN1K)`/D(8(PQ MC'4,`TQ[.@IR^&D\)6D>S2/F*"2C\QE9T2S*AY#DMKTF>D="FLP"-B!,P`6S M_7^VX(5/&;1HP9N]4MH!W&O.3C:`B-*=2?T.0`NI.QA$[,%#07@C6M-,DCBD M%$1\3UHM@/%[!^;;?\(-Y2]!ON:Q\=,_29#>TQ_Y_XFW[Y"M*YO)TM8#PAD: M+E37"DIDJ5B7&\M2EF4*EH6W,^P!ZNDW*X2)G$\S1])6OU)O>&()X97 M!U)B=]LVZ^62(6.[T-^*]7<:\VMKF2P7$DO6W*91D@W):S'#38UMHO9<"?_: M9HV2K]T%D8-!09M6N&3%;WL`8Z)B+UZH2MDZ6*/V'C"N%!,*NJ3I M"4X-K&(!ICBNQI-)UR@]:#7]GI#9).>OZBD_\(*VX/>\UG;(P&N#2!@D8=WU MT78%W241L/+X<5+5H<$`3@M>Y[N"YTN_D/R1SBIRG9$L3*/BJ0#5.:4VO>#) M4R2]\Z!B/A4VM9*U.;&&`",.0`-([GD-0XIL"2%2-5,F-/H`\R90?7@ECD"QX>GBU392$T2I6OEMGL>?66YT6>G86#2L?YNE1OY(W MFLSNHD52+#J2O.)AK+\P(IEJ^NI*#)NC:22&\\^#7>>@@QE2J*RM#75KQ;V/ MKB;FPV3AVL"P/DRN&-"VV=BY M,ZJ'C6JJ#)V40HSJ6X-B!KZ6,MD'@RM55@C8$(KF5P,HRWT^GY.0OP^T?=[J M/GB^9=*Q,,IF<&LVB=N]I<#"*J"V?@<-<^ATX-[7X$&F%FP".5Z+:]7C=+C9 M+W+IHAGKQMWNP5Z4NYR&W_;R ML+55<5`\F?U[C4N$,.^H6=K-H"-WE?!JPJKVDA6MI888TLYLA[&FNM:`RJ5I MBU`KH@:Q'O_1VD7T3&:3+",\T0A3$S1P)2/P%6)H M(]A!FXR=Z0.EKH%W18*,/-)X=KEQ-%_R`RT MAAQY9KTT,:G;B[=H[60N2SC6E6&'\)^]K+@%:G>ER`;"$V+WLJXZ90L)R]J! MO/;C6X#EGG61\0]D0] MKN,@)[,SPN0/HUTJ_BHFN]3@R9*F^4YMT#J`=]ONOA$#['7OF:?T;-].7F1? M-NVYW^>MAR5DP;F[]K&J]H"?B)JT[B97FWB*5XF>5C!7[]]T33J(R`PJ?DVT MCP4K)-A95$'B*49MIS^AH1%HD[HK%A462+ M?M&XXV@_M7T(>#R+LA7-@E@;DRU"+"XKA&/#)F23?O%9X6IZ##NLZQ>Z.1>8 MH0'S\L"[:#@A4"-49>Y]>GX?HP-M6AUC<*Y:%VZZ'04.([76<4G#UPP]3$ZM M,EL?2XC.J!U4#K]!/IZV26QDXF&8(O+V_2X\4HDMKU%ER%$%_U*Z21<:L_P! MOJ1N-^88OZ]N)_H(V6/N#WD=AVY)L35^$S"3W*=!D@7A$(H@`6*U)K8-%\22 M-=Q.3>:T)"%T%4E`L7DGI//B@QYIVL0D0 MD22#`B.22I2U)J/R$H9ZMK"`125#^WNN M[J>-F-C'0>%"H@2^]H'1%(*1]E07J>0!H M@*"M.$C!DB%#Z0".40ZI!#AOQ]52,>@++*RBU=>@?$Z*$&&1%7.[:89P><$5 M+3$@;W::FV-B2/4D%SJ64*;I:(B#F.Y>B4KDCM[XZIGKD8=!*%#3&X9W4CBT M(\*7]\V%1,-G+ACT@#3/,/,63+ZJYC:R\"W58CZ*O(13FH2LXUTE?#H_95I$ M>;`K!WL;9=\<)B=P[I-D]I6)F.;\%#=2OL&*HFDZE9S&9:&YP]AP(?&11H>T M77@.0>H^MJ`&FG8R"1119*P;Q><0+$>?^W1'%CSQZS*9TW09#"'MJ3JW?"+) M>GO(:1YEVYSSP68(9M6Y;Q#I.7][Z[,Q43E_+2>T?^_B5T$4:K!ZC,(@Q MS])`[:&G:=KM1XASK'5Z![)$$%_KB>Z^\;=DQ6M\)`O%-%W5O(E3L+DSA:_7 M_%1D.M\](Y8L=C)"KJELWU!9TMZ]:ZI&C^KK#3D=P*KJ3A(6XWC83A M'<:DJQS>?K&WMJD&=OGCLJKVXD@H:M]1YXR$[Q?TZ4/Q3GFZX2K_6/X'U_;' MBK:[G__U]:ZA5OL/._FK?QB*0TF,3B6JR+VBW2EWBVIGWE^E5TZCJ#Z^(:-" MO&JQ!N;A^XMW[:T3QS?D7]P\S_A#=K*I838EP?;;IMJZ[9^AK2TF!$/WP>H8 M5FF%(6U;=(DG&&;C"`R/;)1X M#6FI-E&N:$U5X0!&U-GCE1`YWMD6":00,77J4808:/'`C M3[M;!UR%R02H[VRC&1\CJ.S^PO_G(<@(^^7_`U!+`P04````"`#4AFE'[6FQ MK-`-``!QFP``$``<`&ES_7WY"2;%D2*?FEK8P34*"Q.#.QTK[=_L.AT+Y(=(GU*]SRI"`M(R!F<[LU`[OWTXU__\N%O MG?0NB!APUNEHYE<9 MG$A_#!/BH0I,GKR&E/UYNC=6:GK2[;Z\O.R_'.US,>KVCH^/NZ9T+R6501GA MX<%!K_O[Q]M'(W9!3*N).Y1I$WU(N0K*O`Y$F#(>=77Q@,@YN2X-U)PA2_RN M&Q>FI`*&5L'ONUB:$C+.6#0IIPV4Z*K9%+I(U$$J$-2?\U4SY1A@I$&T:G7< M%3Q$KI@L:S)UN"COT=?00?S[;09>*L42*95YZB7,OD\8DK,RKF2PA*V`&@Y"Q9H\K?+Y-AY1H1, MYRQ#(@?&X*3`V)*R$*4$'40*KKF87,*01"%:%;'/$0GID&JO0P@38&J)(%.L MB!B!NB,3D%/B0Z4#L0]ZGNF%A#&NB,(!P#Q+GTZGE`UY\@@?ZB9_DK;[!QAZ MIDN>Z`9UNB?I9!IJJ,VSL6GC"&,GK>Z/J8!]]$M*H1N4HSF8]H8L$@TVFMTN MZDU%$.$7I!1&#!3"IR`4!9GIL]UM6>63<%6KD,6/PB8;%_N/3PXVMTQI]M#T!`9R,:1!;9W[-1:9"%UC\B%.< MU_$NN1_ID2/[)\[FWA535.',C+U<3$R#_-#-2\@+CR0$??:C^3O?/Q/NA,3% MF>L#]1F7VUDY7_(T]>VF+O<'LK=PN?GE=ODA^OD1O0*)SR\XDSRD@8F3SDFH MYT3O<0R@9.OO4G]/EQT^K?+X47V/>V_NB4"J,2B*7OFN16`9@;D;.UDGSI_R M81]'-6.&C#%:A<&-XEL7BHL"/O06(EOX2CJ0Y/XPTX',3[?KW]5RO=2^OR!R M[%V'_*7U?<[WEU3Z(9>1@,XYD5@ZO,_8'`-20>-"J1?/Y7,!^,.(T*!DA;2P M6&&Y@Y2CFC*W;K6Y_')-X>(+@@D^FP&3Y`&:C]>+*/%Q(H)-MT)569(Q[4U!E!Z MK`?F4RC.+2Y:=^\YSJ.4$676]$O"6KBL<#U`J(-;7`RJV9,@..;XI8._I_(("SI1?ER%R1'CE#`>Q,+:',!*\<$%F3O-JV@6S:0!*7GOGHX#5;A45$55-X MNWI32/%/JVKAWS#7^L!G)%2SLY$`=TR^C@SWC'!<#`>#?!NN938_LV,:4.LC,;="=\68=)"/)023\XM-BMBXP2E8O.R$!\M8]$B M4`L!2P:_A,2]T5*!1INU7S,)7"_[6[&!?%`SZ=N"LQ(XEK[C('7O?]6$J>U+ MU7#="QB"$!!BPN0_E^#-1;20K`")+3*S4[K#Z)(MR1*( MVB!M*QLIBOM_]J?Z8:W7&6;+5LM6Z)?0QQ2'U>G MD@\#F'))53$14DKE#N@+N>^L$(U:(J8%9S5P+&&*B]8=Z]<%J@U4UD3,FEYT M$;N'RI(4DQ6U=A1<8\OH+`B,)B3,O`%-!CQ2R:Z,-=S91%;5)M*[>IM(BPJS M[V][ILIT5ZG-&]=K&3#2B[2,&XN`%TG<,V,1Q5A"^[+]FI#8SJW:"-WS81UX MVKEP'9RL0Z:5TCT+OBLY8U6&53O.52?$Z"L$9U)"68XR4^8>V;XOI+PTJQ?S MMMZOXWU;%K)`X1[$G$BTH]=*D%A/;A=)W./5]R7GM9=@:0>J&L<[F(_&)E=\ M\.&%``QV"0OZ:@SB@;N"R/4G-TP8CTCMT5R$R3M M!W-JL[J75"5G`.HB^W_16S]T\[?])4^6;P4T=P+2R90+Y;'22P9M%V3&EWS> M/E:=WIWF5J/\VLV:"J0,NN9W]>NT7.%9LU)# MK6M\WSDX[!Q^OV:]Y=>!UM$ARWD7,VIUCK7K>^\W5F<]5;:E1\G=I744"858 MXMJ*(MD+45?K$BG?6EW">M5J?1W"]?NBXRI62_TVMN3OSD+$FJJ4W>]:1Y1.O2H)2Q"Z&2Z9/.0E1!G^0"6Z/0Z=X9 M_AU`\!A-I^%,'X45Q%A&=%` M*JHB;82YC?ITSUQ8?$*19,]C-`SU`NET3XD(R0E2:]GI[YAVBL,0#YY,/4$D MDN2@U:2+D$AYD69?\[:4ES;3B'[Z#D0?0ZW16%UP(<`W`^B2.0ZZV+!8!:ES MV'(+=@U)*+^,83?LWHB[>@7A4PGW.`'!G%HFY+*N_;7%)?@C^.GIO2:ZZ>IU M2L7"J@HO%*AWHRWDU/X-]$-<_C^#("/8K&%L*'LW6LG/1NN:C21/O!MM9%GK MK3:1S43O1@NYD3+:UEB[HJS=<%`_4N93&Y2-SI):*MQ0RK'4F93`L@8&%:XF M7M/X>B(:YXWYBV`74YJQ<90'51S<1\25C"CI*QY!B2?73AC MP97YZ$)F[[HXTM6C;MJ@=C69AGP&H('028D\4+;RQH&55=1E1&,-^#FD1*+\ M!Q+0^$S,&&?'Z>QQ)K'2&ZX$O.8-6X5GQPQ>S=3&&OE/'O(1]6\8_E,0ACCJ M122\CS\S,\L;68^Z<4;>Z#TL$KJ3@DZBYIF$RQ2=O>\/,U'1#4.]&9CWPW^C M:IQ,P6G\*N]`]8<+6'!-&8X%2?!XJ>\;">9OX)DA)7T+;V'T9E*R M`PT.6Z"(F&U[J!G$GWQ"G\!`O^KT19PEZWM$?AVS5S2P/QQ2'X1$;7^!61K9 M%MIX!5GC&GG\CF!9\%XL:9[RSR#.PI";+)!MY>XD:IQ)]T3ACS@+^POC+V/^ M@DWI%ML4R]ZJE#=R1;;FF1WG[,@(([3DGJ\'-.F>S'15&3LKZ!J6!9P/ZZX\ MF9.H>4@EBR(],)B(3DT6EDRI(B'];[)*Q*!8OX>5M7-5SF;,?G5@YL]4 M?Q+\FHL'""*SHN@/+WDT4,,H3+YF)9=<48_AJWK`-\7;[YK\S8N"[Q0)@>CY:V4Z[I,^0MK:+;#<-X5%B$ M5='MA&%]5@NP#-E.F/4(SU"([2H)=\,T6DC,5I#MA%EZ`JS5%)<(=\.T%U[+ ML`59\\S*77>+,WC\#0.]W<2".!`_FTY#&A\)+=B[)O_..^(Q&IQ)24>L=`&S M'6F-[*;Z42]X5"X;NI,6SS M!0FNC,WF^`L109S1D;E30`^@NPFVH'1O"./Q)Q"3XD[[5Z^X:9OVFS@`[<^> M/1OA0*??EKEAVBY)?7,-XG9]OF*5C?.VWK$T#TB8&?#RGYYX`%^?=8MO^J'I M=23&=^L*V)U5=SJHX109CVH76F@89E\]<-$T(\.REJ'%=RQ<-#L,:3I-N2S- MT.R>I>:T?QSLZFU.-$KOX1:MM=%E+1Z9[5]=_(UGZ53I]-SUX4&OEP]Z732- M"V7+E"U9SU60[8)91S5L.MH9@^[XLU$5E3ZH,JR,MK$&6B(F2W'3HILKAJL. M7+&<$T&CR?PSB(4CE&ZRQH%S$4G%)R#."J?!\P6-5?WP$I_E/ MF;W>XBZCE:1QYGQB&+9Q$>@M49^S].[&].6(_B"DHWBO$)>+"Q-79,N."*E2 MWSYH@#&/)#SJ-]!+1NN2TL:A%Q^!*;6@I*AQZM]%6K'^<'YV9_&B4>8,DXMH MJ6&!C_TN_+;'$%)MTX%,%@W)%&75ITS!",37ZQ;Q;3KQK0KX\W]02P$"'@,4 M````"`#4AFE'7!K-?4.$``!(40D`$``8```````!````I($`````:7-R+3(P M,34P.3,P+GAM;%54!0`#'Q9!5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`-2&:4=6E=>$;P\``"CE```4`!@```````$```"D@8V$``!I`Q0````( M`-2&:4=-\0?472D``#"P`@`4`!@```````$```"D@4J4``!I`Q0````( M`-2&:4?$H-.U.I8``*1&"@`4`!@```````$```"D@?6]``!I`Q0````( M`-2&:4?J2HC#>T,``(C-!``4`!@```````$```"D@7U4`0!I`Q0````( M`-2&:4?M:;<`T``'&;```0`!@```````$```"D@4:8`0!I'-D550%``,?%D%6=7@+``$$)0X```0Y`0``4$L%!@`````&``8`%`(` '`&"F`0`````` ` end XML 18 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814
Loss per Share
3 Months Ended
Sep. 30, 2015
Loss per Share [Abstract]  
Loss per Share
4. Loss per Share

 

Basic and diluted earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents. At September 30, 2015 and 2014, the calculation of diluted weighted average shares did not include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company's net loss position.

 

Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of September 30, 2015 and 2014, were as follows:

 

    September 30,  
    2015     2014  
Series B preferred stock     59,065       59,065  
Common stock warrants     360,800       396,574  
Common stock options     2,364,346       2,180,858  
                 
Total potential dilutive securities     2,784,211       2,636,497  

 

XML 19 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814
Inventory (Details) - USD ($)
Sep. 30, 2015
Jun. 30, 2015
Inventory [Line Items]    
Raw materials $ 264,900 $ 143,669
Work in process 156,759 204,760
Finished goods 38,898 55,526
Total inventory 460,557 403,955
Inventory, Noncurrent 569,854 569,854
Enriched Barium Inventory [Member]    
Inventory [Line Items]    
Inventory, Noncurrent 469,758 469,758
Raw Materials [Member]    
Inventory [Line Items]    
Inventory, Noncurrent $ 100,096 $ 100,096
XML 20 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814
Loss per Share (Details) - shares
3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential dilutive securities 2,784,211 2,636,497
Series B Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential dilutive securities 59,065 59,065
Common Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential dilutive securities 360,800 396,574
Common Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential dilutive securities 2,364,346 2,180,858
XML 21 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fixed Assets (Details) - USD ($)
3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Jun. 30, 2015
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 7,718,394   $ 7,689,676
Less accumulated depreciation (7,251,504)   (7,114,836)
Fixed assets, net 441,890   574,840
Depreciation and amortization expense 136,668 $ 169,970  
Production Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 3,180,933   3,180,933
Office Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 226,995   224,576
Furniture and Fixtures [Member]      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 148,265   148,265
Leasehold Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 4,129,977   $ 4,129,977
Other [Member]      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 7,224  
XML 22 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
Share-Based Compensation (Schedule of Share-Based Compensation Expense) (Details) - USD ($)
3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation $ 32,312 $ 21,453
Cost of Product Sales [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation 17,558 7,972
Research and Development Expenses [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation 3,565 3,117
Sales and Marketing Expenses [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation 3,492 2,158
General and Administrative Expenses [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation $ 7,697 $ 8,206
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
Certificates of deposit
3 Months Ended
Sep. 30, 2015
Certificates of deposit [Abstract]  
Certificates of deposit
3. Certificates of deposit

 

The Company has maintained all excess cash in certificates of deposit at certain banks in certificates of deposit and through the Certificate of Deposit Account Registry Service (CDARS), which is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 limit to be fully insured by the Federal Deposit Insurance Corporation (FDIC). The Company ensures that principal amounts of certificates of deposit are fully insured. There may from time to time be short periods following maturity that amounts held in the money market account at the CDARS host bank will exceed FDIC coverage. In cases where the period that uninsured amounts will be held beyond ten banking days, the funds will be transferred to the primary operating account of the Company's operating subsidiary, IsoRay Medical, Inc. (Medical), that incorporates a sweep function that keeps the funds FDIC insured during that time.

 


    As of September 30, 2015  
    Under 90     91 days to     Six months to     Greater  
    Days     six months     1 year     than 1 year  
CDARS   $ 6,528,858     $ -     $ 5,362,454     $ 5,135,116  

 

    As of June 30, 2015  
    Under 90     91 days to     Six months to     Greater  
    Days     six months     1 year     than 1 year  
CDARS   $ 3,523,167     $ 500,064     $ 5,339,343     $ 5,106,775  

 

XML 24 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
Share-Based Compensation (Schedule of Stock Option Activity) (Details) - USD ($)
3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Number of Options    
Outstanding at September 30, 2015 2,364,346  
Vested and expected to vest at September 30, 2015 2,267,045  
Vested and exercisable at September 30, 2015 1,967,880  
Weighted Average Exercise Price    
Outstanding at September 30, 2015 $ 1.93  
Vested and expected to vest at September 30, 2015 1.94  
Vested and exercisable at September 30, 2015 $ 1.96  
Weighted Average Remaining Contractual Term    
Outstanding at September 30, 2015 4 years 6 months 7 days  
Vested and expected to vest at September 30, 2015 4 years 4 months 24 days  
Vested and exercisable at September 30, 2015 3 years 6 months 18 days  
Average Intrinsic Value    
Outstanding at September 30, 2015 $ 591,185  
Vested and expected to vest at September 30, 2015 570,238  
Vested and exercisable at September 30, 2015 $ 583,083  
Options exercised 45,994 133,564
Aggregate intrinsic value of option exercised $ 21,654 $ 252,308
Stock options granted  
XML 25 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814
Related Party Transaction (Details) - USD ($)
3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Related Party Transaction [Line Items]    
Maintenance costs $ 3,000 $ 3,000
Software implementation costs $ 3,000 $ 3,000
XML 26 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Balance Sheets - USD ($)
Sep. 30, 2015
Jun. 30, 2015
Current assets:    
Cash and cash equivalents $ 1,587,009 $ 5,226,740
Certificates of deposit (Note 3) 11,891,312 9,362,574
Accounts receivable, net of allowance for doubtful accounts of $30,000 and $30,000, respectively 1,130,540 1,049,041
Inventory 460,557 403,955
Other receivables 10,406 19,615
Prepaid expenses and other current assets 260,549 263,597
Total current assets 15,340,373 16,325,522
Fixed assets, net of accumulated depreciation 441,890 574,840
Certificates of deposit, non-current (Note 3) 5,135,116 5,106,775
Restricted cash 181,262 181,262
Inventory, non-current 569,854 569,854
Other assets, net of accumulated amortization 240,403 245,031
Total assets 21,908,898 23,003,284
Current liabilities:    
Accounts payable and accrued expenses 411,032 498,253
Accrued protocol expense 152,465 124,131
Accrued radioactive waste disposal 141,500 129,500
Accrued payroll and related taxes 129,540 212,795
Accrued vacation 96,847 127,515
Total current liabilities 931,384 1,092,194
Long-term liabilities:    
Warrant derivative liability 166,000 181,000
Asset retirement obligation 969,336 947,849
Total liabilities $ 2,066,720 $ 2,221,043
Commitments and contingencies (Note 8)
Shareholders' equity:    
Preferred stock, $.001 par value; 7,001,671 shares authorized $ 59 $ 59
Common stock, $.001 par value; 192,998,329 shares authorized; 55,013,553 and 54,967,559 shares issued and outstanding 55,014 54,968
Treasury stock, at cost, 13,200 shares (8,390) (8,390)
Additional paid-in capital 82,546,112 82,467,111
Accumulated deficit (62,750,617) (61,731,507)
Total shareholders' equity 19,842,178 20,782,241
Total liabilities and shareholders' equity $ 21,908,898 $ 23,003,284
Series A Preferred Stock [Member]    
Shareholders' equity:    
Preferred stock, $.001 par value; 7,001,671 shares authorized
Series B Preferred Stock [Member]    
Shareholders' equity:    
Preferred stock, $.001 par value; 7,001,671 shares authorized $ 59 $ 59
Series C Preferred Stock [Member]    
Shareholders' equity:    
Preferred stock, $.001 par value; 7,001,671 shares authorized
Series D Preferred Stock [Member]    
Shareholders' equity:    
Preferred stock, $.001 par value; 7,001,671 shares authorized
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
Basis of Presentation
3 Months Ended
Sep. 30, 2015
Basis of Presentation [Abstract]  
Basis of Presentation
1. Basis of Presentation

 

The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries (IsoRay or the Company). All significant intercompany accounts and transactions have been eliminated in consolidation. Certain amounts in the prior-period financial statements have been reclassified to conform to the current-period presentation.

 

In the opinion of management, the accompanying unaudited interim consolidated financial statements and notes to the interim consolidated financial statements contain all adjustments, consisting of normal recurring items, necessary to present fairly, in all material respects, the financial position of IsoRay, Inc. and its wholly-owned subsidiaries.  These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company's annual report filed on Form 10-K for the year ended June 30, 2015.

 

The results of operations for the periods presented may not be indicative of those which may be expected for a full year.  The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading.

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, the reported amounts of revenues and expenses during the reporting period, and the disclosures of contingent liabilities.  Accordingly, ultimate results could differ materially from those estimates. The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2016 will be 0%.

XML 28 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
Sep. 30, 2015
Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 1,587,009 $ 5,226,740
Warrant derivative liability 166,000 181,000
Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 1,587,009 $ 5,226,740
Warrant derivative liability
Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents
Warrant derivative liability $ 166,000 $ 181,000
Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents
Warrant derivative liability
XML 29 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fixed Assets (Tables)
3 Months Ended
Sep. 30, 2015
Fixed Assets [Abstract]  
Schedule of Fixed Assets
    September 30,     June 30,  
    2015     2015  
Production equipment   $ 3,180,933     $ 3,180,933  
Office equipment     226,995       224,576  
Furniture and fixtures     148,265       148,265  
Leasehold improvements     4,129,977       4,129,977  
Other     7,224       -  
                 
      7,718,394       7,689,676  
Less accumulated depreciation     (7,251,504 )     (7,114,836 )
                 
Fixed assets, net   $ 441,890     $ 574,840  
XML 30 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
Preferred Dividends (Details) - Series B Preferred Stock [Member] - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2015
Dec. 31, 2014
Dec. 31, 2013
Dividends Payable [Line Items]      
Preferred dividends paid   $ 10,632 $ 10,632
Accrued but undeclared dividends $ 7,974    
XML 31 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurement (Tables)
3 Months Ended
Sep. 30, 2015
Fair Value Measurements [Abstract]  
Schedule of Fair Value Measurements

Fair value at September 30, 2015

 

    Total     Level 1     Level 2     Level 3  
Cash and cash equivalents   $ 1,587,009     $ 1,587,009     $ -     $ -  
Warrant derivative liability     166,000       -       166,000       -  

 

Fair value at June 30, 2015

 

    Total     Level 1     Level 2     Level 3  
Cash and cash equivalents   $ 5,226,740     $ 5,226,740     $ -     $ -  
Warrant derivative liability     181,000       -       181,000       -  
XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814
New Accounting Pronouncements
3 Months Ended
Sep. 30, 2015
New Accounting Pronouncements [Abstract]  
New Accounting Pronouncements
2. New Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, "Revenue Recognition". The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

 

In July 2015, the FASB issued ASU No. 2015-11 – Inventory. The guidance requires an entity's management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

XML 34 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Balance Sheets (Parenthetical) - USD ($)
Sep. 30, 2015
Jun. 30, 2015
Accounts receivable, allowance for doubtful accounts $ 30,000 $ 30,000
Preferred stock, par or stated value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 7,001,671 7,001,671
Common stock, par value per share $ 0.001 $ 0.001
Common stock, shares authorized 192,998,329 192,998,329
Common stock, shares issued 55,013,553 54,967,559
Common stock, shares outstanding 55,013,553 54,967,559
Treasury stock, shares 13,200 13,200
Series A Preferred Stock [Member]    
Preferred stock, par or stated value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series B Preferred Stock [Member]    
Preferred stock, par or stated value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 59,065 59,065
Preferred stock, shares outstanding 59,065 59,065
Series C Preferred Stock [Member]    
Preferred stock, par or stated value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series D Preferred Stock [Member]    
Preferred stock, par or stated value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 1,671 1,671
Preferred stock, shares outstanding 0 0
Common stock, shares issued 0 0
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814
Related Party Transaction
3 Months Ended
Sep. 30, 2015
Related Party Transaction [Abstract]  
Related Party Transaction
12. Related Party Transaction

 

During the three months ended September 30, 2015 and 2014, the Company continued to engage the services of APEX Data Systems, Inc., owned by Dwight Babcock, the Company's Chairman and Chief Executive Officer, to modify and maintain the Company's web interfaced data collection application to aggregate patient data in a controlled environment. The cost recorded during the three months ended September 30, 2015 and 2014 from APEX Data Systems, Inc. for the maintenance of the web interfaced data collection applications in combination with the updating of the Company website was $3,000 and $3,000 respectively. An additional $3,000 was spent on the implementation of Customer Relationship Management (CRM) software in the three months ended September 30, 2015 and 2014.

XML 36 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814
Document and Entity Information - shares
3 Months Ended
Sep. 30, 2015
Oct. 19, 2015
Document and Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2015  
Entity Registrant Name IsoRay, Inc.  
Entity Central Index Key 0000728387  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   55,013,553
Entity Current Reporting Status Yes  
Trading Symbol ISR  
XML 37 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
Concentrations of Credit and Other Risks
3 Months Ended
Sep. 30, 2015
Concentrations of Credit and Other Risks [Abstract]  
Concentrations of Credit and Other Risks
13. Concentrations of Credit and Other Risks

 

The Company's cash, cash equivalents and investments are deposited with several financial institutions with FDIC coverage. At times, deposits for a limited period of time in these institutions may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances.

 

For the three months ended September 30, 2015 and 2014, there were two and one customers that each represented 10% or more of total net revenue, respectively.

 

At September 30, 2015, two customers each accounted for 10% of the Company's total accounts receivable with a single customer (a group of seven legal entities) that represents 30% of total accounts receivable. At June 30, 2014, one customer (a group of seven legal entities) accounted for 27% of total accounts receivable.

 

Accounts receivable are typically not collateralized. The Company maintains ongoing dialogue with its customers about invoice payments. Some of our customers are small outpatient surgery centers that pay invoices for our products at the time they receive a decision regarding payment by the insurer providing benefits which in the case of prostate cancer is predominately Medicare. A qualitative review of outstanding customer balances is performed at least quarterly and the allowance for doubtful accounts is adjusted based on historical performance of the customer and management knowledge regarding specific invoices. Accounts are charged against the allowance for doubtful accounts once collection efforts are deemed unsuccessful.

 

Single source suppliers presently provide the Company with several components. Management believes that it would be able to locate other sources for these components subject to any regulatory qualifications, if required.

 

XML 38 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Statement of Operations - USD ($)
3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Consolidated Statements of Operations [Abstract]    
Product sales, net $ 1,261,322 $ 1,042,101
Cost of product sales 1,177,863 1,096,903
Gross profit / (loss) 83,459 (54,802)
Operating expenses:    
Research and development 143,903 176,610
Sales and marketing 278,421 353,743
General and administrative 751,712 575,951
Total operating expenses 1,174,036 1,106,304
Operating loss (1,090,577) (1,161,106)
Non-operating income (expense):    
Interest income 57,417 72,695
Change in fair value of warrant derivative liability 15,000 306,000
Interest expense (950) (3,451)
Non-operating income (expense), net 71,467 375,244
Net loss (1,019,110) (785,862)
Preferred stock dividends (2,658) (2,658)
Net loss applicable to common shareholders $ (1,021,768) $ (788,520)
Basic and diluted loss per share $ (0.02) $ (0.01)
Weighted average shares used in computing net loss per share:    
Basic and diluted 55,012,901 54,868,053
XML 39 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814
Share-Based Compensation
3 Months Ended
Sep. 30, 2015
Share-Based Compensation [Abstract]  
Share-Based Compensation
7. Share-Based Compensation

 

The following table presents the share-based compensation expense recognized during the three months ended September 30, 2015 and 2014:

 

 

  Three months
ended September 30,
 
  2015     2014  
Cost of product sales $ 17,558     $ 7,972  
Research and development expenses   3,565       3,117  
Sales and marketing expenses   3,492       2,158  
General and administrative expenses   7,697       8,206  
Total share-based compensation $ 32,312     $ 21,453  

 

As of September 30, 2015, total unrecognized compensation expense related to stock-based options was $381,596 and the related weighted-average period over which it is expected to be recognized is approximately 1.56 years.

 

A summary of stock options within the Company's share-based compensation plans as of September 30, 2015 was as follows:

 

       
 
     
        Weighted   Weighted  
 
        Exercise   Average  
 
    Number of   Price   Contractual   Intrinsic  
    Options   (Years)   Term   Value  
                   
Outstanding at September 30, 2015     2,364,346   $ 1.93     4.52   $ 591,185  
Vested and expected to vest at September 30, 2015     2,267,045   $ 1.94     4.40   $ 570,238  
Vested and exercisable at September 30, 2015     1,967,880   $ 1.96     3.55   $ 583,083  

  

There were 45,994 options exercised during the three months ended September 30, 2015 and 133,564 options exercised during the three months ended September 30, 2014. The Company's current policy is to issue new shares to satisfy option exercises. The intrinsic value of the employee options exercised in the three months ended September 30, 2015 and 2014 was $21,654 and $252,308, respectively.

 

There were no stock option awards granted during the three months ended September 30, 2015 and 2014, respectively.

 

XML 40 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fixed Assets
3 Months Ended
Sep. 30, 2015
Fixed Assets [Abstract]  
Fixed Assets
6. Fixed Assets

 

    September 30,     June 30,  
    2015     2015  
Production equipment   $ 3,180,933     $ 3,180,933  
Office equipment     226,995       224,576  
Furniture and fixtures     148,265       148,265  
Leasehold improvements     4,129,977       4,129,977  
Other     7,224       -  
                 
      7,718,394       7,689,676  
Less accumulated depreciation     (7,251,504 )     (7,114,836 )
                 
Fixed assets, net   $ 441,890     $ 574,840  

 

Depreciation expense related to property and equipment for the three months ended September 30, 2015 and 2014 was $136,668 and $169,970, respectively.


XML 41 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814
Share-Based Compensation (Tables)
3 Months Ended
Sep. 30, 2015
Share-Based Compensation [Abstract]  
Schedule of Share-Based Compensation Expense
  Three months
ended September 30,
 
  2015     2014  
Cost of product sales $ 17,558     $ 7,972  
Research and development expenses   3,565       3,117  
Sales and marketing expenses   3,492       2,158  
General and administrative expenses   7,697       8,206  
Total share-based compensation $ 32,312     $ 21,453  
Schedule of Stock Option Within Share-Based Compensation Plans
       
 
     
        Weighted   Weighted  
 
        Exercise   Average  
 
    Number of   Price   Contractual   Intrinsic  
    Options   (Years)   Term   Value  
                   
Outstanding at September 30, 2015     2,364,346   $ 1.93     4.52   $ 591,185  
Vested and expected to vest at September 30, 2015     2,267,045   $ 1.94     4.40   $ 570,238  
Vested and exercisable at September 30, 2015     1,967,880   $ 1.96     3.55   $ 583,083  
XML 42 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814
Certificates of deposit (Tables)
3 Months Ended
Sep. 30, 2015
Certificates of deposit [Abstract]  
Schedule of Certificates of Deposit
    As of September 30, 2015  
    Under 90     91 days to     Six months to     Greater  
    Days     six months     1 year     than 1 year  
CDARS   $ 6,528,858     $ -     $ 5,362,454     $ 5,135,116  

 

    As of June 30, 2015  
    Under 90     91 days to     Six months to     Greater  
    Days     six months     1 year     than 1 year  
CDARS   $ 3,523,167     $ 500,064     $ 5,339,343     $ 5,106,775  
XML 43 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
Preferred Dividends
3 Months Ended
Sep. 30, 2015
Preferred Dividends [Abstract]  
Preferred Dividends
10. Preferred Dividends

 

On December 17, 2014, the Board of Directors declared a dividend on the Series B Preferred Stock of all currently payable and accrued outstanding and cumulative dividends through December 31, 2014 in the amount of $10,632. The dividends outstanding and cumulative through December 31, 2014 of $10,632 and through December 31, 2013 of $10,632 were paid as of those dates.

 

As of September 30, 2015, there were accrued but undeclared dividends on Series B Preferred Stock outstanding in the amount of $7,974.

 

XML 44 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies
3 Months Ended
Sep. 30, 2015
Commitments and Contingencies [Abstract]  
Commitments and Contingencies
8. Commitments and Contingencies

 

Patent and Know-How Royalty License Agreement

 

The Company is the holder of an exclusive license to use certain “know-how” developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor's patent application was ultimately abandoned, only a 1% “know-how” royalty based on Net Factory Sales Price, as defined in the agreement, remains applicable. To date, management believes that there have been no product sales incorporating the “know-how” and therefore no royalty is due pursuant to the terms of the agreement. Management believes that ultimately no royalties should be paid under this agreement as there is no intent to use this “know-how” in the future.

 

The licensor of the “know-how” has disputed management's contention that it is not using this “know-how”. On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time.

 

Class Action Lawsuit Related to Press Release

 

On May 22, 2015, a class action complaint for violation of the federal securities laws was filed in U.S. District Court against IsoRay, Inc., our CEO/Chairman and our CFO.  The complaint related to a press release issued by the Company on May 20, 2015 and is purportedly brought on behalf of all purchasers of IsoRay, Inc. common stock from May 20, 2015 through and including May 21, 2015. 

 

On October 16, 2015, an amended class action complaint for violation of the federal securities laws was filed in U.S District Court for Eastern District of Washington against IsoRay, Inc. and our CEO/Chairman. The class period remains unchanged at 27 hours and our CFO was dropped as a defendant. The Company has until December 15, 2015 to respond to the amended complaint.

 

The complaint, as amended, asserts that the purchasers were misled by the press release, and seeks, among other things, damages and costs and expenses.  We cannot predict the outcome of such proceedings or an estimate of damages, if any. We believe that these claims are without merit and intend to defend them vigorously.

 

Property Transaction between Medical and The Port of Benton

 

Initial Property Transaction

 

On September 10, 2015, the Company's operating subsidiary, Medical, entered into a Real Estate Purchase and Sale Agreement with The Port of Benton, a municipal corporation of the State of Washington. The Agreement is for the sale of undeveloped real property of approximately 4.2 acres located adjacent to the Company's existing manufacturing facility and corporate offices. The purchase price for the property is One Hundred Sixty-Eight Thousand Dollars ($168,000) which is payable on October 30, 2015, the original expected date of closing prior to the First Addendum/Amendment.

 

In addition to the feasibility studies required on all aspects of the property required by Medical to close, Medical is also bound to comply with a Development Plan for a ten year period which requirements include but are not limited to the following:

 

(1)         Certain specified site configurations and design with a minimum of 12,000 square feet of warehouse and production space and 4,000 square feet of office space;

 

(2)         Completion of all construction in two years;

 

(3)         Use of facility as primary production facility for ten (10) years; and

 

(4)         Provision of jobs for not less than 25 full time employees.

 

Failure to comply with these covenants will result in a breach of the Agreement and if not cured, will obligate Medical to pay the Port the difference in the sales price and the appraised value of the property at the time of default.

 

First Addendum / Amendment to Property Transaction

 

On October 15, 2015, the Company's operating subsidiary, Medical, entered into a First Addendum / Amendment to Real Estate Purchase & Sale Agreement to the Real Estate Purchase and Sale Agreement with The Port of Benton, a municipal corporation of the State of Washington, that was entered into on September 10, 2015.

 

This addendum modified the following:

 

(1) Extended the feasibility contingency from a period of sixty (60) days to one hundred and twenty (120) days to expire on or before January 8, 2016 with no further extensions.

 

(2) Extended the closing of sale to on or before February 5, 2016.

 

All other terms and conditions of said Real Estate Purchase & Sale Agreement dated September 10, 2015 remained the same and continue in full force and effect.

 

XML 45 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements
3 Months Ended
Sep. 30, 2015
Fair Value Measurements [Abstract]  
Fair Value Measurements
9. Fair Value Measurements

 

The table below sets forth the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015 and June 30, 2015, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category.  

  

Fair value at September 30, 2015

 

    Total     Level 1     Level 2     Level 3  
Cash and cash equivalents   $ 1,587,009     $ 1,587,009     $ -     $ -  
Warrant derivative liability     166,000       -       166,000       -  

 

Fair value at June 30, 2015

 

    Total     Level 1     Level 2     Level 3  
Cash and cash equivalents   $ 5,226,740     $ 5,226,740     $ -     $ -  
Warrant derivative liability     181,000       -       181,000       -  

 

XML 46 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
Shareholders' Equity
3 Months Ended
Sep. 30, 2015
Shareholders' Equity [Abstract]  
Shareholders' Equity
11. Shareholders' Equity

 

Warrant derivative liability

 

Based on the guidance contained in ASC 815 “Derivatives and Hedging”, management has concluded that the warrants issued in the 2011 offering should be classified as a derivative liability and has recorded a liability at fair value.

 

Change in fair value of the warrant derivative liability is as follows.

 

    Three months ended     Three months ended  
    September 30, 2015     September 30, 2014  
Change in fair value of warrant derivative liability:   $ (15,000 )   $ (323,000 )

 

A summary of the change in fair value of derivative warrant liability is as follows for the fiscal years presented.

 


    Quantity1     Amount  
Balance at June 30, 2014     238,696     $ 573,000  
Change in fair value         (374,605 )
Warrants exercised     (13,209 )     (17,395 )
Balance at June 30, 2015     225,087     $ 181,000  
Change in fair value           (15,000 )
Balance at September 30, 2015     225,087     $ 166,000  

 

1

Quantity of warrants either issued or outstanding as of the date of valuation.


 

Warrants

 

The following table summarizes all warrants outstanding as of the beginning of the fiscal year, all activity related to warrants issued, cancelled, exercised or expired during the period and weighted average prices for each category.

 

          Weighted average  
    Warrants     exercise price  
Outstanding as of June 30, 2015     385,800     $ 1.22  
Warrants expired     (25,000 )     2.00  
Outstanding as of September 30, 2015     360,800     $ 1.17  

 


The following table summarizes additional information about the Company's common warrants outstanding as of September 30, 2015:

  

Number of

Warrants

  Exercise Prices  

Expiration

Date

130,713     1.56   May 2016
199,437     0.94   October 2016
25,650     0.94   December 2016
5,000  
0.98   June 2017
360,800  
   

 

XML 47 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies (Royalty Agreements) (Details)
3 Months Ended
Sep. 30, 2015
USD ($)
a
ft²
item
Commitments and Contingencies [Abstract]  
Percentage of royalty payment 1.00%
Unrecorded Unconditional Purchase Obligation [Line Items]  
Payments to acquire land | $ $ 168,000
Area of land | a 4.2
Number of full-time employees, commitment | item 25
Capital Addition Purchase Commitments [Member]  
Unrecorded Unconditional Purchase Obligation [Line Items]  
Term of agreement 2 years
Capital Addition Purchase Commitments [Member] | Warehouse Space [Member]  
Unrecorded Unconditional Purchase Obligation [Line Items]  
Area of property 12,000
Capital Addition Purchase Commitments [Member] | Office Space [Member]  
Unrecorded Unconditional Purchase Obligation [Line Items]  
Area of property 4,000
Primary Use Agreement [Member]  
Unrecorded Unconditional Purchase Obligation [Line Items]  
Term of agreement 10 years
XML 48 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814
Inventory (Tables)
3 Months Ended
Sep. 30, 2015
Inventory [Abstract]  
Schedule of Components of Inventory
    September 30,     June 30,  
    2015     2015  
Raw materials   $ 264,900     $ 143,669  
Work in process     156,759       204,760  
Finished goods     38,898       55,526  
                 
    $ 460,557     $ 403,955  
Schedule of Components of Non-current Inventory
    September 30,     June 30,  
    2015     2015  
                 
Enriched barium, non-current   $ 469,758     $ 469,758  
Raw materials, non-current     100,096       100,096  
                 
Total inventory, non-current   $ 569,854     $ 569,854  
XML 49 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
Basis of Presentation (Details)
12 Months Ended
Jun. 30, 2016
Scenario, Forecast [Member]  
Anticipated effective income tax rate 0.00%
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814
Concentrations of Credit and Other Risks (Details) - item
3 Months Ended 12 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Jun. 30, 2015
Sales [Member] | Customer Concentration Risk [Member]      
Concentrations of credit risk      
Number of customers 2 1  
Accounts Receivable [Member] | Credit Concentration Risk [Member]      
Concentrations of credit risk      
Concentration risk, percentage 30.00%   27.00%
Number of customers 1   1
XML 51 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (1,019,110) $ (785,862)
Adjustments to reconcile net loss to net cash used by operating activities:    
Allowance for doubtful accounts (11,321)
Depreciation of fixed assets $ 136,668 169,970
Amortization of other assets 20,725 7,734
Change in fair value of derivative warrant liabilities (15,000) (306,000)
Accretion of asset retirement obligation 21,487 19,644
Share-based compensation 32,312 21,453
Changes in operating assets and liabilities:    
Accounts receivable, gross (81,499) (37,889)
Inventory (56,602) (47,742)
Other receivables 9,209 47,824
Prepaid expenses and other current assets 3,048 (46,136)
Accounts payable and accrued expenses (87,221) (65,167)
Accrued protocol expense 28,334 14,029
Accrued radioactive waste disposal 12,000 12,000
Accrued payroll and related taxes (83,255) (130,779)
Accrued vacation (30,668) (4,944)
Net cash used by operating activities (1,109,572) (1,143,186)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of fixed assets (3,718) (7,453)
Additions to licenses and other assets (16,097) $ (2,296)
Proceeds from the maturity of certificates of deposit 3,526,999
Purchases of certificates of deposit (6,055,737) $ (22,355)
Purchases of certificates of deposit - non-current $ (28,341) (4,645,139)
Change in restricted cash (13)
Net cash used by investing activities $ (2,576,894) (4,677,256)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from sales of common stock, pursuant to exercise of warrants 70,411
Proceeds from sales of common stock, pursuant to exercise of options $ 46,735 145,275
Net cash provided by financing activities 46,735 215,686
Net decrease in cash and cash equivalents (3,639,731) (5,604,756)
Cash and cash equivalents, beginning of period 5,226,740 7,680,073
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 1,587,009 2,075,317
Non-cash investing and financing activities:    
Reclassification of derivative warrant liability to equity upon exercise $ (17,000)
XML 52 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814
Inventory
3 Months Ended
Sep. 30, 2015
Inventory [Abstract]  
Inventory
5. Inventory

 

Inventory consisted of the following at September 30, 2015 and June 30, 2015:

 

    September 30,     June 30,  
    2015     2015  
Raw materials   $ 264,900     $ 143,669  
Work in process     156,759       204,760  
Finished goods     38,898       55,526  
                 
    $ 460,557     $ 403,955  

 

    September 30,     June 30,  
    2015     2015  
                 
Enriched barium, non-current   $ 469,758     $ 469,758  
Raw materials, non-current     100,096       100,096  
                 
Total inventory, non-current   $ 569,854     $ 569,854  

 

Inventory, non-current is (i) raw materials that were ordered in quantities to obtain volume cost discounts for key components of our brachytherapy seed including titanium lids, titanium tubes, gold wires that are used for imaging markers, and our proprietary seed core, which were ordered based on current and anticipated sales volumes and will not be consumed within an operating cycle, and (ii) enriched barium, which is classified as non-current, and is only expected to be utilized if required to obtain volumes of isotope that is not able to be purchased from an existing source in either the short- or long-term. Management does not anticipate the need to utilize the enriched barium within the current operating cycle unless there is an unanticipated interruption to the isotope supply that requires its use. If such a need were to occur, then management would evaluate the need to reclassify some or all of the inventory as a current asset.


XML 53 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814
Certificates of deposit (Details) - USD ($)
Sep. 30, 2015
Jun. 30, 2015
Under 90 Days [Member]    
Summary of Investment Holdings [Line Items]    
Certificates of Deposit $ 6,528,858 $ 3,523,167
91 Days to Six Months [Member]    
Summary of Investment Holdings [Line Items]    
Certificates of Deposit 500,064
Six Months to 1 Year [Member]    
Summary of Investment Holdings [Line Items]    
Certificates of Deposit $ 5,362,454 5,339,343
Greater than 1 Year [Member]    
Summary of Investment Holdings [Line Items]    
Certificates of Deposit $ 5,135,116 $ 5,106,775
XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 84 169 1 true 40 0 false 7 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.isoray.com/role/isr-daei Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Consolidated Balance Sheets Sheet http://www.isoray.com/role/isr-cbs1 Consolidated Balance Sheets Statements 2 false false R3.htm 003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.isoray.com/role/isr-cbsp1 Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Consolidated Statement of Operations Sheet http://www.isoray.com/role/Statement-ConsolidatedStatementofOperations Consolidated Statement of Operations Statements 4 false false R5.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://www.isoray.com/role/isr-csocf Consolidated Statements of Cash Flows Statements 5 false false R6.htm 101 - Disclosure - Basis of Presentation Sheet http://www.isoray.com/role/Disclosure-BasisofPresentation Basis of Presentation Notes 6 false false R7.htm 102 - Disclosure - New Accounting Pronouncements Sheet http://www.isoray.com/role/Disclosure-NewAccountingPronouncements New Accounting Pronouncements Notes 7 false false R8.htm 103 - Disclosure - Certificates of deposit Sheet http://www.isoray.com/role/Disclosure-Certificatesofdeposit Certificates of deposit Notes 8 false false R9.htm 104 - Disclosure - Loss per Share Sheet http://www.isoray.com/role/Disclosure-LossperShare Loss per Share Notes 9 false false R10.htm 106 - Disclosure - Inventory Sheet http://www.isoray.com/role/Disclosure-Inventory Inventory Notes 10 false false R11.htm 107 - Disclosure - Fixed Assets Sheet http://www.isoray.com/role/Disclosure-FixedAssets Fixed Assets Notes 11 false false R12.htm 108 - Disclosure - Share-Based Compensation Sheet http://www.isoray.com/role/Disclosure-Share-BasedCompensation Share-Based Compensation Notes 12 false false R13.htm 109 - Disclosure - Commitments and Contingencies Sheet http://www.isoray.com/role/Disclosure-CommitmentsandContingencies Commitments and Contingencies Notes 13 false false R14.htm 110 - Disclosure - Fair Value Measurements Sheet http://www.isoray.com/role/Disclosure-FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 111 - Disclosure - Preferred Dividends Sheet http://www.isoray.com/role/Disclosure-PreferredDividends Preferred Dividends Notes 15 false false R16.htm 112 - Disclosure - Shareholders' Equity Sheet http://www.isoray.com/role/Disclosure-ShareholdersEquity Shareholders' Equity Notes 16 false false R17.htm 113 - Disclosure - Related Party Transaction Sheet http://www.isoray.com/role/Disclosure-RelatedPartyTransaction Related Party Transaction Notes 17 false false R18.htm 114 - Disclosure - Concentrations of Credit and Other Risks Sheet http://www.isoray.com/role/Disclosure-ConcentrationsofCreditandOtherRisks Concentrations of Credit and Other Risks Notes 18 false false R19.htm 303 - Disclosure - Certificates of deposit (Tables) Sheet http://www.isoray.com/role/Disclosure-CertificatesofdepositTables Certificates of deposit (Tables) Tables http://www.isoray.com/role/Disclosure-Certificatesofdeposit 19 false false R20.htm 304 - Disclosure - Loss per Share (Tables) Sheet http://www.isoray.com/role/Disclosure-LossperShareTables Loss per Share (Tables) Tables http://www.isoray.com/role/Disclosure-LossperShare 20 false false R21.htm 306 - Disclosure - Inventory (Tables) Sheet http://www.isoray.com/role/Disclosure-InventoryTables Inventory (Tables) Tables http://www.isoray.com/role/Disclosure-Inventory 21 false false R22.htm 307 - Disclosure - Fixed Assets (Tables) Sheet http://www.isoray.com/role/Disclosure-FixedAssetsTables Fixed Assets (Tables) Tables http://www.isoray.com/role/Disclosure-FixedAssets 22 false false R23.htm 308 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.isoray.com/role/Disclosure-Share-BasedCompensationTables Share-Based Compensation (Tables) Tables http://www.isoray.com/role/Disclosure-Share-BasedCompensation 23 false false R24.htm 310 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.isoray.com/role/Disclosure-FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.isoray.com/role/Disclosure-FairValueMeasurements 24 false false R25.htm 312 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.isoray.com/role/Disclosure-ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.isoray.com/role/Disclosure-ShareholdersEquity 25 false false R26.htm 40101 - Disclosure - Basis of Presentation (Details) Sheet http://www.isoray.com/role/Disclosure-BasisofPresentationDetails Basis of Presentation (Details) Details http://www.isoray.com/role/Disclosure-BasisofPresentation 26 false false R27.htm 40301 - Disclosure - Certificates of deposit (Details) Sheet http://www.isoray.com/role/Disclosure-CertificatesofdepositDetails Certificates of deposit (Details) Details http://www.isoray.com/role/Disclosure-CertificatesofdepositTables 27 false false R28.htm 40401 - Disclosure - Loss per Share (Details) Sheet http://www.isoray.com/role/Disclosure-LossperShareDetails Loss per Share (Details) Details http://www.isoray.com/role/Disclosure-LossperShareTables 28 false false R29.htm 40601 - Disclosure - Inventory (Details) Sheet http://www.isoray.com/role/Disclosure-InventoryDetails Inventory (Details) Details http://www.isoray.com/role/Disclosure-InventoryTables 29 false false R30.htm 40701 - Disclosure - Fixed Assets (Details) Sheet http://www.isoray.com/role/Disclosure-FixedAssetsDetails Fixed Assets (Details) Details http://www.isoray.com/role/Disclosure-FixedAssetsTables 30 false false R31.htm 40801 - Disclosure - Share-Based Compensation (Schedule of Share-Based Compensation Expense) (Details) Sheet http://www.isoray.com/role/Disclosure-Share-BasedCompensationScheduleofShare-BasedCompensationExpenseDetails Share-Based Compensation (Schedule of Share-Based Compensation Expense) (Details) Details http://www.isoray.com/role/Disclosure-Share-BasedCompensationTables 31 false false R32.htm 40802 - Disclosure - Share-Based Compensation (Schedule of Stock Option Activity) (Details) Sheet http://www.isoray.com/role/Disclosure-Share-BasedCompensationScheduleofStockOptionActivityDetails Share-Based Compensation (Schedule of Stock Option Activity) (Details) Details http://www.isoray.com/role/Disclosure-Share-BasedCompensationTables 32 false false R33.htm 40803 - Disclosure - Share-Based Compensation (Narrative) (Details) Sheet http://www.isoray.com/role/Disclosure-Share-BasedCompensationNarrativeDetails Share-Based Compensation (Narrative) (Details) Details http://www.isoray.com/role/Disclosure-Share-BasedCompensationTables 33 false false R34.htm 40901 - Disclosure - Commitments and Contingencies (Royalty Agreements) (Details) Sheet http://www.isoray.com/role/Disclosure-CommitmentsandContingenciesRoyaltyAgreementsDetails Commitments and Contingencies (Royalty Agreements) (Details) Details http://www.isoray.com/role/Disclosure-CommitmentsandContingencies 34 false false R35.htm 41001 - Disclosure - Fair Value Measurements (Details) Sheet http://www.isoray.com/role/Disclosure-FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.isoray.com/role/Disclosure-FairValueMeasurementTables 35 false false R36.htm 41101 - Disclosure - Preferred Dividends (Details) Sheet http://www.isoray.com/role/Disclosure-PreferredDividendsDetails Preferred Dividends (Details) Details http://www.isoray.com/role/Disclosure-PreferredDividends 36 false false R37.htm 41203 - Disclosure - Shareholders' Equity (Schedule of Derivative Warrant Liability) (Details) Sheet http://www.isoray.com/role/Disclosure-ShareholdersEquityScheduleofDerivativeWarrantLiabilityDetails Shareholders' Equity (Schedule of Derivative Warrant Liability) (Details) Details http://www.isoray.com/role/Disclosure-ShareholdersEquityTables 37 false false R38.htm 41204 - Disclosure - Shareholders' Equity (Schedule of Warrant Activity) (Details) Sheet http://www.isoray.com/role/Disclosure-ShareholdersEquityScheduleofWarrantActivityDetails Shareholders' Equity (Schedule of Warrant Activity) (Details) Details http://www.isoray.com/role/Disclosure-ShareholdersEquityTables 38 false false R39.htm 41205 - Disclosure - Shareholders' Equity (Additional Information about Warrants) (Details) Sheet http://www.isoray.com/role/Disclosure-ShareholdersEquityAdditionalInformationaboutWarrantsDetails Shareholders' Equity (Additional Information about Warrants) (Details) Details http://www.isoray.com/role/Disclosure-ShareholdersEquityTables 39 false false R40.htm 41301 - Disclosure - Related Party Transaction (Details) Sheet http://www.isoray.com/role/Disclosure-RelatedPartyTransactionDetails Related Party Transaction (Details) Details http://www.isoray.com/role/Disclosure-RelatedPartyTransaction 40 false false R41.htm 41401 - Disclosure - Concentrations of Credit and Other Risks (Details) Sheet http://www.isoray.com/role/Disclosure-ConcentrationsofCreditandOtherRisksDetails Concentrations of Credit and Other Risks (Details) Details http://www.isoray.com/role/Disclosure-ConcentrationsofCreditandOtherRisks 41 false false All Reports Book All Reports In ''Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Consolidated Statements of Cash Flows'', column(s) 4 are contained in other reports, so were removed by flow through suppression. isr-20150930.xml isr-20150930_cal.xml isr-20150930_def.xml isr-20150930_lab.xml isr-20150930_pre.xml isr-20150930.xsd true true XML 55 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814
Shareholders' Equity (Schedule of Warrant Activity) (Details)
3 Months Ended
Sep. 30, 2015
$ / shares
shares
Warrants  
Balance, beginning of period | shares 385,800
Warrants expired | shares (25,000)
Balance, end of period | shares 360,800
Price  
Beginning balance outstanding $ 1.22
Warrants expired 2.00
Ending balance outstanding $ 1.17
XML 56 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814
Loss per Share (Tables)
3 Months Ended
Sep. 30, 2015
Loss per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Loss per Share
    September 30,  
    2015     2014  
Series B preferred stock     59,065       59,065  
Common stock warrants     360,800       396,574  
Common stock options     2,364,346       2,180,858  
                 
Total potential dilutive securities     2,784,211       2,636,497